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Abstract 
 
Lysosomal storage disorders (LSDs) are rare diseases caused by inherited 
mutations in genes coding for proteins of the endolysosomal system. The lysosome 
is an organelle responsible for the degradation of dysfunctional organelles and for 
the catabolism, and subsequent recycling, of macromolecules within the cell. When 
this process becomes defective the substrates of lysosomal catabolism accumulate; 
these can include lipids, proteins, polysaccharides, nucleotides and diverse 
combinations of all three. The phenotypic spectrum of these diseases in isolation, 
and even more so as a group, is extremely broad but an almost universal 
consequence of lysosomal dysfunction is severe, early onset neurodegeneration. 
Neurodegenerative diseases of ageing such as Alzheimer’s disease, Parkinson’s 
disease and Huntington’s disease represent a major challenge to the provision of 
human healthcare in light of an ageing global population. Whilst some commonalities 
exist between these three diseases a myriad of hypotheses for the onset of 
pathology has been proposed. There is growing evidence for involvement of the 
lysosome in all three of these diseases.  
 
We have been looking at specific lysosomal pathologies such as lipid storage, 
endocytosis and Ca2+ dysregulation in forms of these three neurodegenerative 
diseases of ageing whilst using LSDs as models to inform our study. We have found 
that lysosomal alkalisation in familial models of Alzheimer’s disease results in 
changes to lipid and Ca2+ homeostasis in this compartment and identified a 
lysosomal ion channel, transient receptor potential cation channel, mucolipin 
subfamily, member 1 (TRPML1), as a key constituent of this process. Our study of 
models of Huntington’s disease have implicated the Niemann-Pick type C1 protein 
(NPC1) in the pathogenesis of this disease and identified ways in which this could be 
therapeutically targeted. Finally, we have found evidence of Ca2+ dyshomeostasis 
throughout the cell in genetic models of Parkinson’s disease which have defects in 
lysosomal proteins. Taken together, these studies strengthen the evidence for 
lysosomal involvement in neurodegenerative diseases of ageing, albeit with different 
mechanisms in each case, whilst expanding on the molecular basis for these 
processes. Accordingly, our understanding of the mechanisms underlying the 
pathogenesis of these diseases has improved and new therapeutic targets have 
been identified by these studies.  
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MLIV : Mucolipidosis type IV 
MLN64 : metastatic lymph node 64 protein 
ML-SA1 : Mucolipin synthetic agonist 1 
MPS : Mucopolysaccharidosis 
MR CatB : Magic red cathepsin B substrate  
MR Cat L : Magic red cathepsin L substrate  
MRI : Magnetic resonance imaging  
mTORC : mammalian Target of rapamycin complex 
MVB : Multivesicular body 
NAADP : nicotinic acid adenine dinucleotide phosphate  
NAADP-AM : nicotinic acid adenine dinucleotide phosphate acetoxy methyl ester 
NB-DNJ : N-butyl-deoxynojirimycin 
NCL : Neuronal ceroid lipofuscinoses  
NFT : Neurofibrillary tangle 
NPC : Niemann-Pick type C  
NPC1 : Niemann-Pick type C1  
NPC2 : Niemann-Pick type C2  
NSC : Neural stem cell  
ORAI : Calcium release-activated calcium channel protein 1 
PA : Phytic acid 
PDL : Poly-D-lysine 
PEN : Presenilin enhancer protein 
PET : Positron emission tomography  
PFA : Paraformaldehyde 
PGRN : Progranulin 
PI : Phosphoinositol  
PI(3,5)P2 :  Phosphoinisitol 3,5-bisphosphate  
PL : Phospholipid 
polyQ : Poly-glutamine 
PS : Presenilin 
PS1 : Presenilin 1  
PS1/2 : Presenilin 1 and 2  
PS2 : Presenilin 2  
PTFE : Polytetrafluoroethylene 
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PVDF: Polyvinylidene fluoride 
Rab 5 : Ras-related protein Rab-5 
Rab 7 : Ras-related protein Rab-7 
Rab11 : Ras-related protein Rab-11 
REST : RE1-silencing transcription factor 
ROI : Region of interest 
RPE : Retinal pigment epithelium 
RyR : Ryanodine Receptor 
S-1-P : Sphingosine-1-phosphate 
SERCA2 : Sarcoplasmic endoplasmic reticulum ATPase 2 
SERCA3 : Sarcoplasmic endoplasmic reticulum ATPase 3 
SLOS : Smith-Lemli-Opitz Syndrome 
SNARE : Soluble NSF Attachment Protein receptor 
SNpc : Substantia Nigra pars compacta 
SOCE : Store-operated Ca2+ entry 
SphB : Sphingoid base 
SphM : Sphingomyelin 
SphO : Sphingosine 
SRT : Substrate reduction therapy 
STD : Standard 
STIM : stromal interaction molecule 
TFEB : Transcription factor EB 
TLC : Thin layer chromatography 
TMED4 : Transmembrane emp24 protein domain containing 
TMEM106B : Transmembrane protein 106B 
TPC2 : Two-pore channel 2 
TRND : Therapeutics for rare and neglected diseases 
TRPM8 : Transient receptor potential cation channel, subfamily M, member 8  
TRPML1 : Transient receptor potential cation channel, mucolipin subfamily,  
       member 1 
TRPML3 : Transient receptor potential cation channel, mucolipin subfamily,  
                  member 3 
UCH-L1 : Ubiquitin carboxyl-terminal estrase L1 
UPS : Ubiquitin proteasomal system 
vATPase : Vacuolar ATPase 
VSP10 : Vacuolar sorting protein 10 
VTA : Ventral tegmental area 
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WT : Wild type 	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1.1. – The Lysosome  
 
Lysosomes are membrane bound organelles with an acidic lumen primarily 
responsible for macromolecular degradation and recycling within cells. Present in all 
mammalian cell types, with the exception of mature red blood cells, they were initially 
characterised as a ‘cellular stomach’, situated at the terminus of the endocytic 
system where they digest macromolecules delivered by endocytosis, phagocytosis 
and autophagy (Appleqvist et al., 2013). More recently, however, they have 
increasingly been recognised as important signalling compartments (Morgan et al., 
2011); mediators of secretion and plasma membrane repair (Andrews et al., 2014); 
key players in energy metabolism and lipid homeostasis (Settembre et al., 2014) and 
interactors with other cellular compartments (Penny et al., 2015). Accordingly 
lysosomes are now recognised as vital contributors to, and potential therapeutic 
targets for, a myriad of diseases such as cancer (White, 2015), cardiovascular 
disease (Mei et al., 2015) and neurodegenerative conditions (Nixon, 2013) in addition 
to the lysosomal storage disorders (LSDs) which are caused by a loss of function in 
lysosomal proteins (Cox and Chachon Gonzalez, 2012).   
 
Lysosomes were discovered, somewhat serendipitously, by Christian De Duve after 
a study of enzymes present in different fractions of liver homogenate, separated by 
centrifugation, revealed an interesting phenomenon. In freshly prepared fractions the 
activity assay of the liver enzyme, non-specific acid phosphatase, appeared 
abnormally low but recovered when samples stored in a refrigerator for 5 days were 
re-assayed. Further experimentation involving biochemical activation of the enzyme 
suggested that the acid phosphatase must be enclosed within membranous sacs. 
Utilising this enzyme activity assay De Duve and colleagues were able to study 
which cellular fractions the enzyme was present in; in doing so they found a 
distribution pattern spread between mitochondrial and microsomal fractions. From 
this they established that the enzyme was probably associated with a novel group of 
particles different from both mitochondria and microsomes. Accordingly, they 
developed a more selective five-fraction centrifugation procedure and discriminated 
between the organelles present in these particles by using enzyme markers. Using 
this process five additional enzymes were found to be concentrated in the same 
fraction as acid-phosphatase. Four of these were hydrolases with acidic pH optimum 
sharing the latency properties of acid-phosphatase. The fifth was non-latent and was 
later traced to another new cytoplasmic particle with similar physical properties to 
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lysosomes which De Duve and colleagues named the peroxisome. Due to the 
presence of five acid hydrolases in the same membrane limited cytoplasmic particle, 
a digestive function was proposed for these structures and the term lysosome (Greek 
for ‘digestive bodies’) was coined (Applemans et al., 1955; de Duve et al., 1955; de 
Duve, 2005).  
 
Further electron microscopy (EM) studies showed that lysosomes were electron 
dense organelles of heterogeneous shape and size which contribute about 5% to the 
overall volume of the cell (Luzio et al., 2007). The general structure of a lysosome is 
shown in figure 1.1.1.  
 
 
 
 
Figure 1.1. – Basic characteristics of the lysosome. The soluble proteins such as 
hydrolytic enzymes and adaptor proteins are detailed alongside transmembrane proteins of a 
variety of functions. The lumen is maintained at low pH by active translocation of proteins 
facilitated by the vATPase protein complex. X is a generalised representation of a specific 
transport substrate.  
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1.1.1. – The lysosomal membrane and lysosomal transmembrane proteins 
 
The lysosomal membrane has a heavily glycosylated inner lumen referred to as the 
glycocalyx which is mainly composed of lysosomal membrane associated proteins 1 
and 2 (LAMP1 and 2). These transmembrane glycoproteins help to prevent the 
lysosome from self-digestion thus maintaining lysosomal integrity (Schwake et al., 
2013). This role is illustrated by a study which showed increased lysosome mediated 
cell death in response to chemotherapeutic agents in tumour cells which had 
decreased levels of LAMP1 and LAMP2 (Fehrenbacher et al., 2008).  
 
In addition to the LAMP proteins there are at least 50 other lysosomal 
transmembrane proteins which are targeted to this compartment by dileucine or 
tyrosine motifs (Schwake et al., 2013). A number of these transmembrane proteins 
are known to be vital to the correct function of lysosomes as inherited mutations in 
the genes which code these proteins cause LSDs (eg. The Niemann-Pick type C1 
disease protein or NPC1) (Carstea et al., 1997). Although a vast array of research 
has been conducted into these proteins many of their functions still remain elusive. In 
fact a prominent reason for the identification of many of these proteins is that the 
genes coding for them were identified as mutated in patients with LSDs.  
 
A subset of lysosomal transmembrane proteins, such as the lysosomal cobalamin 
transporter ATP-binding cassette, subfamily D, member 4 (ABCD4), function as 
efflux permeases to allow the recycling of substrates produced by degredative 
processes in the synthesis of new macromolecules (Coelho et al., 2012). The 
coupling of hydrolytic enzymes and efflux permeases form a salvage pathway, which 
leads into the synthesis of macromolecules in an energetically favourable fashion 
when compared to de novo synthesis (Kitatani et al., 2008). 
 
Ion transport into and out of lysosomes is facilitated by an array of specific 
transporters and channels. Concerted action of these proteins maintain metal ion 
homeostasis vital for proper lysosomal function. Transition metal ions arrive in the 
lysosomal lumen after endocytic degradation of macromolecules such as the plasma 
protein ceruloplasmin which carries divalent copper ions (Cu2+). Chemically active 
ions such as Cu2+ combined with the acidic environment of the lysosome promotes 
Fenton-like chemical reactions which generate free radicals and lead to lysosomal 
membrane damage (Kurz et al., 2010). Extrusion of Cu2+ from the lysosomal lumen is 
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facilitated by copper-transporting ATPase 2 in order to prevent such processes 
(Guggilla et al., 2015). Other chemically active ions such as Fe2+, Fe3+, Mn2+, Zn2+ 
and Co2+ can also cause damage to lysosomal membranes so must be removed 
from the lumen. Various proteins facilitate this although, not all the pathways have 
been delineated and a number of these proteins appear to be selective for more than 
one ion (Kiselyov et al., 2011). As such, these pathways and the diseases which 
arise or are compounded by their deregulation remain a major area of research. 
 
In addition to ion export, lysosomes require appropriate concentrations of ions that 
are important in cellular signalling, such as Ca2+, for normal function. This is 
particularly important in relation to fusion with other endocytic vesicles (Luzio et al., 
2007). Accordingly, some ion transporters in the lysosomal membrane are 
responsible for the import of these ions. These will be discussed in section 1.3. 
  
1.1.2. – Proteins of the lysosomal lumen 
 
Hydrolytic enzymes are situated in the lysosomal lumen and drive catabolism. These 
enzymes, which have acidic pH optima, degrade a wide variety of macromolecules 
such as proteins, carbohydrates, lipids, RNA and DNA often in a sequential and 
stepwise manner into their constituent parts (Schroder et al., 2010). As these 
enzymes are synthesised in the endoplasmic reticulum (ER), transport pathways are 
required for the enzymes to be delivered to the lysosome where proteolytic removal 
of propeptides from the proenzyme is the final step in the production of active 
enzyme (Braulke and Bonifacino, 2009).  
 
1.1.3 – Transport of functional proteins to the lysosome 
 
The majority of lysosomal proenzymes are delivered by the mannose-6-phosphate 
(M6P) receptor pathway. This begins with addition of a mannose containing 
oligosaccharide to proteins in the ER before the translocation to the cis-Golgi 
alongside other proteins of the secretory pathway. Here a specific 
phosphotransferase facilitates the specific addition of GlcNac-1-phosphate to  
specific mannose residues on the protein. The resultant phosphodiester-tagged 
protein is translocated to the trans Golgi and the M6P tag is exposed by 
phosphodiesterase mediated removal of GlcNac residues (Braulke and Bonifacino, 
2009).  
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Lysosomal proenzymes can now bind to the M6P receptor (M6PR) and the complex 
translocates to the endolysosomal system due to presence of dileucine motifs, a 
process which utilises adaptor proteins such as adaptor protein 2 (AP2), on the 
cytoplasmic tails of M6PRs (Mattera et al., 2011). M6PRs have the greatest affinity 
for the bound proenzymes at pH 6-7, accordingly, as the complex progresses 
through the endolysosomal system to more acidic compartments dissociation of the 
proenzyme occurs. The M6PR is recycled to the Golgi from the late-endosome, 
whilst the proenzyme progresses to the lysosome where it is cleaved and activated 
by enzymes such as cathepsin D (Braulke and Bonifacino, 2009). 
 
Some lysosomal proenzymes utilise M6P independent pathways to reach the 
lysosome. A particular example of this is lysosomal membrane protein 2 (LIMP2) 
which transports β-glucosidase proenzyme from the Golgi to the lysosome (Zachos 
et al., 2012). β-glucosidase, like many lysosomal enzymes, is ‘tethered’ to 
membranes by specific post-translational glycosylation. This brings β-glucosidase to 
an area where it can associate with LIMP2 in a pH-dependant manner similar to 
M6PR-proenzyme binding. LIMP2 has transmembrane domains, one of which has a 
short cytoplasmic tail containing a dileucine motif, which allows the complex to 
translocate to the endosome and the proenzyme can dissociate in the more acidic 
compartments (Blanz et al., 2015). Cathepsin-mediated cleavage then mediates 
conversion from proenzyme to enzyme.  
 
A final characterised pathway for transport of proteins to the lysosome utilises 
Vacuolar sorting protein 10 (VSP10) family members including sortilin and SorlA 
(sortilin-related receptor). These are suggested to be multifunctional receptors 
capable of transporting numerous proteins such as the adaptor protein prosaposin 
(Canuel et al., 2009) and lysosomal enzymes such as cathepsin D in a manner that 
does not require glycosylation (Canuel et al., 2008).  
 
1.1.4. – Lysosomal activator proteins 
 
In order for proper function of hydrolytic enzymes, particularly those which degrade 
complex lipids, a class of soluble proteins called activator proteins are required. 
These proteins solubilise and present specific substrates to their companion 
enzymes for example Saposin C presents glucosylceramide to β-glucosidase in an 
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energetically favourable orientation to allow efficient catabolism (figure 1.1.). Saposin 
C is one of four homologous proteins produced by sequential proteolytic cleavage of 
prosaposin (Vaccaro et al., 1997). An illustration of the importance of these proteins 
comes from the observation that loss of function can lead to lysosomal storage 
phenotypes virtually indistinguishable from loss of function in the specific acid 
hydrolase they interact with (Grabowski and Horowitz 1997).  
 
1.1.5. – Lysosomal pH maintenance 
 
The entire array of lysosomal proteins are reliant on the correct pH in the lysosome 
which is typically between 4.5 – 5.0 dependant upon cell type (Wolfe et al., 2013). As 
such, the vacuolar-type H+ ATPase (vATPase) enzyme complex responsible for 
transporting H+ ions into the lysosome is a ‘master regulator’ of lysosomal function. 
The mammalian vATPase enzyme complex consists of 13 subunits which can be 
sub-divided into 8 peripheral proteins (V1 proteins) and 5 membrane intrinsic 
proteins (V0) many of which have various isoforms that exhibit cell-specific 
expression profiles (Toei et al., 2010). Functionally the vATPase can be divided into 
subdomains (Muench et al., 2011). The ATP catalytic subdomain is a 
heterohexameric structure which utilises ATP hydrolysis to power the central rotor. 
This motion is then transferred to the ion pump subunit which takes the form of a 
rotating ring constructed from multiple subunits and can transfer protons into the 
lysosomal lumen against the concentration gradient (Saroussi and Nelson, 2009). 
Whilst the vATPase is the best understood regulator of lysosomal acidification the 
less well characterised Cl-/H+ antiporter CLC-7 also provides key contributions to 
lysosomal pH homeostasis (Graves et al., 2009) and further study of the interplay 
between both of these remains an important field of research. 
 
From discussion of the major protein classes responsible for lysosomal function we 
can see that the lysosome is an intricately regulated organelle which is not only 
optimised as the degredative centre of the cell but can interact with various other 
cellular organelles and metabolic pathways. The intricate regulation of lysosomal 
activity also illustrates how dysfunction in a single protein in the lysosome can lead to 
a myriad of complex pathologies within the lysosome and as a result within cells and 
organisms.  
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1.2. – The greater lysosomal system 
 
Although lysosomes are commonly presented as a defined organelles they are 
dynamic compartments constantly fusing with other compartments and remodelling 
as they separate again. Accordingly, viewing lysosomes as just a store of acid 
hydrolases, without appreciation of the cycles of fusion and fission with late 
endosomes and autophagosomes, prevents the full appreciation of its role as an 
important hub in cellular homeostasis. It also prevents a thorough understanding of 
how dysfunction within this hub can impact the entire cell. As such we must view 
lysosomes within the greater lysosomal system (figure 1.2.) and take into account the 
interactions that occur between it and the major cellular pathways such as 
endocytosis (Pryor et al., 2009), autophagy (Nixon, 2013), proteasomal degradation 
(Ryhanen et al., 2009), signalling and Ca2+ homeostasis (Morgan et al., 2011). This 
interdependence between lysosomes and the pathways which contribute to the 
greater lysosomal system is exemplified by the discovery of a gene regulatory 
network linking the greater lysosomal system at the transcriptional level. This 471 
gene CLEAR (Co-ordinated Lysosomal Expression and Regulation) network is 
governed by the master gene transcription factor EB (TFEB) (Settembre et al., 2015).  
 
1.2.1 - Endocytosis 
 
Endocytosis is an important cellular pathway responsible for the internalisation of cell 
surface and extracellular material which is a vital process linking a cell to its external 
environment. An example of this is neurons of the central nervous system (CNS) 
utilising endocytosis in order to recycle neurotransmitters, a process which 
contributes to both signalling and neuroplasticity (Melikian 2004).  
 
The canonical representation of the endocytic pathway progresses from the plasma 
membrane proceeding through increasingly acidic endosomal compartments, the 
early then late endosomes, to the lysosome. The initial stages of this pathway are 
characterised by the molecular components of the initial membrane invaginations 
resulting in two major pathways: clathrin-dependent endocytosis and clathrin-
independent endocytosis (Mayor and Pagano, 2007). Clathrin-dependent 
endocytosis utilises clathrin coated pits on the plasma membrane to internalise 
receptor/cargo complexes. The resultant small (~100 nm) vesicles are sorted at the 
early endosome where a proportion are recruited back to the plasma membrane as 
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recycling endosomes or progress to the lysosome for degradation and subsequent 
recycling of products (Mousavi et al., 2004). Clathrin-independent endocytosis often 
occurs at small (50nm) flask-like invaginations in the plasma membrane named 
caveolae which in concert with the endosomal system organise membrane 
microdomains which are vital to cell signalling (Mayor and Pagano 2007). Other 
forms of clathrin-independent endocytosis are macropinocytosis, which forms large 
vesicles up to 5µm consisting of extracellular debris suspended in fluid, and 
phagocytosis in specialised cells (Lim and Gleeson 2007). 
 
 
Figure 1.2. – The greater endolysosomal system. Endocytic pathways are detailed by 
black arrows, autophagic processes by orange arrows and interactions with the Golgi by blue 
arrows. pH is shown by the key on the left hand side of the image.   
 
Beyond the initial invagination of defined regions of plasma membrane and 
subsequent scission to generate the early endocytic vesicles which fuse to form early 
endosomes (Huotari and Helenius, 2011) there are common steps in the onward 
transport of cargo. These are membrane budding to form nascent vesicles and 
transport to a defined destination followed by docking and fusion with the target 
membrane (Scott et al., 2014). These processes are facilitated by various protein 
families which interact with the endocytic vesicles manipulating them accordingly 
(Cullen 2008).  
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The Annexin proteins, such as Annexin A2, are one of these families. Annexin A2 is 
a Ca2+-dependent phospholipid binding protein which interacts with actin in order to 
regulate the location of endocytic vesicles (Babiychuk et al., 2006). Rab proteins are 
a family of 40 or so small GTPases which play a vital role in endocytic processes; 
particularly vesicle tethering (Zerial and McBride 2001). For example Rab5A helps 
facilitate tethering of early and late endosomes (Porteryaev et al., 2010) and Rab7 is 
a key mediator of tethering between late-endosomes and lysosomes 
(Vanlandingham and Ceresa 2009). Tethering allows SNARE complex formation, the 
constituents of which are dependant upon the types of tethered vesicles. Once the 
SNARE complex forms, fusion can be initiated by release of Ca2+ from the vesicle 
lumen and a hybrid organelle is formed from the late-endosome and lysosome (Luzio 
et al., 2007).  
 
As the hybrid organelle contains the full complement of lysosomal enzymes, and 
appropriate pH, it is proposed to be the site of macromolecule degradation. In this 
situation the lysosome itself is fundamentally an enzyme storage granule which 
periodically undergoes fusion with the late-endosome to form the hybrid organelle 
which is the degradative compartment. The lysosomes must then reform in a 
complex process that appears to require the retromer complex, lumenal Ca2+ 
sequestration (Pryor et al., 2000) and the endolysosomal cation channel TRPML1.  
 
In addition to the hybrid organelles, multi-vesicular bodies are present as a subset of 
the compartments constituting the endolysosomal system. These contain membrane 
bound intraluminal vesicles which result from membrane invagination. These can 
also fuse with lysosomes and are extremely important in lipid catabolism (Wang et 
al., 2011).  
 
However, as the processes governing fusion and fission of these compartments and 
their constant state of flux, the majority of the literature (particularly that describing 
disease processes), still employs the classical description of the late endosome and 
lysosome as separate compartments with the major degradative processes occurring 
in the lysosome. For clarity this model, shown in figure 1.2., will be used in this 
thesis.  
 
With these different methods of internalisation and scope for deviation from the 
degredative pathway the endocytic system can co-ordinate recycling of cell surface 
receptors, deliver signalling ligands to the correct locations within the cell and 
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internalise and reorganise membrane components (Scott et al., 2014). As these 
activities are tightly regulated within the endocytic system it can easily be understood 
that correct lysosomal function is necessary to maintain the availability of the many 
constituents required for the cell to orchestrate these pathways.  
 
1.2.2. – Autophagy  
 
As shown in figure 1.2.1. the lysosome is also the endpoint for the various 
autophagic pathways within cells. There are three of these ‘self-eating’ pathways 
currently characterised and in concert they are vital for the maintenance of cellular 
energy and metabolic homeostasis (Nixon 2013).  
 
The simplest of these pathways in microautophagy during which the lysosome 
remodels its membrane in order to directly engulf cytosolic material by pinocytosis. 
This is generally a non-specific process although micropexophagy, piecemeal 
microautophagy of the nucleus, and micromitophagy can be activated in response to 
specific cellular stresses (Li et al., 2012).  
 
Chaperone mediated autophagy (CMA) is a selective form of proteolysis which 
degrades specific cytoplasmic proteins after direct translocation across the lysosomal 
membrane. Proteins targeted for CMA contain a pentapeptide KFERQ motif which is 
recognised by the cytosolic chaperone heat shock cognate protein of 70kD (HSC70). 
Substrate bound HSC70 interacts with lysosomal-associated membrane protein 2A 
(LAMP-2A) and the substrate unfolds before active translocation across the 
lysosomal membrane and subsequent proteolytic degradation (Cuervo and Wong., 
2014).   
 
Macroautophagy involves the formation of double-membrane vesicles which 
sequester regions of the cytosol into structures known as autophagosomes, which 
are mildly acidic and can be characterised by the presence of the 
phosphatidylethanolamine lipidated protein, LC3-II (Kabeya et al., 2000). This 
process is most often associated with clearance of dysfunctional organelles such as 
aged mitochondria but it may also be used for the degradation of lipids, 
carbohydrates, polyubiquinated proteins and RNA (Eskelinen and Saftig, 2009). The 
majority of these are subject to non-selective microautophagy however a number of 
selective pathways are present such as mitophagy (for the degradation of 
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mitochondria) and pexophagy (for the degradation of superfluous peroxisomes) 
(Farre et al., 2013). Regardless of the method of induction the end-point is fusion 
with the endolysosomal system before degradation of the autophagosomal cargo. 
Accordingly, optimal lysosomal function is essential for the efficient clearance of 
autophagosomes and a reduction of autophagosomal flux is observed in most LSDs 
(Ballabio and Gieselmann 2009; Raben et al., 2009). It is interesting to note that a 
reduction in autophagosomal flux is also associated with ageing and 
neurodegenerative disease (Nixon, 2013). 
 
1.2.3 - The ubiquitin proteasomal system 
 
Although the ubiqutin proteasomal system (UPS) does not directly involve transit of 
substrates through the lysosome it is the major degredative pathway for short-lived 
cytosolic proteins and, as such, co-ordinates some of its proteolytic activities with 
autophagic pathways which are directly lysosomal dependant. Autophagic induction 
has been observed in response to proteasome inhibition (Ryhanen et al., 2009) 
suggesting a compensatory role. This is further evidenced by an increase in 
polyubiquinated proteins, the primary substrate for proteasome degradation, in 
response to inhibition of autophagy (Lilienbaum, 2013). It has been suggested that 
the UPS may compensate for the reduced autophagic flux observed in 
neurodegenerative disease states (Nedelsky et al., 2008). This remains a potentially 
interesting area for further research.  
 
1.2.4 - Interaction with other cellular compartments 
 
In addition to the other constituents of the lysosomal system the lysosome also must 
interact with other cellular organelles beyond their degradation (mitophagy, 
pexophagy) and trafficking of enzymes to the lysosome from the ER via the Golgi 
(discussed in 1.1.3). An area of particular interest is lysosome and ER membrane 
contact sites which may play roles in lipid trafficking and Ca2+ homeostasis. These 
membrane contact sites are regions of close apposition (<20nm) between organelles 
and it has been predicted that around 82% of lysosomes are in contact with the ER in 
human fibroblasts (Penny et al., 2015). With such a high proportion of lysosomes in 
contact with the ER these microdomains have emerged as an interesting new area of 
research which also extend to other compartments in the endocytic system. 
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Lysosomes also play a key role as mediators of plasma membrane repair. In 
response to ‘cell wounding’ (survivable disruption to the plasma membrane) Ca2+ 
influx induces lysosomal exocytosis and lysosomes from a specific pool fuse with the 
breach. This results in the luminal epitopes of lysosomal proteins such as LAMP-1 
being exposed to antibodies applied to non-permeabilised cells (Andrews et 
al.,2014).  
 
Considering lysosomes as part of the greater endolysosomal system and their 
interaction with other cellular compartments and organelles, the necessity for 
intricate regulation becomes obvious. Correct homeostasis of the important signalling 
ion, Ca2+, is vital for this.  
 
1.3 – Ca2+ regulation in the endolysosomal system 
With the appreciation of the lysosome as a dynamic compartment situated at the hub 
of a pathway which is vital to cellular homeostasis has come an understanding that 
strict molecular regulatory systems must govern the interaction of all components of 
the endocytic system. After it was recognised that the endolysosomal system 
represented a significant reservoir of intracellular Ca2+ (Morgan et al., 2011), and 
given the role of Ca2+ in regulating vesicular fusion and trafficking, lysosomes 
emerged as a key regulator of endolysosomal function (Luzio et al., 2007). Known 
Ca2+ concentrations along with key proteins involved in endolysosomal Ca2+ 
regulation are shown in figure 1.3.  
 
1.3.1. – The endolysosomal system as a Ca2+ store 
 
When endocytosis occurs at the plasma membrane, delivering material to the early 
endosome, the cell also takes in a large amount of extracellular fluid which contains 
a high concentration of Ca2+ (1mM) (Lloyd-Evans et al., 2010). A study of early-
endosomal Ca2+ levels using endocytosed Ca2+ and pH probes revealed that Ca2+ 
was lost from the endosome within a few minutes during which time endosomal 
acidification took place. Interestingly the acidification of endosomes was inhibited by 
reductions in extracellular Ca2+ and Ca2+ loss from the endosomes was blocked by 
inhibition of the vATPase suggesting an interaction between these two aspects of 
early-endosomal function (Gerasimenko et al., 1998). The protein underlying this 
reaction is transient receptor potential cation channel, mucolipin subfamily, member 
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3 (TRPML3) – a Ca2+ release channel located in the early endosomal membrane 
which allows Ca2+ to flow from the early endosomal lumen to the cytosol at a mildly 
acidic pH (Martina et al., 2009).  
 
 
Figure 1.3. – Cellular Ca2+ stores with illustrations of important channels for Ca2+ flux. 
Defined Ca2+ concentrations of various stores are shown, pH of different compartments is 
illustrated by the key on the right of the diagram. The direction of Ca2+ movement through 
channels is shown by arrows. Adapted from Lloyd- Evans et al., 2010 
 
Shortly after endocytosis, material is contained within endosomes of low Ca2+ 
concentration (4-40 µM) and a mildly acidic pH (pH~6). Subsequent studies have 
shown that lysosomal Ca2+ is approximately 500 µM (pH 4-4.5) (Lloyd-Evans et al., 
2008). This shows that past a certain point in the endolysosomal system, Ca2+ efflux 
is abolished and the store actively fills with Ca2+. Currently it remains unclear at what 
point in the endocytic system this occurs and the concentration of Ca2+ in the late 
endosome has not yet been characterised (Lloyd-Evans et al. 2010). The presence 
of putative leak channels, such as transient receptor potential cation channel, 
mucolipin subfamily, member 1 (TRPML1), which are active at around pH 5 (similar 
to late endosomal pH) (Raychowdhury et al., 2004) suggests that late-endosomal 
Ca2+ concentration is below that of the lysosome and that reduction in the levels of 
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Ca2+ in the homotypic organelle is required for the subsequent fission and return to 
discrete compartments.  
 
1.3.2 - Endolysosomal Ca2+ influx channels 
 
Another unknown in Ca2+ regulation in the endocytic system is the identity of the 
proteins which regulate Ca2+ influx. Information from Saccharomyces cerevisiae and 
Arabidopsis thaliana reveal two types of protein capable of transporting Ca2+ into the 
vacuole - the approximate equivalent of the lysosome in these organisms. Whilst the 
first type of protein (H+/Ca2+ exchangers) are not present in mammals (Lloyd-Evans 
et al., 2010) Ca2+ ATPases, the other type of protein, have been observed in 
mammals. In addition to this, Ca2+ ATPase activity has been reported in lysosomal 
preparations and a specific isoform of the sarcoplasmic/endoplasmic reticulum Ca2+ 
ATPase (SERCA) SERCA3a has been identified as the protein responsible for Ca2+ 
entry into platelet dense-core granules (a lysosome related organelle) (Lopez et al., 
2005). Further information comes from the reserve granule of sea urchin egg 
homogenate – another approximate equivalent to the lysosome.  In this system Ca2+ 
entry required a proton gradient and ATP but was only slightly sensitive to vanadate 
– suggestive of ATPase function but not that of a P-type ATPase as these proteins 
are inhibited by Vanadate (Churchill et al., 2002). It still remains to be seen if either 
or indeed both of these classes of channel are present within lysosomal membranes.  
 
Although much work is still required to investigate endolysosomal Ca2+ influx 
channels, a number of endolysosomal Ca2+ efflux channels have been identified, 
although the precise function and ion selectivity of many of these channels remain a 
subject of spirited debate. Two channels important to the work contained in this 
thesis are discussed below. 
 
1.3.2.1 – TRPML1 
 
TRPML1 (also known as mucolipin 1, MCOLN1) is a selective cation channel found 
in the late endosomes and lysosomes. It is required for correct functioning of these 
compartments as evidenced by the studies of cells from patients with Mucolipidosis 
type IV (section 1.5.3.) who have mutations in the gene MCOLN1 which codes for 
TRPML1 (Sun et al., 2000).  
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It has long been established that TRPML1 is permeable to Ca2+ however various 
studies have also reported outward permeability (from the lumen to the cytoplasm) to 
K+, Na+, Fe2+ and Zn2+ (Kiselyov et al., 2009; Dong et al., 2009). A potential 
confounding factor in these studies is that they are often made under non-
physiological conditions either adding high concentrations of the ions in question or 
utilising lysosomes which are expanded by treatment with vacuolin-1 a cell-
permeable triazine. Vacuolin-1 recruits various compartments of the endolysosomal 
system to create a fused compartment the majority of which is composed of early 
endosomes, which have low levels of lumenal Ca2+ (Gerasimenko et al., 1998; Cerny 
et al., 2004). Importantly, only the permeability to Ca2+ has been replicated by 
various groups under different experimental conditions (Raychowdhury et al., 2004) 
suggesting that TRPML1 is indeed permeable to Ca2+ in an outward direction.  
 
TRPML1 open probability and, therefore, Ca2+ release is modulated in two ways. The 
first of these is due to a change in pH. Raychowdhury et al. demonstrated that 
reductions in pH reduced the open probability of TRPML1 but this did not occur in 
TRPML1 channels with mild disease causing mutations (Raychowdhury et al., 2004). 
This data is suggestive of a role for TRPML1 in Ca2+ release from late endosomes. 
Secondly, agonists for TRPML1 have been characterised. The first is 
Phosphoinositol (3,5)-bisphosphate (PI(3,5)P2) a lipid present in low concentrations 
within cells mainly localised in the endolysosomal system. The enzyme Fab1/PIKfyve 
is responsible for the synthesis of PI(3,5)P2 from PI(3)P and this lipid can then act as 
an endogenous ligand of TRPML1 by increasing the open probability of the channel 
(Dong et al., 2010). This process is thought to be important to the fission of late-
endosomes and lysosomes vital for correct endocytic function (Luzio et al., 2007). A 
synthetic agonist of Mucolipin, Mucolipin Synthetic Agonist 1 (ML-SA1) has also 
recently been discovered (Shen et al., 2012) and this has allowed further study of 
TRPML1. This was identified by chemical screening of a known agonist of the related 
channel TRPML3 and it has been noted that care needs to be taken when using this 
agonist as it can activate related channels (TRPML2 and TRPML3). It is also 
interesting to note that there are differences in channel activation in response to 
MLSA1 dependant upon the species of TRPML1 being investigated. For example 
ML-SA1 can activate murine TRPML1 in the absence of PI(3,5)P2  (Shen et al., 2012) 
whereas ML-SA1 increases the sensitivity to PI(3,5)P2  in D.melanogaster. (Feng et 
al., 2014). Accordingly, experiments using this agonist must be carefully controlled.  
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There is also debate as to whether or not nicotinic acid adenine dinucleotide 
phosphate (NAADP), one of the major intracellular messengers promoting Ca2+ 
release, invokes Ca2+ release from TRPML1 (Zhang et al., 2011). This finding 
remains to be confirmed by multiple research groups as NAADP stimulation of a 
different lysosomal Ca2+ efflux channel, TPC2, has been. 
 
1.3.2.2. – TPC2 
 
Two-pore segment channel 2 (TPC2) has been shown to localise to the late-
endosomes and lysosomes and contain the dileucine motifs required to target 
proteins to this locale (Brailoiu et al. 2010). A concerted period of study suggested 
TPC2 as the target for Ca2+ release from acidic stores in response to NAADP after 
overexpression and knockdown studies produced the expected changes in NAADP 
response (Ruas et al., 2015). More specific recordings of TPC2 in lipid bilayers and 
patch-clamped methods revealed Ca2+ permeability and gating by NAADP, a study 
by Pitt et al. used immunopurified TPC2 incorporated into a lipid bilayer to provide 
additional data regarding the pH range in which TPC2 is activated (Pitt et al., 2010). 
This study showed that TPC2 is a dual sensor of luminal Ca2+ and pH and that at low 
pH it binds NAADP reversibly to TPC2 allowing for sustained Ca2+ release, whereas 
at neutral pH NAADP becomes irreversibly bound preventing subsequent activation.  
 
There has been some recent controversy suggesting that TPC2 is an NAADP-
independent Na2+ channel stimulated instead by PI(3,5)P2 (Wang et al., 2012). This 
study may have been influenced by the complication that experimentally 
manipulating a single protein within the endolysosomal system tends to have 
implications for the function of other proteins. Recently it has been shown that this 
study also utilised a mouse model as a TPC2 knockout when 90% of the protein was 
still present and subsequent experiments were used to show that TPC2 is indeed a 
Ca2+ permeable channel stimulated by NAADP (Ruas et al., 2015).  
 
1.3.3. – The endolysosomal system in relation to cellular Ca2+ homeostasis 
 
As with the degredative aspects of lysosomal function, the lysosome and 
endolysosomal Ca2+ regulation cannot be correctly considered without appreciation 
of the impact of other cellular Ca2+ stores. 
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The most abundant of these Ca2+ stores is the ER which has a luminal Ca2+ 
concentration of ~1mM (Lloyd-Evans et al., 2012). This store has been extensively 
characterised as the location of Ca2+ release in response to the two other major 
intracellular Ca2+ release messengers; inositol triphosphate (IP3) and cyclic 
adenosine triphosphate ribose (cADPR) (Verkhratsky, 2002). The study of ER Ca2+ 
has also benefitted from extensive pharmacological manipulation of the store by 
inhibition and stimulation of key Ca2+ uptake and release proteins. One example of 
this is thapsigargin mediated inhibition of SERCA2, leading to an increase in 
cytosolic Ca2+, as the inward pumping of Ca2+ ions by this Ca2+ ATPase prevents 
filling of the ER Ca2+ store, leading to the unmasking of Ca2+ leak channels such as 
Presenilin 1 (Bezprozvanny, 2009). This causes subsequent Ca2+ induced Ca2+ 
release (CICR) from ryanodine receptors and IP3 receptors (Shoback et al., 1995). 
Another mechanism is specific stimulation of the ryanodine receptor family of Ca2+ 
release channels by ryanodine, crucial in processes such as neurotransmission, 
which is also inhibitory at higher concentrations (Lloyd-Evans et al., 2003).  
 
As previously mentioned, lysosome-ER membrane contact sites have been 
suggested to play important roles in Ca2+ homeostasis (Penny et al., 2015). 
Interestingly, release of Ca2+ from lysosomes by osmotic swelling in response to the 
glycyl-L-phenylalanine 2-napthylamide (GPN), an agent commonly used to induce 
lysosomal Ca2+ release, generates subsequent Ca2+ release from the ER by CICR 
(Kilpatrick et al., 2013). CICR has been recapitulated after stimulation of TPC2 by 
NAADP and both pheneomena may centre around lysosome-ER membrane contact 
sites. Due to this, CICR must always be considered when measuring lysosomal Ca2+ 
release as the ER Ca2+ store is more concentrated and of a larger volume than the 
lysosome. Accordingly, this secondary release, which is difficult to resolve 
temporally, may overwhelm lysosomal Ca2+ release and prevent correct analysis of 
the lysosomal Ca2+ store. 
 
1.4. – Lipids and the endolysosomal system 
 
Another key regulator of endolysosomal function is correct lipid composition 
throughout the different compartment membranes. This is not only important as lipids 
are highly bioactive molecules which can mediate and/or modulate a great deal of 
protein function but also because lysosomes are the centres for lipid catabolism and 
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as such must be able to efficiently process large amounts of lipid (Kolter and 
Sandhoff, 2005). Due to this, an understanding of lipid biochemistry, including 
biosynthesis and breakdown, is required to properly understand lysosomal function 
and to investigate the causes and consequences of lysosomal dysfunction. The most 
well studied class of lipids associated with the endolysosomal system are the 
sphingolipids, although given the fact the ‘sphingo’ moniker was given to this class of 
lipids to reflect their enigmatic nature it is unsurprising that, there still remains a great 
deal to learn about these lipids (Hannun, 2008).  
 
1.4.1. – Sphingolipid Biosynthesis 
 
The de novo biosynthesis of sphingolipids begins on the cytosolic face of the ER with 
serine palmitoyl transferase facilitating the condensation of L-serine and palmitoyl 
CoA to generate 3-ketosphinganine. This is reduced to sphinganine by 3-
ketosphinganine reductase followed by sphinganine N-acyl transferase mediated 
acylation to form dihydroceramide. In mammals, this step is carried out by 1 of 6 
ceramide synthases which are expressed in a tissue specific manner to provide 
sphingolipids with appropriate chain lengths for that tissue. Dihydroceramide is 
subsequently reduced by dihydroceramide desaturase to form ceramide, the 
hydrophobic membrane anchor of sphingolipids which now contains a sphingosine 
backbone (Gault, et al., 2010).  
 
Further metabolism, to either sphingomyelin (SphM) or glycosphingolipid (GSL), 
ceramide must be transported by either the ceramide ER transfer protein (CERT) or 
secretory vesicle flow to the cytosolic leaflet of the Golgi Apparatus. Here a glucose 
moiety may be added to ceramide to form the simplest of the glycosphingolipids 
glucosylceramide (GlcCer) by glucosylceramide synthase. The subsequent addition 
of a galactose moiety to form lactosylceramide (LacCer) is performed by 
lactosylceramide synthase which is situated within the Golgi lumen where GlcCer 
must be transported by either multidrug transporters or the GlcCer transporter protein 
four-phosphate adaptor protein 2 (FAPP2) (Gault et al., 2010). The sialylation 
(addition of a sialic acid group) of LacCer by GM3 synthase on the cis-Golgi 
produces the simple ganglioside, GM3, from which concurrent sialylation reactions 
produce firstly GD3 and the subsequently GT3. In turn GM3, GD3 and GT3 are the 
Ganglioside precursors of the o, a and b series of gangliosides. Using the a series as 
an example GM3 has a GalNac group added by a glycosyltransferase to form GM2 
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which undergoes a subsequent glycosylation to add a further galactose moiety 
forming GM1a before sialylation of the terminal galactose forms GD1a. These 
terminal steps of Ganglioside biosynthesis occur at the trans Golgi where cell type 
specific differential expression of multiple sialylases and glycosylases form the 
myriad of glycosphingolipids (GSLs) produced (Simpson et al., 2004). After 
biosynthesis these complex GSLs reach the outer leaflet of the plasma membrane, 
where they generate membrane heterogeneity and facilitate transmembrane 
signalling events via the secretory system (Gault et al., 2010). 
 
 
Figure 1.4. – The ganglioside biosynthetic pathway. Sugar constituents are described in 
the key below the figure. Ganglioside biosynthetic enzymes linked to disease are also shown. 
Image taken from Simpson et al., 2004. 
 
The important membrane lipid sphingomyelin is formed on either the cytoplasmic 
side of the trans-Golgi or at the plasma membrane where the transferase 
sphingomyelin synthase joins ceramide with phosphatidylcholine (Gault et al., 2010. 
De novo production of sphingolipids from first principles is often not the major 
production route as in some cell types salvage pathways, predominantly lysosomal 
salvage of sphingosine, contribute up to 90% of GSL generation (Schulze and 
Sandhoff, 2011). Accordingly, correct sphingolipid catabolism is vitally important to 
cells.  
 
1.4.2. – Sphingolipid Catabolism 
 
Sphingolipids, primarily located in the outer leaflet of the plasma membrane, are 
degraded in lysosomes after internalisation by the endolysosomal system although 
some sphingolipids present in other membranes may reach the lysosomes as a 
result of autophagy. Within the endolysosomal system lipids are internalised to 
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luminal intraendosomal vesicles (LIEVs) generated by budding and fission events 
under the control of the endosomal sorting complex required for transport (ESCRT). 
It is thought that LIEVs are targeted for degradation in the lysosome by a lipid sorting 
process beginning early on in the endolysosomal system (Schulze and Sandhoff, 
2011).  
 
LIEVs are platforms for sphingolipid catabolism as they separate lipids from the 
glycocalyx and expose them to the aqueous interface required for the function of 
adaptor proteins and hydrolytic enzymes both of which are water soluble. As 
previously mentioned, the enzymes and adaptor proteins work in concert to degrade 
GSLs in a stepwise manner by removal of terminal sugar residues (Schulze and 
Sandhoff, 2011). As illustrated in figure 1.5., the loss of activity in either the enzyme 
or adaptor protein required for each step results in a lysosomal storage disorder in 
which the sphingolipid preceding this step is the primary storage substrate.  
 
Figure 1.5. – Lysosomal sphingolipid 
catabolism. Selected lysosomal catabolic 
pathways which lead into the production of 
ceramide and subsequently the sphingoid 
base sphingosine. Lysosomal catabolism is 
indicated by black arrows, grey arrow 
indicates the efflux of lipids from the 
lysosome. Degredative enzymes are as 
follows: ACerase (acid ceramidase), ASM 
(acid sphingomyelinase), GCase 
(glucocerebrosidase). The NPC1 protein is 
also indicated as it is required for lysosomal 
sphingosine efflux. 
 
 
 
 
 
 
 
 
 
 
In addition to the presence of the activated proteins in an acidic environment, anionic 
lipids are required for sphingolipid degradation. This was demonstrated by the in vitro 
observation that GM2 was not degraded by the enzyme, hexosaminidase, in 
liposomal membranes which did not contain anionic lipids – subsequent addition of 
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the anionic phospholipid, lysobisphosphatidic acid (LBPA), was required to stimulate 
the reaction. It is interesting to note that in liposomes with greater than 10 mol% 
anionic phospholipids, GlcCer can be degraded by its specific catabolic enzyme 
glucocerebrosidase in the absence of saposin C. When the concentrations of luminal 
cholesterol and LBPA in the endolysosomal system are compared, cholesterol 
concentrations decrease with pH while the LBPA concentrations increase. The result 
of this is that LIEVs in the lysosome are cholesterol-depleted and LBPA-rich resulting 
in a structure of high membrane fluidity and curvature optimised for sphingolipid 
degradation by hydrolytic enzymes. This process of LIEV formation predominantly 
takes place in the multivesicular bodies where the highly unsaturated phospholipid 
LBPA is required to generate curvature of membranes (Schulze and Sandhoff, 
2011).   
 
As previously mentioned, salvage pathways are able to remove certain degradation 
products from the catabolic pathway to feed back into biosynthesis of new GSLs. 
Complete GSL degradation results in the simplest of these, ceramide. Ultimately by 
the action of acid ceramidase this is degraded to the sphingoid base sphingosine 
(Park and Schuchman, 2006). This can leave the lysosome by an undefined 
mechanism where it can be utilised by ceramide synthases to produce ceramide and 
is the classical example of sphingolipid recycling (Gault et al., 2010). Sphingosine, 
however, may also be converted to sphingosine-1-phosphate by specific 
phosphatases; which is a critical signalling molecule, and this process illustrates how 
lysosomal catabolism and efflux of substrates can impact upon multiple other cellular 
pathways (Kunkel et al., 2013). Turnover of this molecule and the sugar constituents 
of GSLs is a vital energy saving measure for the cell as it is estimated by in vitro 
experiments that half the plasma membrane is endocytosed per hour, although not 
all this material is degraded but a significant amount is recycled to the membrane by 
lipid transport pathways (Schulze and Sandhoff, 2011)  
 
1.4.3. – Endolysosomal Sphingolipid Transport Pathways 
 
From discussion of lipid catabolic pathways we can see that lysosomal lipid transport 
is vital for cell membrane homeostasis. For sphingolipids, the transport of ganglioside 
GM1 is well studied using fluorescent or radiolabelled analogues. These lipids are 
internalised by endocytosis of the plasma membrane although it does not appear to 
be reliant on a specific endocytic pathway. The majority of GM1 is sorted in the early 
	   39	  
endosome and recycled back to the plasma membrane without metabolic processing 
by vesicles budding from late endosomal compartments. Those gangliosides not 
immediately recycled are transported to the Golgi apparatus in healthy cells, where 
they can be trafficked to the plasma membrane by secretory vesicle flow with or 
without further modification (Pagano et al., 2000). It is unclear which endolysosomal 
vesicles these lipids pass through and at what point they leave the endocytic system. 
Evidently some of these gangliosides traverse the entire endocytic system and are 
targeted to lysosomes for degradation (Pagano et al., 2003). What is clear about this 
pathway, however, is that it is dysregulated in LSDs as discussed in section 1.5. 
When deregulated, it is hypothesised that sphingolipids can ‘escape’ the 
endolysosomal system and be transferred to the ER. Although this pathway remains 
hypothetical, the results of sphingolipid interference with ER processes such as Ca2+ 
homeostasis has been widely reported (Vitner et al., 2010; Lloyd-Evans et al., 2003).  
 
From the above discussion it is clear that sphingolipid processing in the 
endolysosomal system is intrinsically linked to correct cell function and, when 
defective, is a cause of disease. While the array of proteins illustrate the complex 
protein network required for sphingolipid processing, biophysical interactions with 
other lipids are also key. The importance of the anionic phospholipid LBPA has been 
described, however, the biosynthetic and degredative pathways controlling levels of 
this lipid remain elusive (Chevallier et al., 2008). The delivery of another lipid, 
cholesterol, which interacts biophysically with sphingolipids in the endolysosomal 
system is better understood but questions still remain as to how it is distributed from 
this system.  
 
1.4.4. – Cholesterol and the Endolysosomal System  
 
Cholesterol is internalised in cells by clathrin-dependant endocytosis of low density 
lipoprotein (LDL) complexed to the LDL receptor until acidification of the endosomal 
system promotes dissociation in late endosomes (Chang et al., 2006). While the LDL 
receptor is recycled back to the plasma membrane, free cholesterol is liberated from 
LDL by the enzyme acid lipase, inherited dysfunction in which is the basis of the LSD 
Wolman’s disease (Du et al., 2013; Hoffman et al., 1993). Free cholesterol can then 
be transported to the ER in a dynamin-dependant process where it is effluxed to the 
plasma membrane or to mitochondria for the production of steroid hormones 
(Robinet et al., 2006; Miller, 2013). Beyond disruption to LIEV membrane fluidity this 
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efflux is important as it impacts upon cholesterol intake and efflux in addition to the 
regulation of cholesterol synthesis by negative feedback (Bjorkhem et al., 2010).  
 
The redistribution of cholesterol to the plasma membrane involves vesicular transport 
under the control of Rab11 and MLN64 mediated cholesterol transport to 
mitochondria (Hollta-Vuori and Ikonen, 2006). As the biophysical properties of 
cholesterol allow ‘flip-flop’ translocation within lipid bilayers without assistance from 
proteins it is entirely possible that cholesterol efflux may occur as a result of 
membrane dynamics at ER-lysosome contact sites (Hamilton 2003). Another 
proposed mechanism suggests cholesterol is effluxed by an, as yet undefined, 
transport protein to cytosolic sterol carrier proteins. A candidate for the cholesterol 
transporter arose from study of the LSD Niemann-Pick type C after cells from 
patients with this disease were observed to have endolysosomal free cholesterol 
accumulation (Carstea et al. 1997). Two proteins are associated with this disease, 
further discussed in section 1.5.2., a late-endosomal and lysosomal transmembrane 
protein, NPC1, and a soluble lysosomal glycoprotein NPC2 (Scott and Ioannou, 
2004;Infante et al., 2003). It has been shown experimentally that NPC2 can bind 
cholesterol in the lysosomal lumen and that the N-terminus of NPC1 can also bind 
cholesterol (Infante et al., 2003, Kwon et al., 2009). This led to the proposal that 
NPC2 removes cholesterol from LIEVs before ‘handing-off’ cholesterol to NPC1 for 
efflux from the endolysosomal system. Whilst this proposal still remains an elegant 
solution it has not been proved, despite considerable effort, that NPC1 can transport 
cholesterol. Other contentions remain to be addressed, which will be discussed in 
section 1.5.2. (Lloyd-Evans and Platt, 2010). More recently, the lysosomal 
membrane protein LIMP-2 has been shown to be capable of functioning as a 
cholesterol efflux channel (Neculai et al., 2013). 
 
Discussion of the endolysosomal system has revealed the inherent complexity that is 
associated with this important cellular pathway. Accordingly it remains unsurprising 
that loss of function in proteins active within this system, leading to LSDs, result in 
severe cellular dysfunction and complex disease pathology.  
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1.5. – Lysosomal Storage Disorders 
 
Lysosomal storage disorders (LSDs) are a group of 70 or so genetically distinct 
inborn conditions with a combined frequency estimated to be between 1 in 5000 and 
1 in 7500 live births (Cox and Chacon Gonzalez, 2012) although this may be higher 
when misdiagnosed or undiagnosed cases are accounted for (Platt et al., 2012) and 
new technologies such as whole exome sequencing provide insight which may 
pertain to milder variants of disease (Wassif et al., 2015). Interestingly, LSDs are 
also prevalent in the animal kingdom with naturally occurring variants of human 
diseases identified in animals from mice (Lopez and Scott, 2008) to flamingos (Zeng, 
2008.). 
 
LSDs are predominantly caused by loss of function mutations in lysosomal enzymes 
or late-endosomal and lysosomal transmembrane proteins. As a result 
macromolecular storage occurs which can include accumulation of 
glycosaminoglycans (Coutinho et al., 2012), glycosphingolipids, cholesterol (Lloyd-
Evans et al., 2010) and lipofuscin (Seehafer and Pearce, 2006); a heterogeneous 
storage material associated with the majority of neurodegenerative diseases and 
ageing (Ottis et al., 2012). Although the primary storage material in some LSDs is 
clearly defined, controversy exists with regard to which molecule is stored first in 
others (Lloyd-Evans and Platt, 2010). Further complexity is added to this situation by 
significant overlap in secondary storage materials between LSDs. As a result it is 
also extremely difficult to determine which storage material, or materials, trigger 
different aspects of pathogenesis (Vitner et al., 2010). 
 
The further subdivision of LSDs into classes is fraught with difficulty due to 
convergent storage profiles, defects in proteins of unknown function and in some 
cases such as the ‘enigmatic lysosomal disorders’, known as lipofuscinoses, where 
genetic defects are present in apparently unrelated genes not all of which are 
present in the endolysosomal pathway although in all cases lipofuscin is stored (Platt 
et al., 2012). However, the classical subdivision of LSDs by storage substrate still 
remains useful. These major classes of LSDs are shown in the table below with 
some specific LSDs important to this thesis detailed.  
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Primary Class Sub-class Disease  Protein 
deficiency 
Primary 
storage 
material 
Secondary 
storage 
materials 
Other 
organelles 
affected 
Inheritance Gene symbol 
and 
localisation 
Lipidoses Sphingolipidoses Gaucher Disease β-Glucosidase GlcCer, 
GlcSph 
Chol (ER) ER Autosomal 
recessive 
GBA1 
1q21 
   Saposin C GlcCer, 
GlcSph 
Chol (ER) ER Autosomal 
recessive 
PSAP 
10q21-q22 
  Niemann-Pick 
type C  
NPC1 SphO Chol, GSLs, 
LBPA, SphM 
Mitochondria Autosomal 
recessive 
NPC1     
18q11-q12 
   NPC2  Chol, GSLs, 
LBPA, SphO, 
SphM 
Mitochondria Autosomal 
recessive 
NPC2   
14q24.3 
 Mucolipidoses Mucolipidosis type 
IV 
TRPML1 Unknown Lipofuscin   MCOLN1 
19p13.2 
Mucopolysaccharidoses  MPS diseases Glycoamnoglcan 
degredative 
enzymes 
GAGs GSLs  Majority 
autosomal 
recessive, one 
X-linked 
recessive 
 
Lipofuscinoses  NCL diseases Various lysosomal 
and some non-
lysosomal proteins 
Unknown Disparate group 
of diseases 
characterised by 
lipofuscin 
accumulation 
ER Autosomal 
recessive 
 
 
Table 1.1. – General classification of lysosomal storage disorders. LSDs important to this thesis are detailed. GlcCer = glucosylceramide, GlcSph  = 
glucosylsphingosine, GSLs = Glycosphingolipids, SphO = Sphingosine, SphM = Sphingomyelin, Chol = Cholesterol, GAGs = glycosaminoglycans. (Matha 
and Winchester, 2012) 
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Figure 1.5. – Generalised schematic illustrating hypothetical disease cascades present 
in lysosomal storage disorders. Adapted from Platt et al., 2012 
 
Despite relative simplicity in terms of causative gene defect, monogenic conditions 
commonly of autosomal recessive inheritance, the pathogenic cascades which lead 
to the final clinical phenotypes in LSDs remain complex (Cox and Chacon Gonzalez, 
2012). As previously mentioned macromolecular storage is not always clearly 
temporally defined and in addition to this other organelles are often affected by the, 
initially lysosomal, storage (Platt et al., 2012). Attempts to reconcile these 
observations has lead to the proposal of a hypothetical cascade of events in LSD 
pathology (figure 1.5.) which includes processes observed in a number of LSDs 
although it does not necessarily apply to all LSDs (Platt et al., 2012). This 
generalised scheme will be further illustrated by discussion of three LSDs. One of 
these has a defect in a lysosomal hydrolase - Gaucher Disease; and two have 
defects in endolysosomal transmembrane proteins - Niemann-Pick type C disease 
and Mucolipidosis type IV.   
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1.5.1. – Gaucher Disease 
 
Gaucher disease is the most common LSD with a predicted carrier frequency of 
around 1 in 100 and is most common in Ashkenazi Jewish populations (Chen and 
Wang 2008; Grabowski, 2012). It is caused by autosomal recessive inheritance of 
mutations in the GBA1 gene, which codes for the lysosomal enzyme 
glucocerebrosidase (GCase). GCase is a lysosomal hydrolase which catabolises the 
simplest glycosphingolipid glucosylceramide (GlcCer) into ceramide by removal of 
the glucose moiety after it has been presented in an energetically favourable 
confirmation by the adaptor protein, saposin C (Grabowski et al., 2012), as discussed 
in section 1.4.2. this is also influenced by lipid composition with low levels of 
cholesterol and higher levels of LBPA helping to facilitate catabolism (Shulze and 
Sandhoff, 2011). Accordingly, mutations in saposin C also lead to Gaucher disease 
although this is characterised as an atypical form (Horowitz and Zimran, 1994).  
 
This accumulation of lipid causes a broad phenotypic spectrum with wide variation in 
age of onset and neurological manifestations. Gaucher can be sub-classified into 
type 1, 2 and 3; a process largely dependant upon age of onset and neurological 
involvement (Pastores et al., 2000). Type 1 Gaucher is the mildest and most 
prevalent form accounting for around 95% of cases; it is considered ‘non-
neuropathic’ with an average age of onset in the early 20’s, although this can vary 
widely and some patients never present with symptoms (Pastores et al., 2000). This 
strongly suggests that there are a number of disease modifying genes for Gaucher 
(Grabowski, 2008). Type 2 Gaucher, also known as infantile Gaucher, is an 
extremely severe disorder with neurological manifestations in infants, which 
commonly leads to death before 2 years of age. Type 3 is known as the sub-acute 
neuropathic form, and previously as ‘juvenile Gaucher’, is symptomatic early in life 
and although some patients die in childhood others can live beyond middle age. 
Type 1 Gaucher may be extremely mild and as such remain undiagnosed, however, 
the most frequent clinical sign is an enlarged spleen due to lipid storage which may 
also extend to the liver (splenomegaly/hepatosplenomegaly) but other more specific 
symptoms may be noticed such as the characteristic Ehrlenmeyer flask deformity of 
the thigh bones (Pastores et al, 2000; Faden et al., 2009)). Although type 1 Gaucher 
is considered non-neuropathic recent evidence linking GBA1 mutations as a genetic 
risk factor for Parkinson’s disease is suggestive of milder neuronal impairment in 
these patients (Sidransky et al., 2009). For patients with type 1 Gaucher Disease it is 
well established that enzyme replacement therapy (ERT) is an effective and safe 
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treatment. This treatment was pioneered by Roscoe Brady using enzyme purified 
from human placenta and,although this has since been superseded by treatment with 
recombinant enzyme, it was very effective in terms of reducing hepatosplenomegaly 
and ameliorating skeletal pathology(Brady et al., 1974; Brady, 2006). An unfortunate 
clinical limitation of ERT is that enzymes do not cross the blood-brain barrier to any 
significant extent so it cannot treat CNS disease, this limits clinical outcomes when 
treating the neuropathic forms of Gaucher (Scarpa et al., 2015). This is particularly 
true of type 2 Gaucher where severe neurological pathogenesis is life-threatening 
early on in a patient’s life (Pastores et al., 2000). 
 
Neurological pathology in Gaucher can often begin with either hyperextension of the 
neck and dysphagia or supranuclear gaze palsy although not all patients present this 
way and a variety of other clinical features including ataxia, neuropathic pain and 
seizures may be observed (Pastores et al., 2000).  
 
In human cases and mouse models of neuropathic Gaucher there is specific 
neuronal loss in cortical layers III and V (Wong et al., 2004) and this pathology has 
been further described in mouse models to be most pronounced in motor and 
somatosensory regions (Farfel-Becker, 2011). Hippocampal neuron loss is also 
observed in both patients and mice but this was shown to manifest later than the 
cortical phenotypes in mouse models. In the inducible Karlsson mouse model of 
Gaucher astrogliosis, neuroinflammation and microglial activation have been 
observed prior to neuronal loss and markers of these processes correlate with 
neuron loss in post-mortem human brain samples (Farfel-Becker et al., 2011). The 
localisation of inflammation and progressive neuron loss is reflective of clinical 
presentation.  
 
Due to the unsuitability of ERT for treatment of the CNS, a different therapeutic 
approach has been utilised for neuropathic forms of Gaucher – substrate reduction 
therapy (SRT). Miglustat (chemical name N-butyl-deoxynorjirimycin, trade name 
Zavesca, Actelion Pharmaceuticals Ltd. Allschwill, Switzerland) is an orally available 
iminosugar which reversibly inhibits glucosylceramide synthase (Ficicioglu, 2008, 
Platt et al., 2004) preventing the synthesis of glucosylceramide and thus reducing the 
accumulation of undigested substrate. Miglustat is blood-brain barrier (BBB) 
permeable and has shown therapeutic benefit in treating neuropathic Gaucher and 
patients who are unsuitable for ERT. 
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It is interesting to consider that although the levels of the primary storage substrate 
GlcCer have been shown to be elevated in patients, and are reduced in response to 
beneficial therapy (Aerts et al., 2011), there are multiple studies which report that 
levels of the lysosomally derived de-acylated analogue of GlcCer, 
glucosylsphingosine (GlcSph), correlate more closely with disease severity. This may 
be particularly relevant for neurological phenotypes of Gaucher as it has been 
reported that GlcSph is significantly elevated in the brains of type 2 and 3 Gaucher 
patients but elevated to a much lesser extent in the brains of type 1 patients (Dekker 
et al., 2012; Mirzaian et al., 2015).  
 
When it is considered that the primary pathogenic substrate has not been confirmed 
it is unsurprising that the pathogenic cascade of events has not been clearly 
delineated. Various proposals of pathogenic mechanisms involving autophagic 
dysfunction (Liebermann et al., 2012) and mitochondrial defects (de la Mata et al., 
2015) have been made but perhaps the most well studied affect of the lysosomal 
dysfunction in Gaucher on another organelle is that which impacts the ER – 
particularly in relation to Ca2+ homeostasis. ER Ca2+ dyshomeostasis has been 
reported in a number of the sphingolipidoses although the specific mechanisms 
which lead to this differ in each LSD (Vitner et al., 2010). In Gaucher it has been 
shown that pharmacologically elevated intracellular GlcCer leads to increased Ca2+ 
store release in cultured neurons and that this was a result of stimulation of 
ryanodine receptors (RyR, one of the ER Ca2+ release channels, section 1.3.3.). It 
was further confirmed that only specific sphingolipids had this effect with only GlcCer, 
galactosylceramide (GalCer) and GlcSph causing ER Ca2+ release. This pathology 
was also confirmed in ER microsomes prepared from the brain of a type 2 Gaucher 
patient when compared to those prepared from a control brain in the same study 
(Lloyd-Evans et al., 2003) and similar results have been recapitulated in iPSC 
derived neurons containing mutations in GBA1 which are known to cause 
neuropathic Gaucher (Schondorf et al., 2014).  
 
Recently, the link between mutations in GBA1 and Parkinson’s disease have been 
the source of much interest in the field (Sidransky et al., 2009; Nalls et al., 2013). 
This will be further discussed in chapter 5.   
 
The complexity arising from loss of function mutations in a simple gene and the 
intriguing link to Parkinson’s (Sidransky et al., 2009) disease highlights the need for 
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further study into this LSD. It is also worth noting that disease complexity increases 
when dysfunction arises in transmembrane proteins.  
 
1.5.2. – Niemann-Pick type C Disease 
 
Niemann-Pick type C (NPC) is a neurovisceral lysosomal storage disorder in which 
multiple lipids are stored within the late-endosomes and lysosomes of cells (Vanier, 
2010). The disease is estimated to have an incidence of approximately 1 in 90,000 
(Wassif et al., 2015).  
 
Patients with NPC suffer from severe neurodegeneration with a pronounced ataxic 
phenotype caused by the selective loss of cerebellar Purkinje neurons. A variety of 
other phenotypes falling within a broad phenotypic spectrum may also be observed. 
In the viscera the lipid storage within the liver and spleen cause 
hepatosplenomegaly; respiratory dysfunction and dysphagia may also become 
problematic leading to aspiration pneumonia which is a prevalent cause of death 
(Vanier 2010).  
 
In the classical presentation of NPC, clumsiness and gait disturbance become 
evident in middle to late childhood and are often the first evidence of 
neurodegeneration although abnormalities in saccadic eye movements may be 
present before this (Rottach et al., 1997). As the disease progresses, cognitive 
impairment becomes increasingly evident alongside psychiatric problems, epilepsy, 
sleep disturbances and loss of speech. Death of these patients generally occurs at 
around 15 - 25 years (Vanier et al., 2010). Although this classical presentation of 
NPC accounts for around 60-70% of all cases the age of presentation varies from the 
perinatal period to over 50 years. There is also a variant form of NPC in which 
patients do not have cholesterol storage and present with the disease much later 
(Vanier, 2010).  
 
NPC is inherited in an autosomal recessive fashion and is predominantly (95% of 
cases) caused by mutations in the NPC1 gene, the protein product of which is a 
transmembrane protein, NPC1, situated in the limiting membrane of the late 
endosome. This is a large, 1278 amino acid, protein with 13 transmembrane 
domains and large hydrophilic intraluminal loops (Ioannou, 2005). The remaining 5% 
of cases are caused by mutations in the NPC2 gene which codes for the soluble 
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lysosomal 151 amino acid protein, NPC2 (Ioannou, 2005). It is known that NPC2 can 
bind and transport luminal cholesterol exchanging it with the N-terminus of NPC1 
(Infante et al., 2003,), the function of which remains enigmatic (Lloyd-Evans et al., 
2010). Recently analysis of massively parallel exome sequencing datasets has 
suggested that common variants in NPC1 may be much more prevalent than 
previously expected suggesting a previously unanticipated late-onset form of NPC 
disease (Wassif  et al., 2015). Whilst this remains to be confirmed by clinical studies 
it may be interesting to analyse other LSDs in this way in order to ascertain if late-
onset forms of this class of disease are prevalent.  
 
Due to the fact mutations in either NPC1 or NPC2 result in the same clinical features 
and cellular phenotypes, it is clear that they act within the same pathway to maintain 
lysosomal function (Sleat et al., 2004). NPC1 contains a sterol-sensing domain 
similar to proteins such as patched, which is a cholesterol regulated protein and 
accordingly this is suggestive of NPC2-transported cholesterol (Bablola et al., 2007), 
or other sterols such as the cholesterol precursor 7-DHC (Platt et al., 2014), being a 
regulator of NPC1 function (Lloyd-Evans et al., 2010). The remainder of the NPC1 
protein consists of a predicted 13 transmembrane domains with a number of large 
loops projecting into the late-endosomal lumen and the challenge remains to 
determine what the primary function of this protein is. Interestingly the yeast 
homologue of NPC1, Ncr1p, is capable of correcting lipid storage phenotypes in 
mammalian cell lines in which NPC1 has been knocked out suggesting a 
evolutionarily ancient function (Malathi et al., 2004).  
 
When either of the NPC proteins become dysfunctional a complex array of lipids 
including cholesterol, sphingomyelin, various glycosphingolipids and the primary 
constituent of sphingolipids, sphingosine, become stored within the late-endosomes 
and lysosomes of cells in which they can be observed as punctate staining by 
microscopy (Lloyd-Evans et al., 2010). In 2008, Lloyd-Evans et al. temporally 
delineated the onset of lipid storage after inactivation of NPC1 finding that the 
primary lipid to accumulate was sphingosine followed by the accumulation of 
cholesterol, sphingomyelin and glycosphingolipids. In this study they characterised 
depletion of the late-endosomal and lysosomal Ca2+ store as the subsequent event 
following sphingosine accumulation, as mentioned previously, endolysosomal Ca2+ 
homeostasis is required for correct endocytic trafficking (Luzio et al., 2007) and in the 
absence of this, transport defects occur. The authors concluded that this was 
responsible for the eventual accumulation of more complex lipid species within the 
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endolysosomal system. This accumulation of lipids was recapitulated in control cells 
in which the lysosomal Ca2+ had been specifically chelated (Lloyd-Evans et al., 
2008).  
 
The fact that sphingosine is the initial substrate stored after NPC1 interaction, may 
provide information as to the primary function of the NPC1 protein. Within the acidic 
environment of the late-endosome and lysosome sphingosine becomes protonated 
upon the amino group gaining a net-positive charge, the only lipid accumulating in 
NPC to do so. As such, a specific transporter would be required to extrude 
sphingosine from the lysosome and a transporter capable of this has not yet been 
characterised, whereas transporters for the other species of storage lipid have been 
(Lloyd-Evans et al., 2010). A class of transporter protein highly conserved in 
evolution which can transport charged amines such as sphingosine is the RND 
permease family of transporters. In 2004, Scott et al. proposed that NPC1 was the 
only known mammalian member of this family and it has been subsequently shown 
that NPC1 can transport known substrates of this family such as acriflavine, and is 
inhibited by hydrophobic amphiphilic amines such as U18666a and can be stimulated 
by amines such as imidazole (Scott et al., 2004). Accordingly, NPC1 may be a multi-
substrate efflux pump responsible for the extrusion of charged amines such as 
sphingosine from the late-endosomal and lysosomal lumen. This however does not 
exclude a cholesterol transporting function and currently there is no evidence for the 
direct transport of any molecule across the lysosomal membrane, accordingly the 
function of NPC1 remains enigmatic (Lloyd-Evans et al., 2010).  
 
In the European Union (EU), miglustat has been approved for the treatment of 
neurological manifestations of NPC disease and this has shown some improvement 
in saccadic eye movement velocity and swallowing capacity, alongside slower 
deterioration in ambulatory index (Patterson et al., 2007; Patterson et al., 2015). 
Although the exact mechanism for therapeutic benefit after miglustat treatment in 
NPC has not been confirmed the inhibition of complex glycosphingolipid (GSL) 
formation (Platt et al., 1994) and reduction in sphingosine, both of which accumulate 
in NPC disease is thought to be important (Haslett et al., Unpublished). Another 
treatment option for NPC is supplementation with the nutraceutical curcumin. As a 
weak SERCA2 antagonist, curcumin reduces Ca2+ uptake by the ER, which results in 
increased cytosolic Ca2+. In turn, this can help overcome the lysosomal Ca2+ release 
defect in NPC cells which helps rectify lipid mistrafficking phenotypes and 
subsequently reduces lysosomal storage. The effectiveness of curcumin has been 
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demonstrated in the mouse model of NPC which benefits from an increased lifespan 
and outcomes in behavioural testing (Lloyd-Evans et al., 2008) although it has been 
difficult to confirm these benefits in patients due to the variety of curcumin 
supplements which have been utilised – particularly as these supplements vary 
greatly in both curcumin concentration and additional constituents (Maguire et al. 
submitted). 
 
A further therapeutic option for NPC disease is 2-hydroxypropyl-β-cyclodextrin 
(HPβCD), which has been developed for the clinic by the NIH led Theraputics for 
Rare and Neglected Diseases (TRND) program after initial discovery by academic 
researchers (Davidson et al., 2009) and initial reports of compassionate use in 
patients (Matsuo et al., 2013). HPβCD is a cyclic oligosaccharide commonly used to 
increase solubility and dissolution rate of poorly water soluble drugs, as such it has 
been extensively tested for use as an excipient and is well tolerated by a variety of 
animals (Ottinger et al., 2014). Accordingly HPβCD has been tested in NPC mouse 
and cat models and has been shown to reduce intracellular storage, promote 
Purkinje neuron survival and extend lifespan when either injected into the spinal 
canal (intrathecal injection) or directly onto the brain (intracerbroventricularly) 
(Davidson et al., 2009; Vite et al., 2015).  
 
Despite the clinical interest, the mechanism of HPβCD action has not been well 
defined. In addition to the in vitro observation that intracellular cholesterol storage is 
reduced, a study by Chen et al. proposed that this was due to HPβCD stimulating 
Ca2+-enhanced lysosomal exocytosis (Chen, 2010). It is also interesting to note that 
HPβCD does not reduce storage and ameliorate neurological symptoms in other 
LSDs including a sphingolipidosis suggesting an NPC specific mechanism of action 
(Davidson et al., 2009). Finally and, perhaps, most compelling of all is the 
observation that peripheral administration of HPβCD can reduce brain lipid storage 
despite a lack of significant BBB permeability (Pontikis et al., 2013). Further research 
is required to resolve these issues and in doing so may provide avenues for rational 
improvement of HPβCD as a therapy for NPC.  
 
Recent studies indicate that the development of NPC therapies may also benefit 
research and treatment of other diseases, some of which are much more commonly 
occurring. These include the implication of the NPC1 protein in endolysosomal 
cholesterol mistrafficking in Smith-Lemli-Opitz Syndrome, a disease of cholesterol 
biosynthesis (Platt et al., 2014); inhibition of the NPC1 protein by mycobacterium 
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tubercolosis to facilitate survival within the endolysosomal system by preventing 
phagosome-lysosome fusion (Lloyd-Evans et al., Unpublished); and, reports of 
Alzheimer’s disease phenotypes in NPC patients (Malnar et al., 2014). 
 
NPC disease is arguably the most thoroughly researched LSD caused by a 
transmembrane protein, and yet, the protein function still remains elusive. 
Nevertheless the delineation of storage events which follow protein loss of function 
has provided valuable insights which have allowed for rational therapy design. In the 
majority of other LSDs caused by the loss of function of a transmembrane protein 
this has not yet been achieved, and presents additional difficulty when studying 
diseases such as Mucolipidosis type IV.  
 
1.5.3. – Mucolipidosis type IV 
 
Mucolipidosis type IV (MLIV) is an extremely rare LSD, caused by mutations in the 
gene MCOLN1, with severe neurodevelopmental and neurodegenerative 
phenotypes. Originally associated with the Ashkenazi-Jewish population this 
autosomal recessive disorder has since been shown to be pan-ethnic (Bach, 2001) 
with an estimated incidence that has been difficult to determine accurately due to a 
number of mutations causing only mild phenotypes which are likely misdiagnosed 
(Wakabayashi et al., 2011). Two mutations are commonly found in patients of 
Ashkenzi-Jewish ancestry, both of which reduce expression of TRMPL1 at the level 
of mRNA. Additional missense mutations have been reported in conserved regions of 
the TRPML1 protein, which are particularly interesting as they may be associated 
with milder disease phenotypes involving partial protein dysfunction (Wakabayashi et 
al., 2011.) 
 
The protein product of the gene is TRPML1, a six transmembrane domain protein of 
580 amino acids, with intraluminal N and C termini (LaPlante et al, 2002; Nilius et al., 
2007). Without TRPML1 function cells accumulate a wide variety of substrates in the 
lysosomes including lipofuscin, phospholipids, gangliosides and glycosaminoglycans, 
alongside a cellular vacuolation phenotype (Wakabayashi et al., 2011). This storage 
is likely the result of profound endocytic mistrafficking (Fares and Greenwald, 2001) 
caused by the loss of luminal Ca2+ homeostasis which is mediated by TRPML1 
(section 2.3.2.1.). Recently, Ca2+ release from TRPML1 has been associated with the 
regulation of autophagy and induction of lysosome biogenesis by TFEB although the 
	   52	  
impact of this on disease phenotypes has not yet been established (Medina et al., 
2015).  
 
Diagnosis of MLIV remain a challenge as a lack of characteristic neurological 
findings may result in misdiagnosis as cerebral palsy of spastic paraplegia. It is often 
the eye abnormalities such as corneal clouding progressing to visual degeneration 
alongside severe cognitive impairment that define the ‘typical’ MLIV patient 
(Wakabayashi et al., 2011). Considering the lipofuscin accumulation in the 
endolysosomal system and the ‘enigmatic’ nature of MLIV’s cellular phenotypes and 
clinical signs, this disease may arguably be better characterised as a lipofuscinosis 
(Carcel-Trullols et al., 2015). Regardless of the merits of classifying this disease as 
either a lipofuscinosis or mucolipidosis, it does serve to highlight the difficulties 
presented by the classification and subdivision of LSDs.  
 
Unfortunately, the above considerations may be key contributing factors to the lack of 
a specific therapy for MLIV, with only symptomatic amelioration currently a 
therapeutic option.   
 
1.6. – Convergent themes in the study of LSDs 
The hypothetical cascade of LSD pathogenesis as shown in figure 1.5.1. and the 
subsequent examples of LSDs have illustrated the complexity borne out of the loss of 
a single functional protein. Considering the three diseases discussed in detail, and 
LSDs in general, several convergent themes emerge. These are lipid 
dyshomeostasis, neurodegeneration and the impact of these upon therapy. 
 
1.6.1. – Lipid Dyshomeostasis 
 
A large number of the LSDs are primary lipid disorders caused by defects in primary 
lipid catabolic enzymes within the endolysosomal system (Platt, 2014). However the 
impact of lipid storage on LSD pathology can be expanded when it is considered that 
lipid storage is observed in many LSDs, which do not have a primary lipid catabolic 
defect (Kreutz et al., 2013). A clear example of this is ganglioside storage observed 
in mucopolysaccharidosis type 1 (Hurler syndrome). The primary defect in this LSD 
is in an enzyme which catabolises glycosaminoglycans, alpha-L-iduronidase. It is 
proposed that structural similarity between glycoasminoglycans and the terminal 
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glycosylation present on certain gangliosides can inhibit enzymes such as 
hexosaminidase resulting in ganglioside GM2 accumulation (Heinecke et al., 2011). 
This is a clear example of steric hindrance contributing to secondary substrate 
storage illustrated in figure 1.5.1. 
 
A similar pathological process that can cause further lipid storage is endocytic 
mistrafficking of sphingolipids. As discussed in section 1.4.3., sphingolipids are 
endocytosed and those not recycled back to the plasma membrane are sorted to 
either the Golgi or lysosomes. Although the mechanisms for this sorting are not well 
defined, the accumulation of sphingolipid in the endosomal system as a result of 
mistrafficking is a clearly defined phenotype in many LSDs (Pagano et al., 2000). 
This has been assayed by either the addition of fluorescently tagged sphingolipid or 
the addition of fluorescently tagged protein such as cholera toxin subunit B (CtxB) 
which bind specifically to ganglioside GM1 (Blank et al., 2007; Benktander et al., 
2013) in the plasma membrane, triggering internalisation and subsequent transport. 
The amount of fluorescently tagged probe that accumulates in cells from different 
LSDs varies (Pagano, 2003). As with the mechanistic basis of this trafficking, it is not 
entirely understood how sphingolipid mistrafficking occurs although the distribution of 
cholesterol and maintenance of Ca2+ homeostasis in the endolysosomal system 
appears to be important (Pagano, 2003; Choudhury et al., 2004; Luzio et al., 2007). 
Nevertheless, the distribution of fluorescent analogues added to cells to assay this 
system remain a useful method for the examination of lysosomal dysfunction by 
inhibitory compounds or the benefit mediated by therapies designed to reduce 
endolysosomal dysfunction.  
 
Lipids and in particular sphingolipids are a particularly bioactive class of 
macromolecule and as such when levels are higher than usual or they are not 
localised appropriately they can cause a myriad of defects in areas of the cell outside 
of the endolysosomal system (Platt, 2014). An intriguing example of this is the action 
of sphingolipids which accumulate in LSDs on the ER. In Gaucher, and some other 
sphingolipidoses, the accumulating substrates can escape the endolysosomal 
system by an undefined mechanism and modulate ER Ca2+ channels (Lloyd-Evans 
et al., 2013). The mechanisms underlying this ‘escape’ are not well defined but may 
involve membrane contact points (Penny et al., 2015). Conversely, to this situation of 
excessive lipids being redistributed to other membranes and organelles, the lack of 
lipids due to their sequestration in endolysosomal compartments may be disruptive to 
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some cellular pathways. This appears to be particularly important in neurons and will 
be further discussed in 1.6.2.  
 
1.6.2.  – Neurodegeneration 
 
Consideration of the LSDs discussed is section 1.5 and the broader range of LSDs 
reveals that the majority are neuropathic and profound neurodegeneration is a major 
phenotype (Cox and Chacon Gonzalez, 2012). Whilst this is a major challenge for 
the treatment of LSDs they do provide a unique model for the study of 
neurodegeneration as compromised lysosomal function causes neuronal death by 
apoptosis or necrosis – features which are found in common neurodegenerative 
disease such as Alzheimer’s disease (Okouchi et al., 2007; Troulinaki et al.,2012).  
 
As with the cellular pathology of LSDs, discussed above, the neuropathology of 
LSDs is a complex cascade which may be reliant upon primary storage substrates, 
secondary storage substrates or subsequent dysfunction in other cellular organelles 
and pathways. Due to this complex pathology neuropathology in LDSs may include 
any number of the following: disruption of neuronal architecture, abnormal 
inflammatory response, increased oxidative stress, dysregulated Ca2+ homeostasis, 
lipid mistrafficking, abnormal proteolysis and evidence of decreased autophagic flux. 
(Pagano, 2003; Farfel-Becker et al., 2011; Platt et al., 2012; Nixon, 2013; Schondorf 
et al.,2014) 
 
1.6.2.1. – Changes to neuronal architecture 
 
Some of the most striking CNS pathology of LSDs is the observation of 
meganeurites, axonal spheroids and ectopic dendrites. Meganeurites are hugely 
enlarged axonal hillocks containing storage bodies most often containing the primary 
storage substrate and thus considered disease specific (Walkley and James, 1984). 
Axonal spheroids are more variable, containing an array of material in enlargements 
distal to the axon initial segment region and are considered more similar across 
different storage disorders. Ectopic dendritogenesis, which does not occur in mouse 
models of LSDs, is the phenomenon of increased proliferation of malformed 
dendrites from neurons although the consequences of this remain unclear although 
the presence of dysfunctional synapses and subsequent neuronal injury caused by 
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these has been proposed as a pathological mechanism (Walkley et al., 1990; 
Walkley, 1998).  
 
1.6.2.2. – Neuroinflammation 
 
A common neuropathalogical event in the brains of LSD patients is the presence of 
‘activated’ microglia with pathological secretion of cytokines. This activation of 
microglia has been shown to correlate with levels of storage and onset of symptoms 
in animal models of LSDs such as Gaucher mice. In these mice, extensive elevation 
of markers of oxidative stress were also present, a process observed in a number of 
other animal models of LSDs (Farfel-Beker et al., 2011). It is suggested the initiating 
events that cause the onset of chronic inflammation and increased oxidative stress 
are caused by the accumulation of different substrates, whether primary or 
secondary, in different LSDs before the pathways converge later on in the 
pathogenic cascade. Nevertheless, they represent a significant challenge for the 
treatment of CNS pathology in LSDs and may provide links to the pathology 
observed in more common neurodegenerative diseases (Vitner et al., 2010).  
 
 
1.6.2.3. – Protein aggregation 
 
Protein aggregation and inclusion body formation are cardinal features of the more 
common neurodegenerative diseases which most commonly onset in later life. In 
Alzheimer’s disease extracellular plaques of beta-amyloid (Aβ) protein are observed 
alongside intracellular neurofibriliary tangles comprised of aberrantly phosphorylated 
Tau. The presence of amyloid plaques or pathogeneic changes to Aβ levels have 
been reported in a range of LSDs (Martins et al., 2015) including NPC (Maulik et al., 
2013). The mechanisms leading to such pathology are not well defined although 
defects in endocytosis, proteolysis and autophagy are thought to play an important 
role (Nixon, 2005; Nixon 2013). The defined protein aggregate most strongly related 
to Parkinson’s disease are Lewy bodies (although these can also be present in other 
forms of dementia including Alzheimer’s disease variants); and intracellular protein 
aggregates primarily composed of α-synuclein (Sardi et al., 2015). Recently it has 
been ascertained that GBA1 plays a greater role in the genetic aetiology of dementia 
with Lewy bodies than it does for Parkinson’s disease (Nalls et al., 2013). This 
suggests that there is a mechanistic link between either loss of function of GCase or 
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increased GlcCer and α-synuclein aggregation and this remains an area of intense 
research (Mazzulli et al., 2011). It is important to consider, however, that protein 
aggregation may be a protective response which is initiated to sequester toxic 
soluble proteins as such the contribution of aggregates to pathogenic cascades 
particularly early on in disease pathogenesis is debated (Arasante et al., 2004).  
 
1.6.2.4. – Ca2+ dyshomeostasis 
 
Within the CNS, correct homeostasis of Ca2+ homeostasis becomes increasingly 
important as excitable cells such as neurons utilise Ca2+ for many signalling events 
(Surmeier et al., 2011) and Ca2+ is also used by astrocytes to regulate growth factor 
secretion and neurotransmitter uptake and release (Volterra et al., 2014). A result of 
this high dependence upon Ca2+ is a vulnerability to Ca2+ overload, which is toxic to 
neurons, activating nitric oxide synthesis generation of free radicals and apoptosis. 
The most well characterised from of excitotoxicity is induced by the major excitatory 
neurotransmitter of the mammalian CNS – glutamate (Wang and Qin, 2010). 
Dysfunction in the endolysosomal pathway associated with decreased autophagic 
flux can play an important role in excitotoxic neuron death, so it is not surprising that 
a number of LSDs are thought to be susceptible to this process (Kovacs et al., 2006). 
This is especially true when we consider that elevated intracellular Ca2+ levels are, in 
part, reduced by buffering from intracellular Ca2+ stores such as the ER and 
mitochondria. When we consider that LSDs such as Gaucher have dysregulated ER 
Ca2+ stores it would be surprising if excitotoxic neuron death did not play a role in 
pathology (Lloyd-Evans et al., 2003; Schondorf et al., 2014). Increased levels of Ca2+ 
in cells also increase mitochondrial stress which can initiate caspase dependant 
apoptosis pathways (Kiselyov et al., 2007). Ca2+ excitotoxicity has been implicated in 
Huntington’s disease, Alzheimer’s disease and Parkinson’s disease and may be a 
common pathway to pathology in diseases where neurons are lost (Wang and Qin, 
2010).  
 
In addition to neuronal Ca2+ levels being important in the brain, astrocytic Ca2+ 
responses are also vital to correct brain function. Although the contribution of these 
responses to spatial and temporal regulation of neural signalling is less well 
understood, it is becoming an increasing area of study. A particularly interesting area 
of study is the implication of dysregulated astrocytic Ca2+ signalling in Alzheimer’s 
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disease models where it has been observed early in pathogenesis (Vincent et al., 
2010).  
 
1.6.2.5. – Decreased autophagic flux 
 
The excitable nature of neurons means that they also have high energy demands, 
particularly in the areas surrounding synapses where active transport processes and 
high rates of protein turnover place high demands on metabolism. This is particularly 
important when we consider that neurons are post-mitotic cells and as such become 
increasingly susceptible to the build up of dysfunctional organelles and toxic proteins 
as they age. Co-ordinated action of mitophagy, macroautophagy and chaperone 
mediated autophagy is therefore of vital importance for the maintenance of correct 
neuronal function by preventing the accumulation dysfunctional organelles and toxic 
proteins (Nixon, 2013). The reduced autophagic flux observed in the majority of 
LSDs result in increased susceptibility to such toxic processes driving the formation 
of dystrophic neurites (Boland et al., 2008). Essentially in situations where lysosomal 
function is compromised and autophagy is subsequently reduced neurons become 
dysfunctional at a very early age leading to the early-onset neurodegeneration 
observed in LSDs (Liebermann et al., 2012). 
 
1.7. – Summary 
 
This discussion of LSDs has served to highlight the complexity arising from these 
monogenic disorders and the detrimental effects they can have on patients with 
profound neurodegeneration one of the most common and severe patient outcomes 
(Cox and Chacon Gonzalez, 2012). We have also observed that milder forms of 
lysosomal disease are potentially more prevalent than currently recognised (Wassif 
et al., 2015) and that those originally not considered to have neurodegenerative 
pathology may result in a predisposition to more common neurodegenerative 
diseases (Sidransky et al., 2009). Accordingly, the study of lysosomal pathology and 
the involvement of proteins which are the primary defects in LSDs is an area of 
intense interest in neurodegenerative disease research. Hopefully, by applying our 
knowledge of pathogenic cascades following lysosomal dysfunction we can identify 
new therapeutic targets in diseases such as Alzheimer’s, Huntington’s and 
Parkinson’s 
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1.8. – Aims 
 
In chapter 3 of this thesis we will investigate lysosomal dysfunction in cells which do 
not have functional Presenilin proteins. Mutations in these proteins are known to 
cause familial Alzheimer’s and lysosomal dysfunction leading to reduced autophagic 
flux has been suggested to be important in this pathogenesis (Nixon, 2013). Although 
lysosomal dysfunction is an established observation in presenilin cells the molecular 
basis of this remains to be clarified with both disruption of lysosomal pH (Lee et al., 
2010; Coffey et al., 2015) and lysosomal Ca2+ (Coen et al., 2012) having been 
implicated. Accordingly we will utilise cells in which presenilin proteins have been 
knocked out to investigate lysosomal dysfunction in a simple model of presenilin 
deficiency in order to establish molecular targets which could be used to investigate 
more patient relevant models of familial Alzheimer’s.  
 
The specific aims of chapter 3 are to: 
 
• Investigate whether PS1-/- cells had phenotypes mimicking NPC1 disease 
• Determine whether the lysosomal Ca2+ defect observed in PS1-/- cells could 
be recapitulated using our laboratories extensive expertise in the area. 
• If a lysosomal Ca2+ defect in PS1-/- cells is confirmed we will investigate the 
mechanisms underlying this defect.  
 
In chapter 4 we will investigate the expanding area of interest which relates to the 
accumulation of lysosomes in models of Huntington’s disease (Castiglioni et al., 
2012; Camniaso et al., 2012; Erie et al., 2015). As there is also evidence of 
dysregulation of lipid levels and endocytic trafficking defects in these cells we are 
interested to see if any of the lysosomal phenotypes which are present are 
reminiscent of any LSDs. This study ha the potential to highlight new therapeutic 
targets. In order to do this we will utilise cellular models of Huntingtons created from 
well characterised animal models of the disease alongside emerging iPSC-derived 
patient models of the disease. 
 
The specific aims of chapter 4 are to: 
 
• Perform a robust phenotyping of various Huntington’s cell lines to determine 
the extent of lysosomal dysfunction in the disease. 
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• Investigate the potential mechanism leading to lysosomal dysfunction in 
Huntington’s. 
• Determine any therapeutic intervention points which have the potential to 
correct lysosomal dysfunction in Huntington’s cells.  
 
In chapter 5 we will investigate whether cellular Ca2+ dysregulation which has been 
implicated in the pathogenesis of Parkinson’s (Surmeier etal., 2011) is prevalent in 
genetic models of Parkinson’s disease. Recently it has been suggested that changes 
to lysosomal Ca2+ signalling may be an initiating factor in this Ca2+ dysregulation 
(Hockey et al., 2015). To study this we will utilise fibroblasts from KRS patients who 
carry mutations in the lysosomal protein ATP13A2 and suffer from a form of early 
onset Parkinson’s (Ramirez et al., 2006). As this protein is both lysosomal and 
proposed to be involved in ionic transport these cells represent an ideal model in 
which we can investigate if Ca2+ dysregulation is widespread in genetic models of 
Parkinson’s disease. We will also study primary astrocytes in which Gaucher disease 
phenotypes have been induced by either genetic or pharmacological means in order 
to see if the Ca2+ dysregulation reported in models of Gaucher (Lloyd-Evans et al., 
2003; Schondorf et al., 2014) is present and what impact this has upon astrocytic 
Ca2+ signalling. 
 
The specific aims of chapter 5 are to: 
 
• Determine if the loss of ATP13A2 function results in changes to lysosomal 
Ca2+ homeostasis. 
• Determine what impact these Ca2+ changes, if any, may have on other 
cellular Ca2+ stores 
• Investigate what effects the induction of Gaucher phenotypes has on Ca2+ 
signalling within astrocytes.  
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Chapter 2 
 
 
 
Materials and Methods 
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All chemicals were obtained from Sigma Aldrich, Poole, UK unless otherwise stated.  
 
2.1. – Cell Culture 
 
2.1.1. – Blastocyst-derived cells 
 
WT and PS1-/- mouse blastocyst-derived (BD) cells were obtained from Dr. Ralph 
Nixon, Nathan Kline Institute, USA. These cells were maintained in sub-confluent 
conditions in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% Foetal Calf 
Serum (FCS) and 2mM L-Glutamine at 37°C and 5% CO2 in a humidified incubator. 
These cells have previously been used in the study of lysosomal phenotypes by Lee 
et al. (2010). 
 
2.1.2. – Mouse Embryonic Fibroblasts 
 
WT, PS1-/- and PS1/2-/- mouse embryonic fibroblasts (MEFs) were obtained from Dr. 
Ralph Nixon, Nathan Kline Institute, USA. These cells were maintained in sub-
confluent conditions in DMEM with 10% FCS and 2mM L-Glutamine at 37°C and 5% 
CO2 in a humidified incubator. These have previously been used for the study of 
lysosomal Ca2+ by Coen et al. (2012). 
 
2.1.3.  – Down’s syndrome Human Fibroblasts 
 
Human fibroblasts (HF) with trisomy of chromosome 21 along with an age matched 
control cell line were obtained from Dr. Ralph Nixon, Nathan Kline Institute, USA. 
These cell have been previously described in Jiang et al. (2010). All cells were 
maintained in sub-confluent conditions in DMEM with 10% heat inactivated foetal calf 
serum and 2mM L-Glutamine at 37°C and 5% CO2 in a humidified incubator. 
 
2.1.4. – Induced pluripotent stem cell derived neural stem cells 
 
HD patient induced pluripotent stem cell (iPSC) derived neural progenitor cells 
(NPCs) were obtained from Prof. Nick Allen, Cardiff University, UK. In this study they 
are referred to as neural stem cells (NSCs) in order to avoid confusion with the 
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Niemann-Pick type C (NPC) proteins. These cells have 180 polyQ repeats in the 
huntingtin (HTT) protein and were the starting point for neuronal differentiation in the 
HD iPS consortium study (HD iPSC Consortium, 2012). The control cells used in this 
study were H9 neural stem cells. Cells were maintained as a near confluent 
monolayer on a laminin coated growth surface in Advanced DMEM/F12 medium (Life 
Technologies, Warrington, UK) with 20ng/ml epidermal growth factor (EGF), 20ng/ml 
fibroblast growth factor (FGF) and 5µg/ml heparin at 37°C and 5% CO2 in a 
humidified incubator.  
 
2.1.5.  – ST14A embryonic striatal cells 
 
Conditionally immortalised ST14A from cells expressing fragments of human HTT 
corresponding to amino acids 1-548 with different degrees of poly Q expansion (Q15 
and Q120) were obtained from the Coriell Cell Repository, Coriell Institute for 
Medical Research, New Jersey, USA. These cells are a well-characterised line 
originally derived from day 14 embryonic rat striatal primordia. All cells were 
maintained in sub-confluent conditions in DMEM with 10% heat inactivated FCS and 
2mM L-glutamine at 33°C and 5% CO2 in a humidified incubator. These cells have 
been studied in numerous publications pertaining to Huntington’s disease (Ehrlich et 
al., 2001; Valenza et al., 2005; Maglione et al., 2010; Marullo et al., 2012). 
 
2.1.6.  – PC12 pheochromocytoma cells 
 
PC12 cells with inducible expression of full length human HTT with different degrees 
of polyQ expansion (Q23 and Q145).were obtained from the Coriell Cell Repository, 
Coriell Institute for Medical Research, New Jersey, USA. These cells are a well 
characterised Huntington’s model originally generated from a rat pheochromocytoma 
(Edwardson, 2003). Cells were maintained in partial suspension culture in DMEM 
F12 with 15% Horse serum (Life Technologies), 2.5% FCS, 1% penicillin/ 
streptomycin, 0.2 mg/ml Zeocin (Invivogen, San Diego, USA) and 0.2 mg/ml G418 
(Invivogen). 
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2.1.7. – Differentiation of iPS derived Neural Stem Cells into neurons 
 
The iPSC derived cell lines 21n1, 33n1, 60n5 and 109n4; examined in the HD iPS 
consortium study were differentiated into neurons representative of the lateral 
ganglionic eminence (LGE). Each cell line has a poly-glutamine repeat length as 
described by the first number in the cell line with the number following n the clone 
number. All cell cultures are grown at 37°C and 5% CO2 in a humidified incubator 
utilising methods adapted from (HD iPSC Consortium, 2012; Rushton et al. 2013). 
 
iPSC neural progenitor cultures greater than 70% confluent grown in matrigel (BD, 
Oxford, UK) coated vessels were selected for differentiation. For the first 3 days, 
cells were grown in SLI media, consisting of Advanced DMEM F12 (Life 
Technologies) with 1% Glutamax (Life Technologies), 1% penicillin/streptomycin, 2% 
MACS neurobrew without retinoic acid (Milteyni, Bisley, UK), 10µM SB431542 
(AbCam, Cambridge, UK), 1µM LDN193189 (Stemgent, Lexington, USA) and 1.5µM 
IWR1 (Tocris, Bristol, UK), which was changed daily. Cells were passaged by 1:1.5 
split after 4 days using Accutase (Life technologies) in the presence of 10µM the 
ROCK inhibitor Y-27632 (AbCam) and plated onto matrigel coated 6 well plates and 
grown in SLI medium which is changed daily. At 8 days, cells were again passaged 
by the same method but maintained in LI medium (Advanced DMEM F12 with 1% 
Glutamax, 1% penicillin/streptomycin, 2% MACS neurobrew without retinoic acid, 
1µM LDN193189 and 1.5µM IWR1), which is again changed daily. At day 16, these 
cultures can either be further expanded for cryopreservation or passaged for LGE 
neural differentiation. Cells were obtained from Sun Yung (Allen lab, Cardiff 
University) at this stage.  
 
For neural differentiation, a single cell suspension was obtained by Accutase 
treatment in the presence of 10µM Y-27632 and cells were counted then the volume 
of cell solution adjusted to 1X106 cells/ml. 80µl of this cell suspension was then 
plated onto glass coverslips or Ibidi 8 well µ-slides coated with PDL and matrigel to 
achieve a final cell number of 80,000/coverslip. After 1 hr incubation at 37°C and 5% 
CO2 in a humidified incubator each well was gently flooded with SCM1 medium 
consisting of Advanced DMEM F12 with 1% Glutamax, 1% penicillin/streptomycin, 
2% MACS neurobrew with retinoic acid (Milteyni), 2µM PDO332991 (Tocris), 10µM 
DAPT (Tocris), 10ng/ml BDNF (Milteyni), 0.5µM LM22A4 Tocris), 10µM Forskolin 
(Tocris), 3µM CHIR 99021 (Tocris), 0.3mM GABA (Tocris), 1.8mM CaCl2 and 0.2mM 
Ascorbic acid. This media was changed every 2-3 days until day 23 when the cells 
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were changed into SCM2 medium. SCM2 medium consists of Advanced DMEM F12 
with 1% Glutamax, 1% penicillin/streptomycin, 2% MACS neurobrew with retinoic 
acid, PDO332991 2µM, 10ng/ml BDNF, LM22A4 0.5µM, CHIR 99021 3µM, CaCl2  
1.8mM and 0.2mM Ascorbic acid 0.2mM. Cells were then maintained in this medium 
with media changes every 2-3 days until 30 - 44 days after initiation of the protocol 
as determined by the experiment. At this stage, cells have been characterised as 
mature LGE neurons by DARPP32 staining and were used for experimentation as 
appropriate.  
 
All neuronal differentiations were performed either by, or with assistance from Dr. 
Sun Yung (Allen Lab, Cardiff University).  
 
2.1.8.  – Kufor-Rakeb Syndrome Human Fibroblasts 
 
Human fibroblasts with mutations in the ATP13A2 protein were obtained from Prof. 
Christine Klein, Lubeck, Germany. Patient 1 is identified as L6025 and Patient 2 as 
L3292, these cells are described in Dehay et al. (2012). Both cell lines contain 
mutations which lead to misfolded protein which is retained in the ER (Ramirez et al., 
2006). The control cell line GM05399 was obtained from Coriell Cell Repositories, 
New Jersey, USA. All cells were maintained in sub-confluent conditions in 
Dulbecco’s modified Eagle’s medium (DMEM) with 10% heat inactivated foetal calf 
serum (FCS) and 2mM L-Glutamine at 37°C and 5% CO2 in a humidified incubator. 
 
2.1.9. – GD Mouse Model Primary Astrocytes  
 
WT and Gaucher murine astrocytes were isolated from post-natal day 1 Gaucher 
mice utilising a method adapted from Hirst et al. (1998). Briefly, brains were taken 
from the pups and meninges removed before dissociation by trypsinisation (0.25% 
w/v) for 15 min at 37°C followed by passage through a 23g needle. After 
centrifugation at 100rpm for 5 minutes to remove trypsin solution cells were 
resuspended in DMEM with 10% FCS, 2mM L-Glutamine and 1% 
penicillin/streptomycin and the preperations from each brain were plated in a 25cm2 
tissue culture flask. Cells were maintained in culture in DMEM with 10% FCS, 2mM 
L-Glutamine and 1% penicillin/streptomycin at 37°C and 5% CO2 with at least 2 
passages occurring prior to use. Subsequently, these cells were maintained in 
DMEM with 10% FCS, 2mM L-Glutamine and 1% penicillin/streptomycin at 37°C and 
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5% CO2 as a near confluent monolayer in a humidified incubator. This nestin – 
flox/flox mouse model does not express Gba1 in neurons and astrocytes and is used 
to model neurodegenerative Gaucher disease (Farfel-Becker., 2011).  
 
2.1.10. – Control primary astrocytes 
 
Primary astrocytes were isolated from post-natal day 1 C57BL/6 mice by Jenny 
Lange (King’s College, London). These cells were maintained in DMEM with 10% 
FCS, 2mM L-Glutamine and 1% penicillin/streptomycin at 37°C and 5% CO2 as a 
near confluent monolayer in a humidified incubator. These cells were treated with 
conduritol β epoxide (CβE) to pharmacologically induce GlcCer storage (Das et al., 
1987). and model Gaucher disease for experiments independent to those in which 
the cells prepared in 2.1.9. were utilised.  
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2.1.11. – Summary table of cell lines 
 
A summary of all the cell lines utilised in this thesis detailing the chapters they were 
used in is provided below.  
 
Cell Line Origin Genetic 
Change 
Relevant 
Disease 
Utilised 
in Chapter 
Described 
in                                                                                                                                                                                                                                                                                              
Section 
Blastocyst-
derived 
(BD) cells 
Mouse PS1-/- Alzheimer’s 3 2.1.1. 
Mouse 
embryonic 
fibroblast 
(MEF) cells 
Mouse PS1-/- and 
PS1/2-/- 
Alzheimer’s 3 2.1.2. 
Down’s 
syndrome 
patient 
fibroblasts 
Human Trisomy 21 Alzheimer’s 3 2.1.3. 
iPSC-
derived 
neural stem 
cells (NSCs) 
Human HTT polyQ 
expansion 
Huntington’s 4 2.1.4. 
ST14A cells Rat Q120 human 
HTT 
overexpression 
Huntington’s 4 2.1.5. 
PC12 cells Rat Q145 human 
HTT 
Huntington’s 4 2.1.6. 
iPSC-
derived 
neurons 
Human HTT poly Q 
expansion 
Huntington’s 4 2.1.7. 
Kufor-
Rakeb 
syndrome 
patient 
fibroblasts 
Human ATP13A2 
mutation 
Parkinson’s 5 2.1.8. 
GD mouse 
model 
primary 
astrocytes 
Mouse GBA1-/- Parkinson’s 5 2.1.9. 
Control 
primary 
astrocytes 
Mouse N/A Parkinson’s 5 2.1.10. 
 
Table 2.1. – Summary of cell lines utilised in this thesis. The species the cell line 
originated from, genetic change and neurodegenerative disease of relevance are detailed 
along with the chapter the cell were used in and the section of this chapter they were 
described in.  
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2.2 . – Pharmacological modulation of cell lines 
 
2.2.1. – U18666a treatment  
 
BD cells on glass coverslips or Ibidi 8 well µ-slides as appropriate were left to adhere 
overnight then treated with 2µg/ml U18666a in growth medium for 20 – 24 hr as 
appropriate. U18666a has been extensively characterised as a pharmacological 
inducer of NPC disease phenotypes (Lloyd-Evans et al. 2008).  
 
2.2.2. – Concanamycin A treatment 
 
BD cells in tissue culture tanks or Ibidi 8 well µ-slides as appropriate were left to 
adhere overnight then treated with 50nM Concanamycin A for 9 – 12 hr as 
appropriate. Concanamycin A is a well characterised inhibitor of vATPase (Coen et 
al. 2012).  
 
2.2.3. – Ned19 inhibition of TPC2 
 
Ned19 (Enzo, Exeter, UK), an inhibitor of Ca2+ release mediated by NAADP was 
used to model lysosomal Ca2+ release phenotypes observed in PS1-/- cells. BD cells 
were treated with Ned-19 at 0.5µM for 24 hr. (Naylor et al., 2009). 
 
2.2.4. – YM201636 inhibition of PIKfyve 
 
BD cells on Ibidi 8 well µ-slides were left to adhere overnight then treated with 10µM 
YM201636 in growth medium for 1 hr. YM201636 is a potent inhibitor of mammalian 
phosphatidylinositol phosphate kinase (PIKfyve), the enzyme required for 
biosynthesis of phosphatidylinositol (3,5) bis-phosphate (PI(3,5)P2) which is the 
endogenous activator of TRPML1. (Jefferies et al. 2008).  
 
2.2.5. – Inhibition of TRPML1 using anti TRPML1 antibody 
 
BD cells on Ibidi 8 well µ-slides were left to adhere overnight then treated with 5 
µg/ml of polyclonal anti-TRPML1 (Sigma) in growth medium for 16 hr. This antibody 
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had been titrated to a level where increased Lysotracker staining was observed in HF 
cells (Lloyd-Evans, Unpublished). This phenotype is observed in MLIV cells were 
TRPML1 function is lost and was used as evidence of inhibition of this lysosomal 
channel. Other anti TRPML1 antibodies were tested on HF cells but no increase in 
Lysotracker staining was observed (Lloyd-Evans, Unpublished). This method has 
previously been used to inhibit TRPML1 (Zhang et al., 2012). 
 
2.2.6. – Hydroxypropyl-β-Cyclodextrin Treatment  
 
BD cells grown in the conditions described above conditions were treated with 0.4 
mg/ml Hydroxypropyl-β-Cyclodextrin (HPβCD) in growth medium for 24 hr as per 
Chen et al., 2010) HPβCD has been established to reduce cholesterol accumulation 
in cell models of NPC1 disease and improve phenotypes in animal models of NPC1 
(Davidson et al., 2009; Vite et al., 2015).  
 
2.2.7. – Miglustat Treatment  
 
ST14A cells or iPSC derived neurons grown in appropriate conditions were treated 
with 50µM Miglustat (Enzo) in growth medium for 5 days. Miglustat (N-butyl-
denojirimycin, NB-DNJ) is an approved treatment for the neurological manifestations 
of NPC disease in the European Union and these treatment conditions have been 
established as beneficial in cell models of NPC disease (Haslett et al. Unpublished). 
It is a form of substrate reduction therapy (SRT) which reduces levels of 
glycosphingolipids by inhibition of the biosynthetic enzyme glucosylceramide 
synthase (Platt et al., 1994; Patterson et al., 2015). 
 
2.2.8. – Phytic acid Treatment 
 
HF cells on glass coverslips or Ibidi 8 well µ-slides as appropriate were left to adhere 
overnight then treated with 1mM Phytic acid in growth medium for 7-15 days as 
appropriate. Phytic acid is a non-specific chelator of heavy metal cations effective in 
acidic microenvironments (Maguire et al. Unpublished).   
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2.2.9. – Conduritol β epoxide treatment of primary astrocytes 
 
Control primary astrocytes (3.1.10) grown in six well plates were treated with 200µM 
conduritol β epoxide (CβE) (Matreya LLC, State College, USA) in astrocyte growth 
medium for five days prior to plating in Ibidi 8-well µ-slides. Medium was changed 
every 2 days. CβE is a specific, irreversible inhibitor of GCase and is commonly used 
to pharmacologically model Gaucher disease (Das et al., 1987; Manning-Bog., 
2009). 
 
2.3. – Cell Biology  
 
2.3.1. – Fixed cell biology 
 
2.3.1.1. – Paraformaldehyde fixation of cells 
 
Cells plated on glass coverslips had growth media removed and were washed once 
in DPBS before incubation with 4% paraformaldehyde (PFA) for 8 min at room 
temperature. Post incubation cells were washed once with DMEM containing 10% 
FCS in order to prevent over fixation before 3 further washes in DPBS. Fixed cells 
were stored in DPBS at 4°C until staining. 
 
2.3.1.2. – Methanol fixation of cells 
 
Cells plated on glass coverslips had growth media removed and were washed once 
in DPBS before incubation with methanol for 5 min at -20°C. Post incubation cells 
were washed 3 times in DPBS. Fixed cells were stored in DPBS at 4°C until staining. 
 
2.3.1.3. – Blocking Buffer 
 
1% bovine serum albumin (BSA) to prevent non-specific antibody interactions and 
0.01% saponin to aid permeabilisation of cells in DPBS. This was stored in aliquots 
at -20°C until use. 
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2.3.1.4. – Primary Antibodies for Immunocytochemistry 
 
Primary antibodies utilised in the studies described in this these are listed below in 
alphabetical order.  
 
2.3.1.4.1. – Annexin A2 
 
Visualisation of levels of Annexin A2 (AnA2) was used as an indication of endocytic 
trafficking dysfunction as a result of Ca2+ dyshomeostasis. In healthy cells plasma 
membrane localisation of AnA2 is observed whereas a small perinuclear cluster of 
AnA2 is observed in cells where endolysosomal Ca2+ dyshomeostasis is 
dysregulated. PFA fixed cells were incubated with a 1:200 dilution of mouse 
monoclonal anti-AnA2 (Novus, Oxford, UK) in blocking buffer overnight a 4°C.  
 
2.3.1.4.2. – LAMP-2  
 
LAMP-2 was used as a marker of late-endosomal and lysosomal morphology and 
expansion. Methanol fixed cells were incubated with 2% FCS and 2% BSA in PBS 
for 30 min at room temperature. Cells were then incubated for 30 min at room 
temperature with rat monoclonal anti-mouse LAMP-2 ABL-93 (developmental studies 
hybridoma bank, University of Iowa, USA) or anti-human LAMP-2 H4B4 
(developmental studies hybridoma bank) at a 1:100 dilution in 2% FCS and 2% BSA 
in PBS.  
 
2.3.1.4.3. – LBPA 
 
Visualisation of levels and localisation of lysobisphosphatidic acid (LBPA/BMP) was 
used to determine lipid levels and localisation. PFA fixed cells were incubated with a 
1:1000 dilution mouse monoclonal anti-ZPLBPA (Echelon, Salt Lake City, USA) in 
blocking buffer overnight a 4°C.  
 
2.3.1.4.4. – NPC1  
 
Visualisation of levels and localisation of the Niemann-Pick C1 (NPC1) protein was 
used to study lipid trafficking dysfunction in the late-endosome and lysosome. PFA 
fixed cells were incubated with a 1:200 dilution rabbit polyclonal anti-NPC1 (Novus) 
in blocking buffer overnight a 4°C.  
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2.3.1.4.5. – NPC2  
 
Visualisation of levels and localisation of the Niemann-Pick C2 (NPC2) protein was 
used to study lipid trafficking dysfunction in the lysosome and as a lysosomal marker 
where appropriate. PFA fixed cells were incubated with a 1:200 dilution rabbit 
polyclonal anti-NPC2 (Sigma) in blocking buffer overnight a 4°C.  
 
2.3.1.4.6. – SERCA2 
 
Visualisation of levels of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA2) 
was used as an indication of ER density and to investigate changes, which may lead 
to Ca2+ dyshomeostasis. PFA fixed cells were incubated with a 1:200 dilution of 
mouse monoclonal [IID8] to SERCA2 ATPase (Abcam) in blocking buffer overnight at 
4°C.  
 
2.3.1.4.7. – TMED4 
 
Visualisation of levels of Transmembrane Emp24 Protein Transport Domain 
Containing 4 (TMED4) was used as an indication of ER stress. In healthy cells Golgi 
localised staining of TMED4 is evident, in cells with ER stress lightly punctate extra-
Golgi staining is evident. PFA fixed cells were incubated with a 1:200 dilution of 
TMED4 (Novus) in blocking buffer overnight at 4°C.  
 
2.3.1.5. – Secondary Antibodies for Immunocytochemistry 
 
Post incubation with primary antibodies, cells were washed 3 x 5 min in Dulbecco’s 
phosphate buffered saline (DPBS). They were then incubated for 30 min at room 
temperature with epitope compatible Dylight 488 secondary antibody (Vector) or 
Dylight 594 secondary antibody (Vector, Peterborough, UK) at a 1:200 dilution in 
blocking buffer. Cells were washed in DPBS 3 x. Secondary antibody controls were 
performed on all cell lines and during initial experiments with primary antibodies. 
 
2.3.1.6. – Filipin staining  
 
Visualisation of levels and localisation of un-esterified cholesterol was achieved 
using the autofluorescent polyene antibiotic filipin which is widely used as a 
histochemical stain. (Vanier., 2015). PFA fixed cells were incubated in a 125µg/ml 
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solution of filipin in DMEM with 10% FCS for 30 min at room temperature before 
three washes in DPBS. 
 
2.3.1.7. – Lysenin staining  
 
Lysenin is a protein isolated from the coelomic fluid of the earthworm Eisenia foetida 
which binds specifically to sphingomyelin; as such it was used to visualise levels and 
localisation of sphingomyelin within cells. (Taskir., 2012). PFA fixed cells were 
incubated in a 33ng/ml solution of Lysenin toxin (Peptides International, Louisville, 
USA) in blocking buffer overnight a 4°C before 3 x 5 min washes in DPBS.  Cells 
were then incubated with primary anti-lysenin antibody (Peptides International) at a 
1:1000 dilution in blocking buffer for 1 hr at room temperature. After 3 x 5 min 
washes in DPBS cells were incubated with a Dylight 594 anti-rabbit IgG (Vector) as 
described in 2.2.4. 
 
2.3.1.8. – FITC-Cholera Toxin B subunit staining  
 
The cholera toxin B subunit binds to Ganglioside GM1 and can be visualised by the 
FITC-tag applied to the protein (Blank et al., 2007). PFA fixed cells were incubated in 
a 1µg/ml solution of FITC- Cholera Toxin B subunit (CtxB) in blocking buffer 
overnight a 4°C before 3 washes in PBS. 
 
2.3.1.9. – Nuclear Co-Staining  
 
Nuclei were visualised by 10 min incubation with 2µg/ml Hoechst 33342 
trihydrochloride trihydrate in DPBS.  
 
2.3.1.10. – Coverslip Mounting 
 
Coverslips were mounted onto glass slides in 0.4 g/ml mowiol 4-88 in DPBS and left 
to dry in the dark at room temperature for at least 16 hr prior to imaging.  
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2.3.2. – Live Cell Staining 
 
2.3.2.1. – Imaging Buffer 
 
Hank’s balanced salt solution (HBSS) with 1mM HEPES, 1mM MgCl2 and 1mM 
CaCl2, all live cell analysis was conducted in this buffer unless otherwise stated.  
 
2.3.2.2. – Autofluorescence 
 
Cells grown in Ibidi µ well microscope slides were washed once in imaging buffer 
then imaged live. All excitation wavelengths were imaged to check levels of 
autofluorescence and then multiple pictures were taken after excitation at 470nm to 
image the autofluorescence observed in cells and post mortem analysis of patients 
with lysosomal storage diseases such as the neuronal ceroid lipofuscinoses (Di 
Guardo., 2015). 
 
2.3.2.3. – Lysotracker  
 
Lysotracker green DND-26 or lysotracker red DND-99 (Life Technologies) was used 
to investigate the volume of acidic compartments (pH < 5.5) within cells. Cells grown 
in Ibidi µ well microscope slides were washed once in imaging buffer then incubated 
with 200nM lysotracker in imaging buffer for 15 min at room temperature. Cells were 
washed once more in imaging buffer then imaged live.  
 
2.3.2.4. – ER tracker  
 
ERtracker blue-white DPX (Life Technologies) was used to investigate the volume of 
the ER within cells. Cells grown in Ibidi µ well microscope slides were washed once 
in imaging buffer then incubated with 200nM ER tracker in imaging buffer for 15 min 
at room temperature. Cells were washed once more in imaging buffer then imaged 
live.  
 
2.3.2.5. – Cholera toxin B trafficking assay 
 
When applied to live cells CtxB binds to ganglioside GM1 in the plasma membrane 
(Blank et al., 2007; Benktander et al., 2013) and is internalised by retrograde 
endocytic transport to the Golgi apparatus in healthy cells (Singh et al., 2003). A well 
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characterised defect in lysosomal storage diseases is incomplete trafficking of 
sphingolipids resulting in retention within the endocytic system (Pagano E., 2003).  
 
Cells grown on coverslips had growth medium replaced with ice cold growth medium 
containing 1µg/ml FITC CtxB and incubated for 30 min at room temperature, medium 
was kept ice cold to prevent premature internalisation. Pulse medium was then 
removed and cells were incubated in pre-warmed normal growth medium for a chase 
period calibrated for each cell line at 37°C and 5% CO2. Three 10 min back 
exchanges were then carried out in ice cold growth medium supplemented with 2% 
BSA and 0.1mg/ml heparin sulphate. These back exchanges remove non-specifically 
bound GM1 from the plasma membrane.  Cells were washed once in DPBS and PFA 
fixed. 
 
During microscopy representative images of field of cells were taken and in 
subsequent analysis the subcellular localisation of the FITC tagged protein was 
identified and each cell was scored for either correct trafficking to the Golgi, defective 
endo-lysosomal trafficking or an intermediate between the two states.  
 
2.3.2.6. – Magic Red cathepsin assays 
 
To examine the in situ activities of cathepsin B and L in cells specific fluorescent 
probes for each enzyme were used. These are substrates specific for cathepsin B or 
L and fluoresce upon cleavage. 
 
Cells grown in Ibidi µ well microscope slides were washed once in imaging buffer 
then incubated with Magic Red cathepsin B (MR Cat B) or Magic Red cathepsin L 
(MR Cat L) (Immunocytochemistry technologies) for 15 min at 37°C and 5% CO2 or 
30 min at 33°C and 5% CO2. Dependant upon the normal growth conditions of the 
cell. Cells were washed once more in imaging buffer then imaged live. 
 
2.3.2.7. – FITC Sphingosine transport assay 
 
FITC-tagged sphingosine (FITC-SphO) has previously been shown to adopt a 
punctate localisation in cells which have disrupted activity of NPC1 (Lloyd-Evans et 
al., unpublished). Importantly, the tagged SphO utilised in this study has been shown 
to cause NPC disease cellular phenotypes when applied to cells as has been 
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observed with un-modified SphO; this strongly suggests that the addition of a FITC 
tag to SphO does not disrupt the protein interactions.  
 
Cells treated with 1µM FITC-SphO for 10 min were examined by microscopy to 
ensure a punctate distribution of FITC-SphO representing traffic to acidic organelles 
and initial retention in these compartments due to the pKa of SphO, this has been 
confirmed by lysotracker co-staining (Lloyd-Evans et al., Unpublished). Cells were 
then left in growth medium for 24 hr before re-imaging to determine the final location 
of FITC-SphO and analyse the cells for either diffuse or punctate distribution.  
 
2.3.2.8. – Glutamate induced Ca2+ dyshomeostasis in neurons 
 
iPSC derived neurons grown as described in 2.1.7. for 37 - 44 days had BDNF 
withdrawn from growth media for 24 hr prior to loading with Fura2-AM (Life 
Technologies) in growth medium for 30 min at 37°C and 5% CO2. Before removal of 
the staining solution and 15 min incubation at room temperature in external cell 
solution for these experiments. This consisted of 135mM NaCl, 5mM KCl, %mM 
HEPES, 10mM glucose, 1.2mM MgCl2 and 1.25mM CaCl2.  
 
The method was adapted from that described in the HD iPSC Consortium report 
(2012). Briefly, coverslips were transferred to a perfusion chamber on an inverted 
microscope (Olympus, Southend-on-Sea, UK) with monochrome based fluorimiter 
(Cairn Research, Faversham, UK) and continuously perfused using a rapid perfusion 
system (BioLogic science instruments, Claix, France). Fura2 was alternately excited 
at 340 and 380nm and images recorded every 2 seconds using a CCD camera 
(Hamamatsu, Hamamatsu City, Japan). Cell body regions of interest were defined 
and all values recorded were adjusted for background fluorescence. Cells were then 
perfused with 60mM KCl to induce depolarization and confirm cell viability. 
Subsequently cells were perfused with 300µM glutamate and 30µM glycine for 5 min 
before 5 min washout in external cell solution. This process was repeated 5 times 
before a prolonged pulse of 300µM glutamate and 30µM glycine was added to cells 
for 2 hr. Subsequently external cell solution wash out was performed and cells were 
subjected to a final 10mM KCl perfusion.   
 
Cells were counted as having lost Ca2+ homeostasis when the Fura2 ratio exceeded 
that of the 1 min prolonged pulse baseline (plateau) and did not return. Subsequently 
survival curves were plotted with the loss of Ca2+ homeostasis counted as a ‘death’ 
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event. These experiments were all performed by, or with assistance from Polina 
Yarova (Kemp lab, Cardiff University) who also analysed the data subsequently.  
 
2.4.  - Microscopy 
2.4.1. – Fluorescence microscopy 
 
All fluorescence microscopy was performed on an inverted AX10 inverted 
microscope (Zeiss, Cambridge, UK) with LED lightsource and Colibri controller 
(Zeiss). Images were taken in monochrome with a Axiocam MRm CCD digital 
camera (Zeiss) using Axiovision software release 4.7.1 (Zeiss). Pseudocolouring was 
added to images using Photoshop CS3 (Adobe, California, USA). Subsequent image 
analysis was performed using ImageJ (NIH, Bethesda, USA). In all cases cells from 
different genotypes and treatments were imaged alongside control cells and identical 
LED power and exposure time were applied to all images. Subsequent image 
analysis was performed with identical adjustments.  
 
2.4.2. – Thresholding image analysis 
 
For experiments in which the level of brightness of a probe was being compared a 
thresholding procedure was used to determine if there were any differences between 
cell lines. Representative images of field of cells taken during microscopy underwent 
identical alterations in brightness and contrast in photoshop CS3. In ImageJ, images 
were changed to 8-bit monochrome and the total number of cells were counted using 
the cell counter plugin. Subsequently the threshold was adjusted so that 
approximately 50% of cells from control experimental populations were highlighted. 
All images were then subjected to these settings and the cell counter plugin was 
used to count the number of cells above the threshold value. Accordingly cells could 
be analysed in a semi-quantitative manner. Greater than 30 cells were analysed per 
experimental repeat.   
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2.5. – Ca2+ measurements 
 
2.5.1. – Cytosolic Ca2+ probe loading 
 
Cells were plated on Ibidi µ-Slide 8 well imaging dishes and left to adhere overnight. 
Post incubation, cells were loaded with either 5µM Fluo3-AM (Stratech Scientific 
LTD, Newmarket, UK; Life Technologies) or 5µM Fura2-AM (Teflabs, Austin, USA) in 
DMEM with 1% BSA and 0.025% Pluronic acid F127 for 1 hr at room temperature 
then washed in imaging buffer and left for 10 min at room temperature to allow de-
esterification of the calcium probe. Imaging buffer was adapted to exclude Ca2+ 
where this was required for experimental considerations.  
 
2.5.2. – Cellular Ca2+ measurement 
 
Intracellular Ca2+ responses were recorded using a Colibri LED microscope system 
with an Axiocam Mrm CCD camera and Axiovision software version 4.7 with the 
additional physiology module for live cell Ca2+ imaging (Zeiss). Cytoplasmic regions 
of interest (ROIs) were drawn over the cell and a minimum number of 5 cells were 
analysed per field of view per experiment. Prior to agonist addition recordings of the 
Ca2+ probe baseline was used to provide comparative basal Ca2+ measurements of 
cells within the same experiment. All agonist-induced Ca2+ responses were 
compared by peak height. Data was subsequently analysed using Graphpad Prism. 
Experiments utilising Fluo3 were converted to % of control against the control cell 
line (WT BD cells in all cases). This was to make the experiments comparable in the 
absence of a loading control. This was not necessary for Fura2 as a loading control 
is present as part of this probe making experiments comparable.  
 
2.5.3. – Lysosomal Ca2+ release measurements 
 
Release of lysosomal Ca2+ was measured using methods adapted from those 
previously described (Lloyd-Evans et al., 2008). Post loading with a cytosolic Ca2+ 
probe addition of 300µM GPN (Sigma, Alfa Aesar,Ward Hill, USA; Cayman, Ann 
Arbor, USA) was used to induce lysis of the lysosome, 100-250nM NAADP-AM 
(synthesised according to Parkesh et al., 2008) was used to release Ca2+ from the 
TPC2 channel and 5mM NH4Cl was used to de-protonate the lysosome and 
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subsequently release Ca2+ as required for the experiment. In later experiments 10µM 
Nigericin was used to induce Ca2+ release from the lysosome due to the action of 
nigericin as a Ca2+ - K+ antiporter. This change in protocol was due to inconsistent 
observations of lysosomal lysis in response to some batches of GPN from Alfa Aesar 
and Cayman. This was observed during the time experiments in chapter 5 were 
taking place and was also used in 3.2.3.11. and 3.2.3.15. In order to prevent the 
release of Ca2+ from other cellular stores as a result of Ca2+ induced Ca2+ release 
(CICR) in some experiments cells were pre-treated with either 1 µM or 5µM 
thasigargin (Sigma) to prevent ER release, or 2 µM or 5 µM ionomycin (Calbiochem) 
to prevent release from all other cellular Ca2+ stores. 
 
2.5.4. – ML-SA1 induced Ca2+ release measurements 
 
ML-SA1 (Calbiochem) is a synthetic agonist which induces Ca2+ release from 
TRPM1 as described in (Shen et al., 2012) To study Ca2+ release in response to ML-
SA1 cells were treated with 20µM ML-SA1 (BD blastocysts) or 50µM ML-SA1 
(Human fibroblasts). All experiments with ML-SA1 were conducted in he absence of 
Ca2+ in imaging buffer.  
 
2.5.5. – ER Ca2+ release measurements 
 
Release of ER Ca2+ was measured by addition of between 1µM and 5µM 
thapsigargin (Sigma), dependant upon cell type, or 10µM ryanodine post loading with 
a cytosolic Ca2+ probe. In order to evaluate if cells were more susceptible to Ca2+ 
release decreased concentrations (0.1µM thapsigargin) of antagonist was used. 
Thapsigargin is a non-competitive inhibitor of SERCA2 which actively transports Ca2+ 
into the ER; at the concentrations used thapsigargin causes ER Ca2+ channel 
unmasking releasing Ca2+ from Ca2+ leak channels causing subsequent CICR from 
ryanodine and IP3 receptors on the ER. It is not necessary to remove other Ca2+ 
stores when measuring ER Ca2+ release as it is the largest cellular Ca2+ store so the 
input from other Ca2+ stores is negligible when this experiment is conducted in the 
absence of extracellular Ca2+. In some experiments 10µM ryanodine was used to 
induce Ca2+ release from the ryanodine receptors (RyRs) on the ER.  
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2.5.6. – Mitochondrial Ca2+ release measurements 
 
Mitochondrial Ca2+ release was induced by de-polarisation of mitochondria by 10µM 
rotenone post loading with a cytosolic Ca2+ probe. Prevention of release from other 
Ca2+ stores was not possible for this store as it would either cause mitochondrial 
release (ionomycin) or raise mitochondrial Ca2+ levels due to the uptake of cytosolic 
Ca2+ released from other stores such as the ER.  
 
2.5.7. – Store operated Ca2+ entry measurements 
 
Cells loaded with cytosolic Ca2+ probe in Ca2+ free imaging buffer were induced to 
release ER Ca2+ with 1-5 µM thapsigargin. This activates STIM proteins which 
translocate from the ER to the plasma membrane where they bind ORAI to facilitate 
plasma membrane Ca2+ entry. Accordingly when the Ca2+ release induced by 
thapsigargin has returned to baseline 1mM Ca2+ is added to the imaging medium and 
response are measured. 
 
2.6. – Biochemistry 
 
2.6.1. – Thin Layer Chromatography 
 
Lipid species within cells were quantified using a thin layer chromatography method 
adapted from Maue et al. (2012). 
 
2.6.1.1. – Lipid Extraction 
 
Cells were harvested from tissue culture flasks by trypsinisation before pelleting by 
centrifuge and 3 washes in DPBS. Cell pellets were subjected to 3 rounds of freeze-
thaw and homogenised by 50 strokes in a PTFE coated glass pestle and mortar 
homogeniser on ice. Homogenate was centrifuged at 1000rpm for 5 min at 4°C and a 
small aliquot of supernatant taken for BCA protein assay (conducted as per 
manufacturers instructions). Aliquots of samples were then taken from the entire 
homogenate equal to the maximum amount of protein (<1mg) available across all the 
desired samples. Volumes were equalised with MilliQ water and lipids were extracted 
	   80	  
by adding 5 original volumes of chloroform:methanol 1:2 to each sample before 
gentle agitation by roller for 16 hr at 4°C. Samples were then centrifuged at 3000rpm 
for 10 min at 20°C and the supernatant collected. The pellet was re-extracted with 5 
original volumes of chloroform:methanol 1:2 and agitated gently by roller for 3 hr at 
room temperature. Samples were again centrifuged at 3000rpm for 10 min at 20°C 
and supernatant collected. Combined supernatant was then dried down under a 
stream of N2. 
 
To remove excessive salt from the samples resuspension by vigorous vortexing in 2 
ml of chloroform:methanol 1:2 was followed by the addition of 3ml of PBS and 3ml of 
chloroform:methanol 1:2  and samples vortexed then centrifuged at 500rpm for 2 min 
at 20°C to give a clear phase separation. The aqueous upper phase was removed 
and the remaining organic lipid containing lower phase after this process was dried 
down under nitrogen.  
 
2.6.1.3. – Preparation of standards for TLC 
 
A total lipid brain extract (Avanti Polar lipids, Alabaster, USA) was solubilised in 
chloroform:methanol 1:1. The lipid species present in this extract have been verified 
using standard preparations of different lipids (Avanti Polar Lipids, Sigma, Matreya). 
150 µg of brain extract was loaded per cm of lane onto each plate. 
 
2.6.1.2. – TLC separation of lipid species 
 
A pre-dried silica gel HPTLC plate (Merck, Kenilworth, USA) was used to separate 
the lipid species, samples were resuspended in chloroform:methanol 1:1 by vortexing 
and sonication and applied at the nottom of the plate in lanes of a size dependant 
upon the starting amount of material extracted (approx. 0.3cm for samples below 
0.5mg protein, 0.5 cm for samples between 0.5-1mg of protein and 1cm for samples 
between 1-2mg protein). Loaded plates were ran in a pre-equilibrated TLC tank with 
a mobile phase of chloroform:methanol:water 65:25:5 until the solvent front was 1cm 
from the top edge of the TLC plate. This mobile phase was changed to 
chloroform:methanol:water 80:10:5 if separation of cholesterol and ceramide was 
required. 
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2.6.1.4. – Development of separated lipid species 
 
Plates for general lipid analysis were dried under a stream of hot air prior to spraying 
with p-Anisaldehyde spray reagent consisting of 50ml glacial acetic acid, 1ml 
concentrated sulphuric acid and 0.5ml p-Anisaldehyde. Plates were sprayed until 
saturation. Saturated plates were then charred by gradual warming up to 95°C.  
 
2.6.1.5. – Analysis of lipid species 
 
Post heating plates were scanned immediately in both grayscale and colour. 
Coloured images were used to assist with lipid species identification and grayscale 
images were used for densiometric analysis using ImageJ. In order to do this the gel 
analysis plugin was utilised in order to plot the grayscale values from bands on the 
TLC. These plots were used to calculate the area under the curve of each of the 
bands relating to known lipids, baseline decay was taken into account when defining 
the extent of these peaks.  
 
2.6.2. – Western blotting  
 
Homogenised samples from cell pellets corresponding to 5µg of protein (determined 
by BCA assay, as per manufacturers instructions) was denatured in sample buffer 
SDS containing sample buffer for 1hr at 60°C. Denatured protein samples were 
separated by gel electrophoresis across a 10% SDS-PAGE gel at 160V for 2 hr. 
Proteins were then transferred onto PVDF transfer membrane soaked in methanol 
(Merck-Millipore, Billerica, USA) using a semi-dry transfer method at 40mA for 2 hr.  
 
Transfer membranes were then blocked overnight at 4°C in 5% milk powder solution. 
Before incubation with anti-TRPML1 primary antibody (Santa Cruz, Dallas, USA) at 
1:1000 dilution overnight at 4°C in 5% milk powder solution. After repeated washing 
in TBS buffer with 0.05%  TWEEN-20 an anti-rabbit secondary antibody was applied 
at a 1:10000 dilution. Subsequently transfer membranes were washed in ECL 
development solution and exposed onto X-ray film (Santa Cruz) prior to 
development.  
 
Bands were analysed utilising the same methodology described for TLC analysis 
above.  
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2.7. – Statistical analysis 
 
For statistical analysis each n refers to an experiment initiated from an independent 
plating of cells, for microscopy or Ca2+ analysis, or an independent cell culture, for 
western blot or TLC analysis.   
 
T tests were performed for experiments in which values from 2 conditions were being 
compared. In relation to Ca2+ analysis and threshold counting, these values were 
experimental means from individual measurements. With respect to western blotting 
and TLC analysis these were individual bands from these studies these were 
generated from independently prepared cell cultures. One way ANOVA with 
Bonferroni post test were used to analyse experiments in which 3 or more conditions 
were present. The data used in this analysis was as described above for T tests. 
Analysis of survival curves was conducted by Logrank test. All these tests were 
performed using in Graphpad Prism version 4.0c. 
 
For experiments in which groups of cells within a cell culture were being compared 
Chi2  (Χ2) tests were used. In these tests the expected value was generated from the 
mean of the groups in the cell culture that was being compared against. As standard 
error of the mean (SEM) was small (<10%) in all the experiments these tests were 
utilised to compare this remains robust. Individual Χ2 values were calculated for each 
experimental repeat of these experiments and are shown in the text. For experiments 
in which 5 or more repeats had been conducted Χ2 values are presented as a mean 
of the individual values +/- SEM. Χ2 values were calculated in Microsoft excel.  
 
Statistical test for each experiment are shown in figure legends, as are indicators of 
significance which are as follows: * = P < 0.05, ** = P < 0.01, *** = P < 0.001, **** = P 
< 0.0001.  
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Chapter 3 
 
 
 
How do Ca2+ and lipid 
dyshomeostasis in the 
endolysosomal system contribute 
to familial Alzheimer’s disease? 
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3.1. – Introduction  
 
3.1.1. – Alzheimer’s disease 
 
Alzheimer’s disease is the most common neurodegenerative disease in North 
America and Europe, worldwide a new case is estimated to be reported every 7 
seconds (Cornutiu, 2015). It is a form of slowly progressing dementia which often 
begins with subtle, symptoms, which may go unrecognised. Commonly patients 
present with the disease around the 6th decade of life with symptoms such as short 
term memory loss which progresses to incapacitation over an average course of 8-10 
years. During this time, patients may suffer from a variety of symptoms including 
confusion, poor judgment, language disturbance, agitation, withdrawal and 
hallucinations (Mckhann et al., 2011). As with other forms of dementia, the incidence 
of Alzheimer’s increases markedly with age and a combination of subtle initial 
symptoms and convergent phenotypes with other forms of dementia mean that many 
cases remain undiagnosed (Bird, 1998).  
 
In addition to the clinical presentation of dementia, Alzheimer’s patients are also 
observed to have gross cerebral atrophy by computed tomography scan (CT) or 
magnetic resonance imaging (MRI) and diffuse cerebral hypometabolism by positron 
emission tomography (PET) (Bird, 1998; Weiner, M.W., 2015). In the post-mortem 
brain extracellular plaques consisting of the protein β-amyloid (Aβ) and intraneuronal 
tangles of aberrantly phosphorylated tau protein are observed and analysis of patient 
cerebro-spinal fluid (CSF) reveals alterations in the levels of these proteins (Snider et 
al., 2009). Lewy bodies consisting of α-synuclein may also be present in the 
amygdala in some cases highlighting the convergent pathology observed in various 
form of dementia (Bird, 1998; Popescu et al., 2004;).  
 
The majority of Alzheimer’s cases, approximately 95%, are considered idiopathic. 
Currently there are no known environmental agents which have been proved to be 
directly involved in Alzheimer’s although twin studies have implicated both genes and 
environment (Bird, 1998). Recently, there has been a concerted effort within the 
Alzheimer’s research community to identify predisposing genetic variation using large 
datasets in the hope of identifying disease modifiers (Escott-Price et al., 2014; 
Lambert et al., 2013).  
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3.1.2 - Familial Alzheimer’s disease 
 
The remaining approximately 5% of Alzheimer’s patients are considered to have 
familial Alzheimer’s disease (FAD) as two or more cases have been observed in 
directly related individuals. Of all Alzheimer’s cases 95% are classified as late-onset 
(LOAD) as symptoms begin to manifest in the sixth decade of life; the remaining 5% 
experience symptoms prior to this age and are considered early-onset (EOAD) (Raux 
et al., 2005). 
 
The first gene linked to Alzheimer’s by investigation of families presenting with EOAD 
was APP which codes for the β-amyloid precursor protein (Goate et al., 1991). This 
protein is the precursor of β-amyloid (Aβ) which had been isolated from the brain of a 
patient with Down’s syndrome and was originally linked to Alzheimer’s due to the 
universal presence of Alzheimer’s in patients with trisomy 21 (Masters et al., 1985). 
With this suggestion of chromosome 21 as the location for a causative Alzheimer’s 
gene, and another study showing duplication of the APP locus was present in 
sporadic Alzheimer’s patients (Delebar et al., 1987), mutations in APP were identified 
as a cause of EOAD (Goate et al., 1991) and subsequent publications corroborated 
these findings (Chartier-Harlin et al., 1991; Murrel et al., 1991; Mullan et al., 1992). A 
combination of these studies helped establish the amyloid hypothesis of Alzheimer’s 
disease Hardy and Allsop, 1991; Hardy and Higgins, 1992). This entailed five major 
predictions: (i) Other kindreds with Alzheimer’s would be identified with APP 
mutations, (ii) Aβ is a normal product of APP metabolism and that the mutations 
would influence Aβ production, (iii) other Alzheimer’s genes would be identified and 
these would influence Aβ production, (iv) regulatory variants in APP would 
predispose to LOAD, (v) Aβ deposition is a central event in the pathogenesis of 
Alzheimer’s (Goate and Hardy, 2012).  
 
Initially, these predictions seemed to bear weight with Presenilin genes 
(PSEN1/PSEN2) identified as another cause of familial EOAD and the demonstration 
that Presenilin formed the catalytic core of the complex capable of metabolising APP, 
thus affecting Aβ production. Such observations have lead to the development of 
Alzheimer’s disease animal models and informed therapeutic study. Confirmation of 
predictions iv and v have proven more elusive; variants predisposing to LOAD have, 
as yet, not been directly linked to APP regulation. For example, the most common 
variant predisposing to LOAD is the ε4 allele of Apolipoprotein E (APOε4), which 
causes a dose-dependant increase in risk and decrease in age of onset of 
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Alzheimer’s. This gene influences cholesterol metabolism, and although this has 
been linked to changes in Aβ clearance, it is not directly implicated in APP regulation. 
The final prediction of the amyloid hypothesis remains unproven, as Aβ lowering 
therapies have not proven efficacious in the treatment of Alzheimer’s, accordingly the 
role of Aβ, APP and the amyloid hypothesis remains debatable (Goate and Hardy, 
2012).  
 
As previously mentioned, the other ‘hallmark’ of post-mortem Alzheimer’s pathology 
is the intracellular accumulation of aberrantly phosphorylated tau protein in structures 
known as neurofibrillary tangles (NFTs) (Liu et al., 2015). Tau proteins are highly 
expressed in the neurons where they assist in the stabilization of microtubules and 
are encoded by MAPT, alternative mRNA splicing of which provides the six tau 
isoforms present in human brains (Goedert et al., 1989). Tau has been implicated in 
LOAD (Gerrish et al., 2012) where the presence of NFTs correlates well with 
neuronal loss (Gomez-Isla et al., 1997). In Alzheimer’s, tau protein becomes 
hyperphosphorylated and accumulates in the form of paired helical filaments which 
accumulate in the form of larger filaments of around 10nm. It has been suggested 
that a ‘tau protein hypothesis’ may better explain Alzheimer’s pathogenesis that the 
amyloid hypothesis (Maccioni et al., 2010) however most studies now agree that an 
interplay between hyperphosphorylaed tau and Aβ underlie this process. It is 
hypothesised that a dual pathway model may exist with the intracellular presence of 
Aβ as smaller aggregates, such as oligomers, as an initiating factor driving 
subsequent pathology including tau hyperphosphorylation (Walsh and Selkoe, 2007). 
Although such a pathway remains to be proven it would implicate the endolysosomal 
system in Alzheimer’s pathogenesis, as both early processing of Aβ and the 
clearance of hyper-phosphorylated tau is dependent upon the endolysosomal system 
(Lin et al., 2014; Wang et al., 2009).  
 
Recently, genome-wide association studies (GWAS) have utilised advances in 
sequencing technology in order to assess common genetic variability at the level of 
the whole genome between large groups of patients and controls. Such studies have 
identified over 20 genetic loci which, in isolation, impart a low risk of late-onset 
Alzheimer’s disease (LOAD) upon patients. Interestingly, these genetic loci partition 
into a small number of distinct biological pathways with the predominant effects upon 
three main processes: the immune system and inflammatory responses, cholesterol 
and lipid metabolism and endolysosomal vesicle trafficking (Escott-Price et al., 2014; 
Lambert et al., 2013). Accordingly the implication of genes such as BIN1, PICALM 
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(Lambert et al., 2013) and SORL1 (Nicholas et al., 2015) provide further evidence 
that the endolysosomal system is important to the pathogenesis of Alzheimer’s 
disease. 
 
3.1.3. – The endolysosomal system in Alzheimer’s disease 
 
As previously mentioned the processes which occur within the endolysosomal 
system may be central to the pathogenesis of the various forms of Alzheimer’s. 
Changes to this system within neurons have also been reported to be one of the 
primary pathogenic events in Alzheimer’s. This has been observed in patients with 
Down’s syndrome decades before the onset of Alzheimer’s and has been proposed 
as an initiating factor underlying changes leading to the elevation of Aβ levels in 
patients with sporadic Alzheimer’s (Cataldo et al., 1997; Cataldo et al., 2000).  
 
One of the primary links between the endolysosomal system and Alzheimer’s is the 
importance of this pathway for the processing of APP. Glycosylated APP situated at 
the plasma membrane is subject to continuous turnover by two well-delineated 
mechanisms although other mechanisms may be involved in this processing. One 
mechanism begins with α-cleavage of APP by aspartyl proteases at a site within the 
extracellular domain to generate a large soluble N-terminal fragment which enters 
the extracellular milieu and a C-terminal fragment (CTF) which remains membrane 
associated. The alternate mechanism is initiated when plasma membrane APP is 
internalised within early endosomes prior to β-cleavage to generate a smaller soluble 
N-terminal fragment than α-cleavage and accordingly a larger CTF. The aspartyl 
protease which cleaves these β-CTFs, γ secretase, requires an acidic pH optimum 
and is predominantly present in the endolysosomal system. Aβ can be generated 
from β-CTFs by intramembrane γ-cleavage to yield mainly 40 aa Aβ (Aβ40) with a 
smaller amount of 42 aa Aβ (Aβ42). Changes in the ratio of Aβ42:Aβ40 are 
considered to be one of the better biomarkers of Alzheimer’s (Nixon, 2005; Spies et 
al., 2010). Inhibition of endocytosis in model systems have been shown to decrease 
Aβ generation with the converse true of acceleration (Koo et al., 1994; Grbovic et al., 
2003). γ-cleavage of APP is mediated by the γ-secretase complex which consists the 
proteins presenilin 1 (PS1) and 2 (PS2), nicastrin, anterior pharynx defective 1 (apH-
1) and presenilin-enchancer protein (PEN) (Edbauer., 2003; Nixon., 2005). The 
various components of this complex have been identified throughout the autophagic 
and endolysosomal system clearly implicating this system in APP processing and 
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highlighting how dysfunction in this pathway can impact upon Aβ production 
(Pasternak et al., 2003).  
 
Interestingly, the well established risk factors for Alzheimer’s disease such as APoE 
alleles (Ji et al., 2006) and the causes of faimilial Alzheimer’s such as APP and PS1 
have all also been further implicated in lysosomal dysfunction particularly disruption 
of lysosomal proteolysis (Lee et al., 2010). When the effect of other contributors to 
Alzheimer’s pathogenesis such as Aβ peptide, oxidised lipids and lipoproteins have 
also been shown to disrupt lysosomal proteolysis (Glabe 2001) and increase the 
substrates entering this system by Rab5 upregulation (Grbovic et al., 2003) it is not 
surprising that these phenotypes remain an area of intense study. The implications of 
impaired lysosomal proteolysis particularly in relation to defects in autophagic 
processes will be discussed in section 3.1.4.  
 
A variety of other proteins in the endolysosomal system including both 
transmembrane proteins from various organelles and soluble lysosomal hydrolases 
have also been implicated in Alzheimer’s pathogenesis. A number of these identified 
lysosomal hydrolases such as lysosomal acid lipase (LAL) (von Trotha., 2006), 
identified by linkage analysis, and acid sphingomyelinase (ASM), identified as a 
potential therapeutic target in animal models of familial Alzheimer’s, link lysosomal 
catabolism and endocytosis to cholesterol and lipid homeostasis (Grimm et al., 2005; 
Lee et al., 2014.), another pathway implicated in LOAD by GWAS studies (Lambert 
et al., 2013). It is interesting to note that there is significant interplay between these 
two pathways as previously described.  
 
Endolysosomal transmembrane proteins such as TRPML1 and NPC1 have also 
been implicated in Alzheimer’s pathogenesis. The recent connection to TRPML1 has 
been identified in a preclinical model of HIV infection used to investigate the 
premature deficits in cognition often experienced by HIV-infected patients who have 
responded to anti-retroviral therapy (Bae et al., 2014). Conversely the connection 
between NPC1 and Alzheimer’s is long established even to the degree where NPC 
disease is referred to as ‘childhood Alzheimer’s’ partially due to the presence of 
NFTs in post-mortem patient brains, it is interesting that this is not strongly 
associated with the presence of plaques; a rare occurrence (Love et al., 2005; Saito 
et al., 2002; Nixon 2005). As discussed in section 1.5.2. loss of function in the NPC1 
protein is associated with the lysosomal accumulation of a variety of lipids and the 
resultant effect of cholesterol storage in NPC1 models upon APP processing, 
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including the accumulation of APP-CTFs (Jin et al., 2004; Boland et al., 2010) and 
redistribution of presenilin to the early endocytic system has been studied (Burns et 
al., 2003). Given that the accumulation of other lipids including sphingolipids, which 
have been implicated in Alzheimer’s disease pathogenesis (Grimm et al., 2010) also 
accumulate in NPC1 deficient lysosomes further work may be necessary to 
determine whether endocytic dysfunction or lipid dysregulation is the preliminary 
pathogenic event underlying Alzheimer’s phenotypes in models of NPC disease. Yet 
further complexity is added to this situation when the presence of NFTs in NPC 
patients is considered, particularly, as it is one of only a small number of disorders 
where NFTs can be robustly observed in the absence of tau mutations and, in some 
cases, Aβ deposition (Love et al., 2005; Saito et al., 2002; Nixon 2005). Interestingly, 
tau mutation have been shown to exacerbate NPC phenotypes suggesting an 
interaction between the two proteins (Malnar et al., 2014). Given that a myriad of 
lysosomal defects have been found within Alzheimer’s disease patients and models it 
is perhaps somewhat surprising that few genetic links directly implicating the 
lysosome in pathogenesis have been discovered. Nevertheless, it remains an 
important area of study as increasing numbers of genes and pathways which 
predispose individuals to Alzheimer’s disease are shown to either cause or be 
compounded by endolysosomal dysfunction (Lambert et al., 2014). It may transpire 
that the role of the lysosome as a hub for the many cellular pathways which comprise 
the greater lysosomal system (section 1.2) and the importance of these pathways to 
neuronal cell function (1.6.2.) underlies this potential link. 
 
3.1.4. – Autophagy and Alzheimer’s disease 
 
One pathway which forms part of the greater lysosomal system and terminates at the 
lysosome that has been extensively studied in relation to Alzheimer’s is autophagy 
(Nixon, 2005; Nixon, 2013). The architecture of neurons places particular strain on 
this system as dysfunctional organelles must be transported large distances by 
retrograde transport of autophagosomes to reach the cell body where the majority of 
lysosomes are located. In young neurons, this task and the subsequent clearance of 
autophagic substrates such as dysfunctional organelles proceeds efficiently, however 
as neurons age this process begins to slow and as terminally differentiated cells they 
are not aided by reductions in these substrates due to cell division. Accordingly they 
are vulnerable to the accumulation of autophagic substrates (Boland et al., 2008); a 
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process which has been strongly linked to the accumulation of protein aggregates 
observed in many neurodegenerative diseases (Nixon, 2013).  
 
In a number of Alzheimer’s disease models and post-mortem samples from 
Alzheimer’s patients dystrophic neurites, reminiscent of the meganeurites observed 
in LSDs, filled with autophagic vacuoles have been reported (Walkley et al., 1990). 
Although some of this accumulation may be caused by increases in the induction of 
autophagy, a lack of clearance of these organelles due to defects in the lysosome 
has been proposed as the major contributing factor. This proposal is supported by 
observations detailing LSD-like accumulations of autophagic vacuoles, particularly 
autolysosomes, when lysosomal proteolysis is disrupted in wild-type mice and the 
compounding of these phenotypes when the same disruptions in mouse models of 
Alzheimer’s (Boland et al., 2008; Yang et al., 2008; Lee et al., 2011). The further 
study of these phenotypes in presenilin deficient cell lines and animal models of 
familial Alzheimer’s have revealed some interesting mechanistic suggestions (Lee et 
al., 2010).  
 
3.1.5. – Endolysosomal dysfunction in presenilin deficient models of 
Alzheimer’s 
 
In 2010, Lee et al. proposed that decreases in lysosomal proteolysis observed in 
cells deficient in PS1 was the result of lysosomal alkalisation and cathepsin 
activation, resulting from improper targeting of the V0a1 subunit of v-ATPase to the 
lysosome. As discussed in section 1.1.5., this protein complex is responsible for 
lysosomal acidification. The targeting defect was the result of defective N-
glycosylation of V0a1 due to the removal of a selective binding event with PS1, which 
is necessary to facilitate the interaction of the unglycosylated protein with the Sec61 
alpha/oligosaccharyltransferase complex. The resulting autophagic pathology and 
the accumulation of pathogenic protein aggregates was proposed to result from this 
initial event (Lee et al., 2010). Although lysosomal alkalisation was also observed in 
fibroblasts from Alzheimer’s patients and have been reported by a number of other 
groups, this phenotype has been the subject of contention (Avrahami et al., 2013; 
Coen et al., 2012; Wolfe et al., 2013). Some aspects of this contention may be that 
correct measurement of lysosomal pH is technically difficult which may be best 
illustrated by a recent paper by Coffey et al. (2014) which showed lysosomal 
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alkalisation in fibroblasts from familial Alzheimer’s patients in the region of 0.2 - 0.3 
pH units.  
 
Subsequently, a paper which contends the findings of Lee et al. was published. In 
this paper Coen et al. (2012) propose that lysosomal alkalisation is not present and 
that the accumulation of autophagic vacuoles is the result of reduction in lysosomal 
Ca2+ preventing the fusion of autophagic vacuoles with lysosomes (Coen et al., 
2012). Although the authors did not provide a mechanism for this process it has been 
suggested that reduced ER Ca2+ leak results in less ability for the lysosome to fill with 
Ca2+(Bezprozvanny, 2012).  
 
3.1.6. – Ca2+ dyshomeostasis in Presenilin 1 deficient cells. 
 
This study expands observations of Ca2+ dyshomeostasis in familial Alzheimer’s to 
the lysosome. Previously studies on Ca2+ dyshomeostasis in Alzheimer’s have 
focussed on the ER and the proposal that PS1 is a Ca2+ leak channel in this 
compartment (Tu et al., 2006; Popugaeva et al., 2013). A summary of the findings 
relating to Ca2+ dyshomeostasis in cells deficient in Presenilin 1 is shown in figure 
3.1.  
 
It is proposed that the loss of PS1-mediated Ca2+ leak from the ER leads to elevation 
in the Ca2+ content of this store. As a compensatory mechanism, the activity of ER 
Ca2+ release channels such as the ryanodine receptor (RyR) and IP3 receptor (IP3R) 
are potentiated and release more Ca2+. This is accompanied by downregulation of 
store-operated Ca2+ entry (SOCE) (Popugaeva et al., 2013). There are varied reports 
of the result this has on cytosolic Ca2+ (Brunello et al., 2009; Tu et al., 2006) although 
the varied levels, including transient elevations in Ca2+ from the ER, are thought to 
lead to increased mitochondrial buffering of Ca2+ and subsequently the increased 
levels of Ca2+ in this organelle (Huang., 2014; Zampese., 2011). The recent addition 
of the lysosome to stores which are deregulated in PS1-/- cells is also shown. If 
reductions in Ca2+ release from lysosomal Ca2+ channels such as TPC2 and 
TRPML1 are present then this may result in lack of vesicular fusion and, therefore, 
autophagic impairment.  
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Figure 3.1. – Ca2+ dyshomeostasis in cell as a result of loss of function in PS1. Changes 
to Ca2+ stores are shown by black arrows, pathogenically changes to Ca2+ releases are 
shown by thin arrows, red arrows indicate elevated release, grey arrows indicate reduced 
release. Protein loss of function is indicated by black crosses. Adapted from Popugaeva et 
al., 2013 and Lloyd-Evans et al., 2010. 
 
Of particular interest here is the similarity of this phenotype to that in NPC disease, a 
condition strongly linked to Alzheimer’s-like pathology. It is also interesting to note 
that punctate staining with the cholesterol probe, filipin, has been observed in cells 
deficient in both PS1 and PS2 (Thimiri Govinda Raj., et al 2011), a phenotype which 
has also been observed in patient fibroblasts with the E693del APP mutation 
(Nomura et al., 2013). As this phenotype and reduced lysosomal Ca2+ are observed 
in NPC disease we are interested in investigating if presenilin deficiency has any 
further NPC phenotypes.  
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3.2. – Procedures  
 
In section 3.3.1. we will investigate lipid phenotypes observed in cellular models of 
NPC1 disease using PS1-/- blastocyst-derived (BD) cells (2.1.1.) and PS1-/- and 
PS1/2-/- MEF cells (2.1.2.). Lipid phenotypes will be examined using the cell biology 
techniques described in 2.3.1. followed by biochemical quantification of lipid levels 
using thin-layer chromatography (2.6.1.). Subsequently, in section 3.3.2. we will use 
the most suitable of these two cell lines (identified by the studies in 3.3.1.) to conduct 
an examination of other cellular phenotypes observed in NPC1 disease models. 
These will include endolysosomal trafficking assays (2.3.2.5.) and analysis of cell for 
the storage of autofluorescent material (2.3.2.2.). 
 
We will then undertake a thorough examination of lysosomal Ca2+ homeostasis using 
the techniques described in section 2.5 (section 3.3.3.). Where possible at least 3 
independent plating replicates will be used in these experiments and appropriate 
statistical analysis will be performed as detailed in individual figure legends. In 
instances where 3 independent plating replicates were not performed, due to 
unavailability of cells or time restrictions this will be shown in the figure legend. 
These studies will include numerous controls to confirm the specificity of agonists, 
such as ML-SA1, utilised in this study. 
 
Finally, is section 3.3.4, we will apply a combination of these techniques to study if 
any phenotypes we have identified are present in a different model utilised for 
Alzheimer’s research, Down’s syndrome patient fibroblasts.  
 
Statistical analyses as described in section 2.7 have been performed on all these 
experiments as appropriate, details of these are given in individual figure legends.  
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3.3. – Results 
 
3.3.1. – Lipid dyshomeostasis in Presenilin 1 deficient cells suggests complex 
lysosomal pathology 
 
As discussed in section 3.1.5. a number of recent studies have suggested that 
disruption of PS function in cells can lead to a number of phenotypes which are 
suggestive of NPC1 dysfunction (Coen et al., 2012; Thimiri Govinda Raj., et al 2011). 
Currently most of these analyses have involved the visualisation of cholesterol within 
cells so we were interested to see if other lipids known to accumulate in NPC1 
(Lloyd-Evans et al., 2008) disease do so in PS1-/- cells.  
 
 
 
Figure 3.3.1. – Sphingolipid, phospholipid and cholesterol distribution in PS1-/- cell 
lines. Representative microscopy images of wild-type (WT) and PS1-/- BD cells alongside 
wild-type (WT) and PS1-/- MEFs showing levels of cholesterol (white) visualised by filipin, 
sphingomyelin (SphM, red) visualised by IHC against the lysenin toxin, LBPA (green) 
visualised by IHC and ganglioside GM1 (GM1, green) visualised by FITC-tagged CtxB. 
Hoechst 33342 stained nuclei are shown in blue. n = 3. Scale bar = 7.5µm. 
 
Accordingly, we visualised cholesterol with filipin staining, the sphingolipid 
sphingomyelin with lysenin toxin, the phospholipid lysobisphospatidic acid (LBPA) 
with an antibody and the glycosphingolipid, ganglioside GM1, utilising cholera toxin B 
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subunit. All these lipids accumulate in cells with NPC1 disease phenotypes and as 
such we would expect elevated levels of all those lipids accompanied by 
redistribution to a punctate distribution indicative of lysosomal accumulation if NPC1 
phenotypes were present in PS1-/- cells (Lloyd-Evans et al., 2008). 
 
As figure 3.3.1. demonstrates, this is not observed in either of the PS1-/- cell lines 
investigated. Although there appears to be some accumulation of cholesterol in 
punctate bodies this is not accompanied by the concomitant increase in 
sphingomyelin and ganglioside observed in NPC disease, these lipids can instead be 
seen to decrease. There is an accumulation of LBPA, which is somewhat reminiscent 
of NPC disease, however, this lipid becomes elevated as compartment size in the 
endolysosomal system increases, a phenotype likely to occur in cells with any 
deficiency in clearance of substrates from the lysosomal system. As such, this 
increase appears to be a non-specific phenotype resulting from expansion of the 
endolysosomal system in PS1-/- cells.  
 
It is interesting to note that the lipid phenotypes observed in PS1-/- BD cells seem to 
be more severe than those observed in PS1-/- MEF cells. In preliminary experiments, 
MEF cells with a double knockout of PS1 and PS2 were more similar to the results 
obtained in BD cells. This is suggestive of greater redundancy in MEF cells with 
regard to the knockout of either PS1 or PS2 alone in these cells perhaps explaining 
why PS1/2-/- MEF cells are commonly used to study presenilin deficiency. For clarity, 
and more relevance to patient phenotypes, we continued to perform most 
subsequent experiments in PS1-/- BD cells as they represent a robust phenotype 
without the loss of function of multiple proteins – a situation not observed in familial 
Alzheimer’s.  
 
As some hallmarks of NPC1 disease still remain in these cells we decided to further 
investigate lipid phenotypes in PS1-/- BD blastocysts alongside the same cells in 
which we had pharmacologically induced NPC1 disease phenotypes using the well-
characterised molecule U18666a. This induces robust NPC1 phenotypes which 
relate temporally to the onset of cellular dysfunction in NPC1 disease (Lloyd-Evans 
et al., 2008).   
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Figure 3.3.2. – Sphingolipid and cholesterol distribution changes in PS1-/- BD cells 
lines compared to NPC-like lipid storage phenotypes. A – Representative microscopy 
images of wild-type (WT) and PS1-/- BD cells alongside cells treated with 2µg/ml U18666a as 
a positive control for NPC lipid storage. Images show levels of cholesterol visualised by filipin 
(white), LBPA (green) visualised by IHC and ganglioside GM1 (GM1, green) visualised by 
FITC-tagged CtxB. Hoechst 33342 stained nuclei are shown in blue. n = 3. Scale bar = 
7.5µm. B – Images demonstrating the different cholesterol distributions observed in PS1-/- BD 
blastocysts visualised by filipin (white). C – Quantification of the percentage of cells in each 
cell population which have the different cholesterol distributions. Error bars = SEM, n = 8 for 
all conditions apart from PS1-/- + U18666a where n = 5. Scale bar = 7.5µm. *** = P<0.001 by 
Χ2 test.  
 
When PS1-/- cells are compared to cells in which NPC1 disease phenotypes have 
been induced it is clearly evident that the cellular disease phenotypes are clearly 
distinct. The accumulation of cholesterol and LBPA observed in PS1-/- cells is not 
only lower than in cells in which NPC1 disease phenotypes have been induced, it is 
also spatially distinct. Less punctate staining is observed in the perinuclear regions of 
cells with individual punctae much more evenly distributed throughout the cells in a 
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diffuse pattern. The clear decrease in ganglioside GM1 is partially reversed by 
U18666a treatment suggesting that different cellular pathways lead to the alterations 
in levels of this lipid.  
 
When the distribution of cholesterol is analysed in PS1-/- cells there are four different 
distribution patterns observed. Predominating among these, is a diffuse punctate 
distribution distinct from cells with an induced NPC phenotype, although some cells 
demonstrate the perinuclear punctate distribution which predominates in NPC cells. 
Another population of cells show cholesterol in a perinuclear location reminiscent of 
the endocytic recycling compartment (ERC) whilst others do not show any overt 
cholesterol accumulation (figure 3.3.2. B). Quantification of these distribution patterns 
(figure 3.3.2. C) further highlights the difference between WT cells and PS1-/- cells (P 
< 0.001, Χ2 = 1879.55 +/- 90.51 (SEM), df =2), and also those that have had PS1-/- 
cells and NPC1 phenotypes induced by treatment of WT cells with U18666a (P < 
0.001, Χ2 = 1505.97 +/- 24.21 (SEM), df = 2). It can also be observed that NPC1-like 
phenotypes can be induced in PS1-/- cells by U18666a treatment ( P < 0.001, Χ2 = 
1226.89 +/- 49.56 (SEM), df = 2). This analysis was conducted using the means of 
the first cell line in the comparison as the expected value and comparing individual 
experimental repeats of the second cell line to this, in this instance the mean Χ2 
value is then provided for brevity. As inter-repeat variation was low (SEM < 2.5%) in 
these experiments this analysis remains robust.  
 
As chelation of lysosomal Ca2+ to reduce the levels that can be released by the cell 
also creates identical lipid storage phenotypes to those observed in NPC1 disease 
(Lloyd-Evans et al., 2008) it is unlikely that the phenotype of reduced endolysosomal 
Ca2+ is causing the lipid changes observed in PS1-/- cells. From initial inspection the 
distribution of LBPA also reflects the distribution of cholesterol showing the 
differences in distribution are likely to be not solely specific to cholesterol implicating 
changes in endocytic vesicle trafficking in this redistribution. 
 
 
As the analyses described above do not provide quantification of lipid levels we were 
interested to see if these changes could be validated by biochemical quantification. 
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Figure 3.3.3. – Biochemical quantification of sphingolipids, sterols and phospholipids 
in PS1-/- BD cells. A – Representative images of thin-layer chromatography analysis of 
various lipids in wild-type (WT) and PS1-/- BD cells (PS1-/-) ran alongside identified lipid 
standards (STD). Chol/Cer = combined levels of cholesterol and ceramide, GlcCer = 
glucosylceramide, GalCer = galactosylceramide, LBPA = lysobisphosphatidic acid, PL = 
phospholipids, S SphL = simple sphingolipids and SphM = sphingomyelin. B – Densiometric 
quantification of lipid levels in PS1-/- BD blastocysts as a percentage of the lipid levels in 
control BD blastocysts. Lipid species are labeled as in A. Error bars = SD. n = 3.** = P < 0.01, 
* = P < 0.05 calculated by T test.  
 
 
Biochemical quantification of lipid species supports the lipid alterations observed by 
cell biology. An accumulation of cholesterol (P < 0.05, t = 4.544, df = 4, F2,2 = 16.95) 
and LBPA (P < 0.05, t = 3.339, df = 4, F2,2 = 1.429) is accompanied by reductions in 
sphingomyelin (P < 0.01, t = 6.153, df = 4, F2,2 = 1.310) and simple 
glycosphingolipids such as GlcCer (P < 0.01, t = 6.509, df = 4, F2,2 = 2.150, figure 
3.3.3.). This, previously reported (Mutoh et al., 2012), reduction may help to explain 
why levels of gangliosides such as GM1 are reduced as GlcCer is the first GSL 
synthesised within cells and is required for the synthesis of more complex GSLs. It is 
interesting that most GSLs are synthesized from the recycling of their various 
constituent molecules as opposed to de novo synthesis (Schulze and Sandhoff, 
2011). This may be indicative of lower activity in lysosomal hydrolytic enzymes 
although this would be accompanied by punctate lipid accumulation when the 
distribution of lipids is visualised, this remains to be further investigated and defective 
biosynthesis may be the sole cause of this phenotype.  
 
Interestingly, there is also evidence of increased phospholipid accumulation, 
although this was not statistically significant, within PS1-/- cells. Phospholipidosis 
phenotypes are associated with lysosomal alkalisation (Nujic et al., 2012) and are not 
observed in genetic models of NPC1. There is evidence of phospholipid 
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accumulation in cells treated over long periods of time with U18666a however this is 
a non-specific phenotype observed after the onset of NPC disease phenotypes 
(Waller-Evans et al., Unpublished). In preliminary experiments, using a probe for 
phospholipidosis, no increase was seen in PS1-/- cells in relation to control cells, 
however, it is anticipated this is due to lower loading of the probe in PS1-/- cells due 
to trafficking defects (figure 3.3.8.).  
 
Robust accumulation of sphingoid bases (P < 0.01, t = 6.267, df = 4, F2,2 = 11.40, 
figure 3.3.3.) is also observed in PS1-/- cells. These lipids would include sphingosine 
the most simple of sphingolipids, and, the substrate shown to accumulate first in 
NPC1 disease (Loyd-Evans et al., 2008). This method does not, however, 
differentiate between this lipid and biosynthetic sphingoid bases such as 
sphinganine, the important signaling lipid sphingosine-1-phosphate and 
lysosphingolipids such as lyso-sphingomyelin. Accordingly, a number of processes 
may contribute the increase in this band and these phenotypes should be further 
investigated.  
 
 
 
Figure 3.3.4. – Biochemical quantification of sphingolipids, sterols and phospholipids 
in PS1-/- and PS1 and PS2-/- MEF cells. A – Representative images of thin-layer 
chromatography analysis of various lipids in wild-type (WT) and PS1-/- MEFs (PS1-/-) and PS1-
/- and PS2-/- MEFs (PS1/2-/-) ran alongside identified lipid standards (STD). Chol/Cer = 
combined levels of cholesterol and ceramide, GlcCer = glucosylceramide, GalCer = 
galactosylceramide, LBPA = lysobisphosphatidic acid, PL = phospholipids, S SphL = simple 
sphingolipids and SphM = sphingomyelin. B – Densiometric quantification of lipid levels in PS 
deficient MEFs as a percentage of the lipid levels in control MEFs. Lipid species are labeled 
as in A. Error bars = SD. n = 2. ** = P<0.01, calculated by one way ANOVA with Bonferroni 
post test.  
 
 
As expected from the investigation of lipids in PS1-/- MEFs by cell biology (figure 
3.3.1.) similar phenotypes are observed in PS deficient MEFs although they are not 
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as robustly observed until both PS1 and 2 are removed. This is particularly evident in 
the levels of sphingomyelin observed in cells. In PS1-/- MEFs there is actually a trend 
towards increased sphingomyelin predominantly through increases in the lower band 
of this lipid before both species become significantly reduced to around 20% in 
PS1/2-/- cells (P < 0.01, t = 1.773, df = 1).  
 
The band observed below sphingomyelin on the TLC in figures 3.3.4. is most likely to 
be a species of ganglioside which has not yet been defined. Initial TLC analysis of 
ganglioside levels in all of the cell lines discussed above show the reductions in 
ganglioside GM1 observed in these cell lines by cholera toxin B analysis and 
disruption in many other ganglioside species although this class of lipids remains to 
be fully analysed.  
 
 
 
 
Figure 3.3.5. – Biochemical quantification of cholesterol, ceramide, LBPA and 
glycosphingolipids in PS1-/- BD cells. A – Representative images of thin-layer 
chromatography analysis of various lipids in wild-type (WT) and PS1-/- BD cells (PS1-/-) ran 
alongside identified lipid standards (STD) in a mobile phase designed to optimize the 
separation of cholesterol and ceramide. Chol = cholesterol, Cer = ceramide, GlcCer = 
glucosylceramide, GalCer = galactosylceramide and LBPA = lysobisphosphatidic acid. B – 
Densiometric quantification of lipid levels in PS1-/- BD blastocysts as a percentage of the lipid 
levels in control BD blastocysts. Lipid species are labeled as in A. Error bars = SD. n = 3 from 
three independent cell cultures. *** = P < 0.001, ** = P < 0.01, * = P < 0.05 calculated by T 
test.  
 
Adaption of the TLC performed in figures 3.3.3 and 3.3.4 by modulation of the mobile 
phase to separate cholesterol and ceramide reveals that both lipids are increased in 
these cells (P < 0.05, t = 2.797, df = 4, F2,2 = 1.750 and P < 0.001, t = 19, df = 4, F2,2 
= 38.66). The elevation of cholesterol is as expected from filipin staining of these 
cells (figure 3.3.1 and figure 3.3.2.) and the changes in other species of lipid 
glycosphingolipids (P < 0.05, t = 3.597, df = 4, F2,2 = 3.683 for GalCer and P < 
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 0.01, t = 6.311, df = 4, F2,2 = 5.683 for GlcCer) and LBPA ( P < 0.05, t = 2.865, df = 
4, F2,2 = 16.60) are confirmed. It is interesting that ceramide is also robustly increased 
to 150% of control levels in these cells. This is a phenotype observed in a variety of 
cellular and animal models of Alzheimer’s along with clinical samples (Haughey et 
al., 2010). Ceramide elevation has not been reported in models of NPC1 disease 
further highlighting the divergent phenotypes between cells from this disease and 
PS1-/- cells.  
 
 
 
Figure 3.3.6 – Biochemical quantification of cholesterol, ceramide, LBPA and 
glycosphingolipids in PS1-/- and PS1 and PS2-/- MEF cells. A – Representative images of 
thin-layer chromatography analysis of various lipids in wild-type (WT) and PS1-/- MEFs    
(PS1-/-) and PS1-/- and PS2-/- MEFs (PS1/2-/-) ran alongside identified lipid standards (STD) in 
a mobile phase designed to optimize the separation of cholesterol and ceramide. Chol = 
cholesterol, Cer = ceramide, GlcCer = glucosylceramide, GalCer = galactosylceramide and 
LBPA = lysobisphosphatidic acid. B – Densiometric quantification of lipid levels in PS 
deficient MEFs as a percentage of the lipid levels in control BD blastocysts. Lipid species are 
labeled as in A. Error bars = SD. n = 2 from two independent cell cultures. *** = P<0.001, ** = 
P<0.01, * = P<0.05 calculated by one way ANOVA with Bonferroni post test.   
 
Subsequent assay of these phenotypes in MEF cells deficient in PS1 reveal the 
expected pattern of alterations in lipid levels suggested by previous analyses (figure 
3.3.4 and figure 3.3.5.). The decrease in GSLs is further exacerbated in PS1 and 
PS2-/- cells reducing to less than 50% of control levels for GlcCer (P < 0.01, t = 22.37, 
df = 1). Accumulation of cholesterol and LBPA is not especially evident in these cells 
as suggested by cellular staining for these lipids (figure 3.3.1.). The levels of 
ceramide are the converse of the pattern observed for sphingomyelin levels (P < 
0.001, t = 9.505, df = 1, figure 3.3.4) suggesting that the decrease in this lipid is a 
result of conversion to ceramide by sphingomyelinase enzymes. This is particularly 
interesting as reduction in the activity of the member of this family active in the 
lysosomes, acid sphingomyelinase (ASM) has been shown to improve autophagic 
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defects in mouse models of FAD (Lee et al, 2014). This is potentially a target for 
further investigation, as increases in levels of ceramide induce apoptosis so this 
phenotype may be a major cause of neuronal loss.  
 
 
 
 
Figure 3.3.7 – Changes in levels of sphingolipids, phospholipids and cholesterol in 
PS1-/- cells in response to vATPase inhibition and NPC-like phenotype induction. A – 
Representative images of thin-layer chromatography analysis of various lipids in untreated 
wild-type (WT) blastocysts and those treated with 50nM Concanamycin A for 12 hr used to 
inhibit vATPase alkalising lysosomes or 24hr 2ug/ml treatment of U18666a to induce an NPC 
phenotype ran alongside identified lipid standards (STD. Chol/Cer = combined levels of 
cholesterol and ceramide, GlcCer = glucosylceramide, GalCer = galactosylceramide, LBPA = 
lysobisphosphatidic acid, PL = phospholipids, S SphL = simple sphingolipids and SphM = 
sphingomyelin. B – Densiometric quantification of lipid levels in treated and untreated BD 
blastocysts as a percentage of the lipid levels in untreated BD blastocysts. Lipid species are 
labeled as in A. Error bars = SD. n = 2. *** = P < 0.001, ** = P < 0.01, * = P < 0.05 calculated 
by one way ANOVA with Bonferroni post test.   
 
The induction of NPC1 phenotypes using U18666a in BD cells leads to the expected 
increase in lipids seen in models of this disease with at least trends towards 
increases in cholesterol, LBPA, GSLs and sphingomyelin all observed (figure 3.3.7.). 
As seen in figures 3.3.3. – 3.3.6. this lipid profile is distinctly different to that observed 
in cells deficient in PS1 as they have reduced GSLs and sphingomyelin. 
Interestingly, lysosomal alkalisation using the specific inhibitor of vATPase (Coen et 
al., 2012) results in a much more similar profile to that observed in these cells. It can 
be seen that lipids such as LBPA are increased (P < 0.05, t = 5.576, df = 1) and there 
is a trend towards reduction of GSLs. The cholesterol and ceramide band is also 
increased on this TLC (P < 0.001, t = 37.39, df = 1) which likely reflects accumulation 
of cholesterol as there has been no decrease in sphingomyelin levels which appears 
to result in ceramide increase as observed in figures 3.3.5 and 3.3.6. Interestingly, 
there is a redistribution of the sphingomyelin band reminiscent of that seen in PS1-/- 
MEFs. As this seems to be an intermediate phenotype between WT MEFs and 
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PS1/2-/- cells it would be interesting to increase the short time, 12 hr, that cells are 
exposed to concanamycin A and then see if sphingomyelin reductions are observed 
and ceramide levels increase. 
 
Figures 3.3.1. – 3.3.7. show that consideration of lipid phenotypes in Presenilin 
deficient cell lines clearly demonstrates that NPC1 disease phenotypes are not 
present in these cells. Accordingly, it is strongly suggestive that, if present lysosomal 
Ca2+ reductions are not the only form of lysosomal dysfunction in these cells. Further, 
it illustrates that a more likely explanation for the changes in lipid levels and 
distribution observed in these cells is lysosomal alkalisation, this warrants further 
investigation.  
 
3.3.2. – Endolysosomal defects in Presenilin deficient cells reveal further 
complexity 
 
A number of other assays can be used to study lysosomes and potentially provide 
more information as to what processes are defective in the lysosome. As a result of 
our findings with respect to changes in lipids observed in cells, particularly the large 
increases in ceramide accompanied by reductions in sphingomyelin, we are 
continuing to use BD cells for these assays. A particularly interesting process in cells 
which can be used to investigate the result of changes to lipids and endolysosomal 
Ca2+ homeostasis is the endocytic trafficking of lipids from the cell membrane. A 
useful tool for this analysis is fluorescently tagged cholera toxin B subunit which 
binds to ganglioside GM1 in cell membranes and is internalised to the Golgi in 
healthy cells. Defects in this process are observed in the majority of LSDs and have 
been shown to contribute to lipid storage in diseases such as NPC1. 
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Figure 3.3.8. – Endolysosomal sphingolipid trafficking in PS1-/- BD cells. A – 
Representative microscopy images of WT and PS1-/- BD cells pulse (30 min) and chased (90 
min) with FITC-tagged cholera toxin B subunit (CtxB-488), green, co-labelled with the nuclear 
marker Hoechst 33342. In control cells CtxB is internalised to the Golgi. 24hr 2ug/ml 
treatment of U18666a is used as a positive control for sphingolipid mistrafficking and NPC 
phenotypes. B – Qualitative quantification of CtxB-488 localisation as Golgi, punctate or 
intermediate between the two states in PS1-/- BD blastocysts as a percentage of the total cell 
population. Error bars = SD. n = 3 for WT and PS1-/- cells and n= 2 for WT cells + U18666a. 
Scale bar = 7.5µm. *** = P < 0.001 calculated by Χ2 test.  
 
Analysis of this the endocytosis of CtxB bound ganglioside GM1 in PS1-/- cells 
reveals an endolysosomal sphingolipid trafficking defect of unexpected severity. 
U18666a was used as a positive control in this experiment as NPC1 disease has 
been shown to have a sphingolipid trafficking defect which is considered to be more 
severe than many other LSDs (Pagano et al., 2000). Surprisingly, PS1-/- cells had a 
trafficking defect which was more pronounced (figure 3.3.8 A). Quantification of this 
trafficking defect shows that virtually all PS1-/- cells retained FITC-tagged CtxB in the 
endolysosomal system demonstrated by the, at least partial, punctate distribution of 
probe within cells. This was significantly different from WT cells treated with U18666a 
to induce trafficking defects (P < 0.001, Χ2 = 27.79, 26.80 and 31.11 for each 
individual experimental repeat, df = 2). U18666a treated cells showed a phenotype 
intermediate between PS1-/- and untreated WT cells (P < 0.001, Χ2 = 107.43 and 
166.02 for each individual experimental repeat, df = 2, figure 3.3.8. B). This analysis 
was carried out using the means from each cellular condition as inter-repeat variation 
was low (SEM < 5%).  
 
This severe trafficking defect is suggestive of fundamental dysfunction in the 
endolysosomal system of these cells as this assay was performed under conditions 
predisposing all cells to show transport of the probe to the Golgi, this was achieved 
by increasing the chase time after cell were pulsed with CtxB to 90 minutes and 
	   105	  
explains why U18666a treated cells showed a more intermediate distribution than 
previously reported.  
 
Another way of studying dysfunction in the endocytic system is by determining the 
localisation of annexin A2 within cells. In healthy cells this Ca2+ dependent 
phospholipid binding protein should be evenly distributed at the plasma membrane. 
Figure 3.3.9. clearly shows this is not the case in PS1-/- cells.  
 
 
Figure 3.3.9. – Distribution of Annexin A2 
in PS1-/- BD cells. A – Representative 
microscopy images of WT and PS1-/- BD 
cells showing Annexin A2 distribution by 
IHC. B – Quantification of Annexin A2 levels 
by threshold analysis in PS1-/- BD cells as a 
percentage of the total cell population. Error 
bars = SD. Data calculated from three 
independent plating replicates. Scale bar = 
7.5µm. **** = P < 0.0001 by T test. 
 
 
 
 
In PS1-/- cells, levels of annexin A2 appear to be vastly reduced as demonstrated by 
threshold analysis of these images (P < 0.0001, t = 22.53, df = 4, F2,2 = 3.297). The 
remaining annexin A2 appears to be mislocalised and is retained in the perinuclear 
region of cells (figure 3.3.9. A.). This phenotype has previously been reported in 
cellular models of NPC1 where this redistribution was attributed to the low levels of 
lysosomal Ca2+(Lloyd-Evans et al., 2008). Taken together both of these assays of 
endolysosomal trafficking appear to indicate the Ca2+ dyshomeostasis may be 
present in the endolysosomal system of PS1-/- cells although the severity of these 
trafficking abnormalities suggests that more than low levels of lysosomal Ca2+ may 
be contributing to this.   
 
Figure 3.3.10. – Autofluorescent material 
in PS1-/- BD cells. A – Representative 
microscopy images of WT and PS1-/- BD 
cells showing autofluorescence at 470nm 
which may be indicative of lipofuscin 
accumulation. B – Quantification of 
autofluorescence at 470nm by threshold 
analysis in PS1-/- BD blastocysts as a 
percentage of the total cell population. Error 
bars = SD. Data calculated from three 
independent plating replicates. Scale bar = 
7.5µm. ** = P < 0.01 by T test.      
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A final phenotype that can be easily investigated in cells is the presence of punctate 
autofluorescence which indicate endolysosomal accumulation of lipofuscin. 
Interestingly autofluorescence at 470nm was increased in PS1-/- cells (P < 0.01, t = 
7.731, df = 4, F2,2 = 2.173). This phenotype has been reported in a number of 
lysosomal diseases including those such as CLN10 where proteolytic activity in cells 
is reduced due to the loss of functional Cathepsin D and other diseases in which 
endolysosomal Ca2+ dyshomeostasis has been observed such as MLIV. Whilst it is 
not a phenotype which specifically implicates a particular type of lysosomal 
dysfunction it has not been widely reported in cells which have low levels of 
lysosomal Ca2+ or lipid accumulation; but would be expected in cells which have 
proteolytic defects (Guha et al., 2014). This phenotype is also often hard to visualise 
in cells which turn over quickly, even those where accumulation of autofluorescent 
material is considered a hallmark of the disease, accordingly it is interesting that it 
appears to be a robust phenotype in these cells. Again this suggests a profound 
defect may be present in the endolysosomes of these cells.  
 
The increasing complexity revealed by the endolysosomal defects assayed above 
suggest that either multiple forms of dysfunction are present within this system or a 
new pathological mechanism is taking place in these cells. Due to this, a complete 
investigation of endolysosomal Ca2+ homeostasis is required as many of the 
phenotypes described above are indicative of dysfunction within this system. 
 
3.3.3. – Presenilin 1 maintains lysosomal Ca2+ homeostasis by regulating 
vATPase mediated lysosomal acidification 
 
As described in section 3.3.1. and 3.3.2., PS1-/- BD cells are the most suitable cell 
line in which to perform a thorough investigation of endolysosomal Ca2+ homeostasis 
changes which result from loss of presenilin function. This is due to the robust 
phenotypes observed in these cells without the need to remove the function of 
multiple proteins.  	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Figure 3.3.11. – Basal cytosolic Ca2+ in PS1-/- BD cells. A - Representative images of the 
Ca2+ probe Fura2 at both 340nm and 380nm followed by a ratiometric representation of Fura2 
340/380nm. B – Quantification of resting cytosolic Ca2+ measured by ratiometric quantification 
of Fura2 fluorescence. Error bars = range. n = 6 for WT cells and n = 8 for PS1-/- cells. * = P < 
0.05 calculated by T test. C - Representative images of the Ca2+ probe Fluo3. D – 
Quantification of resting cytosolic Ca2+ measured by quantification of Fluo3 fluorescence. 
Error bars = range. n = 4. No significant difference observed by T test. Scale bar = 7.5µm. 
 
We began to investigate Ca2+ dyshomeostasis by determining the basal cytoplasmic 
Ca2+ levels in PS1-/- cells in relation to controls. This was significantly elevated (P < 
0.05, t = 2.798, df = 12, F7,5 = 2.655) in PS1-/- cells, as previously reported, measured 
by Fura2 which provides ratiometric measurement of Ca2+ levels. This shows that the 
differences in Ca2+ probe fluorescence is not a result of differences in probe uptake 
between cell lines. In turn this validates the measurement of basal cytosolic Ca2+ 
elevation with the non-ratiometric Ca2+ probe Fluo3. Although the difference between 
cell lines is not significant in this instance a similar trend has been observed and this 
phenotype has been confirmed using multiple probes in Lee et al. (2015). 
Importantly, the images also show that there is not significant compartmentalisation 
of either of these probes. This is often problematic when cells with endolysosomal 
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dysfunction are being studied. The use of two different Ca2+ probes is also beneficial 
as some agonists can cause changes in pH of the cell which in turn alters the kD of 
these Ca2+ probes, a process which changes Ca2+ binding properties of the probe 
and as a result the fluorescence signal. This can confound results. For example this 
has previously been observed when Fura2 is used as the Ca2+ probe in experiments 
utilising GPN to burst lysosomes (Lloyd-Evans, Unpublished). Accordingly, we have 
used Fluo3 for the majority of experiments in which we utilise this agonist. If pH 
changes are not of concern we use Fura2 for the experiments as the ratiometric 
properties of this dye reduce problems such as photobleaching and extrusion of the 
probe from the cytosol. 
   
 
 
 
Figure 3.3.12. – Lysosomal Ca2+ release in PS1-/- BD cells after GPN induced lysosomal 
rupture in the presence of 5µM ionomycin. A - Representative traces of Ca2+ release in 
Fluo3 loaded cells induced by 300µM GPN. Grey bar indicates the presence of ionomycin, 
black bar indicates the presence of GPN. U18666a treated WT cells are used as a positive 
control for depletion of lysosomal Ca2+. B – Quantification of Ca2+ release measured by 
change in Fluo3 fluorescence. Error bars = SEM. n = 3. ** = P < 0.01 calculated by T test. 
 
After assessing the basal cytosolic Ca2+ levels in cells we attempted to validate the 
findings of Coen et al. (2012) who observed reduced lysosomal Ca2+ in the 
lysosomes of PS1-/- cells. In order to ensure that we only measured release from the 
lysosomes of cells, we used the Ca2+ ionophore, ionomycin, to permeabilise all the 
other cellular Ca2+ stores, lysosomes remain intact as a result of the inability of 
ionomycin to cross the glycocalyx. As such, when we induce osmotic swelling and 
subsequent lysis of the lysosome by GPN, we can be sure that any changes in 
fluorescence of the Ca2+ probe situated in the cytosol are the result of Ca2+ release 
from the lysosome. It is important to note that GPN is cleaved in lysosomes by 
cathepsin C, an enzyme which has a broad pH optima between pH 5-6 (Vanha-
Perttula et al., 1965), accordingly lysosomal alkalisation is not likely to inactivate this 
enzyme and prevent its use in any cell lines which do exhibit this phenotype. Upon 
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stimulation of Ca2+ release with GPN we were able to observe an approximately 75% 
reduction in lysosomal Ca2+ in presenilin deficient cells compared to controls (P < 
0.01, t = 6.847, df = 4, F2,2 = 1321x1010, figure 3.3.12.). The importance of using 
ionomycin before GPN in this experiment is highlighted in figure 3.3.13.  
 
 	  
Figure 3.3.13. – Ca2+ release in PS1-/- BD cells after GPN induced lysosomal rupture. A - 
Representative traces of Ca2+ release in Fura2 loaded cells induced by 300µM GPN. Black 
bar indicates the presence of GPN. B – Quantification of Ca2+ release measured by change in 
Fura2 fluorescence ratio. Error bars = SEM. n = 5 for WT and n = 6 for PS1-/-. ** = P < 0.01 
calculated by T test. 
 
Under conditions where only GPN is added to cells it can be seen that the Ca2+ 
released from PS1-/- cells is significantly elevated when compared to control cells (P 
< 0.01, t = 4.112, df = 9, F4,5 = 1.198. In this situation Ca2+ induced Ca2+ release 
(CICR) from the ER is a major contributor to this Ca2+ response as the close contact 
between lysosomes and the ER concentrate Ca2+ transients in this area and 
potentiate Ca2+ release from a store which is more concentrated than the lysosome 
and also much larger in volume (Kilpatrick et al., 2012). This is particularly 
problematic in cells where the ER levels of Ca2+ are altered, as has been reported in 
PS1-/- cells.  
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Figure 3.3.14. – Ca2+ release from the ER in PS1-/- BD cells after thapsigargin 
stimulation. A - Representative traces of Ca2+ release in Fura2 loaded cells induced by 5µM 
thapsigargin. Black bar indicates the presence of thapsigargin. B – Quantification of Ca2+ 
release measured by change in Fura2 fluorescence ratio. Error bars = SEM. n = 3. * = P<0.05 
calculated by T test. 
 
We were also able to reproduce this data in PS1-/- cells when we induced Ca2+ 
release from the ER using thapsigargin and observed almost double the release (P = 
< 0.05, t = 3.655, df = 4, F2,2 = 24.72, figure 3.3.14.). The impact of ER Ca2+ release 
accounts for the higher Ca2+ release when GPN alone is used (figure 3.3.13.). 
Importantly, the proportional difference between thapsigargin stimulated release is 
higher than with GPN stimulated release suggesting that the higher lysosomal Ca2+ 
in control cells reduces the difference between these cells and presenilin deficient 
cells.  	  
 
 
 
Figure 3.3.15. – Lysosomal rupture and Ca2+ release causes subsequent reduction in 
thapsigargin stimulated ER Ca2+ release. A - Representative traces of Ca2+ release in 
Fura2 loaded cells induced by 5µM thapsigargin in the presence and absence of 300µM 
GPN. Black bar indicates the presence of thapsigargin. B – Quantification of Ca2+ release 
measured by change in Fura2 fluorescence ratio. Error bars = SEM. n = 3. *** = P < 0.001 
calculated by one way ANOVA with Bonferroni post test. . 
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The interaction between lysosomal and ER Ca2+ release in these cells is further 
evidenced by the observation that inducing lysosomal Ca2+ release reduced the 
release of Ca2+ from the ER induced by thapsigargin. Although this only reached 
significance in PS1-/- cells (P < 0.001, t = 7.443, df = 4) there was also a trend 
towards reduction in WT cells. This experiment demonstrates depletion of the ER 
store following lysosomal Ca2+ release and a similar protocol can be utilised in order 
to investigate the effects of more physiologically relevant lysosomal Ca2+ agonists 
upon the ER.  
 
As osmotic lysis of the lysosome is not a physiological process we were interested to 
see what the effects of a physiologically relevant Ca2+ agonist upon lysosomes from 
Presenilin deficient cells was. NAADP is one of the most potent Ca2+ releasing 
second messengers within cells. The target of this ligand is believed to be the 
lysosomal TPC2 channel which releases Ca2+ from the lysosome in order to 
potentiate vesicular binding events (Luzio et al., 2007; Ruas et al., 2015).  
 
 
 
 
 
Figure 3.3.16. – No Ca2+ release in PS1-/- BD cells after stimulation of TPC2 with 
NAADP-AM. A - Representative traces of Ca2+ release in Fluo3 loaded cells induced by 
100nM NAADP-AM. Grey bar indicates the presence of thapsigargin, black bar indicates the 
presence of NAADP-AM, black arrowheads show the addition of 2µM ionomycin to confirm 
cell viability. U18666a treated WT cells are used as a positive control for depletion of 
lysosomal Ca2+. B – Quantification of Ca2+ release measured by change in Fluo3 
fluorescence. Error bars = SEM..n = 3 for WT  cells and n = 3 for PS1-/- cells. **** = P<0.0001. 
 
Using NAADP which has had its charge masked by the addition of an AM group we 
are able to investigate the response of TPC2 in live, unpermeabilised PS1-/- cells. 
When we added this second messenger to cells, in which we have prevented ER 
Ca2+ release with thapsigargin, we were surprised to see almost no Ca2+ release 
from PS1-/- cells (P < 0.0001, t = 34.83, df = 4, F2,3 = 34.95, figure 3.3.16.). As the 
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TPC2 channel is expressed normally in PS1-/- cells, it is most likely changes in 
lysosomal physiology are responsible for the lack of Ca2+ release (Neely-Kayala et 
al., 2012). 
 
The observation of ablated Ca2+ release from lysosomes in PS1-/- cells may be 
explained by the fact TPC2 is a dual sensor of Ca2+ and pH in the lumen of 
lysosomes. When lysosomes are maintaining correct pH, at around 4.5, NAADP in 
the cytosol can transiently bind to the channel or, perhaps, a binding protein in order 
to trigger lysosomal Ca2+ release. If the pH of the lysosomal lumen has become more 
alkaline, then TPC2 channels are blocked as NAADP no longer dissociates from the 
channel (Pitt et al.,2010). This may explain why PS1-/- cells do not release any Ca2+ 
in response to NAADP-AM. 
 
It is important to note that when NAADP-AM was added to PS1-/- cell in the absence 
of thapsigargin robust Ca2+ releases were observed (data not shown). This 
observation demonstrates the potency of CICR on the ER where even the small 
amount of Ca2+ release from the lysosome can potentiate this process. It is also 
interesting that during preliminary calibration experiments for this experiment, higher 
concentrations of NAADP-AM (500nM) were able to induce Ca2+ releases from 
thapsigargin treated PS1-/- cells (data not shown). The activation of TPC2 by NAADP 
is subject to a bell-shaped curve with respect to NAADP (Pitt et al., 2010) 
concentration and as such an optimal concentration must be determined for 
experimentation. As higher concentrations seemed to potentiate release in PS1-/- 
cells, but not controls, it may be that this activation curve has been shifted by a 
change in pH in the lysosomal lumen, this remains to be investigated. 
 
Interestingly, this almost complete ablation of NAADP-AM induced Ca2+ release 
observed in PS1-/- cells may explain the severe endolysosomal sphingolipid 
trafficking phenotype (figure 3.3.8) also observed in these cells. Lack of Ca2+ release 
from the TPC2 channel would lead to a profound defect in endolysosomal vesicle 
fusion, and therefore, the trafficking of substrates through this system. This process 
requires localized Ca2+ fluxes to activate the protein machinery required for fusion 
(Luzio et al., 2007). This observation also provides a potential mechanism for the 
annexin A2 mislocalisation shown in figure 3.3.9. 
 
As a number of the results we have achieved so far have suggested that lysosomal 
alkalisation may be occurring in PS1-/- cells we were interested to see if we could 
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demonstrate increased sensitivity of these cells to Ca2+ release in response to further 
lysosomal alkalisation.  
 
 
 
Figure 3.3.17. – Ca2+ release from PS1-/- BD cells in response to alkalisation with sub-
inhibitory concentrations of NH4Cl. A - Representative traces of Ca2+ release in Fura2 
loaded cells induced by 5mM NH4Cl. Black bar indicates the presence of NH4Cl, black 
arrowheads show the addition of 5µM ionomycin to confirm cell viability. B – Quantification of 
Ca2+ release measured by ratiometric change in Fura2 fluorescence. Error bars = SEM. n = 2. 
No significance calculated by T test. 
 
The first alkalising agent we used to investigate if PS1-/- cells were more susceptible 
to Ca2+ release was NH4Cl as NH4+ has previously been shown to empty lysosomal 
Ca2+ stores by inducing Ca2+ leak after chelation of H+ ions (Christensen et al., 2002). 
Using a lower concentration of NH4Cl than that normally used to induce leak in 
control cells in control cells we were able to induce substantive Ca2+ release from 
PS1-/- cells (figure 3.3.17.). Although this difference was non significant there is a 
clearly evident trend towards more Ca2+ release from PS1-/- cells. When considered 
alongside the lower overall levels of Ca2+ in these compartments it is indicative of 
lysosomal alkalisation in PS1-/- cells leading to increased leak of Ca2+ from the 
endolysosomal system. Subsequent experiments have supported these data. 
Preliminary calibration experiments also revealed a similar pattern of increased Ca2+ 
release in PS1-/- cells at comparable concentrations (data not shown).  
 
As chelation of lysosomal H+ ions in order to induce alkalisation resulted in more 
Ca2+ leak from the endolysosomal system we were interested to see if inducing 
lysosomal alkalisation by vATPase inhibition was capable of doing the same. This is 
particularly interesting as lack of vATPase function in proposed to be the initiating 
factor for lysosomal alkalisation in PS1-/- cells (Lee et al., 2010).  
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Figure 3.3.18. – Sensitivity of PS1-/- BD cells to alkalisation and subsequent Ca2+ 
release in response to sub-inhibitory concentrations of Bafilomycin A1. A - 
Representative traces of Ca2+ release in Fluo3 loaded cells induced by 30nM Bafilomycin A1. 
Black bar indicates the presence of Bafilomycin A1. B – Quantification of Ca2+ release rate 
measured by change in Fluo3 fluorescence over time in seconds. Error bars = SEM. n = 3. * 
= P<0.05. 
 
When vATPase in PS1-/- cells is partially inhibited by the selective inhibitor 
Bafilomycin A1 (Harada et al., 1997) we can see that Ca2+ is released from these 
cells at a 3 fold greater initial rate (P < 0.05, t = 4.494, df = 4, F2,2 = 2.002, figure 
3.3.18.), measured in the change of fluorescence units per second. This is further 
evidence of increased lysosomal alkalisation in these cells and a greater sensitivity of 
the vATPase to inhibition leading to a greater degree of Ca2+ leaking out of this 
system upon inhibition. Importantly, we were able to observe a 60 -70% greater 
release in control cells with high completely inhibitor concentrations of Bafilomycin 
(500nM) after thapsigargin pretreatment further demonstrating the lysosomes in 
control cells have a greater Ca2+ content (data not shown).  
 
The experiments shown in figure 3.3.17. – 3.3.18 demonstrate that lysosomes from 
PS1-/- cells show increased Ca2+ leak in response to alkalisation. However, the 
channel that facilitates this is unknown. An attractive potential candidate for this 
channel is TRPML1. This is thought to be a pH sensitive Ca2+ efflux channel which 
exhibits peak activity within a more alkaline pH range than that observed in 
lysosomes. This suggests that it is most active in an earlier compartment within the 
endolysosomal system (Raychowdhury et al., 2004; Waller-Evans et al., 2015).  
 
 
 
 
 
  
	   115	  
 
 
 
Figure 3.3.19. – Ca2+ release from PS1-/- BD cells in response to the synthetic TRMPL1 
agonist ML-SA1. A - Representative traces of Ca2+ release in Fura2 loaded cells induced by 
20µM ML-SA1. Black bar indicates the presence of ML-SA1, black arrowheads show the 
addition of 5µM ionomycin to confirm cell viability. B – Quantification of Ca2+ release 
measured by ratiometric change in Fura2 fluorescence. Error bars = SEM. n = 12. ** = P < 
0.01. 
 
In order to study the TRPML1 channel we utilised the synthetic TRPML1 agonist ML-
SA1 (Shen et al., 2012). When we treated PS1-/- cells with this agonist we observed 
a vastly increased release compared to control cells (P < 0.01, t = 3.540, df = 22, 
F11,11 = 5.344, figure 3.3.19.). This suggests that TRPML1 is hyperactive in PS1-/- 
cells and is it is likely that this channel mediates efflux of Ca2+ from the 
endolysosomal system into the cytoplasm. Accordingly, we consider the activity of 
this channel as central to the Ca2+ dyshomeostasis observed in PS1-/- cells and that 
excessive Ca2+ leak from TRPML1 may be responsible for the low levels of 
endolysosomal Ca2+, and, contributes to increased levels of cytosolic Ca2+.  
 
In order to confirm this role of TRPML1 we first needed to confirm the specificity of 
ML-SA1 for this channel. Firstly, we wanted to see if ML-SA1 induced Ca2+ release 
resulted in CICR from the ER. 
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Figure 3.3.20. –Thapsigargin mediated ER Ca2+ release in cells after the addition of ML-
SA1. A - Representative traces of Ca2+ release in Fura2 loaded cells induced by 20µM ML-
SA1 in the presence and absence of ML-SA1. Black bar indicates the presence of 
thapsigargin. B – Quantification of Ca2+ release from all cellular populations measured by 
ratiometric change in Fura2 fluorescence. ML-SA1 presence indicated by brackets. Error bars 
= SEM. n = 3 for WT and PS1-/-, n= 2 for WT and PS1-/- in the presence of ML-SA1. No 
significant differences calculated by one way ANOVA with Bonferroni post test.  
 
Accordingly, we replicated the experiment described in 3.3.15. but changed GPN for 
ML-SA1 prior to the addition of thapsigargin in both control and PS1-/- cells. The 
results obtained after ML-SA1 stimulation show only a minimal non-significant 
reduction in both cell lines. In PS1-/- there is a trend towards a reduction in 
thapsigargin mediated Ca2+ release, however, this is much smaller than the 
significant reduction observed with GPN treatment (figure 3.3.15). This indicates that, 
unlike in experiments utilising GPN, the addition of ML-SA1 to cells does not result in 
significant CICR from the ER. As such the differences seen in 3.3.19. are not due to 
the increased levels of ER Ca2+ present in PS1-/- cells. Accordingly, we do not need 
to pre-treat cells with either ionomycin or thapsigargin prior to ML-SA1. 
Subsequently, we decided to clarify that ML-SA1 was specific for TRPML1 and did 
not potentiate Ca2+ release from related channels. 
 
To begin this we utilised mucolipidosis type IV (MLIV) patient fibroblasts which carry 
a mutation leading to no functional expression of the TRPML1 channel. In these cells 
we would expect no Ca2+ release in response to ML-SA1 if the agonist specifically 
induces Ca2+ release from this channel. 
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Figure 3.3.21.  – Analysis of MLSA1 release events in MLIV cells. Confirmation of ML-
SA1 specificity for the TRPML1 channel in the presence of lysosomal alkalization using MLIV 
patient fibroblasts which do not express functional TRPML. A - Representative traces of Ca2+ 
release in Fura2 loaded cells induced by 50µM ML-SA1. Black bar indicates the presence of 
ML-SA1, black arrowheads show the addition of 5µM ionomycin to confirm cell viability. In this 
experiment the imaging buffer contained 1mM Ca2+. B – Quantification of Ca2+ release 
measured by ratiometric change in Fura2 fluorescence. Error bars = SEM. n = 1. C – 
Representative traces of Ca2+ release in Fura2 loaded cells induced by 50µM ML-SA1 after 
12 hr treatment with 50nM Concanamycin A in the presence and absence of 300µM GPN. 
Black bar indicates the presence of ML-SA1, black arrowheads show the addition of 5µM 
ionomycin to confirm cell viability. Control cells are shown in grey, control cells post GPN are 
shown in light grey. MLIV cells are shown in red, with MLIV cells post GPN shown in light red. 
D – Quantification of Ca2+ release from cell treated with 50nM Concanamycin A for 12 hours 
in the presence and absence of GPN measured by ratiometric change in Fura2 fluorescence. 
GPN presence is indicated in brackets. Error bars = SEM. n = 2 for Control and MLIV cells, n 
= 1 for Control and MLIV cells in the presence of GPN.  
 
Upon performing this experiment we observed Ca2+ release from MLIV patient 
fibroblasts treated with ML-SA1, despite the presence of no functional TRPML1 in 
these cells (Wakabayashi et al., 2012). In the initial experiment this was far in excess 
of the Ca2+ release observed in control patient fibroblasts which have active TRPML1 
(figure 3.3.21. A and B). Interestingly, this release was reduced when extracellular 
Ca2+ was not present. This suggests ML-SA1 could result in Ca2+ influx into the 
cytoplasm as a result of interaction with TRPM type channels such as TRPM8 in the 
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plasma membrane (Zhu et al., 2014). Accordingly we performed all experiments with 
ML-SA1 in Ca2+ free imaging buffer.  
   
In order to investigate this in a similar situation to that observed in PS1 cells we 
induced lysosomal alkalisation with concanamycin A. When we did this the response 
from control fibroblasts was significantly increased and that from MLIV fibroblasts 
was ablated. We showed that the Ca2+ released in response to ML-SA1 was 
lysosomal in origin as we were able to prevent this response by using GPN 
pretreatment to remove lysosomes (3.3.21. C and D). Although these preliminary 
experiments do not have sufficient repeats to confirm these observations the results 
obtained suggest that under conditions of lysosomal alkalisation in the absence of 
extracellular Ca2+ ML-SA1 is specific for the TRPML1 channel. 
 
 
	  	  
Figure 3.3.22. – Western blot analysis of TRPML1 levels in PS1-/- cells. No change in 
TRPML1 levels is observed in PS1-/- BD cells. A – Western blotting of TRPML1 in WT and 
PS1-/- BD blastocysts. B – Densiometric quantification of protein levels from all cellular 
populations. Error bars = SD, from three independent cell cultures. 
 
We also confirmed that TRPML1 levels remain unchanged in PS1-/- cells by western 
blotting for the protein (figure 3.3.22.). The band identified as TRPML1 in these 
experiments has been validated as it is reduced by siRNA against TRPML1 in other 
experiments (Waller-Evans et al. Unpublished).  
 
The experiments described in 3.3.20 – 3.3.22. indicate that the increased response 
of PS1-/- cells to ML-SA1 results from the hyperactivity of the TRPML1 channel. 
Accordingly, we began to investigate whether we could modulate the activity of 
TRPML1 in an attempt to re-establish Ca2+ homeostasis within the endolysosomal 
system.  	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Interestingly, our collaborators had observed that intra-luminal endolysosomal Ca2+ 
levels could be restored by treating PS1-/- cells with Ned-19 (Lee et al., 2015). This 
molecule is a NAADP analogue which prevents the activation of NAADP dependent 
lysosomal Ca2+ channels preventing Ca2+ efflux (Naylor et a., 2009). As TPC2 is well 
defined as an NAADP-activated lysosomal Ca2+ efflux channel, Ned-19 is considered 
to be an antagonist of this channel. However, as this channel is essentially 
inactivated in PS1-/- cells further inhibition of this channel would not cause the 
recovery of intra-luminal Ca2+ levels. As TRPML1 is hyperactive in these cells we 
were interested to see if Ned-19 pretreatment had any effect on ML-SA1 induced 
Ca2+ release.  	  	  
 
	  
 
Figure 3.3.23 – Effect of Ned-19 pretreatment on Ca2+ release from PS1-/- BD cells in 
response to the synthetic TRMPL1 agonist ML-SA1. PS1-/- cells were treated with 0.5µM 
Ned-19 for 24 hours. A - Representative traces of Ca2+ release in Fura2 loaded cells induced 
by 20µM ML-SA1. Black bar indicates the presence of ML-SA1, black arrowheads show the 
addition of 2µM ionomycin to confirm cell viability. B – Quantification of Ca2+ release 
measured by ratiometric change in Fura2 fluorescence. Error bars = SEM. n = 9 for WT, n = 8 
for P1-/- and n = 4 for PS1-/- +Ned-19. * = P < 0.05, ** = P < 0.01 calculated by one way 
ANOVA with Bonferroni post test.  
 
As can be seen in figure 3.3.23. Ned-19 pretreatment is able to reduce the 
pathogenically elevated Ca2+ release (P < 0.01, t = 4.337, df = 14) in response to ML-
SA1 to almost control levels in PS1-/- cells (P < 0.05, t = 2.769, df = 6). Although this 
finding was unanticipated as TPC2 and TRPML1 are functionally distinct channels, 
both are activated by phosphoinositiols (Waller-Evans and Lloyd-Evans, 2015; 
Jentsch, et al., 2015). This suggests that they are able to interact with similar lipids. It 
is also interesting that knockout of TPC2 does not abolish Ca2+ signaling events 
initiated by NAADP (Ruas et al, 2015). It may be that that a binding partner to the 
TPC2 channel may be present in cells and this is the site of NAADP binding. If this is 
the case NAADP could interact with multiple channels via this binding partner, as 
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Ned-19 is a functional analogue of NAADP it would be expected that it would also 
interact with this protein and, accordingly, could affect both TPC2 and other 
channels, potentially TRPML1.   
 
The interaction of TRPML1 with the phosphoinisitol-3,5-bisphosphate (PI(3,5)P2) 
results in increased open probability of the channel, resulting in increased 
conductance of Ca2+. The enzyme responsible for production of this phosphoinisitol 
is PIKfyve and this can be inhibited by YM201636 (Jefferies et al., 2008). When cells 
are treated with this inhibitor vacuolation has been reported and this provides a 
measure of the susceptibility of different cell lines to PIKfyve inhibition. The 
vacuolation phenotype observed in PS1-/- cells is markedly more severe to that 
observed in control cells (data not shown). The presence of a significantly greater 
number of vacuoles in PS1-/- cells suggests the they are much more susceptible to 
PIKfyve inhibition and the subsequent reduction in PI(3,5)P2. This is unsurprising, as 
it is known that PS1-/- cells have lower levels of this phosphoinositol. Interestingly, the 
effects of the endolysosomal Ca2+ release agonists upon these vacuoles reveals that 
they are likely lysosomal in origin. Firstly, GPN treatment removes these vacuoles 
showing they contain Cathepsin C and maintain a pH which is at least marginally 
acidic. When the numbers of vacuoles were analysed after ML-SA1 treatment it can 
be observed that, as expected from a channel agonist, it did not remove these 
structures although slight fluctuations in the number of vacuoles observed are likely 
the result of fusion between vacuoles as observed in videos of these cell populations 
(data not shown). Accordingly this data shows that although YM201636 may be used 
to study the effects of PI(3,5)P2 on certain channels it creates a non-physiological 
phenotype within cells and, accordingly, results must be interpreted as such. 
YM201636 treatment does, however, remain the most direct way of modulating the 
activity of PI(3,5)P2 stimulated channels within cells. 
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Figure 3.3.24. – Effect of YM201636 pretreatment on Ca2+ release from TRPML1 in PS1-/- 
BD cells stimulated with ML-SA1. Cells were treated with 10µM YM201636 for 1 hour. A - 
Representative traces of Ca2+ release in Fura2 loaded cells induced by 20µM ML-SA1. Black 
bar indicates the presence of ML-SA1, black arrowheads show the addition of 2µM ionomycin 
to confirm cell viability. B – Quantification of Ca2+ release measured by ratiometric change in 
Fura2 fluorescence. Error bars = SEM. n = 2 for WT, n = 2 for WT + YM201636, n = 2 for 
PS1-/- and n = 3 for PS1-/- + YM201636. ** = P<0.01. 
 
When we looked at the effect of YM201636 treatment on Ca2+ release after 
stimulation of TRPML1 in preliminary experiments we observed a trend towards 
increase in Ca2+ release in PS1-/- cells. Initially this finding was surprising as PIKfyve 
inhibition leads to a reduction in PI(3,5)P2 which is expected to reduce the open 
probability of the channel and as such reduce Ca2+ release from this channel. 
However, when we consider this more carefully it stands to reason that luminal Ca2+ 
levels should increase if the channel is less likely to be open as less Ca2+ is released 
from the store. If confirmed, these data may suggest that TRPML1 is more active in 
presenilin deficient cells as a larger increase in Ca2+ release is observed in these 
cells and only a slight trend towards increase is observed in control cells. Whether 
this drives the vacuolation process remains to be determined as this was also 
significantly more severe in Presenilin deficient cells. This potentially shows that ML-
SA1 can potentiate TRPML1 Ca2+ release in the absence of PI(3,5)P2 in mice as 
previously published by Feng et al. (2014). Whether this is due to similarities in the 
structure of ML-SA1 and PI(3,5)P2 remains to be investigated. In addition to further 
repeats at this concentration of YM201636 it would also be useful to optimize 
YM201636 treatment for the induction of vacuolation phenotypes in control cells as 
this would allow us to study further the role of TRPML1 in healthy cells. As these 
data suggest that YM201636 treatment induced the filling of lysosomal Ca2+ stores 
we were interested to see if this was occurring in cells. 
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Figure 3.3.25. – Effect of YM201636 pretreatment on GPN-induced lysosomal Ca2+ 
release in PS1-/- cells in relation to WT cells in the presence of ionomycin. Cells were 
treated with 10µM YM201636 for 1 hour. A - Representative traces of Ca2+ release in Fluo3 
loaded cells induced by 20µM ML-SA1. Black bar indicates the presence of ML-SA1. B – 
Quantification of Ca2+ release measured by change in Fluo3 fluorescence. Error bars = SEM. 
n = 2. No significance calculated by T test.  
 
By using the ionomycin GPN method described in figure 3.3.12. we are able to do 
this. As previously described the lysosomal system has been significantly altered by 
YM201636 treatment. Due to this and as we were interested in inhibiting the 
hyperactivity of TRPML1 we decided that it would be most relevant to compare the 
two cell lines after PIKfyve inhibition. Upon doing this, the difference in 
endolysosomal Ca2+ content was reduced from a 75% reduction in PS1-/- cells to a 
reduction of approximately 25%. This difference did not reach significance although 
in future repeats it may due to there still being a trend towards reduced Ca2+ in the 
PS1-/- cells. These data suggest that the increase in Ca2+ release in response to ML-
SA1 was a result of an increased releasable pool of Ca2+.  
 
Taken together the data shown if figures 3.3.24. and 3.3.25. are suggestive that a 
potentiation in the activity of the TRPML1 channel is responsible for the increased 
efflux of Ca2+ from lysosomes which, in turn, leads to reduced levels of 
endolysosomal Ca2+. As there is evidence of lysosomal alkalisation in these cells this 
increased efflux is most likely a result of an increased number of compartments of 
the endolysosomal system at an appropriate pH for TRPML1 to remain active when 
in healthy cells it has become inactive due to acidification (Raychowdhury et al., 
2004). 
 
However, as YM201636 represents a non-physiological situation we were interested 
to look at other method with which we could inhibit Ca2+ release from TRPML1 and 
see if this corrected Ca2+ homeostasis. A recent publication had used an antibody 
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raised against TRPML1 as a means of inhibiting this channel (Zhang et al., 2012) so 
we decided to see if we could use this method in PS1-/- cells.  
 
 
 
 
Figure 3.3.26. – Treatment of WT and PS1-/- BD blastocyst cells with an antibody 
against TRPML1. Enlargement of acidic vesicles within cells a phenotype observed upon 
inactivation of TRPML1. Cells were treated with different titrations of anti-TRPML1 for 
16hours before loading with the acidotrophic dye lysotracker green. Representative images 
for each cell population are shown, n = 1. Scale bar = 7.5 µm.  
 
Initially, we used increased levels of lysotracker fluorescence within cells as a marker 
of TRPML1 inhibition as this is one of the most robust phenotypes observed in MLIV 
patient cells which, as discussed previously, have inactive TRPML1. This was 
observed to increase in both control and PS1-/- cells from low antibody concentrations 
of 5 µg/ml, this increase became more evident at 10 µg/ml. Interestingly, although an 
increase was observed at 20 µg/ml this did not seem to have increased compared to 
10 µg/ml and the interaction appeared to reach saturation. As these changes 
seemed potent at 5 µg/ml we decided to continue experiments using that inhibitory 
concentration of antibody. Accordingly, the Ca2+ responses of cells treated with 5 
µg/ml anti-TRPML1 antibody were investigated after stimulation of TRPML1 with ML-
SA1.  	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Figure 3.3.27. – Effect of anti-TRPML1 antibody pretreatment on ML-SA1 induced Ca2+ 
release. Cells were treated with 5 µg/ml anti-TRPML1 for 16 hours. A - Representative traces 
of Ca2+ release in Fura2 loaded cells induced by 20µM ML-SA1. Black bar indicates the 
presence of ML-SA1,black arrowheads show the addition of 2µM ionomycin to confirm cell 
viability. B – Quantification of Ca2+ release measured by ratiometric change in Fura2 
fluorescence. Error bars = SEM. n = 3 for WT and PS1-/- cells, n = 2 for PS1-/- cells + AB. ** = 
P<0.01. 
 
Following incubation with the antibody a significant decrease (P < 0.01, t = 6.543, df 
= 2) was observed in Ca2+ releases in PS1-/- cells (Figure 3.3.27). This was so potent 
it almost returned the cells to the same levels of release as control cells. This 
provides further evidence that the lysosomal Ca2+ channel sensitive to ML-SA1 is 
TRPML1 
 
We were also interested to see if the TRPML1 channel in these cells would be 
amenable to patch clamping to look more closely at channel open and closed states. 
In order to do this the endolysosomal system is expanded by treating cells with 
Vacuolin so that the swollen organelle can be clamped (Wang et al., 2012). Initially, 
we examined the effects of Vacuolin treatment on PS1-/- cells. 
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Figure 3.3.28. – Effect of vacuolin treatment on Ca2+ release in PS1-/- cells. A - 
Representative traces of Ca2+ release in Fura2 loaded cells induced by 1.25µM vacuolin. 
Black bar indicates the presence of vacuolin, black arrowheads show the addition of 5µM 
ionomycin to confirm cell viability. B – Quantification of Ca2+ release measured by ratiometric 
change in Fura2 fluorescence. Error bars = SEM. n = 2. No significance calculated by T test.  
 
When cells were treated with vacuolin Ca2+ release was observed in both cell lines, 
although there is a trend towards elevation of this Ca2+ release in PS1-/- cells (P = 
0.0604, t = 3.883, df = 2, F1,1 = 1,790). Firstly, this is problematic as Ca2+ release at 
this stage would mean that the lumenal levels of Ca2+ in the endolysosomal system 
have been altered prior to any experiments; if the flow of ions is then to be analysed 
the changes in this would affect the subsequent results. This is especially true if both 
cell lines respond differently to vacuolin during the pretreatment, although the impact 
of this that has been observed so far is slight this may be amplified in subsequent 
experiements where Ca2+ release is measured at the lysosomal membrane. 
Interestingly, vacuolin treatment has been shown to change Ca2+ before and it has 
also been reported that the majority of the membrane constraining vacuolin 
expanded vesicles contains markers for early endosomes (Cerny et al., 2004). As 
such, if we were to investigate TRPML1 by this method it would be under non-
physiological conditions and would not contribute to the careful analysis of TRPML1 
function and the modulators of this in PS1-/- cells.  
 
Our experiments in 3.3.1 – 3.3.3 have shown that Presenilin deficient cells have a 
number of interesting phenotypes which could be important to disease processes 
and the further examination of Presenilin deficiency as a means of causing familial 
Alzheimer’s. However, the cells used for these experiments were from mice and 
have complete genetic knockout of PS1 (and in some cases PS2). As patients with 
familial Alzheimer’s have mutations in presenilin proteins rather than knockout of 
those proteins these cells may not be wholly representative of the disease processes 
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occurring in patients. As such, we were interested to investigate the phenotypes we 
have observed in a more relevant cell line.  
 
3.3.4. – Preliminary examination of Lysosomal Pathology in Down’s Syndrome 
is indicative of lipid homeostasis and Ca2+ homeostasis defects 
 
As patient fibroblasts are a well used tool for such experiments and they also closely 
model Ca2+ dyshomeostasis and endocytosis defects observed in many other cell 
lines (Lloyd-Evans et al., 2008) we decided to investigate some of the phenotypes 
observed in 3.3.1 – 3.3.3 in these cells. 
 
Initially, we have used Down’s Syndrome (DS) patient fibroblasts in order to examine 
some of these phenotypes. Patients with DS almost universally exhibit early 
neurodegeneration and post-mortem analysis reveals hallmarks of Alzheimer’s 
disease in the brains of these patients. The cause of DS is trisomy of all or part of the 
21st chromosome and on this chromosome the APP gene is located (Masters et al., 
1985). As such patients with DS have increased levels of this protein leading to 
Alzheimer’s phenotypes, similarly genetic duplication of the APP locus has been 
wobserved in some cases of familial Alzheimer’s (Delebar et al., 1987).  
 
 
Figure 3.3.29. – Sphingolipid, 
phospholipid and cholesterol 
distribution in PS1-/- cell lines. 
Representative microscopy images of 
control and Down’s syndrome patient 
fibroblasts showing levels of cholesterol 
(white) visualised by filipin, sphingomyelin 
(SphM, red) visualised by IHC against the 
lysenin toxin, LBPA (green) visualised by 
IHC and ganglioside GM1 (GM1, green) 
visualised by FITC-tagged CtxB. Hoechst 
stained nuclei are shown in blue. n = 3. 
Scale bar = 15µm. 
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We examined the lipid phenotypes described in section 3.3.1. and found that there 
are some similarities in lipid storage; including the increase in cholesterol and LBPA 
levels as has been previously reported in these cells (Cataldo et al., 2008). 
Interestingly, however, the levels of sphingomyelin and ganglioside GM1 which we 
have shown are decreased in PS deficient cells are elevated in the DS cells. These 
phenotypes are more similar to those observed in NPC and this appears to be 
complemented by the localisation of cholesterol accumulation which, in this initial 
analysis, is in the perinuclear region (figure 3.3.29.). As such it may be interesting to 
subject these cells to the analysis performed in section 3.3.2. As distinct differences 
were also observed by biochemical analysis of lipid levels in PS1-/- cells we subjected 
DS patient cell lines to this.  
 
 
 
 
Figure 3.3.30. – Biochemical quantification of sphingolipids, sterols and phospholipids 
in Down’s syndrome patient fibroblasts. A – Representative images of thin-layer 
chromatography analysis of various lipids in control (Ctrl) and Down’s syndrome patient 
fibroblasts (DS) ran alongside identified lipid standards (STD). Chol/Cer = combined levels of 
cholesterol and ceramide, GlcCer = glucosylceramide, GalCer = galactosylceramide, LBPA = 
lysobisphosphatidic acid, PL = phospholipids, SphB = sphingoid bases and SphM = 
sphingomyelin. B – Densiometric quantification of lipid levels in Down’s syndrome patient 
fibroblasts (DS) as a percentage of the lipid levels in control fibroblasts. Lipid species are 
labeled as in A. Error bars = SD. n = 3. ** = P<0.01, * = P<0.05 calculated by T test.  
 
Upon doing so we, again, observed elevations in lipids which were more similar to 
the differences observed in NPC1 disease (Lloyd-Evans et al., 2008) than in the PS 
deficient cell lines examined in section 3.3.1. This analysis confirms elevations in 
cholesterol (P = < 0.05, t = 3.187, df = 4, F2,2 = 7.671) (although the contribution of 
ceramide to this remains to be observed by running the TLC with the different mobile 
phase) alongside elevations in sphingomyelin (P = < 0.01, t = 5.580, df = 4, F2,2 =  
2.730) and LBPA ( P = < 0.05, t = 3.018, df = 4, F2,2 = 4.003). There is also a trend 
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towards elevation in sphingoid bases in these cells (P = 0.058, t = 2.634, df = 4, F2,2 = 
76.97) and a trend towards elevation of the simple glycosphingolipid GlcCer. 
Considering these data the lipid storage phenotypes observed in DS cells is much 
more reminiscent of NPC disease than the lipid phenotypes observed in PS deficient 
cells.  
 
 
 
 
Figure 3.3.31. – Ca2+ release in response to ML-SA1 in Down’s Syndrome patient 
fibroblasts. A - Representative traces of Ca2+ release in Fura2 loaded cells induced by 50µM 
ML-SA1. Black bar indicates the presence of ML-SA1. B – Quantification of Ca2+ release 
measured by ratiometric change in Fura2 fluorescence. Error bars = SEM. n = 4. No 
significance calculated by T test.  
 
Accordingly, we were interested to see if our novel reports of TRPML1 hyperactivity, 
observed in PS1-/- cells, were present in DS fibroblasts as this is not a phenotype 
seen in cell models of NPC1 disease (Waller-Evans et al. Manuscript in preparation). 
Interestingly, although the lipid accumulation phenotypes we have observed in DS 
cells is much more reminiscent of NPC1 a trend towards increased Ca2+ release in 
response to ML-SA1 was observed in these cells although the differences between 
these cell lines were not as distinct as in PS1-/- cells (figure 3.3.19.). This trend would 
likely become significant if ML-SA1 concentration was titrated until the maximum 
differences between these cell lines occurred.  
 
Although these preliminary studies do suggest some conservation of phenotypes to 
other models of Alzheimer’s, it is clearly shown that there are some differences. It 
would be interesting to see what phenotypes patient relevant mutations in PS1 elicit 
and the subsequent comparison of these to DS patient fibroblasts could provide 
further insights into conserved and divergent mechanisms of disease.   
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3.4. – Summary of Results and Discussion 
 
The results presented in section 3.3. clearly show that PS deficient cells have a 
different phenotype from NPC1 cells in relation to lipid and Ca2+ homeostasis (Lloyd-
Evans et al., 2008). In addition it is shown that the changes in both these systems in 
PS1-/- cells are suggestive of changes to lysosomal pH as an underlying cause.  
 
3.4.1. – Lysosomal alkalization in PS1-/- cells 
 
A number of publications show that it has been difficult to confirm that lysosomal pH 
has been changed in these cells resulting in contrasting views on the subject 
(Avrahami et al., 2013; Coen et al., 2012; Wolfe et al., 2013). Differences in the cell 
lines utilised in these studies may be responsible for some of these differences 
however the probes used to assay lysosomal pH also vary in these studies meaning 
that they are not always directly comparable. Wolfe et al. (2013) have profiled a 
number of these pH probes in a number of different cell lines and found that 
lysosensor yellow/blue dextran has the optimal profile for the assessment of 
lysosomal pH before using it to measure lysosomal pH in a variety of cellular models 
of familial Alzheimer’s including patient fibroblasts and mouse models; in all these 
models lysosomal alkalization was reported. The degree of this elevation in pH was a 
~0.5 pH units in PS1-/- cells.  
 
An additional study by (Coffey et al., 2014) noted that a number of the autophagy 
phenotypes present in PS deficient cells were reminiscent of other conditions in 
which lysosomal pH becomes more alkaline, such as macular degeneration. They 
utilised familial Alzheimer’s patient fibroblasts with the A246E mutation in PS1 and 
observed a modest elevation of 0.2 – 0.3 pH units in these cells. This suggests that 
although we have conducted our experiments in PS1-/- and PS1/2-/- cells that have 
lysosomal alkalisation at the extreme end of the biological spectrum there is still 
significant lysosomal alkalisation in more disease relevant cell lines.  
 
In a recent publication, Lee et al. (2015), our Ca2+ data is presented alongside further 
studies on lysosomal alkalisation and the underlying mechanism leading to this. 
Firstly, inhibition of the vATPase using concanamycin A1 lead to a similar defective 
autophagy phenotype with defects in lysosomal proteolytic enzymes as that 
observed in PS1-/- cells. Our collaborators were also able to correct these defects by 
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re-acidifying the lysosomes of PS1-/- cells. They achieved this by treating cells with 
acidifying nanoparticles which have previously been shown to correct alkalisation 
defects in the endolysosomal system (Balatazar et al., 2012). Importantly, the Ned-
19 treatment which re-filled lysosomal Ca2+ stores by inhibiting the excessive release 
from TRPML1 in PS1-/- cells did not lead to a correction of autophagic defects in the 
same way. Additionally, the application of acidic nanoparticles to cells resulted in the 
re-filling of lysosomal Ca2+ stores and reduction of cytosolic Ca2+ levels in the 
absence of Ned-19.  
 
Lysosomes from control and PS1-/- cells were purified using a method developed in 
our lab (Walker and Lloyd-Evans, 2015). These lysosomal preparations were shown 
to be enriched in lysosomal markers and without markers of other organelles. 
Compared to lysosomes prepared from control cells those prepared from PS1-/- had 
significantly decreased levels of the Voa1 and V1E1 subunits of the vATPase whilst 
the levels of lysosome marker LAMP-1 remained constant. These purified organelles 
were then used to show that the quenching of the proton sensitive dye 9-amino-6-
chloro-2-methoxyacridine (ACMA) was decreased in lysosomes prepared from PS1-/- 
cells showing that they were less able to translocate protons.  
 
Specific siRNA knockdown of Voa1 was also used to induce the same pH, 
autophagic and proteolytic defects in cells demonstrating that this was essential for 
lysosomal acidification and autophagy. Glycosylation of this subunit was also 
investigated utilising Voa1 protein which contained a mutation known to cause 
glycosylation defects in related proteins. This process was found to be critical for 
both its stability and function. Finally, PS1-/- primary neurons were investigated and 
they were found to have the pH, autophagy and proteolysis defects reported in other 
cells alongside decreased lysosomal Ca2+ and increased cytosolic Ca2+ (Lee et al., 
2015). 
 
3.4.2. – Lysosomal Ca2+ homeostasis in PS1-/- cell lines is a result of lysosomal 
alkalisation 
 
Considering the experiments discussed above, and the data shown in section 3.3.3., 
there is evidence that the elevated pH in PS1-/- cells is the primary cause of the 
reduced levels of lysosomal Ca2+ and, as such, is a more primary event in the 
pathological cascade which leads to autophagic dysfunction in PS deficient cells. 
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Nevertheless, Ca2+ dyshomeostasis in the lysosome will contribute this as fusion 
between lysosomes and autophagosomes and their subsequent clearance is 
dependent upon properly regulated lysosomal Ca2+ release (Luzio et al., 2007). The 
changes in Ca2+ homeostasis within the lysosomes are represented diagrammatically 
in figure 3.4.1. 
 
Figure 3.4.1. – Lysosomal Ca2+ 
dyshomeostasis in lysosomes of PS1-/- 
cells is a result of lysosomal 
alkalisation. Reduction in vATPase activity 
is indicated by a grey arrow showing 
reduced translocation of protons. Note the 
removal of the Voa1 subunit from vATPase 
on the lumenal side of the protein complex.  	  	  	  	  	  	  	  	  	  	  	  
The loss of vATPase function due to mistrafficking of the Voa1 subunit of this protein 
complex elevates pH in the lysosomes of PS1-/- cells as proton translocation is less 
efficient. Whilst this could potentially also reduce the activity of the proteins 
responsible for filling the lysosomes with Ca2+ these have not yet been identified, as 
such it is difficult to study this aspect of the problem. PS1-/- cell lines may help 
validate any candidates we discover for these proteins however, as we would expect 
their activities to be reduced in these cells.  
 
Lysosomal Ca2+ release channels have been investigated in much more detail and a 
number described in studies which included single channel recordings of their 
activities at different pH (Raychowdhury et ., 2004; Pitt et al., 2010). Of these 
channels, we are selectively able to activate Ca2+ release from TPC2 with NAADP-
AM although we could not do the same in PS1-/- cells. As discussed, this is due to the 
inability of NAADP to dissociate from the receptor when the pH is above pH 5.0 and 
no Ca2+ release can be induced (Pitt et al., 2010). As Ca2+ release from TPC2 is 
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known to be extremely important for providing the localised Ca2+ elevations near to 
the endolysosomal membranes required for the interaction of proteins such as 
VAMP7 (Luzio et al., 2007) this phenotype is highly likely to contribute to the inability 
of autophagosomes and lysosomes to fuse, resulting in the build up of autophagic 
vacuoles. This has been shown to occur in cellular and animal models of NAADP 
signaling inhibition we have developed following treatment with Ned-19 (Waller-
Evans et al. Manuscript in preparation) which inhibits TPC2 mediated Ca2+ release in 
the absence of pH defects.  
 
We were also able to selectively activate the TRPML1 channel, under the conditions 
discussed in section 4.3.3., with the synthetic agonist ML-SA1. As discussed this is a 
endolysosomal Ca2+ efflux channel which is active at a higher pH than channels such 
as TPC2 (Raychowdhury et al., 2004) and the hyperactivity we have observed in this 
channel is expected in cells which have undergone lysosomal alkalisation. Our 
inhibition of this channel with Ned-19 though initially unexpected may reveal novel 
information with respect to the activation of TRPML1 by different agonists. The fact 
that both channels can be regulated by phosphoinositols may support this 
observation (Waller–Evans and Lloyd-Evans; Jentsch et al., 2015). Further study of 
how these channels act in co-ordination is required to understand this. To do so  
PS1-/- cells may provide a suitable experimental system.   
 
It is interesting that the only other report linking TRPML1 channel activity to the 
pathogenesis of Alzheimer’s disease like pathology implicates the inactivation of this 
channel as an important pathogenic event (Bae et al., 2014). In this publication 
activation of the channel was shown to initiate clearance of interneuronal Aβ, 
although the lysosomal pathology of the model seems very different to what we have 
observed in PS1-/- cells as sphingomyelin levels are elevated in cells and lysosomal 
Ca2+ levels are increased. This data was collected using a genetically encoded Ca2+ 
sensor conjugated to TRPML1 in which a non-naturally occurring, constitutively 
activating mutation has been added (Bae et al., 2014). As such this represents a 
non-naturally occurring system which may have altered Ca2+ homeostasis within 
these cells.  
 
When our findings in relation to the TPC2 and TRPML1 channels are taken together 
it implicated TRPML1 in increased ‘leak’ of Ca2+ from lysosomes and this may 
contribute to increased cytosolic Ca2+ levels alongside the decrease in intraluminal 
endolysosomal Ca2+ levels. As such, hyperactivated TRPML1 may contribute the 
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Ca2+ dyshomeostasis that is observed in many model of Alzheimer’s disease. This 
would be interesting to further investigate by inhibition of TRPML1 Ca2+ release. 
Unfortunately, loss of function in this channel quickly leads to MLIV disease 
phenotypes so there would only be a small window in which these studies would be 
relevant (Waller-Evans et al., Unpublished). As for inhibitor studies the only currently 
known TRPML1 inhibitor is Ned-19 after the discovery in this study that it could 
reduce ML-SA1 mediated Ca2+ release. It also seems that this inhibition will only 
occur in the presence of lysosomal alkalisation. It would be interesting to see if any 
more inhibitors of TRPML1 could be discovered by In silico screening as this method 
has been successful in finding TRPML1 agonists such as ML-SA1 (Shen et al., 
2012).  
 
Another potential way of studying this would be either expressing a constitutively 
active TRPML1 mutant in control cells to see if any of the autophagy and lipidology 
phenotypes observe in PS1-/- cells can be induced. This could be potentially achieved 
by longer term incubation with ML-SA1 although the feasibility of this with respect to 
cell viability has not yet been assessed. Finally overexpression of wild-type TRPML1 
in healthy cells may help recapitulate the phenotype of hyperactivity observed in 
PS1-/- cells.  
 
The studies described above may help us to tease apart which aspects of pathology 
are a result of endolysosomal Ca2+ dyshomeostasis and which are due to lysosomal 
alkalisation. Particularly relevant to this is the recent finding that Ca2+ release from 
TRPML1 stimulates autophagy through activation of the phosphatase calcineurin, 
which binds an dephosphorylates the regulator of lysosomal biogenesis, TFEB 
(Medina et al., 2015). This has the potential to create a detrimental feedback loop in 
PS deficient cells as autophagy stimulation would lead to the generation of more 
autophagic vacuoles which could still not be cleared due to the alkalisation of the 
lysosome. Interestingly, inhibition of calcineurin signaling in neurons carrying a PS1 
mutation rescued signaling defects. It would be particularly interesting to test this 
inhibitor in Presenilin deficient cells. 
 
Although much remains to be done to study the impact of Ca2+ signaling 
dyshomeostasis as a result of lysosomal alkalisation, we now have a basic 
understanding of this process in a simple model of familial Alzheimer’s; PS deficient 
cell lines. This is summarised in figure 3.4.2. which also highlights that the 
mechanism proposed to cause reductions in the lysosomal Ca2+ store by 
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Bezprozvanny (2012) is unlikely to be correct. This is due to the fact that in the cell 
lines we utilised for this study cytosolic Ca2+ is increased so the Ca2+ loading protein, 
or proteins, of the lysosome would have available ions to transport. Lysosomal 
alkalisation however may cause a different defect in the function of these proteins.  
 
 
 
Figure 3.4.2. – An updated picture of Ca2+ dyshomeostasis in PS1-/- cells. Changes to 
Ca2+ stores are shown by black arrows, pathogenically changes to Ca2+ releases are shown 
by thin arrows, red arrows indicate elevated release, grey arrows indicate reduced release. 
Protein loss of function is indicated by black crosses. Protein loss of function is indicated by 
black crosses. Adapted from Popugaeva et al., 2013 and Lloyd-Evans et al., 2010. 
 
Interestingly, this diagram highlights another Ca2+ containing compartment which 
may be interesting to study in models of familial Alzheimer’s; the early endosome. 
Correct acidification of this store is required for Ca2+ efflux, if acidification does not 
take place, then channels such as TRPML3 are not activated (Martina et al., 2009). 
This would suggest there may be increased Ca2+ in early endosomes in PS1-/- cells. 
This observation is an example of how, from this starting point, we can look at the 
myriad of cellular processes Ca2+ can impact and begin to understand the role this 
has in familial Alzheimer’s.  
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3.4.3. Changes to lipid homeostasis in Presenilin Deficient cells are also 
suggestive of lysosomal alkalisation. 
 
Initially we looked at the lipidology of Presenilin deficient cell in order to see that if 
NPC-like phenotypes were present in these cells. The numerous experiments 
conducted in sections 4.3.1. supported by observations of endolysosomal lipid 
trafficking in section 4.3.2. indicate that this is not the case and another complex lipid 
pathology broadly summarised by: decreases in glycosphingolipids accompanied by 
increases in simple sphingolipids, cholesterol and phospholipids is present. Lipid 
dyshomeostasis has been implicated with multiple forms of Alzheimer’s disease and 
were one of the first pathogenic changes reported in post-mortem brain samples 
from patients by Alois Alzheimer (Grimm et al., 2013). Accordingly, I will just discuss 
the changes observed within lipids in relation to changes in the endolysosomal 
system.  
 
The redistribution of cholesterol within PS1-/- cell remains intriguing. The pattern of 
cholesterol accumulation observed in Presenilin deficient cells was predominantly in 
diffuse punctate structures away from the nucleus of cells. This is clearly in contrast 
to the NPC-like accumulation of cholesterol in punctate structures in the perinuclear 
region – these represent cholesterol storage in the late-endosomes and lysosomes 
(Lloyd-Evans et al., 2008). Although the compartment in which cholesterol 
predominantly accumulates in has not yet been confirmed, by co-localisation studies, 
an attractive proposition would be that there is some buildup of cholesterol within 
early endosomes as they are spread throughout cells more towards the plasma 
membrane in a similar pattern to the cholesterol rich punctae. In relation to this it is 
particularly interesting that the early endosomes should appear affected in these 
cells as defects in vATPase activity are also likely to impact upon this compartment, 
as discussed above. It would be interesting to see if the decrease in proton 
translocation observed in PS1-/- cells prevents the efficient extrusion of Ca2+ from 
these compartments which accompanies their acidification (Gerasimenko et al., 
2007). This may provide an explanation for the proposed early endosomal pathology, 
although this must be further investigated by co-localisation studies as previously 
mentioned. 
 
The presence of cholesterol accumulation in other compartments, such as the 
endocytic recycling compartment, was also observed in PS1-/- cells which may 
suggest that cholesterol flux throughout the endolysosomal pathway is reduced. This 
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could be further studied with fluorescently tagged cholesterol and low-density 
lipoprotein. These studies may prove particularly interesting as cholesterol is strongly 
implicated in the pathogenesis of Alzheimer’s by numerous genetic studies, 
implicating genes such as Apoε as Alzheimer’s risk factors (Grimm et al.,2013). 
Accordingly, novel phenotypes concerning the handling of cholesterol in cells from 
Alzheimer’s models may further explain the role of this vital structural lipid.  
 
Reduction of the GSL GlcCer has previously been reported in Presenilin deficient 
cells (Mutoh et al., 2012), and differential levels of gangliosides have been observed 
in numerous models of Alzheimer’s; with some gangliosides elevated and others 
decreased (Yang et al., 2013).  Whilst the explanation for this currently involves the 
reduced activity of glucosylceramide synthase (the enzyme responsible for producing 
GlcCer) it must also be noted that up to 90% of glycosphingolipid synthesis proceeds 
by utilising the products of endolysosomal lipid degradation (Sandhoff and Schulze, 
2011). As we observed a reduction in GlCer after inhibition of lysosomal vATPase 
with concanamycin A this may contribute to the reduction in GSLs. This remains to 
be further investigated.  
 
There was some evidence of elevation in phospholipids in PS deficient cells, as 
expected in cells which have lysosomal alkalisation. Phospholipidosis is a major 
consequence of this process (Nujic et al., 2012). Whilst we did observe a trend 
towards the accumulation of phsopholipids by biochemical assay we were unable to 
see the same process by using in situ fluorescent probes. We ascribed this fact to 
the fact this probe was itself a fluorescently tagged phospholipid which must be 
trafficked into cells through the endolysosomal system, The fundamental defects we 
observed in trafficking in this system, likely due to TPC2 inactivation, may have been 
responsible for decreased uptake of this probe and delivery to the correct 
compartments. Accordingly, development of this technique to use a loading probe or 
measurement of the phospholipids produced would be needed to develop this 
technique.  
 
One particularly interesting consequence of PS1 inactivation was the increased 
levels of ceramide observed alongside decreased sphingomyelin. Ceramide has 
been extensively studied in relation to Alzheimer’s and has been found to be 
elevated in cells, animal models and post mortem brain tissue from Alzheimer’s 
patients (Haughey et al., 2010). As ceramide can be produced by degradation of 
sphingomyelin by sphingomyelinases, the interplay between these two lipids may be 
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particularly important, this is particularly evident as they seem to be differentially 
affected by changes in pH as observed by the differences in sphingomyelin and 
ceramide in PS1-/- and PS1/2-/- MEF cells. This is suggestive of a phenotype that can 
be subtly altered by changes in pH to result in larger changes to lipid levels. Further 
interest has been added by the recent observation that inhibition of acid 
sphingomyelinase (ASM) is protective in some mouse models of Alzheimer’s (Lee et 
al., 2014). As a primary consequence of this would be decreased ceramide, the 
localisation and activity of ASM may be interesting to compare in PS1-/- and PS1/2-/- 
cell lines.  
 
As with the alterations in Ca2+ homeostasis we have described much remains to be 
understood about the changes in lipid homeostasis, but, we have again established a 
baseline for this analysis and highlighted some interesting avenues of interest to 
pursue.  
 
3.4.4. – What do these findings mean with respect to Familial and Sporadic 
forms of Alzheimer’s disease? 
 
The overwhelming majority of this research has been conducted in cells in which 
PS1 or even both PS1 and PS2 have been removed. Accordingly, they do not 
represent the reality of familial Alzheimer’s disease in which the Presenilin protein 
may have loss of function mutations as opposed to complete removal (Roeber et al., 
2015). However, we began research in knockout cells so that our studies were 
directly comparable to recent research conducted in this area. Accordingly, we plan 
to develop this study to test for the phenotypes we have described in patient 
fibroblast cell lines. There are some advantages of starting studies with such cell 
lines as they do represent a clarified background against which we can identify 
targets. With the clarification that lysosomal alkalisation occurs in familial Alzheimer’s 
patient fibroblasts (Coffey et al., 2014) it will be exciting to see which of the 
phenotypes identified in PS1-/- cells with respect to Ca2+ and lipids are present in 
patient fibroblasts. 
 
Whether these phenotypes extend to other form of Alzheimer’s either those caused 
by genetic changes or even sporadic forms of Alzheimer’s also remains to be 
studied. As we have seen from the preliminary study of a small subset of these 
phenotypes in fibroblasts from patients with Down’s syndrome this will not be 
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straightforward as the contrasting findings when comparing lipid and Ca2+ 
phenotypes to PS deficient cell illustrate. Nevertheless, the careful characterisation 
of dysfunction in PS1-/- cells leaves us with a solid base to begin these analyses 
from.  
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Chapter 4 
 
 
 
Lysosomal dysfunction in 
Huntington’s disease implicates the 
Niemann-Pick type C1 protein in 
Pathogenesis 
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4.1. – Introduction 
 
4.1.1. – Huntington’s Disease 
 
Huntington’s disease is a rare neurodegenerative disorder which is predicted to 
affect around 6,000 people in the UK (Evans et al., 2013). It is a progressive 
neurodegenerative disorder which manifests with motor, cognitive and psychiatric 
disturbances. Symptoms of these disturbances tend to onset around the ages of 35-
44 with a median survival time of 15-18 years after onset. (Warby et al., 1998) 
Common findings during the onset of disease include clumsiness, subtle changes to 
eye movements including defects in saccades (Turner et al., 2011), involuntary 
movements and mood disturbances. Around one third of patients also present with 
psychiatric changes. Subsequently chorea becomes more prominent, dysarthia and 
dysphagia worsen and voluntary activity becomes increasingly difficult. This may also 
be accompanied by aggressive outbursts or other symptoms of worsening psychiatric 
changes. In the final stages of disease motor disability becomes increasingly severe 
and patients are often rendered totally dependent, mute and incontinent. The 
average age of death is around 55 years (Warby et al., 1998). 
 
Approximately 25% of patients are diagnosed after the age of 50 years with some 
patients as old as 70 years; these patients tend to present with a chorea, gait 
disturbances and dysphagia. Disease progression follows a more prolonged benign 
course. (Warby et al., 1998) 
 
Within the brains of Huntington’s patients, degeneration localizes to neurons of the 
caudate and putamen (Cowan and Raymond, 2006), particularly the enkephlin and 
dopamine receptor D2 positive medium spiny neurons. These are GABAergic 
inhibitory neurons which are active in the indirect pathway of movement control and, 
as such, this neuronal loss provides the physiological basis for chorea (Mitchell et al., 
1999). Degeneration within the striatum can be observed by MRI prior to disease 
onset and progression of this feature can be a useful for clinical study of Huntington’s 
(Aylward et al, 2004). Glutamate excitotoxicity and subsequent Ca2+ dyshomeostasis 
are proposed to be important in the process of neuronal loss (HD iPSC consortium 
study., 2012). Other regions of the brain affected in Huntington’s are the cerebellum, 
substantia nigra, hippocampus and various regions of the cortex (Vonsattel et al., 
1985; Rub et al., 2013) 
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A prominent feature observed in post-mortem analysis is intraneuronal inclusions 
which contain the protein Huntingtin (Warby et al., 1998); these are, however, not 
considered to be important early on within the pathogenic cascade of Huntington’s as 
they are not present in the areas of selective degeneration within the brain and may 
be the result of a protective mechanism (Kuemmerle et al., 1999; Arrasate et al., 
2004). In addition to pathology within the CNS there is widespread peripheral 
pathology in Huntington’s patients and animal models much of which is proposed to 
occur independently from neurological defects or the result of general malaise (van 
der Burg et al., 2009).  
 
4.1.2. – Inheritance of Huntington’s Disease 
 
Huntington’s is a monogenic disease with an autosomal dominant mode of 
inheritance, accordingly genetic testing is used to confirm diagnosis and genetic 
counselling is vital for patients with families. The gene associated with Huntington’s 
is HTT (cytogenetically located at 4p16.3) which encodes the protein Huntingtin 
(HTT) and is situated on chromosome 4 (Huntington’s Disease collaborative 
research group, 1993). In this gene expansion of a CAG repeat region in exon 1 is 
the only pathogenic variant resulting in an expanded poly-glutamine tract in the 
translated HTT protein. The degree of expansion in the CAG repeat region is used to 
classify each HTT allele as normal, intermediate or Huntington’s causing with a 
single Huntington’s causing allele sufficient for disease pathogenesis (Burugunder, 
2014).  
 
Alleles with a CAG repeat region below 26 are considered normal, those between 27 
and 35 CAG repeats are considered intermediate. Although an individual with this 
allele was originally not considered to be at risk of developing Huntington’s recent 
evidence suggests that psychiatric symptoms may be prevalent in these populations 
and some patients may show late onset Huntington’s phenotypes. Any children these 
patients have will also be at an increased risk of developing Huntington’s as the 
expanded CAG repeat is more unstable and, therefore, more susceptible to 
expansion (Warby et al., 1998).  
 
Disease causing repeat lengths begin at CAG repeats over 36 trinucleotides long. 
These can be further subdivided into reduced penetrance alleles (between 36 and 39 
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CAG repeats), an individual with which may not develop Huntington’s symptoms but 
is considered at risk, and full penetrance alleles (over 40 CAG repeats) individuals 
with which will almost certainly develop disease (Warby et al., 1998). There is a well 
defined inverse correlation between the number of CAG repeats and the age of 
disease onset (Langbehn et al., 2010), with greater CAG expansion linked with more 
severe disease progression in terms of motor, cognitive and functional measures and 
less disease modification by other heritable factors (Gusella and Macdonald, 2009). 
Interestingly, psychiatric symptoms associated with Huntington’s do not appear to be 
dependent upon the size of CAG expansion (Ravina et al., 2008). When CAG 
repeats expand beyond 60 individuals are increasingly likely to have juvenile onset of 
symptoms, these occur before 20 years of age and account for 5-10% of 
Huntington’s cases (Warby et al., 1998). In such cases the presentation of symptoms 
can be quite different with markedly more severe disease progression and cerebellar 
involvement (Rodda., 1981; Ruocco et al., 2006).  
 
4.1.3. – Huntingtin 
 
The protein product of the HTT gene huntingtin (HTT) is a large protein with a mass 
of around 350kDa which is essential for development. Although it is expressed 
throughout the body the highest levels are observed in the brain (Zeitlin et al., 1995; 
Cattaneo et al., 2005). The trinucleotide CAG repeat, which determines if a HTT 
allele is pathogenic, codes for a poly-glutamine tract near the N-terminus of the 
protein. When this tract expands beyond 36 residues the protein is considered 
pathogenic and is often referred to as mutant HTT (mHTT). It is unclear how this 
expansion causes pathogenesis as the endogenous function of HTT has not been 
defined (Labbadia and Morimoto, 2013). However, increases in polyglutamine tracts 
(and the accompanying trinucleotide expansion) are a common feature of a group of 
diseases known as polyglutamine (polyQ) diseases and include several forms of 
spinocerebellar ataxia (Shao and Diamond, 2007).  
 
It is proposed that such proteins become pathogenic after enzymatic cleavage 
generates a protein fragment which becomes misfolded due to the disruption caused 
by the expanded polyQ tract. These misfolded peptides may exert toxicity as a 
monomer or may oligomerise to form micro-aggregates. Toxicity may result from 
transcriptional alteration, metabolic dysfunction, proteolytic impairment and stress 
response abnormalities (Ross, 2002). Ultimately polyQ proteins may form larger 
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aggregated species and ultimately inclusions; these are thought to exert a protective 
influence by reducing the levels of misfolded peptide and micro-aggregates (Arresate 
et al., 2004). mHTT exerts a number of these effects, including transcriptional 
repression of brain-derived neurotrophic factor (BDNF) through a lack of cytoplasmic 
interaction with RE1-silencing transcription factor (REST) (Zuccato et al., 2003; 
Schiffer et al., 2014),  
 
4.1.4. – Huntingtin and the endolysosomal system 
 
A recent study has shown that HTT positively modulates selective autophagy by 
acting as a scaffold by facilitating the binding of p62 (a key protein in this pathway) 
and the autophagosome component LC3, to promote substrate recognition and 
autophagy regulation (Rui., 2015). Loss of this function as a result of polyQ 
expansion in mHTT may explain the autophagy defects observed in Huntington’s 
particularly the observation of ‘empty autophagosomes’ suggestive of a failure in 
sequestration of substrates (Martinez-Vicente et al., 2010). The requirement of 
autophagy for the degradation of aggregated proteins and the fact that mHTT can 
inhibit this process results in a ‘Catch 22’ situation within neurons that are situated at 
the crossroads between the autophagic process and apoptosis. Accordingly, the 
presence of reduced autophagic function in Huntington’s has been extensively 
researched as aggregation prone proteins such as HTT are preferentially degraded 
by this process (Sarkar et al., 2008). As the lysosome is the terminus of the 
autophagic system, dysfunction in this organelle could also contribute to reduced 
autophagic flux.  
 
Increased endolysosomal volume has been observed in iPS derived neurons from 
Huntington’s disease mouse models and iPS derived neurons from homozygous and 
heterozygous Huntington’s patients (Castiglioni et al., 2012; Camniaso et al., 2012). 
In these cells alterations in genes encoding lysosomal proteins were shown to be 
dependent upon the polyQ repeat length of mHTT and result in an increase in 
vesicles positive for the acidotrophic dye lysotracker, a commonly utilised method for 
examination of endolysosomal expansion. In this study the authors concluded that 
increased lysosomal activity was present in these cell lines and this was the reason 
for increased endolysosomal volume (Castiglioni et al., 2012) as opposed to 
substrate storage which is the reason for an expanded endolysosomal system in 
LSDs (Platt et al.,2012). Lysosomes have also been reported to become increasingly 
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concentrated in the perinuclear regions of fibroblasts from Huntington’s patients (Erie 
et al., 2015).  
 
Further studies have also suggested that HTT and interacting proteins are capable of 
stimulating the endolysosomal system. Huntingin interacting protein 1 (HIP1) is a 
protein which is known to be involved in the assembly of endocytic protein 
complexes (Metzler et al., 2001). It interacts with the N-terminus of HTT and this 
process is disrupted in mHTT (Hackam et al., 2000). Changes in the expression of 
HIP1 and modulation of its ability to interact with binding partners can result in varied 
changes to endocytosis including the formation of expanded perinuclear vesicles 
which contain HTT alongside proteins such as clathrin. (Waelter et al., 2001). 
Accordingly HIP1 is an important protein to consider when looking at changes to 
endocytosis in Huntington’s.  
 
There have also been reports of elevated levels of a number of lipids which can 
accumulate in lysosomes in the brains of Huntington’s animal models and a variety of 
cell lines with expanded polyQ repeats in HTT. Cholesterol accumulation has been 
observed in striatal neurons from the HD72 mouse model of Huntington’s, both In 
vitro and In vivo (Trushina et al., 2006). In both experimental models the cholesterol 
accumulation was age related increasing with the time in culture for primary striatal 
neurons extracted from this mouse model and the age of mice for the accumulation 
of this lipid within the brain. Interestingly cells from this mouse model also exhibited 
defects in the internalisation and subsequent transport of the fluorescently tagged 
sphingolipid BODIPY-lactosylceramide (BOD-LacCer) (Trushina et al., 2006). This 
internalisation and transport occurs along the same Caveolin-1 dependent pathway 
as CtxB bound to ganglioside GM1 (Singh et al., 2007). This caveolin-1 dependent 
pathway was found to be required for mHTT dependent cholesterol accumulation 
(Trushina et al., 2006). Despite these initial data there is some debate about the 
levels of cholesterol in animal and cell models of Huntington’s. There are numerous 
reports of polyQ length dependent defects in cholesterol biosynthesis in rodent 
models of Huntington’s with total cholesterol levels reduced in a number of such 
models Valenza et al., 2005; Valenza et al., 2007; Marullo et al., 2012). 
Nevertheless, there have been other reports where although levels of precursors 
were affected total levels of brain cholesterol did not change (Valenza et al., 2007a) 
other groups have reported polyQ length dependent increases in cholesterol in 
different rodent models (Trushina et al., 2014) and it has been reported that down-
regulation of cholesterol biosynthetic genes in D.melanogaster and C.elegans 
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models of Huntington’s is beneficial (Luthi-Carter et al., 2009). The sheer number of 
different animal models of Huntington’s make it difficult to draw any sure conclusions 
from such data.  
 
Further studies have shown increases of cholesterol evident as punctae in cell lines 
and neurons expressing expanded mHTT alongside increased cholesterol levels in 
post-mortem brain samples from the caudate of Huntington’s patients (del Toro et al., 
2010). Recently another study reported increased levels of cholesterol in the caudate 
alongside changes in cholesterol precursors (Kreilaus et al., 2015) Accumulation of 
ganglioside GM1 was also observed in mHTT expressing neurons in the study of del 
Toro et al. (2010). 
 
Conversely, in other studies, the levels of ganglioside GM1 have been shown to be 
reduced in Huntington’s mouse models (Maglione et al., 2010; Di Pardo et al., 2012). 
As the total levels of ganglioside are to some extent governed by lipid catabolism and 
recycling in the endolysosomal system (Schulze and Sandhoff, 2010) defects in 
these compartments may impact upon this phenotype, particularly the plasma 
membrane availability of this lipid. A recent publication has detailed striatal lipid 
accumulation in a mouse model of Huntington’s carrying Q111 mHTT. In this brain 
region sphingomyelin, phosphatidylcholine, cholesterol esters and triglyceride 
species all accumulated and similar results were observed in cellular models with the 
same mHTT (Carroll et al., 2015). 
 
These data all suggest that a thorough examination of lysosomal phenotypes is 
warranted in models of HD with a particular emphasis on storage and trafficking 
manifestations which have been observed in LSDs to see if these processes could 
be contributing to the expansion of the endolysosomal system in the presence of 
HTT with expanded polyQ repeats.  
 
As a variety of lysosomal dysfunction has been reported in cell and animal models of 
Huntington’s we were interested to apply the assays performed in the lab to cellular 
models of this disease in order to assess whether lysosomal dysfunction was 
prevalent in a wide array of cells with an expanded polyQ repeat in huntingtin 
(mHTT) and, if observed, was it reminiscent of any of the phenotypes observed in 
cells with known causes of lysosomal dysfunction.  
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4.2. – Procedures 
 
In section 4.3.1. we will investigate iPSC derived neural stem cells generated from a 
juvenile Huntington’s patient cell line with a polyQ repeat length of 180, these cells 
are described in section 2.1.4.. Firstly, we will investigate these cell for lysosomal 
expansion using LAMP2 as a marker before subsequent investigations into what may 
cause this. As lipids are stored in a variety of LSDs we will utilise cell biology to 
examine these. 
 
In order to try and see if lysosomal phenotypes are present in multiple Huntington’s 
models we will also examine these phenotypes in ST14A cells (section 4.3.2.). These 
cell are described in 2.1.5. As these cells are more easily grown in larger numbers 
they will also be examined by TLC. In addition we will examine another cellular 
model of Huntington’s disease in which polyQ HTT is inducibly expressed in PC12 
cells (section 2.1.6) to supplement the data obtained. 
 
In both of the NSC and ST14A cells discussed above we will also look at lysosomal 
proteins which may be dysfunctional in order to try and identify the mechanism of 
lysosomal dysfunction. Subsequently, we will study if the ST14A cells have specific 
lysosomal dysfunction such as sphingosine trafficking and lysosomal Ca2+ 
homeostasis defects in order to verify this mechanism. The final cell model which we 
will utilise in this study are iPSC derived mature striatal medium spiny neurons 
(section 4.3.3.) with a range of PolyQ repeats. These will be subject to the maximum 
number of analyses possible. 
 
As we are interested in finding new therapeutic targets for neurodegenerative 
disease we will apply therapies known to be of benefit to LSDs to our models of 
Huntington’s disease. Initially, we will preform a preliminary analysis of whether these 
can reduce the lysosomal phenotypes observed in ST14A cells (section 4.3.4.). If we 
observe benefit we will apply these therapeutics to a functional assay of neuronal 
Ca2+ homeostasis in response to glutamate excitotoxicity. This is a well defined 
assay which will demonstrate if we have been able to cause a functional benefit to 
neuronal models of Huntington’s disease.   
 
Where possible 3 or more independent plating replicates will be used in these 
experiments and appropriate statistical analysis will be performed as detailed in 
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individual figure legends. In instances where 3 independent plating replicates were 
not performed due to unavailability of cells this will be shown in the figure legend. 
This has not been possible for all cell lines due to the technical difficulties of 
preparing these cell lines and their availability, this has impacted most upon the 
studies described in section 4.3.1. and 4.3.3.  
 
Statistical analyses as described in section 2.7 have been performed on all these 
experiments as appropriate, details of these are given in individual figure legends.  
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4.3. – Results 
 
4.3.1. – Preliminary Evidence of Specific Lysosomal Dysfunction in iPSC 
neuronal stem cells from Huntington’s Disease Patients 
 
In order to initially analyse if the reported lysosomal dysfunction was prevalent in 
cells which express mHTT we utilised a line of iPSC derived neuronal stem cells 
(NSCs, often referred to as neuronal precursor cells (NPCs) but referred to by the 
alternative name NSCs for clarity) which have 180 glutamine residues in their polyQ 
repeat (HD iPSC consortium study., 2012). Although this is an extreme expansion in 
polyQ repeats compared to the average for Huntington’s patients (Warby et al., 
1998) it was ideal for initial experiments to see if we could observe robust 
differences. Firstly we looked for instances of endolysosomal expansion in these 
cells.  
 
 
 
Figure 4.3.1. – Lysosomal markers in iPS derived neural stem cells. NSCs from a control 
and a juvenile Huntington’s Patient (Q180). Representative immunofluorescence images of 
the lysosomal marker Lysosomal-Associated Membrane Protein 2 (LAMP-2, white) shows 
changes in lysosome and late-endosome number, size and localisation within cells. n = 1. 
Scale bar = 10µm. Data collected with assistance from Naomi Killick, Cardiff University. 
 
In preliminary experiments expansion of the lysosomal system was observed in the 
endolysosomal system of Q180 NSCs when the levels of the lysosomal and late-
endosomal protein LAMP-2 were analysed in cells. It is also interesting to note that 
the recently reported phenotype of perinuclear lysosomal clustering was evident in 
these cells (Erie et al., 2015). As we were able to observe lysosomal expansion we 
were interested to see if we could characterise storage substrates which may be 
responsible for this expansion. Due to multiple reports of lipid accumulation in 
models of Huntington’s (Trushina et al., 2006; del Toro et a., 2010; Carroll et al., 
2015) and the prevalence of lipid storage in the LSDs in general we began by 
probing cells with the various lipid probes commonly employed in our studies.  
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Figure 4.3.2. – Lipid storage phenotypes 
in iPS derived neural stem cells. NSCs 
from a control and a juvenile Huntington’s 
Patient (Q180). Representative 
fluorescence microscopy of filipin stained 
cells (white) show endo-lysosomal 
cholesterol accumulation and lysenin 
stained cells (SphM, red) show increases in 
sphingomyelin levels. Representative 
immunofluorescence images of 
lysobisphosphatidic acid (LBPA, green) 
show increased levels of this lyso-
phospholipid. FITC-tagged cholera toxin B 
subunit is used to visualise the redistribution 
of ganglioside GM1 (green) within Q180 
cells. Hoechst stained nuclei are shown in 
blue in the Lysenin, LBPA and CtxB 
images. n = 1 - 2. Scale bar = 10µm. Data 
prepared with assistance from Naomi 
Killick, Cardiff University. 
 
 
 
 
 
 
 
As shown in figure 4.3.2. a number of lipids were observed to be increased in Q180 
NSCs. Firstly, in line with multiple reports in the literature we observed cholesterol 
elevation. This was particularly evident as punctae in the perinuclear regions of cells 
in which the expanded endolysosomal system was situated suggestive of 
endolysosomal cholesterol accumulation. This punctate accumulation was 
accompanied by less evident plasma membrane staining of cells which may be 
evidence of a defect in recycling this lipid. We next looked at sphingomyelin levels in 
cells and observed clear elevations in this lipid, although the distribution of this was 
throughout the cells as opposed to in clustered punctae. Interestingly, we have 
observed this in LSDs where sphingomyelin accumulates in the lysosome so does 
not exclude lysosomal storage (Halsett et al., Unpublished). This lipid has also been 
reported to accumulate in the brains of Huntington’s mouse models (Carroll et al., 
2015). LBPA levels are also elevated throughout the cell, as has been observed in 
models of NPC (Chevallier et al., 2008). The accumulation of this lipid is also in the 
perinuclear region of cells. Finally we can see relatively constant levels of the 
ganglioside GM1 accompanied by a redistribution from plasma membranes to a 
distinct perinuclear punctate localisation, further indications of lysosomal lipid 
accumulation alongside defective recycling of lipids.  
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As recycling of ganglioside GM1 appeared to be dysfunctional in these cells we were 
interested to use the well characterised CtxB trafficking assay as a means of 
determining whether this was due to an endolysosomal trafficking defects in cells 
with mHTT.  
 
 
 
 
Figure 4.3.3. – Endolysosomal sphingolipid trafficking in iPS derived neural stem cells. 
NSCs from a control and a juvenile Huntington’s Patient (Q180). Representative fluorescence 
microscopy images of pulse-chased FITC-tagged Cholera toxin B-subunit (CtxB-488, green) 
to assay trafficking of ganglioside GM1 through the endolysosomal system. Hoechst stained 
nuclei are shown in blue. n = 1. Scale bar = 10µm. Data collected with assistance from Naomi 
Killick, Cardiff University. 
 
In initial analyses we observed a clear trafficking defect of CtxB-bound GM1 to the 
Golgi in Q180 NSCs represented by increased presence of punctae in these cells as 
opposed to a clear Golgi localisation in control cells. This phenotype has been 
previously reported in primary neurons from the HD72 mouse model (Trushina et al., 
2006). 
 
The presence of lysosomal lipid storage and endolysosomal trafficking defects in 
these cells suggests lysosomal disease phenotypes may be present. Accordingly we 
began to investigate more specific phenotypes previously observed in LSD cells. An 
example of such a phenotype is ER expansion (Wang et al., 2011) which can be 
observed by immunohistochemistry against the ER protein SERCA2. 
 
 
 
Figure 4.3.4. – Endoplasmic reticulum structure in iPS derived neural stem cells. NSCs 
from a control and a juvenile Huntington’s Patient (Q180). Representative 
immunofluorescence images of Sarcoplasmic/Endoplasmic Reticulum Ca2+ ATPase isoform 2 
(SERCA2, white) is used as a marker to examine endoplasmic reticulum morphology. n = 1. 
Scale bar = 10µm. Data collected with assistance from Naomi Killick, Cardiff University. 
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No expansion of the ER was evident after preliminary examination of the ER marker 
SERCA2. Although it was observed that levels of SERCA2 were reduced, which may 
be evidence of other changes in the ER of these cells. This remains to be further 
investigated in Huntington’s cell lines utilising other markers of the ER, and western 
blotting for accurate levels of protein expression. Interestingly, reduced SERCA2 in 
peripheral B-cells has also been suggested as a disease biomarker (Cesca et al., 
2015). 
 
The array of cellular phenotypes which have been observed so far alongside reports 
of cholesterol and sphingomyelin dyshomeostasis and sphingolipid mistrafficking in 
other cellular models of Huntington’s we were interested to see if the distribution or 
levels of the NPC1 protein was affected in Q180 NSCs. 
 
 
 
 
Figure 4.3.5. – Levels of the NPC1 protein in iPS derived neural stem cells. NSCs from a 
control and a juvenile Huntington’s Patient (Q180). Representative immunofluorescence 
images of Niemann-Pick type C1 protein (NPC1, green) show the distribution of this late-
endosomal and lysosomal transmembrane protein within cells. Q180 panel marked + has had 
the brightness enhanced to allow visualisation of NPC1 distribution. Hoechst stained nuclei 
are shown in blue. n = 1. Scale bar = 10µm. Data collected with assistance from Naomi 
Killick, Cardiff University. 
 
As seen in figure 4.2.5. there is preliminary evidence of a reduction in NPC1 protein 
levels in Q180 cells. Interestingly, when the images had their brightness increased, in 
order to observe the localisation of NPC1 (image marked with +), large aggregates 
were observed rather than fine diffuse staining. This phenotype has been observed 
before in cells which have had an NPC1 phenotype induced (Lloyd-Evans., 
Unpublished); as such it is indicative of NPC1 dysfunction in these cells. These 
observations are being further studied by western blotting. 
 
Taken together these preliminary data are suggestive of endolysosomal system 
expansion linked to dysfunction of the NPC1 protein. In addition to the fact that these 
datasets were only preliminary, this cell line was also relatively novel with respect to 
the study of Huntington’s; accordingly we were keen to see if these phenotypes were 
replicated in other more thoroughly researched models of the disease.  
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4.3.2. – Confirmation of lysosomal phenotypes in rat striatal neuronal 
precursor cells overexpressing HTT 
 
One cell line which has been extensively used for such analysis is the ST14A 
R.novegicus neuronal precursor cell line which overexpresses a fragment 
corresponding to amino acids 1-548 of huntingtin with 120 polyQ repeats (HTT Q120 
ST14A) (Ehrlich et al., 2001; Valenza et al., 2005; Maglione et al., 2010). As such, 
these were subjected to the same cell analyses described in 4.3.1. 
 
 
Figure 4.3.6. – Lysosomal markers in 
ST14A cells expressing mHTT. ST14A 
cells expressing fragment 1-548 of the 
human huntingtin protein with different 
polyQ repeat lengths. A – Representative 
immunofluorescence images of lysotracker 
green loaded cells (LT green, white) shows 
changes in lysosome and late-endosome 
number, size and localisation within cells. B 
– Threshold analysis of LT green 
fluorescence. n = 3. * = P < 0.05 by T-test. 
Scale bar = 10µm.  
 
 
 
 
Q120 expressing ST14A cells showed a significant increase (P < 0.05, t = 2.910, df = 
4, F2,2 = 6.068) in lysotracker fluorescence indicative of expansion in the 
endolysosomal system of these cells. This was expected from the prevalence of this 
phenotype in a variety of cell lines (Castiglioni et al., 2012; Camnasio et al., 2012; 
Erie et al., 2015). Increased perinuclear clustering of lysosomes was not as obvious 
in the cells, although this may be due to comparison between the lysosomal 
populations in different parts of the cell being difficult due to divergent fluorescence 
levels. Unfortunately, the same analyses of LAMP-2 by immunohistochemistry 
(4.3.1.) cannot be conducted in these cells as antibodies against LAMP proteins are 
highly species specific and those raised against mouse and human LAMP proteins 
do not bind to the proteins present in ST14A cells. Nevertheless, the general 
increase in endolysosomal compartment size remains a robust phenotype that can 
be analysed quantitatively by threshold counting.  
 
	   153	  
Due to the increased size of the endolysosomal store we would like to see if the lipid 
storage phenotypes observed in NSCs were replicated in these cells.  
 
 
Figure 4.3.7. – Lipid storage phenotypes 
in ST14A cells. ST14A cells expressing 
fragment 1-548 of the human huntingtin 
protein with different polyQ repeat lengths. 
Representative fluorescence microscopy 
images of filipin stained cells (white) show 
endo-lysosomal cholesterol accumulation 
and lysenin stained cells (red, SphM) show 
increases in sphingomyelin levels. 
Representative immunofluorescence images 
of lysobisphosphatidic acid (LBPA, green) 
show increased levels and altered 
localization of this lyso-phospholipid . FITC-
tagged cholera toxin B subunit (CtxB, green) 
is used to visualise the increase of 
ganglioside GM1 within cells. Hoechst 
stained nuclei are shown in blue in the 
Lysenin, LBPA and CtxB images. n = 3 for 
cholesterol, LBPA and GM1, n = 1 for SphM. 
Scale bar = 10µm. 
 
 
 
 
 
 
 
 
As can be seen in figure 4.3.7. lipid accumulation is observed in Q120 ST14A cells 
with a broadly similar pattern to the lipid phenotypes previously demonstrated (figure 
4.3.2.). These lipid accumulations seem to be less severe than the lipid differences 
between control and Q180 NSCs which may be due to less difference between the 
severity of the cell lines; Q180 is an extremely high repeat length for a Huntington’s 
patient (Warby et al., 1998), whereas, much higher repeat lengths are used to 
generate phenotypes in rodent models of Huntington’s compared to those which 
cause human disease (Zuccato et al., 2010; Carroll et al., 2015). The least elevated 
lipid appears to be cholesterol although this may be explained by differential levels of 
cholesterol synthesis reported in Huntington’s cell and mouse models (Valenza et al., 
2005; Valenza et al., 2007; Marullo et al., 2012). Accordingly, cholesterol phenotypes 
are currently under detailed investigation (Clark et al.). Nevertheless, there is still a 
defined accumulation of cholesterol in small punctae in the perinuclear region of cells 
expressing Q120 HTT suggesting a milder cholesterol accumulation than that 
previously observed may be taking place. Sphingomyelin is, similarly, elevated to a 
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lesser degree than in Q180 NSCs although it is clearly elevated throughout the cell. 
LBPA and ganglioside GM1 both increase in Q120 ST14A cells and are redistributed 
to the perinuclear regions of the cell, suggestive of lysosomal lipid accumulation. As 
this is conserved across human and rat cell lines it is strongly suggestive of a lipid 
storage phenotype in cells with expanded polyQ repeats. 
 
 
 
Figure 4.3.8. – Biochemical analysis of lipid levels in ST14A cells. ST14A cells 
expressing fragment 1-548 of the human huntingtin protein with different polyQ repeat 
lengths. A – Representative images of thin-layer chromatography analysis of various lipids in 
Q15 and Q120 ST14A cells ran alongside identified lipid standards (STD). Chol/Cer = 
combined levels of cholesterol and ceramide, GlcCer = glucosylceramide, GalCer = 
galactosylceramide, LBPA = lysobisphosphatidic acid, PL = phospholipids, SphB = sphingoid 
bases and SphM = sphingomyelin. B – Densiometric quantification of lipid levels in Q120 
ST14A cells as a percentage of the lipid levels in Q15 ST14A cells. Lipid species are labelled 
as in A. Error bars = SD. n = 2 - 3. * = P < 0.05, ** = P < 0.01 calculated by T test.  
 
As it was possible to culture greater numbers of ST14A cell lines than the NSCs 
previously examined it was possible to perform a preliminary analysis of lipid levels in 
Q120 cells by biochemical analysis using thin-layer chromatography. Cholesterol 
was elevated by around 25% (P < 0.05, t = 4.422 df = 2, F1,1 = 12.69, in this 
analysis the cholesterol bands for 1 repeat from each cell line were removed due to 
uneven spray distribution). No significant change was observed in sphingomyelin 
levels but LBPA levels were significantly increased (P < 0.05, t = 4.210, df = 3, F1,2 = 
1.080, a LBPA band frm the Q15 cells was removed from this analysis due to uneven 
spraying). We were also able to demonstrate increases in sphingoid bases (P < 0.01, 
t = 4,812, df=4, F2,2 = 5.263) and a decrease in phospholipid levels (P < 0.05, t = 
3.038, df = 4, F2,2 = 1.217). Interestingly, sphingoid bases would be expected to 
increase in cells in which the NPC1 protein was dysfunctional (Lloyd-Evans et al., 
2008). Another lipid which would be expected to increase is GlcCer, however, lipid 
levels were not sufficiently high for accurate analysis by this method. No evidence of 
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increased phospholipids suggests that the pH of lysosomes is not affected by 
increased levels of mHTT. The levels of phospholipid were, in fact, slightly reduced 
(P < 0.05, t = 3.038, df = 4, F2,2 = 1.217). Due to some imperfections in the 
development of this plate this analysis will be repeated in future.  
 
It was also possible to examine the lipidology of another widely used Huntington’s 
disease cell line in order to further confirm the presence of lipid storage across 
various models of Huntington’s. We were able to culture a PC12 cell line inducibly 
expressing full length human mHTT with a 145 amino acid polyQ expansion and 
compare these to a cell line expressing Q23 huntingtin.   
 
 
 
 
Figure 4.3.9. – Biochemical analysis of lipid levels in PC12 cells. PC12 cells expressing 
full length human huntingtin protein with different polyQ repeat lengths. A – Representative 
images of thin-layer chromatography analysis of various lipids in Q23 and Q145 PC12 cells 
ran alongside identified lipid standards (STD). Chol/Cer = combined levels of cholesterol and 
ceramide, GlcCer = glucosylceramide, GalCer = galactosylceramide, LBPA = 
lysobisphosphatidic acid, PL = phospholipids, SphB = sphingoid bases and SphM = 
sphingomyelin. B – Densiometric quantification of lipid levels in Q145 PC12 cells as a 
percentage of the lipid levels in Q23 PC12 cells. Lipid species are labeled as in A. Error bars 
= SD. n = 3. * = P < 0.05 calculated by T test. 
 
In initial analysis of these cells a similar trend of increased cholesterol and sphingoid 
bases occurred. There was also significant elevation in LBPA (P < 0.05, t = 4.488, df 
= 4, F2,2 = 33.87), sphingomyelin was again not elevated. The TLC loaded at these 
protein levels did not provide visible bands of either GlcCer or GalCer so it was not 
possible to quantify these lipids. The levels of phospholipid were also observed to 
increase in these cells (P < 0.05, t = 2.812, df = 4, F2,2 = 14.64). While this may be 
suggestive of a phospholipidosis phenotype indicating lysosomal alkalisation we did 
not observe any of the other phenotypes observed in the study of PS deficient cells 
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in the different Huntington’s cell lines examined. Accordingly, it may be a process 
specific to these cells causing elevations in phospholipid. 
 
 
 
 
Figure 4.3.10. – Endolysosomal sphingolipid trafficking in ST14A cells. ST14A cells 
expressing fragment 1-548 of the human huntingtin protein with different polyQ repeat 
lengths. A – Representative fluorescence microscopy images of pulse, chased FITC-tagged 
Cholera toxin B-subunit (CtxB-488, green) to assay trafficking of ganglioside GM1 through the 
endo-lysosomal system. Hoechst stained nuclei are shown in blue. B – Qualitative 
quantification of CtxB-488 localisation as Golgi, punctate or intermediate between the two 
states in ST14A cells as a percentage of the total cell population. Error bars = SD. n = 3. 
Scale bar = 10µm. *** = P < 0.001 calculated by Χ2 test.   
 
As discussed in 4.3.7., the prevalence of perinuclear lipid accumulation is strongly 
indicative of endolysosomal lipid trafficking defects. These trafficking defects were 
robustly observed in ST14A cells expressing Q120 huntingtin when this process was 
investigated using the CtxB transport assay to study endolysosomal trafficking of 
ganglioside GM1, figure 4.3.10 (P < 0.001, Χ2 = 492.87 for run 1, 430.51 for run 2 
and 742.70 for run 3, df = 4). This analysis was performed by comparing the values 
obtained from the three HTT Q120 repeats of this experiment to expected values 
calculated from the mean of each population in HTT Q15 cells. As variation between 
the three repeats was minimal (SEM = < 6% in all populations) this approach was 
applicable. 
 
A useful tool to examine the activity of the cathepsin enzymes B and L are In situ 
probes which localise to lysosomes and are specifically cleaved by these enzymes to 
yield a fluorescent product. As both these enzymes have been shown to be involved 
in the degradation of Huntingtin (Kim et al., 2006) we thought it would be interesting 
to see if any changes in their activity were observed in cells expressing mHTT. 
 
	   157	  
 
 
Figure 4.3.11. –Lysosomal proteolysis defects in ST14A cells. ST14A cells expressing 
fragment 1-548 of the human huntingtin protein with different polyQ repeat lengths. A – 
Representative fluorescence microscopy images of cells loaded with the magic-red cathepsin 
B substrate (MR Cat B, white) shows the in situ activity of cathepsin B within cells. B – 
Threshold analysis of magic-red cathepsin B fluorescence. n = 4. * = P < 0.05 by T-test. . C – 
Representative fluorescence microscopy images of cells loaded with the magic-red cathepsin 
L substrate (MR Cat L, white) shows the in situ activity of cathepsin L within cells. D – 
Threshold analysis of magic-red cathepsin L fluorescence. n = 4. **** = P < 0.0001 calculated 
by unpaired T-test. Scale bar = 10µm.  
 
The activities of both Cathepsin B (P < 0.05, t = 3.614, df = 6, F3,3 = 9.714)  and 
Cathepsin L (P < 0.0001, t = 9.202, df = 6, F3,3 = 1.151) were significantly reduced in 
Q120 ST14A cells although the degree of reduction in Cathepsin L activity was 
greater. As these enzymes are known to interact with HTT (Kim et al., 2006), which 
was overexpressed in the pathogenic cell line, this is to be expected as the protein 
and fluorescent substrate may act as competitive inhibitors of each other. The fact 
that Cathepsin L activity is more obviously reduced in these cells is supportive of this 
enzyme being more critical for this process than Cathepsin B (Bhutani et al., 2012). 
Of course, the activities of these enzymes could also be an indication of lysosomal 
alkalisation reducing their activity due to divergence from their acid pH optima. This 
is however unlikely, as the lipid changes and other phenotypes observed are not 
similar to those observed in PS deficient cells where lysosomal alkalisation has been 
confirmed (Coffey et al., 2014; Lee et al., 2015).  
 
As the accumulation of autofluorescent material termed lipofuscin is a lysosomal 
storage phenotype which is observed in cells with lysosomal alkalisation and loss of 
Cathepsin activity (although it can be caused by other lysosomal dysfunction), cells 
were subsequently investigated for increased levels of autofluorescence after visible 
excitation at 470 nm.  
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Figure 4.3.12. – Autofluorescent material 
in ST14A cells. ST14A cells expressing 
fragment 1-548 of the human huntingtin 
protein with different polyQ repeat lengths. 
A – Representative fluorescence 
microscopy images of unstained cells at 
470nm excitation wavelength (AF 470nm, 
white) shows the distribution of any 
autofluorescent pigment within cells. B – 
Threshold analysis of autofluorescence at 
470nm excitation wavelength. n = 4. * = P < 
0.05 by T test. Scale bar = 10µm.  
 
 
 
 
Autofluorescence was, in fact, slightly reduced in Q120 mHTT cells (P < 0.05, t = 
3.191, df = 6, F3,3 = 1.020, 4.3.12.) although it was difficult to observe any 
autofluorescence in either cell line. This further confirms that lysosomal alkalisation 
was not present in these cells. Lysosomal alkalisation and subsequent 
autofluorescence are not phenotypes associated with NPC1 dysfunction (Lloyd-
Evans et al., 2008; Waller-Evans., manuscript in preparation) so this further suggests 
that lysosomal storage phenotypes in these cells may be due to dysfunction in 
NPC1. In order to confirm that no changes in lysosomal pH are present in these cell 
lysosensor yellow/blue dextran could be used (Wolfe et al., 2013) although in the 
absence of any evidence of lysosomal alkalisation this does not seem necessary. 
 
In the NSCs we also examined the ER for expansion, as this is specifically 
associated with some lipidoses but not NPC1 disease. The slight reductions 
observed by SERCA2 immunohistochemistry may also be present in Q120 ST14A 
cells in initial experiments (data not shown) and we further examined these cells 
using ER tracker blue white which is a specific fluorescent marker for the ER.  
  
Figure 4.3.13. – Endoplasmic reticulum 
structure in ST14A cells. ST14A cells 
expressing fragment 1-548 of the human 
huntingtin protein with different polyQ 
repeat lengths. A – Representative 
fluorescence images of ER tracker 
blue/white loaded (ERT b/w), white) is used 
as a marker to examine endoplasmic 
reticulum morphology and density. B – 
Threshold analysis of ER tracker blue/white 
fluorescence. n = 4. No significant 
difference observed by T test. Scale bar = 
10µm.  
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Figure 4.3.13. suggests a trend towards a minor reduction in ER density, as Q120 
cells had lower levels of fluorescence indicative of reduced ER size. Interestingly, 
this reduction in fluorescence was not significantly different due to highly evident 
variability in the ER of Q120 HTT cells. ER tracker variability has been observed 
before in cells known to be undergoing ER stress and is supported by preliminary 
observations of increased extra-Golgi localised transmembrane emp24 protein 
domain containing (TMED4) which is a protein marker of ER stress (data not shown) 
(Walker et al., Unpublished).  
 
The combined finding of figures 4.3.6. – 4.3.13. alongside the phenotypes observed 
in Q180 NSCs are suggestive of NPC1 protein dysfunction in cells which express 
mHTT. Accordingly we decided to examine the levels of this protein alongside the 
protein active in the same pathway and a cause of comparable cellular lysosomal 
storage phenotypes Niemann-Pick type C2 (NPC2) (Iouannou, 2005).   
 
 
 
Figure 4.3.14. – Localisation of NPC proteins in ST14A cells. ST14A cells expressing 
fragment 1-548 of the human huntingtin protein with different polyQ repeat lengths. 
Representative immunofluorescence images of Niemann-Pick type C1 protein (NPC1, green) 
show the distribution of this late-endosomal and lysosomal transmembrane protein within 
cells. Representative immunofluorescence images of Niemann-Pick type C2 protein (NPC2, 
red) show the distribution of this soluble lysosomal protein within cells. Hoechst stained nuclei 
are shown in blue. n = 4. Scale bar = 10µm for the upper two images and 5µm for the lower 
images.  
 
	   160	  
In contrast to the reduced levels of protein observed in Q180 cells we observed 
increases in NPC1 in Q120 ST14A cells. It was however, similarly mislocalised with 
dense perinuclear accumulation of the protein, as opposed to fine punctate staining 
expanding throughout the cell (figure 4.3.14.). Interestingly, NPC1 was also excluded 
from large areas of the cell when expanded polyQ huntingtin was present. Although 
the compartments within the cell which NPC1 becomes localised to are yet to be 
defined it is clearly not in the same location as in healthy cells and this could 
potentially be the underlying cause of the specific lysosomal dysfunction observed in 
cellular models of Huntington’s. 
 
There also appears to be an increase in NPC2 in Q120 cells (figure 4.3.14.) and the 
increasingly obvious punctae observed may be the result of cells attempting to 
compensate for reduced levels of NPC1 in the lysosome, as both proteins interact in 
a non-redundant functional co-operativity (Sleat et al., 2004). These data are being 
confirmed by western blotting (Clark et al.).  
 
If NPC1 is not functioning correctly in these cells then a phenotype we would expect 
to see in these cells is reduced lysosomal Ca2+, as this has been observed in all cells 
deficient in NPC1 and in cell lines in which NPC1 has been inactivated (Lloyd-Evans 
et al., 2008).  
 
 
 
 
Figure 4.3.15. – Lysosomal Ca2+ release induced by nigericin in ST14A cells. ST14A 
cells expressing fragment 1-548 of the human huntingtin protein with 120 polyQ repeats after 
nigericin induced lysosomal Ca2+ release in the presence of 5µM ionomycin. A - 
Representative traces of Ca2+ release in Fura2 loaded cells induced by 10µM nigericin. Grey 
bar indicates the presence of ionomycin, black bar indicates the presence of nigericin. 
U18666a treated WT cells are used as a positive control for depletion of lysosomal Ca2+. B – 
Quantification of Ca2+ release measured by ratiometric change in Fura2 fluorescence. Error 
bars = SEM. n = 3. No significance calculated by T test.  
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Figure 4.3.15. shows a trend towards reduced lysosomal Ca2+ release of around 40% 
in Q120 ST14A cells when it is induced by Nigericin after pre-treatment of cells with 
ionomycin to remove all other cellular Ca2+ stores. This remains to be confirmed by 
subsequent repeats. Importantly preliminary experiments and published data both 
show that ER Ca2+ content is changed in cellular models of Huntington’s, as 
expected from reports in the literature (Suzuki et al., 2012), and as such in order to 
accurately determine levels of lysosomal Ca2+ the other cellular stores must be 
prevented from signalling first; accordingly pre-treatment with ionomycin is vital in 
this experiment. 
 
Another assay which is useful for determining if cells have defective NPC1 function is 
the trafficking of FITC-tagged sphingosine (FITC-SphO) which can be loaded into 
cells and the location of fluorescence checked after various incubation times. FITC-
SphO loaded cells were examined after 10 minutes of incubation and these clearly 
show that in both cell lines the probe initially localises to the lysosome where it 
requires an active transport process to exit. This process does not occur in cells 
which do not have active NPC1 protein and punctate distribution of FITC-SphO 
persists (Lloyd-Evans et al., Unpublished).  
 
 
Figure 4.3.16. – Altered FITC-tagged Sphingosine trafficking after 24 hours in ST14A 
cells. ST14A cells expressing fragment 1-548 of the human huntingtin protein with different 
polyQ repeat lengths. A – Representative fluorescence images of FITC-tagged sphingosine 
loaded cells (FITC-SphO, white) after incubation for 10minutes and 24 hours within cells. This 
probe is used to assay the ability of lysosomes to efflux the simple sphingolipid sphingosine. 
B – Localisation analysis of FITC-Sphingosine fluorescence. n = 2. * = P < 0.05 by T test. 
Scale bar = 10µm.  
 
This retention of FITC-SphO in the endolysosomal system observed by persistence 
of punctate staining is present in around 50% of HTT Q120 cells after 24 hours of 
incubation with the probe as opposed to an almost uniform diffuse distribution in 
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HTTQ15 cells (figure 4.3.16. A.). This difference is statistically significant (P < 0.05, t 
= 9.537, df = 2, F1,1 = 2.582). These data are suggestive of NPC1 dysfunction in 
these cells. 
 
Taken together the data presented in sections 4.3.1. – 4.3.2. indicate that 
endolysosomal expansion takes place alongside lipid homeostasis changes which 
are reminiscent of those seen in NPC disease are observed in cellular models of 
Huntington’s. The alterations to the levels and localisation of the NPC1 protein which 
also takes place in these cells and the subsequent analysis of cellular phenotypes 
increasingly specific to NPC1 disease suggest that the NPC1 protein is dysfunctional 
in Huntington’s disease. As these studies were conducted in precursor cell line we 
were interested to see of we could make our study more relevant to the actual 
processes which are ongoing in the brains of Huntington’s patients (Warby et al., 
1998; HD iPSC Consortium, 2012). Accordingly we expanded our studies to iPSC 
derived striatal medium spiny neurons.  
 
4.3.3. – Preliminary examination of lysosomal phenotypes in iPSC derived 
mature Neurons from Huntington’s Disease Patients 
 
In Huntington’s disease the predominant cell type affected are DARRP-32 positive 
medium spiny neurons of the striatum. As NPC1 dysfunction has been observed in a 
variety of cell models of Huntington’s we were extremely interested to see if the 
phenotypes of NPC1 dysfunction were replicated in neuronal cultures representative 
of the lateral ganglionic eminence, shown to be positive for DARPP-32, with 
expanded polyQ repeats differentiated from iPSC derived NSCs (HD iPSC 
Consortium, 2012).  
 
An extra consideration we needed to be aware of for the study of these neurons was 
the number of days post initiation of differentiation from NSCs that we conducted our 
experiments. Differentiation of neurons for 14 days post NSC plating has previously 
been shown to generate mature, electrophysiologically active neurons susceptible to 
glutamate toxicity (HD iPSC Consortium, 2012). However, as the levels of various 
lipids including cholesterol and sphingolipids had not been investigated in these 
neurons it was important to investigate these lipid changes and determine whether 
any particular time post initiation of differentiation exhibited substantial lipid changes. 
Initially, we examined these phenotypes in control neurons with a polyQ repeat 
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number of 33 (Q33) and examined how lipid levels changed with number of days 
post differentiation. Examining these neurons at days 1, 4, 7, 11, 14 and 21 days 
post initiation of differentiation for the levels of cholesterol, sphingomyelin, 
ganglioside GM1 and LBPA (data not shown). Both cholesterol and ganglioside GM1 
levels were elevated with a relatively linear progression in both the cell body and in 
axons. Variations in the levels of sphingomyelin and LBPA were more difficult to 
observe, as these lipids were not strongly stained by the probes utilised in this study. 
Accordingly, we discounted these lipids from initial analysis until staining protocols 
could be improved. Due to the levels of cholesterol and ganglioside GM1 being 
sufficient for clear visualisation after 14 days and the convenience of being able to 
refer to published phenotypes in these cells at this timepoint (HD iPSC Consortium, 
2012) we decided that this was the most suitable stage to examine these cells for 
lysosomal phenotypes.  
 
As with the other cell lines examined in this chapter we began by assaying the 
endolysosomal system for expansion and as the neurons were of human origin we 
were able to utilise both lysotracker and LAMP-2 staining.  
 
 
 
Figure 4.3.17. – Endolysosomal 
expansion in iPSC derived neurons. 
iPSC derived neurons with different polyQ 
repeat lengths in HTT differentiated for 14 
days from NSC cells obtained from human 
subjects. A – Representative fluorescence 
microscopy images of lysotracker red 
loaded cells (LT red, white) shows changes 
in lysosome and late-endosome number, 
size and localisation within cells. B – 
Threshold analysis of LT red fluorescence. 
n = 2 * = P< 0.05 by T test. Scale bar = 
5µm. Cells prepared by Sun Yung, Cardiff 
University. 
 
 
Initially, we examined the difference in lysotracker staining between the two most 
similar neuronal cell lines, with respect to polyQ repeat length, Q33 and Q60 which 
are either side of the divide between unaffected and suffering from Huntington’s. 
Upon doing so it was possible to measure a statistically significant difference 
between lysotracker fluorescence levels and, as such, the difference in the 
endolysosomal volume between these two cell lines (P = < 0.05, t = 5.099, df = 2, 
F1,1 = 51.19). Although a polyQ repeat length of 60 is higher than the repeat length 
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that is average for HD patients these cells remain strongly suited for direct 
comparison. Firstly, 33 polyQ repeats is very high for an unaffected patient (Warby et 
al., 1998) reducing the difference in severity between the two cell lines and, 
secondly, the patient and control that these cells were generated from were siblings 
meaning that they are likely to have very similar genetic backgrounds (HD iPSC 
Consortium, 2012).  
 
 
 
Figure 4.3.18. – LAMP-2 immunofluorescence in iPSC derived neurons. iPSC derived 
neurons with different polyQ repeat lengths in HTT differentiated for 14 days from NSC cells 
obtained from human subjects. LAMP-2 increase is indicative of increased endolysosomal 
compartment size. Representative immunofluorescence images of LAMP-2 protein (LAMP-2, 
green) show the distribution of this late-endosomal and lysosomal transmembrane protein 
within cells. n = 1. Scale bar = 5µm. Cells prepared by Sun Yung, Cardiff University. 
 
As discussed above we were further able to assay for endolysosomal expansion in 
these cells by LAMP-2 immunofluorescence (figure 4.3.18.). We performed this in the 
full range of iPS derived neurons available with polyQ repeat lengths of 21 (Q21), 33 
(Q33), 60 (Q60) and 109 (Q109). In this initial study there is an evident expansion in 
the endolysosomal system which is increased in a polyQ-dependent manner.  LAMP-
2 immunofluorescence also helps to confirm the location of the endolysosomal 
system in these cells as almost entirely in the cell body, no significant fluorescence 
from either probe was observed in axonal regions of these cells. As we have been 
able to observed endolysosomal expansion in these cells we were interested to 
determine if lipid accumulation could be a causative factor for this as observed in 
human NSCs and rat-derived ST14A cells.  
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Figure 4.3.19. – Lipid storage phenotypes in iPSC derived neurons. iPSC derived 
neurons with different polyQ repeat lengths in HTT differentiated for 14 days from NSC cells 
obtained from human subjects. Representative fluorescence microscopy images of filipin 
stained cells (white) show perninuclear cholesterol accumulation and FITC-tagged cholera 
toxin B subunit (CtxB, green) is used to visualise the increase of ganglioside GM1 within cells. 
n = 1. Scale bar = 5µm. Cells prepared by Sun Yung, Cardiff University. 
 
In all of the neuronal populations assayed the levels of both cholesterol and 
ganglioside GM1 levels increased with increases in polyQ repeat length (figure 
4.3.19.), importantly, all of these cell lines have been shown to reach maturity at 14 
days after the intiation of differentiation (HD iPSC Consortium, 2012). The cholesterol 
accumulation was most evident in the cell bodies of these neurons and may have 
been accompanied by a decrease in axonal cholesterol levels, a phenotype very 
similar to that observed in neuronal models of NPC disease. These phenotypes will 
be examined closely in the subsequent repeats of this study.  
 
Increased ganglioside GM1 was more prevalent throughout the cells with both the 
cell body and axons more strongly stained by CtxB. This increase in axonal 
ganglioside GM1 clearly shows that the cell lines with high polyQ repeat lengths have 
comparable levels of axonal outgrowth to other cell lines.  
 
As lipid storage phenotypes were present in neurons with increased polyQ repeat 
lengths, we have begun to utilise the assays described throughout this thesis in order 
to determine if lipid accumulation is likely to be the major cause of lysosomal 
expansion, or, whether there may be accumulation of other substrates. 
Subsequently, we will also perform assays for the more specific NPC1 dysfunction 
phenotypes of reduced lysosomal Ca2+ and increased lysosomal retention of 
sphingosine. Interestingly, in intial experiments with FITC-SphO the probe did not 
immediately localise to punctate structures and many cells had brightly fluorescent 
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nuclei (data not shown). Accordingly, the protcol for investigating the localisation of 
FITC-SphO in neurons may need to be developed.  
 
 
 
Figure 4.3.20. – Autofluorescence in iPSC derived neurons. iPSC derived neurons with 
different polyQ repeat lengths in HTT differentiated for 14 days from NSC cells obtained from 
human subjects. Representative fluorescence microscopy images of autofluorescence after 
stimulation of cell with light at 470nm (AF470nm, white) show the distribution autofluorescent 
material within cells. n = 1. Scale bar = 5µm. Cells prepared by Sun Yung, Cardiff University. 
 
In terms of other lysosomal storage phenotypes we have examined the levels of 
autofluorescence in the closely related Q33 and Q60 cell lines. In a preliminary 
experiment we found no evidence of the accumulation of autofluorescent material 
visible at 470nm excitation in these neurons (4.3.20.). This suggests no lipofuscin 
accumulation in these cells. During the live assay of autofluorescence observable 
levels of fluorescence from all cell lines investigated was observed after cells were 
stimulated by 380nm light. As the levels of the fluorescence was consistent across all 
of the neuronal lines investigated (Q21 – Q109) it was attributed to a constituent of 
the growth medium – PD0332991 which is as an inducer of G1 phase arrest in these 
cell lines (Toogood et al., 2005). Fortunately, after PFA fixation this appeared to have 
been washed out of cells so it does not affect experiments conducted at these 
wavelengths such as filipin staining for cholesterol.  
 
 
 
 
Figure 4.3.21 – Lysosomal proteolysis by cathepsin B in iPSC derived neurons. iPSC 
derived neurons with different polyQ repeat lengths in HTT differentiated for 14 days from 
NSC cells obtained from human subjects. Representative fluorescence microscopy images of 
cells loaded with the magic-red cathepsin B substrate (MR Cat B, white) shows the in situ 
activity of cathepsin B within cells. n = 1. Scale bar = 5µm. Cells prepared by Sun Yung, 
Cardiff University. 
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We were also able to perform an initial examination for the activity of the lysosomal 
enzyme cathepsin B in Q33 and Q60 neurons and observed a similar pattern to that 
observed in ST14A cells expressing different polyQ lengths of HTT. A small 
decrease has been observed in this activity, however, this remains to be quantified in 
subsequent repeats (figure 4.3.21.). Cathepsin L remains to be assayed in these 
cells and as this was more clearly divergent in the ST14A cells (figure 4.3.11.) it may 
be a better assay for changes in the proteolytic capacity of neurons to be examined.  
 
Finally, we investigated the levels and localisation of the NPC1 protein in these 
neurons. Interestingly, isobaric tag for relative and absolute quantification (iTRAQ) 
data has suggested that the levels of this protein are elevated in Q60 cells compared 
to control cell lines (data courtesy of Akimov et al. 2014)(Rauniyar et al., 2014). This 
was the only protein to have increased levels from a list of investigated proteins 
which includes the related protein NPC2, the lysosomal transport protein LIMP-2 
(recently implicated in cholesterol transport), and the cholesterol efflux regulatory 
protein ABCA1. This is further evidence of pathogenic changes in cells related to the 
NPC1 protein which are dependent upon increases in polyQ length.  
 
 
 
Figure 4.3.22. –NPC1 protein distribution in iPSC derived neurons. iPSC derived neurons 
with different polyQ repeat lengths in HTT differentiated for 14 days from NSC cells obtained 
from human subjects. Representative immunofluorescence images of Niemann-Pick type C1 
protein (NPC1, red) show the distribution of this late-endosomal and lysosomal 
transmembrane protein within cells. n = 1. Scale bar = 5µm. Cells prepared by Sun Yung, 
Cardiff University. 
 
 
Initial immunohistochemical analysis of NPC1 in Q21 – Q109 neurons is confirmatory 
of increased levels in neurons with increased lengths of polyQ repeat (figure 4.3.22.). 
This is particularly evident between Q60 cells and controls although it may be more 
variable in higher repeat length neurons. This remains to be further investigated. 
 
These data presented in 4.3.3. show preliminary evidence for the conservation of 
lysosomal storage phenotypes in neurons and potentially implicate the NPC1 protein 
dysfunction as a initiating factor in this. Although NPC disease remains a devastating 
condition there are disease modifying and experimental therapies which have been 
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used to treat patients with the disorder. We were interested to test the disease 
modifying treatment, miglustat, and experimental therapy, hydroxyl-propyl-β-
cyclodextrin (HPβCD) (section 1.5.2.), in our cellular models of Huntington’s to see if 
they may be of benefit to lysosomal storage phenotypes in this disease. 
 
4.3.4. – Preliminary investigation of the impact of therapies beneficial in NPC 
upon lysosomal storage phenotypes in Huntington’s disease cell models 
 
Initially, we investigated the effects of the experimental therapy HPβCD on lysosomal 
storage phenotypes in our cellular models of Huntington’s. Although the mechanism 
of action has not been fully defined for the benefits provided by HPβCD in cellular 
and animal models of NPC1 disease (Davidson et al., 2009; Vite et al., 2015), it is 
well characterised as a cholesterol reducing agent in cellular models of NPC (Chen 
et al., 2010). Initially we tested HPβCD in the NSC cells from a juvenile Huntington’s 
patient. 
 
 
 
Figure 4.3.23. – Effects of hydroxyl-propyl-β-cyclodextrin on cholesterol storage in iPS 
derived neural stem cells. iPS derived neural stem cells from a control and a juvenile 
Huntington’s Patient (Q180). Representative fluorescence microscopy of filipin stained cells 
(white) show endo-lysosomal cholesterol accumulation. Cells are treated with 0.04mg/ml 
hydroxyl-propyl-β-cyclodextrin (HPβCD) for 16 hours. n = 1. Data prepared with assistance 
from Naomi Killick, Cardiff University. Scale bar = 10µm. 
 
As expected a reduction in punctate filipin staining, suggesting a reduction 
endolysosomal lipid storage, was evident in cells treated with HPβCD (Figure 
4.3.23.). HPβCD induced benefits seem to be specific for diseases in which NPC1 
dysfunction is present as it has been shown to improve phenotypes in animal models 
of NPC1 and NPC2 but not in a models of GM1 gangliosidosis and MPS IIIA 
(Davidson et al., 2009). Accordingly, it may provide further evidence of NPC1 
dysfunction in these cells. Due to the observation that HPβCD was of benefit in these 
cells we have begun to expand our study to the other cellular models of Huntington’s 
we have investigated so far.  
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Figure 4.3.24. – Effect of hydroxyl-propyl-β-cyclodextrin on increased endolysosomal 
volume in ST14A cells. ST14A cells expressing fragment 1-548 of the human huntingtin 
protein with different polyQ repeat lengths. A – Representative fluorescence microscopy 
images of lysotracker green (LT Green, white) loaded cells. B – Threshold analysis of LT 
green fluorescence. Cells are treated with 0.04mg/ml hydroxyl-propyl-β-cyclodextrin (HPβCD) 
for 24 hours. Error bars = SD. n = 2. Scale bar = 10µm. No significant difference observed 
one-way ANOVA with Bonferroni post-test. 
 
As differences in lysotracker fluorescence was observed to be a sensitive way of 
studying changes in endolysosomal volume in ST14A cells with different polyQ 
repeat lengths (figure 4.3.6.) this assay was used to see if HPβCD was capable of 
reducing this lysosomal storage phenotype. We utilised an established protocol of 
0.04mg/ml HPβCD for 24 hours in order to do so (Chen et al., 2010). In preliminary 
experiments this was observed as Q120 cells showed a trend towards reduction in 
the number of cells with lysotracker fluorescence above threshold levels (figure 
4.3.24. B.). Surprisingly the number of cell above threshold in the treated cell 
population was lower than in Q15 cells although further repeats are needed to 
confirm these observations.   
 
Nevertheless, this result showed evidence of reductions in lysosomal storage so we 
progressed to examine lipid storage in these cells, in this preliminary analysis the 
levels of cholesterol in Q120 ST14A cells was examined after treatment with HPβCD. 
Upon doing a reduction in cholesterol levels was observed in treated cells. This 
seemed most evident in the perinuclear region of Q120 cells where cholesterol 
punctae were observed indicative of a reduction in endolysosomal cholesterol 
accumulation being specifically affected in these cells. 
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Figure 4.3.25. – Effect of hydroxyl-propyl-
β-cyclodextrin on cholesterol storage in 
ST14A cells. ST14A cells expressing 
fragment 1-548 of the human huntingtin 
protein with different polyQ repeat lengths. 
Representative fluorescence microscopy of 
filipin stained cells (white) show endo-
lysosomal cholesterol accumulation. Cells are 
treated with 0.04mg/ml hydroxyl-propyl-β-
cyclodextrin (HPβCD) for 24 hours. n = 2. 
Scale bar = 10µm. 
 
 
 
 
 
These initial data are promising although the effect of HPβCD upon other lipids 
shown to increase in these cells (sphingomyelin, LBPA and ganglioside GM1) 
remains to be examined. The observations of cholesterol reduction should also be 
confirmed by biochemical analysis.  
 
The final phenotype studied in this preliminary examination of benefit mediated by 
HPβCD on ST14A cells expressing extended polyQ HTT was endolysosomal 
mistrafficking of ganglioside GM1. This provides a sensitive assay with which we can 
examine phenotypic improvement.   
 
 
 
Figure 4.3.26. – Effect of hydroxyl-propyl-β-cyclodextrin on disrupted endolysosomal 
sphingolipid trafficking in ST14A cells. ST14A cells expressing fragment 1-548 of the 
human huntingtin protein with different polyQ repeat lengths. A – Representative 
fluorescence microscopy images of pulse, chased FITC-tagged Cholera toxin B-subunit 
(CtxB-488, green) to assay trafficking of ganglioside GM1 through the endo-lysosomal 
system. Hoechst stained nuclei are shown in blue. B – Qualitative quantification of CtxB-488 
localisation as Golgi, punctate or intermediate between the two states in ST14A cells as a 
percentage of the total cell population. Cells are treated with 0.04mg/ml hydroxyl-propyl-β-
cyclodextrin (HPβCD) for 24 hours. Error bars = SD. n = 2 . Scale bar = 10µm. 
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A marginal improvement was observed in trafficking post treatment with HPβCD 
(figure 4.3.26.). Trafficking defects between control and ST14A cells expressing 
Q120 huntingtin were confirmed to be different (P < 0.001, Χ2 = 539.44 for run 1, 
585.63 for run 2, df = 2). This analysis was performed by comparing the values 
obtained from the three HTT Q120 repeats of this experiment to expected values 
calculated from the mean of each population in HTT Q15 cells. A similar analysis 
was conducted to confirm variation between HTT Q120 cells and HTT Q120 cells 
treated with HPβCD. Although the change in the populations was much more 
marginal the changes were still significant (P < 0.001, Χ2 = 25.42 for run 1, 35.19 for 
run 2, df = 2). As variation between the three repeats was minimal (SEM = < 5% in all 
populations) this approach was applicable. 
 
As this phenotype has not been examined in NPC cells treated with HPβCD this may 
not be due to correction of NPC phenotypes, however, as HPβCD has been 
observed to cause cytoplasmic Ca2+ elevation in cells (Maguire et al., Unpublished) it 
may act in a similar way to curcumin inhibition of SERCA2. Curcumin treatment also 
causes transient elevations in cytosolic Ca2+ and this compensates for the reduced 
intraluminal Ca2+, allowing for endolysosomal trafficking improvements in cells. 
Interestingly, curcumin has been shown to be beneficial to Huntington’s disease 
models. The mechanism underlying this benefit is unclear, however, and curcumin 
can interact with a myriad of pathways within cells although it has been shown to 
mediate benefits via Ca2+ in NPC (Goike et al. Unpublished).  
 
Taken together these data suggest that HPβCD has the potential to be 
therapeutically beneficial in Huntington’s disease as it can reduce lysosomal storage 
phenotypes which we have shown to occur within cells. Accordingly, it would be 
interesting to see if this molecule can be used to reduced neuronal loss in models of 
Huntington’s disease.  
 
As previously mentioned Miglustat is an approved therapy in the EU for the 
neurological manifestations of NPC disease (Patterson et al., 2015). Accordingly we 
were interested to test Miglustat to see if it was of benefit to cellular models of 
Huntington’s. To do this we utilised the cell model most thoroughly characterised in 
this study, ST14A cells expressing HTT with different polyQ lengths.  
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Figure 4.3.27. – Effect of miglustat on cholesterol storage in ST14A. ST14A cells 
expressing fragment 1-548 of the human huntingtin protein with different polyQ repeat 
lengths. Representative fluorescence microscopy of filipin stained cells (white) show endo-
lysosomal cholesterol accumulation Cells are treated with 50 µM Miglustat for 5 days. n = 1. 
Scale bar = 10 µm. 
 
In a preliminary experiment, reduction in cholesterol levels was observed in these 
cells after miglustat treatment. It also appears that some redistribution of cholesterol 
has taken place in these cells, leading to increased plasma membrane staining. This 
is interesting, as in NPC1 deficient cells miglustat does not reduce cholesterol 
storage (Haslett et al., Unpublished). One phenotype clearly shown to be improved 
by miglustat treatment of NPC cellular models and patient samples is the 
endolysosomal trafficking of sphingolipids (Lachmann et al., 2004). Accordingly, this 
was investigated in miglustat treated Q120 cells utilising the CtxB transport assay.  
 
 
Figure 4.3.28. – Effect of miglustat on disrupted endolysosomal sphingolipid trafficking 
in ST14A cells. ST14A cells expressing fragment 1-548 of the human huntingtin protein with 
different polyQ repeat lengths. A – Representative fluorescence microscopy images of pulse, 
chased FITC-tagged Cholera toxin B-subunit (CtxB-488, white) to assay trafficking of 
ganglioside GM1 through the endo-lysosomal system. B – Qualitative quantification of CtxB-
488 localisation as Golgi, punctate or intermediate between the two states in ST14A cells as 
a percentage of the total cell population. Cells are treated with 50 µM Miglustat for 5 days. n = 
1. Scale bar = 10 µm. 
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In the preliminary experiment, conducted after miglustat treatment, there was an 
improvement in endolysosomal ganglioside GM1 trafficking with no punctate staining 
observed in the treated cells and almost half of these cells showing a Golgi 
distribution of CtxB. Potentially, this is an extremely important phenotype as 
endolysosomal lipid trafficking could potentially be at the root of many of the lipid 
disturbances observed in various model of Huntington’s (Trushina et al., 2006; Di 
Pardo et al., 2012).   
 
Taking these data into consideration we have preliminary evidence that therapies 
that have been shown to be beneficial in NPC disease, are able to reduce the 
lysosomal storage phenotypes we observe in cellular model of Huntington’s. We 
have not however shown that these lysosomal phenotypes are involved in the 
pathogenesis of Huntington’s, although, the prevalence of neurodegeneration in 
LSDs including NPC (Vanier, 2009) would suggest that these phenotypes could 
contribute to neuronal loss. Accordingly, to determine if therapies that are capable of 
reducing these phenotypes are protective to neurons, it would be good to investigate 
if they could prevent neuronal loss. This would be strongly suggestive of LSD 
phenotypes being involved in pathogenesis and would also suggest that these 
therapies could be of benefit to Huntington’s patients.  
 
4.3.5. – Prevention of excitotoxic cell death by NPC therapies 
 
Due to the above observations we expanded our study to a neuronal model of 
glutamate induced excitotoxic Ca2+ dyshomeostasis, which has been shown to 
increase in neurons with extended polyQ forms of HTT. In this study the increase in 
Ca2+ dyshomeostasis correlated with increases in markers of cellular death, and, did 
not alter HTT aggregation (HD iPSC consortium study., 2012). Accordingly, it is 
considered a robust way of measuring the levels of cellular death in Huntington’s 
neurons, particularly as we are using the same cell lines utilised in this study, 
initiated by the pathophysiological process of Glutamate excitotoxicity. Due to these 
considerations it is an extremely well suited assay with which to determine if LSD 
therapies were beneficial to neuronal loss it Huntington’s. 
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Figure 4.3.29. – Effect of therapies beneficial in NPC disease upon Ca2+ 
dyshomeostasis in iPSC derived neurons. A – Representative traces of Ca2+ responses 
from neuronal populations subjected to 60 second pulses of 60mM KCl (black arrowheads) or 
300µM glutamate and 30µM glycine (black bar) followed by prolonged treatment with 300µM 
glutamate and 30µM glycine (black bar). All cell populations were subjected to BDNF 
withdrawal for 24 hours prior to the experiment, control cells were untreated, + HPβCD cells 
were treated with 0.04mg/ml +HPβCD for 24 hours prior to the experiment, + Miglustat cells 
were treated with 50µM Miglustat for 5 days prior to the experiment. B – Quantification of 
Ca2+ response measured by change in Fura2 fluorescence during glutamate plateau phase. 
No significant difference in responses was observed by one way ANOVA. Error bars = SD. C 
– Quantification of Ca2+ response measured by change in Fura2 fluorescence ratio after 
addition of 300µM glutamate and 30µM glycine. No significant difference in responses was 
observed by one way ANOVA. Error bars = SD. D – Analysis of the percentage of Q33 
neurons which lose Ca2+ homeostasis during long term application of 300µM glutamate and 
30µM glycine. Cells are considered dyshomeostatic when the Fura2 fluorescence ratio 
exceeds the baseline set at 5 min of prolonged application and does not return to below this 
point. The percentage of cells which maintain Ca2+ homeostasis is plotted against time. ** = P 
< 0.01 and *** = P < 0.0001 calculated by Logrank test. E – Analysis of the percentage of 
Q109 neurons which lose Ca2+ homeostasis during long term application of 300µM glutamate 
and 30µM glycine. Cells are analysed as in D. *** = P < 0.0001 calculated by Logrank test. n 
= 3 – 5 from 3 independent differentiations. Cells prepared by Sun Yung, Cardiff University. 
Experiments performed by or with assistance from Polina Yarova, data analysed by Polina 
Yarova, Cardiff University.  
 
In order to observe Ca2+ dyshomeostasis we removed BDNF from the medium of 
neuronal cultures 24 hours prior to the initiation of experiments. This withdrawal has 
been shown to be necessary to observe Ca2+ dyshomeostasis, and, as BDNF 
depletion in the striatum is a process known to occur in Huntington’s it is 
physiologically relevant (HD iPSC consortium study., 2012). For this study we 
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employed the Q109 cell line as a more severe model of this cell death process was 
likely to provide more stringent examination of any potential therapeutic benefit from 
LSD therapies. 
 
The survival curves shown in 4.3.29. D and E show that Q109 neurons were less 
able to maintain Ca2+ homeostasis after long term glutamate treatment with a quicker 
loss of Ca2+ homeostasis observed and more cells becoming dyshomeostatic by the 
end of glutamate exposure. Loss of Ca2+ homeostasis is observed when the Ca2+ 
levels, shown by ratiometric Fura2 fluorescence, exceed the baseline fluorescence 
calculated from the first minute of prolonged glutamate exposure. This process can 
be observed by escalation in the representative Ca2+ trace from Q109 cells (4.3.29. 
A, dark green) where baseline Ca2+ is quickly lost. As can be seen in the black trace 
from this figure this escalation is much less rapid and severe in Q33 cells.  
 
It is important to note that, although, the individual peak heights elicited in response 
to glutamate do vary between cell lines and treatment conditions (as shown by the 
representative traces in A and the graphs B and C, glutamate plateau height 
glutamate responses from initial pulses and respectively), these responses are also 
variable within cell lines and as such are not significantly different (P > 0.05 in both 
instances, F = 0.7367 for glutamate plateau, F = 0.2695 for glutamate peak). 
Representative traces were chosen which show the relative onset of dyshomeostasis 
in different cell types and treatments.  
 
When we observe cell survival in Q109 cells post treatment with both miglustat and 
HPβCD it is shown that these treatments allow a greater number of neurons to 
maintain Ca2+ homeostasis, which is strongly suggestive of increased survival in 
these neuronal populations. Both miglustat and HPβCD lead to a greater number of 
Q109 neurons maintaining homeostasis (P < 0.001, df = 1, Χ2 = 39.08 for miglustat 
and P < 0.0001, df = 1, Χ2 = 30.96 for HPβCD). These levels were similar to those 
observed in Q33 neurons. Miglustat also showed a clear benefit in the rate of 
neuronal loss during prolonged glutamate exposure, as evidenced by the slower 
decrease in cells maintaining Ca2+ homeostasis (bright green line, 4.3.29. E). It is 
interesting that both treatments also produced a survival benefit in Q33 cells (P < 
0.01, df = 1, Χ2 = 8.597 for miglustat and P < 0.0001, df = 1, Χ2 = 81.83 for HPβCD). 
This survival benefit was much more pronounced after HPβCD treatment and was 
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accompanied by a obvious reduction in rate of Ca2+ homeostasis loss – this remains 
to be further investigated. 
 
These data provide evidence for increased neuronal survival in an in vitro model of 
Huntington’s disease after treatment with therapies shown to be beneficial in NPC 
disease. Not only does this reveal new therapeutic options for Huntington’s, but, it 
provides strong evidence to link the LSD phenotypes we have observed in a variety 
of models of Huntington’s disease contributes to neuronal loss.  
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4.4. – Summary of Results and Discussion 
 
Due to multiple reports of increased lysosomal volume (Catiglioni et al., 2012; 
Camnasio et al., 2012) and alterations in lysosomal localisation in models of 
Huntington’s disease (Erie et al., 2015) we were interested to see if they bore any 
relation to the phenotypes observed in LSDs. In doing so, we observed a number of 
phenotypes which were reminiscent of NPC disease or dysfunction in the NPC1 
pathway (Lloyd-Evans et al., 2008). 
 
4.4.1. – Niemann-Pick type C phenotypes in Huntington’s Disease 
 
In addition to increases in lysosomal volume in cellular models of Huntington’s, we 
have also been able to observe accumulation of the lipids cholesterol, LBPA, 
sphingomyelin and ganglioside GM1 in regions of the cell which are suggestive of 
lysosomal storage of these substrates. This finding has been replicated by other 
studies in the lab by co-localisation of the lysosomal marker LAMP-2 with stored 
lipids (Clark et al. Unpublished.). Cholesterol and LBPA were also shown to be 
elevated biochemically, alongside evidence of sphingoid base accumulation, in cell 
lines which were amenable to this form of study. These studies are currently being 
repeated with the inclusion of further cell lines and tissue from animal models.  
 
Additional phenotypes such as endolysosomal lipid mistrafficking were also observed 
and Huntington’s cells did not appear to be accumulating autofluorescent material or 
have an expanded ER. Taken together, these phenotypes are suggestive of a LSD in 
which the major accumulating molecules are lipids. The particular profile of storage 
lipids observed in this disease is similar to those observed in NPC1 (Chevallier et al., 
2008; Lloyd-Evans et al., 2008). Interestingly, there is also evidence of lysosomal 
proteolytic defects but lack of autofluorescence showed these are unlikely to be a 
result of defective lysosomal pH homeostasis (Guha et al., 2014). As proteolytic 
defects were present in both of the cell lines investigated for this phenotype, it may 
be worth studying further. It may also be worth studying similar phenotypes in cellular 
models of NPC1 as it is unknown if there is any difference between these in situ 
probes in NPC1 deficient cells compared to control cells. 
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Upon studying the subcellular distribution of this protein we found that it was 
differentially localised in all cell lines studied and, although, initial results from NSCs 
suggested decreased levels of the protein subsequent studies have shown that it is 
increased in other cellular model of Huntington’s. This may have been a result of the 
H9 control cell line used alongside NSCs not being ideally suited as it was not iPSC 
derived. The observation of increased NPC1 protein has been validated by iTRAQ 
analysis showing elevated protein levels. Alongside elevation of NPC1 there was a 
clear re-distribution of this protein. Although we have not identified the compartment 
to which NPC1 becomes redistributed lysosomal lipid accumulation is strongly 
indicative of a loss of lysosomal function so it is probable that it has not reached the 
endolysosomal system. The observation of NPC1 mislocalisation and elevation has 
been confirmed in another cellular model of Huntington’s disease prepared from 
Q111 Huntington’s mice. In addition to this western blotting is also being undertaken 
to study protein levels (Clark et al., Unpublished.) 
 
The evidence presented in this chapter includes cells from patients (section 4.3.1.), 
including the population of neurons most susceptible to loss in Huntington’s (4.3.3.), 
and cell lines established from rodent models of polyQ expansion (4.3.2.). NPC1 
phenotypes have been observed in all the cell lines investigated suggesting that it is 
a prevalent phenomenon, although this remains to be further confirmed by repeating 
our studies in neurons. Further evidence is provided by the identification of these 
phenotypes in an additional cellular model of Huntington’s prepared from the striatum 
of the Q111 mouse model (Clark et al., Unpublished)(Carroll et al., 2015). Lipid 
storage has also been observed in the brains of mice with expanded polyQ repeats 
(Carrol et al., 2015) and a full allelic sequence of Huntington’s mouse tissue is 
currently under analysis.  
 
Changes in lipid levels are well studied in Huntington’s and there are varying reports 
of increases in lipids such as cholesterol and ganglioside GM1 (Trushina et al., 2006; 
del Toro etal., 2010; Trushina et al., 2014). It is interesting that, in some of the 
studies in which reductions in lipid levels are observed, a more punctate distribution 
of lipids is also present within cells (Marullo et al., 2012). This may be indicative of a 
lipid trafficking defect which is one of the primary pathogenic events in NPC1 (Lloyd-
Evans et al., 2008). It is also interesting to note, that the changes in lipids observed 
in LSDs are not always simply accumulation but can be more influenced by lipid 
mislocalisation in cells. For example, the levels of cholesterol in NPC brains is not 
elevated but it is redistributed from the plasma membranes of cells to the 
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endolysosomal system (Zervas et al., 2001; Lloyd-Evans et al., 2010) – this may be 
particularly problematic in cells with large extensions such as neurons. Interestingly, 
there are reports of similar processes in human brain samples from Huntington’s 
patients. It has also been reported that dysregulation of cholesterol precursors can 
cause endolysosomal lipid accumulation (Kreilaus et al., 2015); in some cases, such 
as Smith-Lemli-Opitz Syndrome (SLOS), these phenotypes are reminiscent of NPC 
(Platt, 2014).  
 
With respect to the reduction in the levels of certain gangliosides, it is interesting that 
ganglioside biosynthetic defects can also cause the increase of other types of 
ganglioside from different parts of the pathway. For example in GM3 synthase 
deficiency, which causes a childhood epilepsy syndrome, patients do not produce 
ganglioside GM3 or any of its metabolites but do accumulate lactosylceramide and 
the derivative gangliosides Gb3 and Gb4 (Simpson et al., 2004). Interestingly, 
increases in ganglioside GD3 in the R6/2 mouse model of Huntington’s could be 
suggestive of a similar synthetic pathway imbalance occurring in the presence of 
expanded mHTT (Desplats, 2007).  
 
Combined with the observations of lipid dyshomeostasis and endolysosomal 
trafficking defects in the literature, there is an increasing case for an involvement of 
NPC1 in the pathogenesis of Huntington’s. Upon initial examination, there are some 
overlaps in the pathological changes observed in patients including eye movement 
defects, and, movement abnormalities such as dysphagia (Patterson et al., 2007, 
Warby et al., 1998). It is, however, extremely difficult to compare such phenotypes in 
neurodegenerative diseases with complex aetiology. To aid this it may be interesting 
to look at the presentation of Huntington’s in juvenile cases and compare these 
patients with classical NPC patients. Similarly, the recent discovery that there may be 
more adult-onset NPC patients than recently thought (Wassif et al., 2015) may allow 
comparison of NPC and Huntington’s patients of a more similar age. 
 
A similar study could be conducted to look at striatal pathology in NPC, to 
supplement the observations that striatal neurons from NPC mouse models could not 
initiate neurite outgrowth in response to BDNF treatment (Henderson et al., 2000). 
Further study of cerebellar pathology in Huntington’s may also be of interest. There is 
some evidence of the latter, with patients presenting with cerebellar symptoms 
(Rodda et al., 1981; Rub et al., 2013, Sakai et al., 2015) and mouse model of polyQ 
expansions in HTT causing cerebellar dysfunction (Denny et al., 2010). To this end, 
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we performed a preliminary study on the cerebellar regions of mouse brains from the 
Q150 mouse model of Huntington’s and observed some disorder in the purkinje 
neurons populations of which are devastated in NPC1 disease. 
Accordingly, there is clear evidence of NPC phenotypes in Huntington’s disease cell 
models and we are beginning to observe NPC phenotypes in animal models. As a 
result it is interesting to discuss the potential mechanism leading to NPC1 
dysfunction in Huntington’s. 
 
4.4.2. – Proposed mechanism for NPC1 dysfunction in Huntington’s disease  
 
The data in 4.3.2 and 4.3.3 show that relative levels of NPC1 are elevated in 
Huntington’s cells and this has been biochemically confirmed in other Huntington’s 
cell lines, as are levels of NPC2 (Clark et al., Unpublished). There was clearly 
evident mislocalisation of the NPC1 protein in the cells in which this could be 
examined whereas NPC2 maintained a punctate distribution; although this was an 
expected compensatory mechanism. Unfortunately, it was not possible to examine 
the distribution of NPC1 in iPSC derived neurons from Huntington’s patients as the 
cell bodies were too small to see differences in localisation, although, the increase in 
protein levels was recapitulated. Accordingly, mislocalisation of NPC would, 
currently, appear to be the most obvious reason for lipid accumulation similar to that 
observed in NPC disease, this is shown in figures 4.3.5. and 4.3.14.  
 
Reduced levels of NPC1 in the lysosome would lead to reduced sphingosine efflux 
leading to increased levels within the lysosome. (Lloyd-Evans et al., 2008) Although 
sphingosine has not been specifically shown to be elevated in this study the levels of 
sphingoid base were increased and a fluorescently tagged version of this lipid 
constituent was also observed not to leave the lysosome so dysfunction in 
sphingosine handling is evident. Nevertheless, it will be important to biochemically 
characterise the level of sphingosine in Huntington’s model using a more specific 
technique. In NPC, increased levels of sphingosine are proposed to cause a 
lysosomal Ca2+ defect (Lloyd-Evans et al., 2008) a trend towards which has been 
observed in Q120 ST14A cells, and, a significant Ca2+ defect has been observed in 
Q111 murine striatal cells (Clark et al. Unpublished). This Ca2+ defect leads to 
defective endocytosis and subsequently lipid storage – both phenotypes clearly 
evident in this study. Lower levels of lysosomal Ca2+ may also cause autophagy 
defects due to lack of vesicle fusion (Luzio et al., 2007) – we have not yet studied 
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this with relation to NPC1 in these cells although proteolytic defects may be 
indicative of this process occurring. Potential implications for processes within the 
cell as a result of NPC1 mislocalisation are expanded upon in figure 4.4.1. 
 
 
 
Figure 4.4.1. – Proposed mechanism of pathological changes to the lysosomal system 
in cells expressing mHTT. Detailed discussion of the resultant impact upon lysosomal 
processes in cells with expression of HTT with pathogenically expanded polyQ repeats. 
Adapted from Platt et al., 2012 
 
Further research also needs to be conducted as to why NPC1 does not reach the 
late endosome and lysosome. As HTT is proposed to be a scaffold protein important 
during selective autophagy processes by interacting with the proteins important to 
this process (Rui et al., 2015). To this end it has been shown that NPC1 can interact 
with HTT which does not have expanded polyQ repeats in co-immunoprecipitation 
(co-IP) studies (Williams et al. Personal communication). The reverse of this 
experiment is being conducted in our lab where a colleague is attempting to show the 
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interaction of HTT and mHTT with NPC1 by co-IP. This would suggest that the 
aggregation of HTT with expanded polyQ repeats prevents interaction with NPC1 
although this does not exclude aggregate prone HTT trapping NPC1. Other cell lines 
modelling diseases with polyQ repeat expansions are also being tested in this study 
to see if this process is specific to Huntington’s, or, is more prevalent. HTT 
knockdown studies are also being conducted to see if NPC1 phenotypes are 
induced. As mentioned in section 4.1.4. HIP1 is an important protein to consider 
when looking at endocytosis defects in models of Huntington’s (Waelter et al., 2001; 
Metzler et al., 2001). Potential for the interaction of this protein with NPC1 should 
also be considered when investigating the mislocalisation of NPC1.  
 
4.4.3. – Are NPC1 therapies potential treatments for Huntington’s disease.  
 
As shown in section 4.3.5., Ca2+ dyshomeostasis in the well established model of 
glutamate excitotoxicity in iPSC derived neurons from Huntington’s patients showed 
an improved outcome, after the cells were treated with therapies which are of benefit 
in NPC disease. This was evident in terms of both numbers of cells maintaining Ca2+ 
homeostasis, and, increasing the time until Ca2+ dyshomeostasis occurred. Whilst 
this has not yet been proven to be linked to reduced cell death in these neurons by 
direct assay, these processes are very closely linked in mechanisms of neuronal cell 
death and have been shown to take place in the same neurons this study was 
conducted in (HD iPSC Consortium, 2012). Accordingly, this method provides good 
in vitro evidence of potential therapies for Huntington’s which could provide the basis 
for further study. This evidence also supports the data showing lysosomal storage in 
neurons by reducing the pathology in cells using compounds known to reduce 
lysosomal storage. Further, it implicates these storage phenotypes contribute to 
pathogenic processes, as, their reduction leads to improved resistance to glutamate 
excitotoxicity. Although the reduction of the NPC phenotypes observed in neurons in 
response to miglustat or HPβCD has yet to be confirmed, the observation of this in 
different cell lines which share the same phenotype suggests that it will be effective 
in doing so.  
 
It is arguable that miglustat provided the most obvious benefit in Huntington’s 
neurons, as it provided greater delay in the onset of Ca2+ dyshomeostasis. This is 
perhaps fortuitous as miglustat has a number of advantages over HPβCD as a 
therapy. Firstly, miglustat is an approved treatment that has been used to treat two 
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diseases (Gaucher and NPC1) (Platt et al., 2012), accordingly, there is extensive 
safety data on miglustat as a drug and it has been shown to be safe for long term 
administration (Patterson et al., 2015). Miglustat has also been shown to be relatively 
free of side effects with gastrointestinal disturbances; the most commonly reported 
complication (Belmatoug et al., 2011). Contrastingly, HPβCD has only been used in 
cases of compassionate use and initial clinical trials (Ottinger et al., 2014). HPβCD is 
also associated with hearing loss (Crumling et al., 2012). In addition to this, miglustat 
is an orally available therapy so administration to patients is convenient and relatively 
risk free. Again, HPβCD, presents difficulty in this respect. Studies in murine and 
feline animal models have shown that in order to be most beneficial HPβCD should 
be administered by either intrathecal or intercerebroventricular injection (Davidson et 
al., 2009; Vite et al., 2015). Due to this, there are significant complications in the 
administration of HPβCD (Ottinger et al., 2014) making it a less suitable therapy.  
 
In longitudinal studies of NPC patients treated with miglustat it has been observed to 
improve disturbances is saccadic eye movements, reduce dysphagia, stabilise 
auditory acuity and improve the ambulatory index of some patients (Patterson., 
2015). Importantly, with miglustat and other types of substrate reduction therapy 
(SRT) early treatment has been shown to improve patient outcomes. Whilst 
diagnosis remains a challenge for most cases of NPC, Huntington’s patients can be 
more easily identified due to the mechanism of disease inheritance (Warby et al., 
1998). Accordingly, patients could be treated with miglustat in pre-symptomatic 
phases which may lead to increased effectiveness. An example of this is the dietary 
supplementation of erucic acid which acts as a SRT for X-linked 
adrenoleukodystrophy. This shows little benefit in symptomatic patients treated but 
can be useful for the treatment of mildly affected patients (Rizzo et al., 1989). It is 
also worth noting that miglustat has been shown to be amenable to administration in 
combination with other therapies. This has been demonstrated in a recent study 
where it was administered, alongside ibuprofen and curcumin, in an animal model of 
NPC disease to generate increased benefit (Williams et al.,2014).  
 
It is currently unknown how miglustat provides benefit in NPC. Originally, it was 
postulated that reduction of glycosphingolipids such as gangliosides which 
accumulate in NPC provided benefit – this was the expected mechanism of action as 
miglustat inhibits glucosylceramide synthase (Platt et al., 1994). However, a 
knockout mouse model of NPC which also had the ability to synthesise gangliosides 
genetically ablated did not show improvements in pathology (Gondre-Lewis et al., 
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2003). Subsequently, it was realised that miglustat was capable of reducing 
sphingosine in cells (Haslett et al., Unpublished); this has also been observed in the 
CSF of patients treated with miglustat (Wassif et al., Unpublished) and cat models of 
NPC1 (Stein et al., 2012). Interestingly however, miglustat does not reduce the 
storage of lipids such as cholesterol and LBPA and, even, increases sphingomyelin 
storage. This is proposed to involve a secondary defect in the enzyme which 
catabolises sphingomyelin in lysosomes, acid sphingomyelinase (ASM). This 
enzyme is not located in the same compartments as storage lipids and therefore 
cannot catabolise them. Miglustat does not correct this mislocalisation and as such 
sphingomyelin cannot be broken down and accumulates, trapping cholesterol in 
molecular interaction (Haslett et al., Unpublished). Without this secondary defect in 
ASM localisation it is proposed that Miglustat reduces sphingosine resulting in 
increases in lysosomal Ca2+ and endolysosomal trafficking (improvements that are 
present in NPC patient cells treated with miglustat (Lachmann et al., 2004)) resulting 
in reduced lipid storage. This may explain why cholesterol accumulation in Q120 
HTT ST14A cells was reduced after miglustat treatment. A similar correction to this 
has also been shown in cellular models of SLOS where the accumulation of 
endocytosed cholesterol in the endolysosomal system can be reduced by miglustat 
treatment (Lloyd-Evans et al., Unpublished.)  
 
In addition to an, as yet, undefined mechanism of action there are other problems 
with miglustat therapy such as poor blood-brain barrier (BBB) permeability. This is 
demonstrated in a case report of an NPC patient treated with miglustat where the 
concentration in the CSF was far below that in the serum (Lachmann et al., 2004). 
Nevertheless, benefit was observed when NPC deficient cells were treated with CSF 
relevant concentrations of miglustat (0.15µM), as opposed to the normal 
experimental concentration of 50µM; the improvement simply took longer to manifest 
(Haslett et al., Unpublished). This is further evidence that the potential for earlier 
intervention with miglustat in Huntington’s patients may be beneficial. 
 
It is also important to consider that as a form of SRT acting upon glycosphingolipids 
miglustat will reduce the synthesis of gangliosides. These may already be reduced in 
Huntington’s. As previously discussed the potential for other species of ganglioside 
to be elevated in Huntington’s and the possibility that they may accumulate in the 
endolysosomal system could potentially mean that the improvements in endocytic 
trafficking may benefit this aspect of lipid dyshomeostasis. Nevertheless, this 
phenotype of reduction in certain species of ganglioside and the impact miglustat will 
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have upon this must be carefully considered in any instance of miglustat therapy for 
Huntington’s. 
 
Taken into consideration all the points raised above still suggest that miglustat may 
be a useful therapy for the treatment of patients with Huntington’s disease; a disease 
which does not currently have a disease modifying treatment.  
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Chapter 5 
 
 
 
Investigation of Ca2+ 
dyshomeostasis in Genetically 
Influenced forms of Parkinson’s 
Disease 
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5.1. – Introduction  
 
5.1.1. – Parkinson’s Disease 
 
Parkinson’s disease is progressive neurological disorder characterised by motor 
phenotypes first described by James Parkinson in 1817 in “An essay on the shaking 
palsy (Kempster et al., 2007). Although the cardinal features of Parkinson’s: resting 
tremor, bradykinesia, rigidity, postural instability all describe motor phenotypes, a 
large number of non-motor phenotypes have been described in patients with the 
disease in addition to a diverse array of additional motor phenotypes. Non-motor 
phenotypes may include behavioural disorders, autonomic dysfunction and sleep and 
sensory disturbances (Farlow et al., 2004). A sixfold increase in the risk of dementia 
has been reported in Parkinson’s patients (Aarsland et al., 2005) and similar 
neuropathology has been found in patients with other forms of dementia (McKeith et 
al., 1996). In many cases non-motor phenotypes can be as disabling as motor 
phenotypes. 
 
Parkinson’s affects 1-2% of the population over the age of 65 and is the second most 
prevalent form of neurodegeneration (Nuytemans et al., 2010); the incidence is 
predicted to double by 2030 (Dorsety et al., 2007). Parkinson’s onset is usually 
around the age of 60 years. In a generalised scheme patients presenting before age 
20 years are considered juvenile onset, those before 50 years early onset and those 
after this age late onset (Farlow et al., 2004). Parkinson’s disease is considered to be 
of multifactorial aetiology, with environmental exposure to substances such as 
pesticides and metals implicated in increased disease risk (Goldman, 2014). 
However, cases of familial Parkinson’s have been described and, more recently, 
genes which predispose patients to Parkinson’s have been identified (De Rosa et al., 
2015), these will be discussed in section 5.1.2.  
 
The neuropathology of Parkinson’s disease is primarily characterised by the loss of 
dopaminergic neurons which project to the putamen from the substantia nigra pars 
compacta (SNpc). These neurons form the dopaminergic nigrostriatal pathway which 
is particularly involved with the production and regulation of movement. In addition to 
this neuron loss remaining neurons contain filamenteous, proteinaceous inclusions in 
the perikarya. These inclusions are known as Lewy bodies and smaller inclusions in 
neuronal processes are known as Lewy neurites, both are primarily composed of the 
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protein α-synuclein (Dickson, 2012). More recently, smaller inclusions of α-synuclein 
have been reported in the synaptic compartments of neurons raising the question of 
smaller aggregates causing pathogenic processes (Kramer and Schulz-Schaeffer, 
2007). This may support observations made in relation to Alzheimer’s and 
Huntington’s diseases suggesting that larger aggregates of protein are protective to 
neurons by reducing the amount of smaller, more pathogenically active, aggregates 
or toxic soluble protein present (Nilsberth et al., 2004; Arrasante et al., 2004). Lewy 
bodies have been identified throughout the central, and in some cases, peripheral 
nervous systems in patients with Parkinson’s (Braak and Del Tredici, 2009) and in a 
number of other neurodegenerative diseases such as Dementia with Lewy Bodies, a 
disease which has both Parkinson’s and Alzheimer’s phenotypes (McKeith et al., 
2004).  
 
Parkinson’s is characterised by neuronal loss in selective populations of vulnerable 
neurons. Specifically these are the Dopaminergic neurons of the substantia Nigra 
pars compacta (SNpc) which project into the putamen as part of the nigrostriatal 
pathway. (Dickson, 2012) The result is loss of striatal dopamine and dysregulation of 
this pathway which is important for movement (Dauer and Prezdborski, 2006). Due to 
this Parkinson’s patients are often treated with L-DOPA a blood-brain barrier (BBB) 
permeable precursor of dopamine which can be converted within the CNS into 
dopamine. To prevent the excessive peripheral production of noradrenaline from L-
DOPA this drug is commonly co-administered with compounds that inhibit this 
process in the periphery. Unfortunately, a number of motor and non-motor side 
effects are caused by long term administration of L-DOPA. As such research for new 
therapies for Parkinson’s remains an active field (Bastide et al., 2015).  
 
Interestingly protoplasmic astrocytes of the SNpc are shown to have numerous 
interactions with DA neurons (Halliday and Stevens 2011). In Parkinson’s astrocyte-
neuronal crosstalk has been described as a ‘double-edged sword’ with astrogliosis 
providing both protection and damage to neuronal populations (Cabezas et al., 
2013). Increases in Ca2+ excitability of astrocytes has been shown to be a 
consequence of pharmacological disruption of dopamine transmission in a model of 
Parkinson’s. These remain to be investigated in genetic models of Parkinson’s 
disease (Vaarman et al., 2012).  
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5.1.2. – Inherited forms of Parkinson’s disease  
 
Although there have long been indications that some forms of Parkinson’s were 
familial it is only with the advent of new genetic technologies that inherited forms of 
Parkinson’s have been clearly defined. Of these genes mutations in both SNCA and 
LRRK2 lead to autosomal dominant Parkinson’s. SNCA codes for the major 
constituent of Lewy bodies, α synuclein, and LRRK2 which codes for leucine rich 
repeat kinase 2 (LRRK2).  There are also autosomal recessive forms of PD caused 
by inherited mutations in PARKIN, PINK1, DJ-1 and ATP13A2. Subsequently each of 
these genetic loci were designated PARK along with a number defining their 
chronological identification (De Rosa et al., 2015). The identification of genes for all 
these loci remain incomplete and only the six loci mentioned above have been 
confirmed to cause monogenic Parkinson’s. For clarity I will continue to use the 
original gene names. Collectively these genes are though to only account for 3-10% 
of Parkinson’s cases (De Rosa et al., 2012) and this, perhaps, illustrates that 
Parkinson’s is a disease of multifactorial aetiology resulting from a complex interplay 
of multiple factors. In most patients the majority of these remain unknown. 
Considering this, polymorphisms which increase the risk of Parkinson’s may also be 
present in many patients. Accordingly genome wide association studies (GWAS) are 
beginning to reveal these associations (Mullin and Schapira 2015). The most 
prominent of these risk factors to be identified so far is within the GBA1 gene 
(Sidransky et al., 2009) which is the genetic cause of Gaucher disease (section 
1.5.1.).  
 
5.1.2.1. – GBA1 and Parkinson’s 
 
Polymorphisms at the GBA1 locus increase the risk of Parkinson’s 5 fold (Sidransky 
et al., 2009). Although this risk was confirmed by GWAS studies the initial 
observation of type 1 Gaucher patients suffering from the symptoms of Parkinson’s 
disease was published in 1996 (Neudorfer et al., 1996). This was likely to inform the 
suggestion in 2003 that mutations in the glucocerebrosidase (GCase) gene GBA1 
could cause susceptibility to Parkinson’s made by the Sidransky group (Lwin et al., 
2004). In this study Parkinson’s patients were found to have the N370S mutation, 
which causes type 1 Gaucher, and Parkinson’s phenotypes were observed in the 
absence of brain storage of glucosylceramide (Lwin et al., 2004). Subsequent studies 
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showed the prevalence of Parkinson’s in 10 unrelated families of patients with 
Gaucher disease partitioned into carriers of GBA1 mutations, and, that the most 
common genetic cause of Parkinson’s (G2019S causing mutations in LRRK2) was 
not present in these patients (Eblan et al., 2006). While these observations were 
compelling it was suggested that this incidence may be associated with Jewish 
ancestry (Clark et al., 2005). In 2009 (Sidransky et al., 2009) performed a multicentre 
analysis of GBA1 mutations in 5691 Parkinson’s patients alongside 4898 healthy 
individuals which confirmed polymorphisms in GBA1 to be a pan-ethnic risk factor for 
Parkinson’s, a finding confirmed by subsequent GWAS studies. It is interesting to 
note that Parkinson’s patients who carried GBA1 mutations presented, on average 4 
years earlier, with less severe bradykinesia and resting tremor but more severe 
cognitive changes (Sidransky et al., 2009). Considering this, it is perhaps not 
surprising that a subsequent multicentre analysis also found GBA1 to be a risk factor 
for dementia with Lewy bodies (Nalls et al., 2013).  
 
Although mutations in GBA1 are now well defined as a risk factor for Parkinson’s 
disease and, perhaps, α-synucleinopathy in general (Sardi., 2015) the mechanism 
causing this risk has not been delineated. Of particular interest in this regard is 
whether or not the substrate of glucocerebrosidase (GCase), the protein product of 
GBA1, is accumulating. As it has been reported that only 11-15% of normal enzyme 
activity is required in order to prevent the accumulation of glucosylceramide (GlcCer) 
(Schueler et al., 2004) it can be proposed that lipid accumulation cannot occur in 
carriers of GBA1 mutations where enzyme activity is > 50%. A number of hypotheses 
have been mooted to explain this with many focussing on impairment of lysosomal 
function slowing down the clearance of aggregate prone proteins (Bendikov-Bar et 
al., 2014). Other explanations propose disturbed Ca2+ homeostasis within cells may 
be responsible (Schondorf et al., 2014) or that GCase and α-synuclein interact and a 
bidirectional pathogenic feedback loop is caused by increases in α-synuclein 
oligomerisation and accumulation of GlcCer (Mazzulli et al., 2011). One feature of 
these hypotheses is that they do not necessarily point specifically to GBA1 mutations 
as the sole cause; even if loss of GCase function is occurring this could be the result 
in mutation within other lysosomal proteins. An example of this is mutations in 
SCARB2, which codes for LIMP-2, the protein responsible for trafficking GCase to 
the lysosome; this has also been implicated as a risk factor for Parkinson's (Hopfner 
et al., 2013).  
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5.1.2.2. – An expanding role for the lysosome in Parkinson's disease 
 
The role of lysosomal proteins other than GCase in Parkinson’s was thoroughly 
examined by Shachar et al. (2011) in a comprehensive literature review. In this study 
literature related to individual LSDs was studied to determine if there was a 
prevalence of Parkinson's in the patients and carriers of this LSD (or their extended 
families), documented evidence of SN pathology or the presence of synucleinopathy, 
ubiquitin carboxyl-terminal esterase L1 (UCH-L1) downregulation, increased 
presence of ubiquitinated protein aggregates and, finally, evidence of decreases in 
the activity of the lysosomal protein in question in Parkinson's patients. After 
undertaking this analysis the authors concluded that the biochemical and cellular 
pathways linking Parkinson's to LSDs should not be solely restricted to Gaucher 
(Shachar et al., 2011). Recent genetic analyses have supported this conclusion with 
genes such as SMPD1 which causes the LSD Niemann-Pick type A also being 
implicated as a genetic risk factor for Parkinson's (Gan-Or et al., 2015). Accordingly, 
the broader implications of lysosomal dysfunction are becoming an area of intense 
research in relation to Parkinson's pathogenesis. It is interesting that in their recent 
review De Rosa et al. (2015) highlighted five different pathways that were implicated 
in Parkinson's pathogenesis by the array of genes known to cause the disease. Of 
these impairment of cellular clearance pathways is clearly linked to the lysosome, 
and the other pathways (mitochondrial homeostasis, ER stress, ER Ca2+ 
homeostasis, inflammation)(De Rosa et al., 2015) are all affected in various 
lysosomal diseases (Platt et al., 2012). As with the other neurodegenerative diseases 
discussed so far the lysosome, as an important hub for many cellular processes lying 
at the centre of the greater lysosomal network, may be important to a number of 
pathological processes in Parkinson’s. 
 
Recently, studies have begun to highlight lysosomal Ca2+ dyshomeostasis in genetic 
models of Parkinson’s and investigated the links between changes to this cellular 
store of Ca2+ and ER Ca2+ stores. In this regard, the role of LRRK2 as a modulator of 
lysosomal Ca2+ homeostasis with downstream effects on autophagy has been 
determined (Gomez-Suaga et al., 2012). As LRRK2 has also been observed within 
the endolysosomal system (Gomez-Suaga et al., 2014), can act as a modulator of 
both endocytic trafficking (Gomez-Suaga et al., 2014) and lysosomal positioning 
(Dodson et al., 2012) it is likely to play a role in the normal functioning of this system.  
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Recent studies have implicated the TPC2 channel pathogenesis resulting from 
LRRK2 mutation as Ca2+ release from lysosomes stimulated by NAADP-AM was 
increased in patient fibroblasts carrying the most common LRRK2 mutation G2019S. 
In these cells endolysosomal system enlargement was observed alongside increased 
perinuclear clustering, a phenotype also observed in a D.melanogaster model of 
LRRK2 induced Parkinson’s (Dodson et al., 2012). These defects were corrected by 
inhibition with of TPC2 with Ned-19 and localised buffering of exaggerated Ca2+ 
release (Hockey et al., 2015). The close interaction between lysosomes and the ER 
suggest that any potentiation of signals from TPC2 will induce ER Ca2+ release 
events, and thus, they impact upon ER Ca2+ homeostasis (Penny et al., 2015).  
 
Interestingly, the two LSD proteins most strongly linked to Parkinson’s are GCase 
and ASM which cause the LSDs Gaucher and Niemann-Pick type A/B respectively. 
Both these LSDs have been shown to cause elevated Ca2+ release from the ER and 
subsequently elevated cytosolic Ca2+ (Platt et al., 2012). The other two LSDs most 
strongly associated with ER Ca2+ phenotypes are the GM1 and GM2 gangliosidoses 
and in the case of both of these diseases LSD patients and carriers with Parkinson’s 
have been observed (Shachar et al., 2011).  
 
Considering the implication of ER Ca2+ in a number of models of genetic 
susceptibility to Parkinson’s, it is worth investigating Ca2+ homeostasis in the ER. 
Also, due to the close relationship and interaction with the ER (Penny et al., 2015), it 
would be interesting to investigate the lysosome in any novel models of Parkinson’s 
disease caused by proteins which interact with this compartment.  
 
5.1.3.  – Kufor-Rakeb Syndrome 
 
Inherited mutations in ATP13A2 (a 26kb gene with 29 exons located at 1p36.13) are 
the cause of Kufor-Rakeb syndrome (KRS). This is a rare form of juvenile 
Parkinson's disease (Ramirez et al., 2006). The protein product of the gene, also 
called ATP13A2, is a P-type transport ATPase, which localises to the lysosomal 
membrane. It was first reported in five siblings of unaffected consanguineous parents 
from a Jordanian community known as Kufor-Rakeb (Hampshire et al., 2001). The 
ATP13A2 gene was subsequently identified by Ramirez et al. in 2006 after they 
found compound heterozygous mutations in the gene in patients with similar 
phenotypes from another consanguineous family. After this finding they also found 
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ATP13A2 mutations in the Jordanian community for which the disease is named 
(Ramirez et al., 2006). Since this time around 30 additional patients have been 
identified with KRS (Yang and Xu, 2014) and the gene was given the moniker 
PARK9, due to the universal presence of Parkinson's in these patients (Park et al., 
2015).  
 
Due to the fact that KRS has only been recently identified and genetically 
characterised it is unknown what the carrier frequency and disease incidence is. It is 
also currently unclear whether or not carriers of ATP13A2 are more at risk of 
suffering from Parkinson's as in some populations no increase in ATP13A2 mutations 
within patients has been reported (Pan et al., 2015). Other studies have found such 
an increase and consider ATP13A2 to be a risk gene and age of onset modifier in 
Parkinson's (Di Fonzo et al., 2007; Chen et al., 2011). The majority of these studies 
were performed in relatively small patient datasets from single countries analysing a 
single variant and, perhaps, the situation will not be clarified until it is investigated in 
a multicenter analysis similar to that which has shown GBA1 to be a Parkinson's risk 
gene (Sidransky et al., 2009).  
 
The major clinical observations in KRS patients: parkinsonism, supranuclear gaze 
palsy and cognitive impairment usually present before the age of 20 years with the 
oldest age of onset currently reported to be 30 years (Malakouti-Nejad et al., 2014; 
Park et al., 2015). Progression subsequent to disease onset varies widely with a 
generalised divide between slowly progressing disease over the course of years-
decades, in patients with missense mutations, to rapid progression over the course 
of months in patients with frameshift mutations (Park et al., 2015). Parkinson's 
phenotypes suffered by KRS patients predominantly involve bradykinesia and ridgity 
and the prevalence of resting tremor is generally lower. Although patients initially 
respond well to L-DOPA therapy, it is common for side effects such as dyskinesia 
and hallucinations to develop soon after treatment begins (Park et al., 2015). 
Supranuclear gaze palsy has been reported almost universally in patients and is 
accompanied by slowness in saccadic eye movements (Hampshire et al., 2001; 
Malakouti Nejad et al., 2014). Cognitive impairment has also been reported in the 
majority of patients however it is not universal (Park et al., 2015). Histopathological 
examination of KRS patients has not been conducted to date due to the lack of 
availability of post-mortem tissue (Park et al., 2015). Recently there have, however, 
been observations of reduced ATP13A2 levels in the post mortem tissue biopsies 
from patients with sporadic Parkinson’s disease, compared to control brain tissue. In 
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this study it was also reported that the levels of ATP13A2 were elevated in surviving 
dopaminergic neurons, in these neurons ATP13A2 was found to be a constituent of 
Lewy bodies (Murphy et al., 2013).  
 
5.1.3.1. – The ATP13A2 protein 
As previously mentioned wild-type ATP13A2 localises to the lysosomal membrane, 
whereas, mutated forms associated with PD remain in the ER in all cases examined 
so far (Ramirez et al., 2006; Ugolino et al., 2011). Subsequent ER stress phenotypes 
are reported in these cells. When ATP13A2 is defective in cells a myriad of 
lysosomal phenotypes have been reported including lysosomal expansion, lipofuscin 
accumulation, lysosomal alkalinisation, reduced autophagic flux and changes to 
heavy metal ion homeostasis and proteolytic defects (Schneider et al., 2010; Dehay 
et al., 2012; Tsunemi et al., 2014).  
 
Studies into heavy metal ion dyshomeostasis are commonly initiated by the likelihood 
that ATP13A2 is thought to be a divalent cation transporter, due to similarities to 
other proteins of the P5 ATPase family which transport these ions (van Veen et al., 
2014). Thus far, ATP13A2 has been implicated in the transport of Mn2+, Zn2+, Fe2+ 
and Cd2+ (Schmidt et al., 2009; Schneider at al., 2012; Tsunemi et al., 2014) and it is 
thought that loss of function in this protein results in abnormal cation transfer 
between the cytosol and lysosomal lumen. Subsequently, lysosomal dysfunction 
occurs and deposition of cations in the brain is thought to trigger damaging metal-
induced oxidative stress (Ramonet et al., 2012; Park et al., 2014). The changes in 
heavy metal ion homeostasis have also been linked to proteolytic defects which 
result in less efficient degradation of protein such as α-synuclein leading to the 
accumulation of this protein in neurons (Usenovic et al., 2012; Tsunemi et al., 2014). 
In this situation resultant changes in the lysosomal system, the induction of 
lysosomal storage phenotypes, and resultant defects in autophagy, are thought to 
occur (Usenovic et al., 2012; Tsunemi et al., 2014).  
 
Unsurprisingly, mitochondria are affected by these processes and decreased ATP 
synthesis, increased lesioning of mitochondrial DNA, higher oxygen consumption 
rates and an increasingly fragmented mitochondrial network have been reported in 
patient fibroblasts (Grunewald et al., 2012; Park et al., 2014). Importantly, all these 
defects were corrected by re-expression of wild-type ATP13A2.  Subsequent studies 
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showed that increase in intracellular Zn2+ could compound these phenotypes 
although they did not rule out changes to levels of other ions.  
 
Recently, after review of the literature on ATP13A2 and other more well studied P-
type ATPases, (van Veen et al., 2014) contended the view that ATP13A2 is a 
transporter for metal cations. They suggested instead that the protein may, instead, 
act as a flippase likely involved in lipid dynamics during membrane fusion and fission 
events. In a subsequent publication this research group proposed a 10 
transmembrane domain membrane structure for ATP13A2 which included an 
extended hydrophobic N-terminus which interacts with the cytosolic side of the 
lysosomal membrane. Here the lipid can interact with the signalling lipids 
phosphatidic acid (PA) and phosphatidylinositol-3,5- bisphosphate (PI(3,5)P2). Upon 
interaction with these lipid autophosphorylation regulates the activity of ATP13A2, 
and, overexpression of catalytically active protein is protective against toxic insults to 
the mitochondria (Holemans et al., 2015).  
 
It is interesting that Ca2+ homeostasis remains to be investigated in these cells as 
ATPases are prevalent in Ca2+ transport pathways and dyshomeostasis in these 
pathways is prevalent in genetic models of Parkinson’s.  
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5.2. – Procedures  
 
In section 5.3.1. of this chapter well will investigate Ca2+ homeostasis using the KRS 
patient fibroblasts described in section 2.1.8. These cells will be studied against a 
control fibroblast cell line which has been extensively characterised in the Lloyd-
Evans lab with respect to cellular Ca2+ levels.  
 
Cellular Ca2+ stores will be interrogated using the techniques described in section 
2.5. Where possible 3 independent plating replicates will be used in these 
experiments and appropriate statistical analysis will be performed as detailed in 
individual figure legends. In instances where 3 independent plating replicates were 
not performed due to unavailability of cells this will be shown in the figure legend. In 
most cases this relates to the second patient cell line.  
 
Subsequently, section 5.3.2., we will investigate the impact of intralysosomal heavy 
metal ion chelation on the most severe Ca2+ dyshomeostasis phenotypes observed 
in KRS cells using the chelator phytic acid as described in section 2.2.8. These will 
be subject to the same analyses as described for section 5.3.1.  
 
Section 5.3.3. of this chapter will begin to investigate whether primary astrocytes 
have abnormal spontaneous Ca2+ signalling events in models of Gaucher disease. 
This analysis will utilise astrocytes prepared from both genetic Gaucher models 
(section 2.1.9.) and astrocytes independently prepared from control mice which have 
then had Gaucher phenotypes induced by a well characterised inhibitor of GCase 
(section 2.1.10.). As this analysis has so far been preliminary 3 independent 
replicates has not been achieved, repeat numbers are detailed in individual figure 
legends.  
 
Statistical analyses as described in section 2.7 have been performed on all these 
experiments as appropriate, details of these are given in individual figure legends.  
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5.3. – Results 
 
5.3.1. – Ca2+ dyshomeostasis is prevalent in multiple cellular Ca2+ stores in 
KRS patient fibroblasts 
 
Recently, numerous publications have implicated lysosomal Ca2+ homeostasis in the 
pathogenesis of Parkinson’s (Gomez-Suaga et al., 2014; Hockey et al., 2015). Due 
to the cellular location (Ramirez et al., 2006), proposed role in divalent cation 
homeostasis (Ramonet et al., 2012; Park et al., 2014) and implication of 
phosphoinisitols as regulators of the ATP13A2 protein (Holemans et al., 2015) we 
are interested to see if the lysosome or any other cellular Ca2+ stores were altered in 
KRS patient fibroblasts. 
 
 
 
Figure 5.3.1. – Resting cytosolic Ca2+ in KRS patient fibroblasts in the presence and 
absence of extracellular Ca2+. Quantification of resting cytosolic Ca2+ measured by 
ratiometric quantification of Fura2 fluorescence in the absence of extracellular Ca2+ and 
presence of 1mM extracellular Ca2+ (Ca2+). Error bars = range. Data shown is from individual 
cellular values in each experimental repeat. n = 8 for WT and Patient 1 cells in the absence of 
Ca2+, n = 5 for Patient 2 cells in the ansence of Ca2+, n = 3 for WT and Patient 1 cells in the 
presence of Ca2+ and n = 2 for patient 2 cell lines in the presence of Ca2+. * = P < 0.05, 
calculated by one way ANOVA with Bonferroni post test.  
 
Initially, we observed the basal cytosolic Ca2+ levels in two KRS patient cell lines 
used in multiple publications on ATP13A2 (Dehay et al., 2012; Grunewald et al., 
2012; Park et al., 2014) and are known to have inactivating mutations in ATP13A2 
which result in the retention of misfolded protein in the ER (Ramirez et al., 2006).  
The mean basal Ca2+ level of both patient cell lines was comparable to the Ca2+ 
levels in a control fibroblast cell line (extensively characterised in studies of cellular 
Ca2+) in the absence of extracellular Ca2+ in the imaging buffer. It can be observed, 
however, that there was a trend towards an increased range of Ca2+ levels in both 
patient cell lines.  
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Interestingly, in a preliminary investigation this range further increased when 
extracellular Ca2+ was present in the imaging buffer and a statistically significant 
change (P < 0.05, t = 3.783, df = 2) in the mean baseline between patient 2 cell lines 
and control fibroblasts were observed. This wil be investigated more thoroughly in 
future experiments.   
 
Due to these observations, we began to investigate the content and signalling of the 
cellular Ca2+ stores. We began with the lysosome, as this organelle is implicated in 
KRS by the location of the ATP13A2 protein, and the prevalence of dysfunction in 
signalling from this store in other genetic cases of Parkinson’s. 
 
 
 
Figure 5.3.2. – Lysosomal Ca2+ release in response to GPN in KRS patient fibroblasts. 
KRS patient fibroblasts after GPN induced lysosomal rupture in the presence of 2µM 
ionomycin. A - Representative traces of Ca2+ release in Fura2 loaded cells induced by 300µM 
GPN. Grey bar indicates the presence of ionomycin, black bar indicates the presence of 
GPN. B – Quantification of Ca2+ release measured by ratiometric change in Fura2 
fluorescence. Error bars = SEM. n = 4 for control and patient 1 cells, n = 2 for patient 2 cells. 
No significant differences were observed as calculated by one way ANOVA with Bonferroni 
post test.  
 
In order to study total levels of Ca2+ in the lysosomes of KRS patient fibroblasts we 
used the well established method of GPN induced lysosomal lysis after removal of 
the other cellular Ca2+ stores by ionomycin treatment (Lloyd-Evans et al., 2008). 
Figure 5.3.2. shows that no statistically significant change in total lysosomal Ca2+ 
was observed by this method although, there was a trend for increased Ca2+ in both 
patient fibroblast cell lines accompanied by more variable levels of Ca2+ in the 
endolysosomal system. These observations are potentially interesting as an increase 
in lysosomal Ca2+ levels has been implicated in lysosomal diseases which have 
increased storage of autofluorescent material within lysosomes, MLIV (Waller-Evans 
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et al., In preparation) and CLN3 (Walker et al., Unpublished), a phenotype which has 
been reported in cellular and animal models of KRS (Dehay et al., 2012; Schultheis 
et al., 2013; Wohlke et al., 2011). Accordingly, further study of the endolysosomal 
Ca2+ signalling in this disease is warranted.  
 
 
 
Figure 5.3.3. – Lysosomal Ca2+ release in KRS patient fibroblasts in response to 
nigericin. KRS patient fibroblasts after nigericin induced lysosomal Ca2+ release in the 
presence of 2µM ionomycin. A - Representative traces of Ca2+ release in Fura2 loaded cells 
induced by 10µM Nigericin. Grey bar indicates the presence of ionomycin, black bar indicates 
the presence of GPN. B – Quantification of Ca2+ release measured by ratiometric change in 
Fura2 fluorescence. Error bars = SEM. n = 7 for control cells, n = 6 for patient 1 cells and n = 
2 for patient 2 cells. No significant differences were observed as calculated by one way 
ANOVA with Bonferroni post test.  
 
A similar trend towards increased lysosomal Ca2+ was observed when nigericin was 
used to induce lysosomal Ca2+ release. Although this was again non-significant 
showing that there is no change in Ca2+ levels within this store this remains useful 
data as it shows an NPC-like phenotype does not occur in these cells.  
 
As previously discussed although Ca2+ release after lysosomal lysis (GPN) or 
ionophore disruption (Nigericin) provides an accurate estimation of total Ca2+ levels it 
does not represent physiological lysosomal Ca2+ release. In order to do this we can 
use the lysosomal Ca2+ channel agonists NAADP-AM which stimulates the TPC2 
channel on lysosomes (Ruas et al., 2015) and ML-SA1 which causes Ca2+ release 
from the endolysosomal TRPML1 channel (Shen et al., 2012). 
 
In initial experiments after thapsigargin treatment to prevent subsequent CICR from 
the ER we observed Ca2+ release from TPC2 which reflected the Ca2+ levels 
observed in response to GPN (data not shown). This data suggests that any pH 
defect present in these cells is not as robust as that in PS1 deficient cells, as 
discussed in chapter 3, although further experimentation is required to confirm this as 
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very low Ca2+ release was observed from all cells at all NAADP-AM concentrations 
tested. NAADP-AM concentrations may need to be further optimised, as stimulation 
of the TPC2 channel by NAADP is subject to a bell-shaped curve meaning non-
optimal concentrations may inhibit rather than stimulate release (Pitt et al., 2010). To 
investigate TPC2 response in a physiological setting, in which lysosomal Ca2+ 
release is intrinsically linked to ER Ca2+ release, we added NAADP-AM to cells 
without any pre-treatment to remove other cellular Ca2+ stores. This situation also 
mimics the conditions of recent experiments which implicate exaggerated NAADP 
evoked Ca2+ release in the pathogenic cascade which leads to Parkinson’s as a 
result of LRRK2 mutations (Hockey et al., 2015). 
 
 
 
Figure 5.3.4. – Ca2+ response to NAADP-AM in KRS patient fibroblasts. A - 
Representative traces of Ca2+ release in Fura2 loaded cells induced by 250nM NAADP-AM. 
Black bar indicates the presence of NAADP-AM. B – Quantification of Ca2+ release measured 
by ratiometric change in Fura2 fluorescence. Error bars = SEM. n = 3 for control and patient 1 
cells, n = 2 for patient 2 cells. No significant differences were observed as calculated by one 
way ANOVA with Bonferroni post test.  
 
From this experiment it can be observed that no significant increase in Ca2+ release 
in response to NAADP-AM occurred in either of the patient cell lines. However,  
in a similar pattern to that observed in the other studies of lysosomal Ca2+, a trend 
towards increased NAADP-mediated Ca2+ release was observed in patient 1 cells. 
This was not, however, replicated in cells from patient 2 although increased 
variability and a lower number of repeats conducted on these cells may account for 
this. The differences observed in these data are non-significant, however, the 
recurring pattern observed is suggestive of increased signalling from the lysosome 
which may impact upon other cellular Ca2+ stores. Importantly, robust Ca2+ release in 
response to NAADP-AM does not exclude a lysosomal pH defect in these cells. 
NAADP-AM is capable of evoking Ca2+ release in PS1-/- cells which have not been 
pre-treated with thapsigargin as even the minimal amount of Ca2+ released from 
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lysosomes in this situation causes CICR from the ER; this results in robust Ca2+ 
responses. Accordingly, to further study changes in NAADP-induced responses in 
these cells the size of the ER Ca2+ store must be compared. This may demonstrate if 
the potential increases seen after NAADP stimulation are caused by subsequent 
CICR. 
 
 
 
Figure 5.3.5. – Thapsigargin mediated ER Ca2+ release in KRS patient fibroblasts. A - 
Representative traces of Ca2+ release in Fura2 loaded cells induced by 5µM thapsigargin. 
Black bar indicates the presence of thapsigargin. B – Quantification of Ca2+ release measured 
by ratiometric change in Fura2 fluorescence. Error bars = SEM. n = 4 for control cells, n = 6 
for patient 1 cells and n = 4 for patient 2 cells. * = P<0.01, calculated by one way ANOVA with 
Bonferroni post test. No significant differences were observed as calculated by one way 
ANOVA with Bonferroni post test. 
 
As shown in figure 5.3.5. stimulation of Ca2+ release from the ER in KRS patient 
fibroblasts and controls reveals that CICR is unlikely to cause changes in NAADP-
induced Ca2+ signalling. The overall size of Ca2+ release from the ER in response to 
completely inhibitory concentrations of thapsigargin (5µM) show no statistically 
significant differences. The trend towards increased Ca2+ release from patient 1 cells 
(figure 5.3.4.) is also not observed which suggests that any trends towards increases 
in Ca2+ signalling are initiated from the lysosomal Ca2+ store as the responses are 
more closely mimicked in experiments where only that store is being measured 
(figures 5.3.2. and 5.3.3.). It may also explain why there is a trend for lower Ca2+ 
release from patient 2 cells in response to NAADP (figure 5.3.4.) as there is also a 
trend for lower Ca2+ release from the ER. This would result in less potentiation of the 
signal as a result of CICR. In order to study the effects of TPC2 induced Ca2+ 
signalling in response to NAADP-AM upon CICR thapsigargin was used to induce 
Ca2+ release after cells had been treated with NAADP-AM. 
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Figure 5.3.6. – Thapsigargin mediated ER Ca2+ release after NAADP-AM treatment of 
KRS patient fibroblasts. A - Representative traces of Ca2+ release in Fura2 loaded cells 
induced by 5µM thapsigargin after pretreatment with 250nM NAADP-AM. Black bar indicates 
the presence of thapsigargin, grey bar indicates the presence of NAADP-AM. B – 
Quantification of Ca2+ release measured by ratiometric change in Fura2 fluorescence. Error 
bars = SEM. n = 3 for control cells, n = 2 for patient cell lines. * = P < 0.05, calculated by one 
way ANOVA with Bonferroni post test. C – Comparative representative traces of Ca2+ release 
in Fura2 loaded cells induced by 5µM thapsigargin in the absence (solid bar) and presence 
(dashed bar) of NAADP-AM. D – Quantification of the percentage of Ca2+ release measured 
by ratiometric change in Fura2 fluorescence in the presence and absence of NAADP-AM. 
Error bars = SEM. n = 3 for control cells, n = 2 for patient cell lines. 
 
As expected the ER Ca2+ release was reduced in all cells following NAADP-AM 
treatment compared to untreated cells, this is most clearly shown in figure 5.3.6. D. A 
clear trend of a larger reduction was observed in patient cell lines, this became 
significant in cells from patient 2 (P < 0.05, t = 3.820, df = 2). The increased impact of 
NAADP induced Ca2+ release on patient cell lines is strongly suggestive of increased 
CICR induced from lysosomal Ca2+ release. Representation of this data as a 
percentage of thapsigargin release prior to NAADP-AM induced release reveals 
subsequent Ca2+ release to be 25% or less as opposed to greater than 50%. A 
combination of these observations show that KRS cells may to have pathogenically 
hyperactive responses as a result of NAADP signals. These observations may 
underlie the greater variability in baseline Ca2+ observed in KRS patient fibroblasts. 
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The analysis of other Ca2+ channels may help elucidate if excessive signalling from 
the endolysosomal system or ER is the initiating factor in the Ca2+ hyper reactivity 
observed in KRS patient cells.  
 
 
 
Figure 5.3.7. – ML-SA1 potentiated Ca2+ release in KRS patient fibroblasts. A - 
Representative traces of Ca2+ release in Fura2 loaded cells induced by 50µM ML-SA1. Black 
bar indicates the presence of ML-SA1, black arrowheads indicate the addition of 5µM 
ionomycin to confirm cell viability. B – Quantification of Ca2+ release measured by ratiometric 
change in Fura2 fluorescence. Error bars = SEM. n = 4 for control cells, n = 8 for patient 1 
cells and n = 1 for patient 2 cells. *** = P<0.001 calculated by T test.  
 
Utilising the synthetic agonist ML-SA1 we were able to observe increased Ca2+ 
release from the TRPML1 channel of over 2 fold in patient 1 cells. This increase was 
also evident in a preliminary experiment with patient 2 cells (5.3.7.). As previously 
discussed (chapter 3) this channel does not potentiate CICR from the ER to the 
same degree as that observed after NAADP-AM treatment (5.3.6). From our 
observations in PS1-/- cells it could be suggested that this potentiation of TRPML1 
signalling supports the observation of lysosomal alkalisation by (Dehay et al., 2012), 
however, the trend towards increased lysosomal Ca2+ would suggest that a different 
mechanism underlies endolysosomal Ca2+ dyshomeostasis. It must also be noted 
that the control experiments we conducted to clarify that elevated response in PS1-/- 
cells was from the TRPML1 channel remain to be performed in these cells. 
Consequently other TRPM type Ca2+ channels cannot be excluded as the source of 
elevated Ca2+ signals. Interestingly, the presence of elevated lysosomal Ca2+ may be 
indicative of an MLIV like Ca2+ pathology in KRS patient cells. MLIV Ca2+ pathology is 
primarily characterised by an increase in endolysosomal Ca2+. This is accompanied 
by increased variability in the store due to the presence of a small number of large 
Ca2+ rich vesicles thought to be persistent homotypic organelles which result from 
disruptions in the separation of lysosomes and late endosomes (Waller-Evans et al. 
In preparation). Other hallmarks of cellular pathology in this disease is the 
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accumulation of autofluorescent material in the endolysosomal system (Jennings et 
al., 2006) – a phenotype observed in KRS cells (Dehay et al., 2012). In order to 
determine if phenotypes are present in KRS cells intraluminal Ca2+ measurements 
should be performed to determine if any large Ca2+ rich vesicles are present.  
 
Another disease in which lysosomal Ca2+ is elevated and elevated release from this 
store has been implicated in cellular pathology is CLN3 disease. It has recently been 
reported in our lab that cells expressing a mutant form of the CLN3 protein which 
leads to ER retention are more susceptible to Ca2+ release in response to low 
concentrations of thapsigargin (Chandrachud et al., 2015). 
 
 
 
Figure 5.3.8. – Effect of low concentrations of thapsigargin in KRS patient fibroblasts. 
A - Representative traces of Ca2+ release in Fura2 loaded cells induced by 0.1µM 
thapsigargin. Black bar indicates the presence of thapsigargin. B – Quantification of Ca2+ 
release measured by ratiometric change in Fura2 fluorescence. Error bars = SEM. n = 5 for 
control cells, n = 5 for patient 1 cells and n = 3 for patient 2 cells. No significant differences 
were observed as calculated by one way ANOVA with Bonferroni post test. 
 
As can be seen in figure 5.3.8. a trend towards more substantive Ca2+ release was 
observed from patient fibroblasts in relation to control cells. Interestingly, once Ca2+ 
release was initiated in these cells the subsequent release proceeded at comparable 
rates; there was, however, observable variability in the time after thapsigargin 
addition that release occurred, this has not yet been analysed. As increased Ca2+ 
release may be indicative of ER stress in response to misfolded ATP13A2 protein 
retained within this organelle (Ugolino et al., 2011) this phenotype should be further 
studied by subsequent experimental repeats. This phenotype could also be further 
investigated using IHC against targets such as TMED4 as this protein can be used 
as a marker of ER stress in CLN3 mutant cells (Walker et al., unpublished). 
Increased sensitivity to ER Ca2+ release observed in fig 5.3.8. may also be indicative 
of the ability of the ER to more readily potentiate Ca2+ transients originating from 
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other sources in KRS patient fibroblasts and, as such, contribute to Ca2+ 
dyshomeostasis. As this dyshomeostasis seems to also be potentiated by the 
addition of Ca2+ to the extracellular milieu an interesting phenotype to investigate 
would be store-operated Ca2+ entry (SOCE) which is governed by the interaction of 
the STIM protein with the ORAI channel; this is stimulated by the emptying of ER 
Ca2+ stores.  
 
 
 
Figure 5.3.9. – SOCE in KRS patient fibroblasts. A - Representative traces of Ca2+ influx in 
Fura2 loaded cells after the addition of 1mM Ca2+ after ER Ca2+ release had been induced by 
5µM thapsigargin. Black bar indicates the presence of CaCl2, grey bar indicates the presence 
of thapsigargin. B – Quantification of Ca2+ release measured by ratiometric change in Fura2 
fluorescence. Error bars = SEM. n = 5 for control cells, n = 5 for patient 1 cells and n = 4 for 
patient 2 cells. No significant differences were observed as calculated by one way ANOVA 
with Bonferroni post test. 
 
Analysis of the levels of SOCE in patient and control cell lines reveals a similar 
pattern between cells to that observed when total ER Ca2+ levels were analysed 
(figure 5.3.9.), similarly, none of the differences observed are statistically significant. 
This indicates that this process is proceeding normally within cells as the changes 
observed are likely to be related to the size of the initial store. Accordingly, it 
suggests that STIM and ORAI interact normally to facilitate SOCE, and, ER 
stimulated Ca2+ influx is not responsible for the changes in basal Ca2+ levels in KRS 
patient fibroblasts observed when extracellular Ca2+ is present. Another, as yet, 
undefined mechanism may underlie this phenotype.  
 
Further investigation of ER Ca2+ homeostasis in KRS cells may also be achieved by 
direct stimulation of ER Ca2+ channels. For example, stimulation of the ryanodine 
receptor by its eponymous agonist ryanodine. This channel is of particular interest as 
it has been shown to be dysregulated in cell lines and tissue samples obtained from 
LSD patients (Lloyd-Evans et al., 2003; Pelled et al., 2005).  
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Figure 5.3.10. – Ca2+ release from the ryanodine receptor in KRS patient fibroblasts. A - 
Representative traces of Ca2+ response in Fura2 loaded cells after the addition of 1mM Ca2+ 
after ER Ca2+ release had been induced by 5µM thapsigargin. Black bar indicates the 
presence of CaCl2, grey bar indicates the presence of thapsigargin. B – Quantification of Ca2+ 
release measured by ratiometric change in Fura2 fluorescence. n = 9 for control cells, n = 8 
for patient 1 cells and n = 1 for patient 2 cells. *** = P<0.001, calculated by T test.  
 
Figure 5.3.10. clearly shows that Ca2+ release from the ryanodine receptor is 
significantly higher in fibroblasts from KRS patient 1 (P < 0.001, t = 4.467, df = 15) 
with a trend for increased response in patient 2 from a single repeat. As the total 
levels of Ca2+ in the ER are relatively similar to control levels in both patient cell lines 
it appears that release from the ryanodine receptor is potentiated by an, as yet, 
undefined mechanism. An attractive proposition is that this mechanism of 
potentiation may involve low levels of glucosylceramide in the ER, as has been 
observed in Gaucher disease, perhaps providing links between the protein defective 
in this disease (GCase) and ATP13A2 – this remains to be investigated. 
 
The final cellular Ca2+ store which we are currently able to analyse are the 
mitochondria. As these organelles are known to buffer cytosolic Ca2+ levels by Ca2+ 
influx. This store is particularly interesting in KRS, as numerous publications have 
reported mitochondrial defects in cell deficient in ATP13A2 (Grunewald et al., 2012; 
Park et al., 2014). One way to induce mitochondrial Ca2+ release is depolarisation of 
mitochondria with rotenone, which leads to Ca2+ efflux. Recently, it has been 
reported that expression of catalytically active ATP13A2 is protective against 
rotenone induced toxicity (Holemans et al., 2015) so it is of particular interest to look 
at the Ca2+ release induced by rotenone in cells which do not have functional 
ATP13A2.  
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Figure 5.3.11 – Ca2+ release from mitochondria in response to rotenone induced 
depolarisation in KRS patient fibroblasts. A - Representative traces of Ca2+ responses in 
Fura2 loaded cells after the addition of 10µM rotenone. Black bar indicates the presence of 
rotenone. Arrowheads indicate the addition of 5µM ionomycin to confirm cell viability. B – 
Quantification of Ca2+ release measured by ratiometric change in Fura2 fluorescence. Error 
bars = SEM. n = 6 for control cells, n = 8 for patient 1 cells and n = 3 for patient 2 cells. *** = 
P<0.001, calculated by one way ANOVA with Bonferroni post test. 
 
As can be seen in figure 5.3.11. Ca2+ release induced by rotenone in cells was 
significantly elevated in the cell line from patient 1 (P < 0.001, t = 5.926, df = 12) and 
there was a trend towards elevation in the preliminary experiment conducted in 
patient 2 cells. Over a four fold elevation was observed in cells from patient 1. As 
mitochondrial Ca2+ overload and subsequent signalling events is a pro-apoptotic 
event, and functional ATP13A2 is protective against this, the substantial elevations in 
Ca2+ response may represent a contributing factor to the proposed dopaminergic 
neuron loss in ATP13A2. This may be important as mitochondrial dysfunction is pre-
eminent in pathogenic cascades associated with Parkinson’s, and, can be caused by 
elevated cytosolic Ca2+. Nevertheless, this phenotype should be confirmed by In situ 
measurement of mitochondrial Ca2+ in KRS patient fibroblasts especially as 
subsequent experiments in which ER Ca2+ agonists were added after rotenone 
stimulated Ca2+ release resulted in substantially reduced Ca2+ release (data not 
shown). These levels were in excess of that shown after NAADP-AM, this suggests 
that some of this Ca2+ release originated from the ER. It is important to note, 
however, that the most likely method to potentiate ER Ca2+ release after rotenone 
depolarisation of mitochondria is by CICR, suggesting that Ca2+ efflux from 
mitochondria is increased in patient cells as they are initially overloaded with Ca2+. 
Unfortunately, it is difficult to isolate Ca2+ signalling events after mitochondrial 
depolarisation, as we are able to do for the lysosome, ionophores such as ionomycin 
cause release from mitochondria and agonists which release Ca2+ from the ER result 
in increased mitochondrial Ca2+ due to their activity as a cytosolic Ca2+ buffer.  
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When this buffering capacity of mitochondria is considered, alongside the propensity 
for KRS patient cells to have higher levels of cytosolic Ca2+ , it would suggest that 
this phenotype may be pathogenically important. This will be further discussed in 
section 5.4.2. It may be of interest to study cytochrome C release and assay for 
caspase activation in these cells as both caspase 3 and 7 activity has been shown to 
increase in cells from KRS patients (Radi et al., 2012); it would be interesting to see 
if these differences were exacerbated by increased Ca2+ from any of the sources 
discussed above.  
 
Taken together the above data clearly indicates Ca2+ dyshomeostasis in multiple 
cellular stores, many of which have been implicated in KRS pathogenesis in different 
cellular models. Although further work remains to temporally resolve these 
dyshomeostatic events we thought it would be interesting to see if lysosomal heavy 
metal ion homeostasis could play a role in any of these phenotypes.  
 
5.3.2. – Preliminary observations of chelation of lysosomal heavy metals 
reducing excessive Ca2+ signalling events from the ER and mitochondria in 
KRS patient fibroblasts.  
 
Heavy-metal homeostasis has been implicated in KRS since the discovery of 
ATP13A2 as the molecular cause of the disease (Ramirez et al., 2006). Numerous 
publications have further implicated divalent metal ions in the pathogenic cascade of 
events which lead to KRS (Schneider et al., 2010; Ramonet et al., 2012; Tsunemi et 
al., 2014; Park et al., 2014). It is, however, very difficult to accurately determine the 
identities of many ions using fluorescent probes as they generally display a high 
degree of promiscuity with respect to the species of ion they interact with. In 
preliminary experiments we were able to observe quenching of Fura2 loaded 
specifically into the endolysosomal system. This has previously been used as an 
assay for Mn2+ accumulation, although it is not specific for this ion (Kwakye et al., 
2011; Kress et al., 2012). 
 
Whilst chelators can be added to cells loaded with these probes to improve 
specificity, many of these do not function properly in the lysosome due to the highly 
acidic environment. One chelator which has been shown to be effective in the 
lysosome is phytic acid (Maguire et al. unpublished). Although this chelator is non-
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specific it does chelate a number of ions implicated in KRS pathology, and, will do so 
preferentially within the lysosome. Accordingly, we can use it in order to see if heavy 
metal ion accumulation within the lysosomal lumen is important to disease 
phenotypes reported in KRS. We are particularly interested to see if we can reduce 
any of the Ca2+ dyshomeostasis events described above. As such, we have used the 
two assays above which provided us with the most striking differences between KRS 
patient and control fibroblasts. These are ryanodine mediated ER Ca2+ release and 
Ca2+ release from the mitochondria as a result of depolarization by rotenone.  
 
 
Figure 5.3.12. – Effect of phytic acid treatment on Ca2+ release from the ryanodine 
receptor in KRS patient fibroblasts. Cells were treated with 1mM phytic acid for 14days. A 
- Representative traces of Ca2+ response in Fura2 loaded cells after the addition of 10µM 
ryanodine. B – Quantification of Ca2+ release measured by ratiometric change in Fura2 
fluorescence. Error bars = SEM. n = 6 for control cells, n = 7 for patient 1 cells and n = 3 for 
phytic acid treated cells. * = P<0.05, calculated by one way ANOVA with Bonferroni post test. 
 
In order to chelate heavy metal ions cells were treated with 1 mM phytic acid for 14 
days prior to Ca2+ assay in order to effectively chelate heavy metals within the 
lysosome, and, allow cells to adjust to these new conditions. It can be seen from 
figure 5.3.12. that the excessive Ca2+ release from the ryanodine receptor proposed 
to be caused by hyperactivity of this channel is reduced by around 40% by phytic 
acid treatment, although this reduction is not significant the trend indicates that more 
repeats of this experiment would prove beneficial. It remains to be confirmed whether 
the total ER Ca2+ levels have been affected by phytic acid treatment with higher 
concentrations of thapsigargin, it is anticipated that phytic acid will not affect the total 
levels of this Ca2+ store and it is more likely that the effects lysosomal heavy metal 
ion content will lead to the reduction in ryanodine receptor hyperactivity. 
 
With reduction in the hyperactivity of Ca2+ release from the ryanodine receptor we 
would anticipate that there would be a concomitant reduction in the levels of cytosolic 
Ca2+ which would need to be buffered by the mitochondria in order to maintain the 
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comparable levels between control and patient fibroblasts observed in the absence 
of extracellular Ca2+. Accordingly, this was the second Ca2+ phenotype investigated 
in phytic acid treated cells.  
 
 
 
Figure 5.3.13– Effect of phytic acid treatment on Ca2+ release after rotenone induced 
mitochondrial depolarisation in KRS patient fibroblasts. Cells were treated with 1mM 
phytic acid for 14 days (+PA). A - Representative traces of Ca2+ responses in Fura2 loaded 
cells after the addition of 10µM rotenone. Black bar indicates the presence of rotenone. 
Arrowheads indicate the addition of 5µM ionomycin to confirm cell viability. B – Quantification 
of Ca2+ release measured by ratiometric change in Fura2 fluorescence. Error bars = SEM. n = 
3 for control cells, n = 3 for patient 1 cells and n = 3 for phytic acid treated cells. * = P<0.5, 
calculated by one way ANOVA with Bonferroni post test. 
 
The trend towards reduction of the Ca2+ response after rotenone was not as great as 
that shown after ryanodine stimulated Ca2+ release, around 25% reduction as 
opposed to 40%. Again, this trend suggest further repeats of this experiment should 
be performed. As the temporal progression of Ca2+ phenotypes in KRS cells is 
currently unclear this may be due to this phenotype being downstream of excessive 
Ca2+ release from the ER. As such, a longer treatment time may be needed to 
correct this phenotype. As cells are grown in the presence of Ca2+ until imaging 
excessive Ca2+ influx from the extracellular milieu may still be occurring until shortly 
before the experiment in conducted; as such, the mitochondria may still contain 
excessive Ca2+ as a result of this. The reduction observed may be due to reduced 
ryanodine receptor activity not contributing further to this. 
 
As described the onset of these phenotypes remains to be delineated. Phytic acid 
may be beneficial in this regard as if the lysosome is the initiating compartment for 
Ca2+ hyper-reactivity it may be reduced by chelation of heavy metal ions. 
Accordingly, signalling events following the stimulation of lysosomal Ca2+ channels 
TRPML1 and TPC2 by ML-SA1 and NAADP-AM respectively should be investigated 
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in phytic acid treated cells. It is, however, encouraging that phytic acid reduces Ca2+ 
hyper-reactivity in these cells and this therapeutic action should be further 
investigated. 
 
5.3.3. – Preliminary investigation of astrocytic Ca2+ abnormalities in models of 
Gaucher disease reveal potentiation by ER Ca2+ dyshomeostasis 
 
In Gaucher disease astrocytes have been shown to be important in brain pathology 
(Farfel-Becker et al., 2011). These cells have not been examined for 
Ca2+dysregulation; shown to be an early event in this pathogenesis of other 
neurodegenerative diseases. We were interested to see if the Ca2+ dysregulation in 
other cellular models of Gaucher could be extended to primary astrocytes which 
have GCase defects. 
 
 
Figure 5.3.14. – Spontaneous Ca2+ signalling events in primary mouse astrocytes from 
a mouse model of Gaucher disease. A - Representative traces of Ca2+ response in Fluo3 
loaded wild-type astrocytes. B – Representative traces of Ca2+ response in Fluo3 loaded 
Gaucher astrocytes. n = 1. 
 
In order to do this we prepared a culture of astrocytes from a mouse model of 
Gaucher in which GCase expression has been specifically ablated in neurons and 
astrocytes (Farfel-Becker et al., 2011). Upon loading with a cellular Ca2+ fluorophore 
we observed that spontaneous Ca2+ signalling events occurred in these cell lines as 
expected from primary astrocyte preparations (5.3.14. A and B). In this preliminary 
experiment when we compared these responses in cells prepared from WT animals 
to those in which GCase was deficient we observed a striking variability in 
spontaneous Ca2+ signalling events in cells prepared from Gaucher mice. The 
amplitude of this response was appeared to be increased in the Gaucher astrocytes. 
There also may be an increase in Ca2+ signalling events, where cells deviated more 
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than 10% from the current baseline signal. This experiment remains to be repeated 
so that the number of spontaneous signalling events and their amplitude can be 
analysed.  
 
In order to further study these phenotypes and investigate if loss of activity in GCase 
could cause an increase in astrocyte Ca2+ signalling we treated independently 
prepared wild-type astrocyte cultures with a specific, irreversible inhibitor of GCase.  
Conduritol β epoxide (CβE) has been extensively used to model Gaucher in both 
cells and animals and is becoming increasingly utilised as a way to study the 
pathogenic changes accompanying CGase activation, which may lead to Parkinson’s 
disease (Manning-Bog et al., 2009).  
 
 
 
Figure 5.3.15. – Cellular phenotypes in murine astrocytes treated with CβE. A - 
Representative lysotracker green images of control cells and those treated with 200µM CβE 
for six days. B – Threshold analysis of lysotracker green images from both astrocyte 
populations. C – Representative ER tracker blue/white images of control cells and those 
treated with 200µM CβE for six days. D – Threshold analysis of ER tracker blue/white images 
from both astrocyte populations. Error bars = SD. * = P<0.05 calculated by T test. n = 2. Cells 
were prepared by Jenny Lange, KCL. 
 
After 200µM treatment of astrocytes for six days we were able to see significant 
increases in lysotracker signal (P < 0.05, t = 5.258, df = 2, F1,1 = 1.563) indicative of 
increased acidic compartment size due to storage of the glycosphingolipid GlcCer. 
We also observed a trend towards increases to ER density (5.3.15. B), measured by 
increased lysotracker signal. Both these phenotypes can be used as a marker of 
Gaucher phenotypes and provide preliminary evidence that CβE treatment is having 
the desired effect on a novel cell line for Gaucher research although this remains to 
be confirmed by enzyme assay. 
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As we were able to show CβE treatment was able to induce phenotypes indicative of 
GlcCer storage we proceeded to investigate if this resulted in any changes to 
spontaneous Ca2+ signalling in these astrocyte populations.  
 
 
Figure 5.3.16. – Spontaneous Ca2+ signalling events in primary mouse astrocytes with 
pharmacologically induced Gaucher phenotypes. A - Representative traces of Ca2+ 
response in Fura2 loaded wild-type astrocytes. B – Representative traces of Ca2+ response in 
Fura2 loaded astrocytes after treatment with 200µM CβE for six days. C – The number of 
Ca2+ signalling events counted over the course of 5 minutes in both control astrocytes and 
astrocytes treated with with 200µM CβE for six days (+CβE). D – Quantification of the 
amplitude of Ca2+ release events in both control astrocytes and astrocytes treated with 200 
µM CβE for six days (+CβE). Error bars = SEM. * = P < 0.05 calculated by T test. n = 3. Cells 
were prepared by Jenny Lange, KCL.  
 
It can be observed in figure 5.3.16 that similar phenotypes were observed in CβE 
treated astrocytes and those prepared from Gaucher mice. Although the increased 
number of experiments performed on CβE treated astrocytes did not show a 
statistically significant increase in the frequency of Ca2+ signalling events there was a 
also a trend towards an increase (5.3.16. C). When the amplitude of signalling events 
was measured (5.3.16. D) these had increased two-fold (P < 0.05, t = 2.907, df = 4, 
F2,2 = 3.707). It is notable that the overall response profiles shown by cell prepared 
from the Gaucher mouse models and the wild-type astrocytes prepared by our 
collaborator (Jenny Lange, King’s College London) did differ but this is most likely a 
result of reduce time between culturing and experiments in the wild-type astrocytic 
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preparations. Nevertheless, as each of the Gaucher models cells is independently 
controlled by identically prepared cells within the same experiment these results 
remain robust.  
 
As Ca2+ signalling events are exaggerated in CβE treated cells we were interested to 
see if intracellular Ca2+ stores were responsible for this. As it is known that Ca2+ 
signals in astrocytes are primarily induced by ER Ca2+ release, and, this store is 
known to be more responsive in Gaucher disease (Lloyd-Evans et al., 2003) we were 
interested to investigate whether dyshomeostasis in this store could potentiate 
astrocyte Ca2+ signalling. We were able to significantly impact subsequent Ca2+ 
release events using ER Ca2+ agonists in both control and CβE treated as described 
in figure 5.3.17.   
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Figure 5.3.17. – Modulation of spontaneous Ca2+ signalling events by ER Ca2+ agonists. 
A – Quantification of instantaneous Ca2+ release in response to thapsigargin by ratiometric 
change in Fura2 fluorescence from control astrocytes and astrocytes treated with with 200 µM 
CβE for six days (+CβE). B – Quantification of instantaneous Ca2+ release in response to 
ryanodine by ratiometric change in Fura2 fluorescence from control astrocytes and astrocytes 
treated with with 200 µM CβE for six days (+CβE). C – Representative traces of Ca2+ 
response in Fura2 loaded control and CβE treated astrocytes before and after addition of 5 
µM thapsigargin. D – Representative traces of Ca2+ response in Fura2 loaded control and 
CβE treated astrocytes before and after addition of 100 µM ryanodine. E – Quantification of 
the amplitude of Ca2+ release events in both control and CβE treated astrocytes before and 
after the administration of thapsigargin. F – Quantification of the amplitude of Ca2+ release 
events in both control and CβE treated astrocytes before and after the administration of 
ryanodine. Error bars = SEM. In A and B no significant difference was observed by unpaired 
T test. In E and F * = P<0.05, *** = P<0.001, calculated by one way ANOVA with Bonferroni 
post test. n = 3 for control and thapsigargin experiments, n = 2 for ryanodine experiments. 
Cells were prepared by Jenny Lange, KCL.  
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Initial releases from both cell lines after stimulation with thapsigargin were 
comparable within both cell lines suggesting that the overall Ca2+ store in the ER was 
unchanged and elevation of this store was not responsible for the exaggerated Ca2+ 
signalling events observed in Gaucher and CβE treated astrocytes. Interestingly, 
there was a trend towards increased response to ryanodine in treated cells 
suggesting that the ryanodine receptor was more responsive in these cells as has 
previously been described in Gaucher disease (Lloyd-Evans et al., 2003). This 
remains to be investigated in subsequent repeats. Supplementary to this we 
investigated the spontaneous astrocytic Ca2+ responses before and after addition of 
Ca2+ agonists. As we observed in cell from CLN1 disease mouse models (Lange et 
al., unpublished) thapsigargin treatment had a strong trend towards a suppressive 
effect on signalling events; as expected from previous observations that the ER is 
central to astrocytic Ca2+ signalling. This was accompanied by a trend towards 
reduced numbers of signalling events and a significant reduction in amplitude of 
signal (P < 0.001, t = 6.604, df = 4). These observations may implicate the ER in 
exaggeration of these signals.  
 
Converse trends were observed after ryanodine treatment of both astrocyte 
populations as a potentially stimulatory effect on spontaneous Ca2+ signals was 
observed. Although the number of responses remained consistent after ryanodine 
addition there was a trend towards an increase in the amplitude of these responses 
in CβE treated astrocytes. This implicates hyperactivity of the ryanodine receptor as 
previously reported in Gaucher disease (Lloyd-Evans et al., 2003) as a potential 
underlying cause of increased astrocytic Ca2+ responses in these cells. In addition to 
further repeats of these experiments, to confirm the trends observed, it may also be 
interesting to study the effects of inhibition of the ryanodine receptor on these 
responses. This could potentially further implicate this Ca2+ release channel in the 
potentiation of spontaneous Ca2+ signalling events in astrocytes.  
 
If confirmed, the identification of ryanodine receptors as the initiating factor in 
increases in the excitability of astrocytic Ca2+ signalling events may provide an early 
pathogenic change prior to astrogliosis in Gaucher disease which has been shown to 
contribute to neuronal loss and dysfunction in other neurodegenerative diseases 
(Farfel-Becker et al., 2011). As astrocytic excitability has also been implicated in 
Parkinson’s disease (Vaarman et al., 2010) it may be an important pathogenic event 
linking dysfunction in GCase to loss of SNpc dopaminergic neurons – a population of 
neurons shown to be vulnerable to Ca2+ dyshomeostasis (Surmeier et al., 2011).  
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5.4.  – Summary of Results and Discussion 
 
The study of various Ca2+ stores in cells lines which model genetic causes of, and 
susceptibility to, Parkinson’s with lysosomal defects clearly reveals that Ca2+ is not 
correctly maintained by these cells. KRS patient cell lines which have mutations in 
ATP13A2 are hyper responsive to Ca2+ agonists with respect to multiple stores and 
astrocytic models of Gaucher disease appear to have pathogenic elevations seen in 
spontaneous astrocytic Ca2+ responses. Both cell lines are however not SNpc 
Dopaminergic (DA) neurons so in order to understand how the Ca2+ pathology 
observed may lead to the death of these neurons, and the subsequent onset of 
Parkinson’s phenotypes, we have to consider why Ca2+ is particularly important in 
this type of neuron.  
 
5.4.1. – The role of Ca2+ in SNpc Dopaminergic neurons 
 
The DA neurons which are lost in Parkinson’s disease are dependant upon Ca2+ 
channels for autonomous pacemaking. In this process, Ca2+ is used to mediate the 
broad and slow action potentials generated in these neurons. These are generated in 
the absence of synaptic input and instead rely on ambient dopamine levels in the 
regions of the brain they innervate (Surmeier et al., 2011). A consequence of this is 
that Ca2+ homeostasis in DA neurons is distinct from most other cell types as they 
utilise L-type Ca2+ channels with a specific catalytic core in order to allow 
extracellular Ca2+ to enter the cytoplasm (Striessnig., et al 2006). This core allows 
the channel to remain permeable to Ca2+ at more hyperpolarized levels than most 
other channels, thus, predisposes these neurons to autonomous pacemaking 
(Surmeier et al., 2011).  
 
Autonomous pacemaking comes at a substantial metabolic cost to these neurons, as 
cytosolic Ca2+ must be maintained at around 100nM. Accordingly, channels such as 
SERCA2 must pump Ca2+ against the steep concentration gradient in order to 
achieve this. In most neurons the brief spikes of Ca2+ excitability result in influxes of 
Ca2+ that can quickly be sequestered; the prolonged open state of Ca2+ channels in 
DA neurons means that this process has to be constantly functioning. This also puts 
increased stress on mitochondria as they act to buffer increased cytosolic Ca2+, a 
process which puts them under increased basal levels of stress. This process 
appears to be more prevalent in populations of neurones sensitive to cell death 
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during Parkinson’s pathogenesis (Surmeier et al., 2011). Interestingly, genetic forms 
of Parkinson’s, which affect genes expressed in mitochondria, also have this affect 
on DA neurons (Surmeier et al., 2011).  
 
Importantly, other types of neurons which are vulnerable to loss in Parkinson’s also 
undergo autonomous Ca2+ pacemaking and utilise L-type Ca2+ channels whereas 
VTA DA neurons, the population of which remains relatively intact in Parkinson’s 
patients and animal models, do not. As Ca2+ also stimulates Dopamine biosynthesis 
regulation of this key signalling ion is evidently at the heart of many aspects of 
Parkinson’s pathogenesis (Surmeier et al., 2011).  
 
5.4.2. – Ca2+ hyper reactivity in ATP13A2 deficient cells 
 
In our study of KRS patient fibroblasts we were able to observe multiple forms of 
Ca2+ hyperactivity in cells which do not have functional ATP13A2. A benefit of these 
cells is that they have been extensively characterised in numerous publications and 
in many of these publications specific defects in lysosomes (Dehay et al., 2012), and 
mitochondria (Grunewald et al., 2012), have been corrected by re-expression of 
functional ATP13A2 in order to confirm that these defects were due to loss of 
function, as opposed to toxic gain of function. Nevertheless, our study of ER 
phenotypes may benefit from either re-expression of functional ATP13A2 or further 
study in ATP13A2-/- cells as the mutant protein expressed in these cells may be 
responsible for or contributing to the ER Ca2+ dyshomeostasis we observe. 
Additionally, the control human fibroblast cell line utilised in this study is extremely 
well characterised with respect to the lysosomal Ca2+ store, and well characterised 
with respect to the content of other stores (Lloyd-Evans et al., 2008). 
 
The evidence presented in section 5.3.1. shows that the Ca2+ stores in KRS cells are 
dysfunctional leading to increased Ca2+ release in numerous situations (summarised 
in 5.4.1.). The observation that cytosolic Ca2+ may be elevated compared to the level 
in control human fibroblasts by the addition of extracellular Ca2+ is likely to have 
severe effects on DA neurons which are constantly in high states of Ca2+ influx 
during autonomous pacemaking (Surmeier et al., 2011). Reduced ability of cells to 
lower cytosolic Ca2+ would increase the mitochondrial stress phenotypes to which DA 
neurons are susceptible whilst upregulating dopamine biosynthesis, potentially 
initiating a detrimental cycle.  
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Figure 5.4.1. – Ca2+ hyper reactivity in KRS patient fibroblasts. Potentially elevated Ca2+ 
stores are shown by black arrows and channels which are more active in KRS cell are 
labelled with red arrows. Adapted from Lloyd-Evans et al., 2008. 
 
Increased Ca2+ release from the cellular stores assayed would obviously contribute 
to this and dysfunction within mitochondria in these cells. This has been shown by 
increased sensitivity to mitochondrial toxins by Holemans et al., (2015). The next 
step in this study would be to find the initiating factor which underlies this Ca2+ 
dyshomeostasis. siRNA inactivation of ATP13A2 followed by assay of Ca2+ stores at 
different time points would be able to temporally resolve the onset of Ca2+ 
dyshomeostasis in intracellular stores although this may not be necessary due to the 
observations present in the literature in addition to our findings.  
 
As ATP13A2 is a protein which localises to the lysosome (Ramirez et al., 2006) it is 
most likely that initial defects would begin here, however, with respect to ER Ca2+ 
phenotypes these may be caused by the presence of misfolded ATP13A2 protein 
(Ramirez et al., 2006). These stores are also closely linked functionally as discussed 
throughout this thesis. Interestingly, however the reduction of heavy metal ion 
accumulation in the lysosomes of KRS cells reduced the ER signalling defect of 
increased ryanodine receptor Ca2+ release. This is suggestive of dysfunctional 
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lysosomal processes initiated by heavy metal ion accumulation contributing to the ER 
hyper-reactivity, possibly due to Ca2+ signalling from the TPC2 channel having an 
exaggerated impact upon the ER. As this phenotype has been recently shown to be 
present in patient fibroblast carrying dominant LRRK2 mutations (Hockey et al., 
2015) it could be further investigated by the inhibition of TPC2 channels with Ned-19 
– an intervention which may be doubly beneficial in cells which also have increased 
ML-SA1 signalling. Interestingly, LRRK2 and ATP13A2 have recently been linked 
with inhibition of the kinase activity of mutated LRRK2 helping to rescue lysosomal 
defects by a mechanism involving upregulated expression of ATP13A2 (Henry et al., 
2015). It would be interesting to see if LRRK2 kinase inhibition corrected any of the 
defects observed in KRS patient cells.  
 
As previously mentioned increased signalling from the TRPML1 channel can activate 
calcineurin and de-phosphorylate and bind TFEB initiating lysosomal biogenesis 
(Medina et al., 2015). In these cells this may well lead to accumulation of autophagic 
vacuoles as endolysosomal fusion and fission defects are expected in cells which 
have Ca2+ dyshomeostasis in this system. This may be particularly relevant in terms 
of fission defects as observed in cells deficient in TRPML1 (Waller-Evans et al., 
manuscript in preparation), which also have higher endolysosomal Ca2+ levels and 
exhibit trafficking defects. We do not however expect increased release from 
TRPML1 to lead to increased release of Ca2+ from the ER in the same way that 
TPC2 does.  
 
Another way in which the lysosome could affect Ca2+ release from the ER and 
subsequently the mitochondria is by lysosomal lipid accumulation and escape to the 
ER as hypothesised to occur in multiple LSDs (Platt et al., 2012). Interestingly, in 
preliminary biochemical analysis the only lipid significantly elevated in both KRS 
patient cell lines was GlcCer. In Gaucher disease GlcCer accumulation has been 
shown to potentiate the pathogenic release of Ca2+ from ryanodine receptors (Lloyd-
Evans et al., 2003). As this lipid is elevated and Ca2+ release from the ryanodine 
receptor is exaggerated in KRS cells it is an attractive proposal for this GlcCer 
accumulation to be the cause of this; especially as the enzyme responsible for the 
degradation of GlcCer GCase is a genetic risk factor for Parkinson’s (Sidransky et 
al., 2009). In situ enzyme assays of GCase may provide the evidence for this 
process in KRS cells – it may be particularly relevant to see if heavy metal ion 
chelation could modulate any changes in GCase activity observed in KRS cells as 
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this would further indicate that GlcCer accumulation may lead to increased activation 
of the ryanodine receptor. 
 
It is also important to note that increased release of Ca2+ from the ER of cells and 
other methods of increasing cytosolic Ca2+ is proposed to lead to lead to elevations in 
endolysosomal Ca2+ (Lloyd-Evans et al., 2008) and it cannot be absolutely ruled out 
that the ER is the initiating factor in intracellular Ca2+ stress. Nevertheless, evidence 
from this study and others into Ca2+ dyshomeostasis in genetic forms of Parkinson’s 
suggest that lysosomal involvement may be primary.  
 
Whilst these observations remain interesting it will be important to corroborate them 
in different cellular models of KRS. We plan to do this in ATP13A2-/- cells, these 
would provide a potential model in which phenotypes could be assayed in a similar 
way to that detailed in chapter 3. It cannot be ruled out that unrecognised genetic 
variation in KRS patient fibroblast may confound the results we have obtained. 
Accordingly, although they are closer to the reality of KRS they present their own 
challenges and studies utilising them would be strengthened by the addition of 
knockout cell lines. This is why we are planning to perform this study in relation to 
KRS and the converse of this study in relation to familial Alzheimer’s. 
 
5.3.3. – KRS as a neuronal ceroid lipofuscinosis 
 
A variety of the Ca2+ phenotypes we have reported are supportive of the links 
between ATP13A2 and NCLs (Bras et al., 2012). A number of the Ca2+ phenotypes 
present in these cells suggest that there is some overlap with this class of lysosomal 
storage disease. Firstly, the potential for elevated endolysosomal Ca2+ signalling has 
been observed in cellular models of CLN3. Although there are differences here as 
cellular models of CLN3 have been shown to have significant increases in lysosomal 
Ca2+, whereas this was not clearly observed in KRS cells, both have been shown to 
respond excessively to agonists of lysosomal Ca2+ release channels (Walker et al., 
Unpublished). CLN3 cells also exhibited an increased sensitivity towards 
thapsigargin (Chandrachud et al., 2015), another trend exhibited in KRS patient 
fibroblasts. Interestingly, the increased Ca2+ release which resulted from this 
phenotype caused the accumulation of autophagic vacuoles in a Ca2+ dependant 
manner in CLN3 (Chandrachud et al., 2015). This may partially explain the 
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autophagic defects observed in KRS cells and accumulation of autofluorescent 
storage material. 
 
Another condition which causes the accumulation of autofluorescent material is MLIV 
caused by inactivation of the TRPML1 channel (Jennings et al., 2006). Interestingly 
increased levels of endolysosomal Ca2+ have also been measured in this disease 
(Waller-Evans et al., manuscript in preparation). Although MLIV is not considered an 
NCL lysosomal diseases in which endolysosomal Ca2+ is elevated may share a 
number of defects and could possibly form a novel disease grouping which would 
inform us about conserved pathogenesis in LSDs which have previously been 
considered disparate. It would be interesting to see which other LSDs could be 
added to this group which would so far include CLN3, MLIV and KRS. The most 
obvious potential source of other members is the broader family of NCLs as some of 
the causative genes such as CLN5 are proposed to interact with CLN3 (Carcel-
Trullols et al., 2015). Accordingly, it may be interesting to look for phenotypic overlap 
in cells and patients; for example recent findings of synucleinopathy in CLN10 
(Cullen et al., 2009) and clinical observations that movement disorders in diseases 
such as CLN3 and CLN1 are considered to forms of parkinsonism (Schulz et al., 
2013) 
 
5.4.4. – Preliminary evidence of alterations in astrocytic Ca2+ signalling in 
Gaucher disease 
 
As we were interested in extending our study of Ca2+ dyshomeostasis in models of 
genetic susceptibility to Parkinson’s we utilised primary astrocyte models of Gaucher 
disease. We were able to utilise cells from both Gaucher knockout mouse models 
(Farfel-Becker et al., 2011) and a well-characterised pharmacological model of 
Gaucher (Manning-Bog et al., 2009). This was able to add strength to our study as 
we could show that specific inhibition of GCase and the subsequent accumulation of 
GlcCer lead to similar phenotypes of astrocytic Ca2+ signalling hyperactivity.  
 
In the CBE model we were also able to observe the expected phenotype of 
lysosomal expansion and although ER expansion was not highly evident we were 
able to link the increased Ca2+ signalling to the ER by modulating this store using 
thapsigargin and may have implicated the ryanodine receptor in this process. It is 
currently unknown how GlcCer escapes to the ER although lysosome;ER membrane 
	   224	  
contact sites (Penny et al., 2015) would seem to be a natural location for this. 
Interestingly, this increased astrocytic Ca2+ signalling is highly likely to impact upon 
other Ca2+ stores such as the mitochondria were the need for increased absorbance 
of Ca2+ could lead to increases in the basal levels of mitochondrial stress and 
subsequently make these organelles more susceptible to other insults (Surmeier et 
al., 2011).  
 
As with the study we conducted in KRS cells it is important to consider how these 
phenotypes could affect SNpc DA neurons. As discussed in section 5.4.1. these 
neurons take in large amounts of Ca2+ over prolonged periods of time when 
compared to other neurons so increased Ca2+ activity in surrounding cells may well 
increase the chances of cytosolic Ca2+ overload, mitochondrial stress and increased 
dopamine synthesis (Surmeier et al., 2011). This could further increase astrocytic 
Ca2+ signals (Vaarman et al., 2010).  When we consider that the same hyper 
activation of the ryanodine receptors in the DA neurons themselves may also be 
prevalent it can be seen that an increase requirement for Ca2+ homeostasis has been 
added to a system which is already stressed in this regard.  
 
In this study we have provided the first example of increased Ca2+ excitability in 
astrocytes from a genetic model of Parkinson’s disease. It would be particularly 
interesting to examine this phenotype in other genetic forms of Parkinson’s to see if 
the increased astrocytic signalling was also present; KRS and G2019S LRRK2 may 
provide particularly good models for this as Ca2+ the have already been reported to 
exhibit hyper reactivity with regard to Ca2+ signalling (Hockey et al., 2015). It may 
also provide a link to sporadic forms of Parkinson’s as disruption of dopamine 
transmission has also been shown to result in increased astrocytic Ca2+ signalling 
(Vaarman et al., 2011).  
 
5.4.5 – Observations of Ca2+ dyshomeostasis in other forms of PD and the 
potential role in sporadic Parkinson’s 
 
As with our study of Alzheimer’s disease taking observation from cellular models and 
applying them to human disease is never an easy task. We are, however, closer to 
the disease in this study then we were using knockout cell models of Alzheimer’s 
disease as this study has been based on patient mutations and astrocytes models 
which are more closely linked to pathogenesis in Parkinson’s.  
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In these studies we have again, however, been able to provide a good baseline for 
further examination of Ca2+ dyshomeostasis in genetic models of Parkinson’s 
disease. The use of KRS patient fibroblasts was extremely important in this regard as 
these patients represent an extremely severe example of Parkinson’s disease (Park 
et al., 2015). Accordingly, we would expect the important phenotypes to be prevalent 
in this disease model. The observation of clear Ca2+ signalling hyper reactivity was 
encouraging as the very early onset of Parkinson’s phenotypes would suggest that 
the underlying pathology would be very evident. It would be interesting to examine 
similar phenotypes in less severe genetic models of Parkinson’s disease.  
 
To some extent we have initiated this in our examination of astrocytic Ca2+ signalling 
in models of Gaucher. These were clearly evident Ca2+ signalling changes in cells 
that have completely ablated function of GCase and provides an interesting starting 
point for our observations. This phenotype would be much more subtle if only a small 
amount of GlcCer was stored and escaped to the ER. Nevertheless over the course 
of the approximately 50 years Parkinson’s commonly takes to onset these subtle 
changes may be sufficient to increase Ca2+ stress in DA neurons eventually leading 
to cell loss (Surmeier et al., 2011). With numerous other reports of increased Ca2+ 
signalling in genetic models of Parkinson’s this may well be an interesting avenue of 
investigation.  
 
In order to apply these finding to sporadic Parkinson’s disease much more work will 
need to be performed although the Ca2+ phenotypes discussed in this chapter may 
provide a basis for these studies.  
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Chapter 6 
 
 
 
General Discussion and Concluding 
Remarks 
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The studies contained in this thesis have applied techniques developed in the study 
of LSDs and utilised them in the study of more commonly occurring 
neurodegenerative diseases associated with ageing. In doing so we have implicated 
the lysosomal ion channel TRPML1 in the pathogenesis of familial Alzheimer’s 
disease, identified a potential new therapeutic target for Huntington’s disease and 
provided further implicated Ca2+ dyshomeostasis in genetic models of, and models of 
genetic predisposition to, Parkinson’s. The diverse pathologies which are present in 
the different models we have examined clearly show that the lysosome is a 
multifunctional organelle and its location at the centre of the greater lysosomal 
system allows it to influence all aspects of cellular function.  
 
The prevalence of neurodegenerative phenotypes in the majority of lysosomal 
storage diseases clearly implicates these organelles as vital for neuronal survival 
(Cox and Chacon Gonzalez, 2011). Interestingly, a large number of mutations known 
to lead to the onset of various neurodegenerative diseases further implicate 
lysosomes as vital in this process. The lysosome can be considered a ‘hot spot’ for 
neurodegenerative disease. 
 
6.1. – The endolysosomal system as a hot spot for neurodegenerative disease 
 
It has already been discussed how mutations in various genes which affect the 
endolysosomal system can result in Alzheimer’s and Parkinson’s disease, however, 
a number of other genes known to cause other neurodegenerative diseases can also 
impact the vital cellular pathway. Some of these genes are highlighted in figure 6.1. 
 
Charged multi-vesicular body protein 2B (CHMP2B) is an ESCRT complex 
component important in the delivery of a variety of endocytosed cargoes to the 
correct cellular compartments. Truncated forms of this protein, expressed as a result 
of mutations in CHMP2B, have been shown to be the molecular cause of rare forms 
of autosomal dominant frontotemporal dementia (FTD). The impact of these proteins 
on vesicular fusion events in the endolysosomal system is though to be important to 
pathogenesis (Isaccs et al., 2011). 
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Figure 6.1. – Genes associated with neurodegenerative diseases which express 
proteins which localise to, or impact upon, the endolysosomal system. Genes 
associated with Alzheimer’s disease are shown in red, genes associated with Parkinson’s 
disease are shown in blue, HTT is shown in green. Key on the left indicates compartment pH. 
Adapted form Nixon, 2013. 
 
A number of other genes coding for proteins which are expressed in the 
endolysosomal system have also been linked to FTD. These include PGRN 
(progranulin) (Petkau and Leavitt, 2014), and C9ORF72 (c9orf72). Hexanucleotide 
repeat expansion in C9ORF72 have been shown to cause both FTD and 
amyotrophic lateral sclerosis (ALS) and the protein product is known to co-localise 
with markers of the endocytic system in neurons (Farg et al., 2014).  
 
Interestingly, a genetic modifier of the severity of neurodegenerative phenotypes 
caused by both of these genes is TMEM106B the protein product of which, 
transmembrane protein 106B is localised in the endolysosomal system where it can 
regulate lysosomal morphology and function (Gallagher et al., 20134). Accordingly, it 
would be potentially interesting to look at the impact of this protein on LSDs as much 
of the phenotypic variability in patients with these diseases remain unexplained.  
 
Particularly relevant to this thesis is FIG4, this produces a 5’ phosphoinositide 
phosphatase, which regulates levels of PI(3,5)P2. When his protein is deficient 
lysosomal storage phenotypes are observed and patients suffer from a form of 
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Charcot-Marie-Tooth disease (CMT). Recently lysosomal storage phenotypes in cells 
deficient in FIG4 were rescued by ML-SA1 stimulated Ca2+ efflux from ML-SA1. 
Incidentally, this is supportive of our finding that ML-SA1 does not require PI(3,5)P2 
to facilitate Ca2+ release from ML-SA1 (Zou et al., 2015).  
 
As can be observed in figure 7.1.1. there are a myriad of established and newly 
emerging genetic causes of neurodegenerative disease which interact with the 
greater lysosomal system, it is likely that the number of these will continue to grow.  
 
6.2. – Changes in the lysosome with ageing 
 
A key risk factor in virtually all neurodegenerative disease is ageing, with only rare 
diseases causing neurodegenerative phenotypes in juvenile and adolescent patients. 
As LSDs are one of the more common causes of juvenile neurodegenerative disease 
(Cox and Chacon Gonzalez, 2011) they may in some respects be considered 
diseases of early, or accelerated, ageing. The NCLs are a particularly good example 
of this as the characteristic storage substrate lipofuscin (Pearce 2015) is a hallmark 
of aged cells and tissues (Ottis et al., 2012).  
 
An excellent model for the study of cellular ageing processes are retinal pigment 
epithelium (RPE) cells, in particular for the study of age related macular degeneration 
(AMD) (Guha et al., 2014). These cells are particularly vulnerable to lipofuscin 
accumulation, as they phagocytose large amounts of photoreceptor outer segment 
tips subjecting these cells to a high proteolytic load. Interestingly, these cells have 
been shown to be extremely sensitive to alkalisation whether by pharmacological 
means (such as the well characterised phenomenon of chloroquine induced 
retinopathy) (Ben-Zvi et al., 2012); genetic disruption of proteins important for 
lysosomal pH maintenance (such as ClC-7) (Kasper et al., 2005); or, by the amount 
of time for which they have been cultured (Sparrow and Boulton, 2005). Autophagy is 
known to play a key role in the health of these cells and the elevation of pH has been 
shown to impair the fusion of autophagosomes and lysosomes (Kawai et al., 2007). 
These cells have also been used for the study of techniques which can re-acidify 
lysosomes such as the acidic nanoparticles described in chapter 3 (Baltazar et al., 
2012). Interestingly the derivative of artemisinin, artesunate, has also been shown to 
be capable of re-acidifying lysosomes (Yang et al., 2014). If this is successful in RPE 
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cells then it could potentially be used to treat PS1-/- cells and other diseases in which 
lysosomal alkalisation is present.   
 
Another model of cellular ageing processes is S.cerevisiae, in which the vacuole is 
considered to be the equivalent of the mammalian lysosome. Hughes and 
Gottschling, (2012). showed that mitochondrial dysfunction in replicatively aged yeast 
arises from vacuolar alkalisation. In a mutational screen the authors identified that 
ovexpression of two subunits of the yeast vATPase, VMA1 and VPH2, reduced 
mitochondrial dysfunction in aged yeast cells; a process which could be blocked by 
concanamycin A. Subsequently, they were able to show that alkalisation was evident 
in mother cells, but not daughter cells, and was increased in mother cells which had 
had greater numbers of daughter cells budding from them – the cells which were 
considered to have aged. Interestingly, lysosomal alkalisation was reduced in yeast 
subjected to caloric restriction, and, modulated by differential expression of amino 
acid transporters. Amino acid starvation has recently been shown to govern the 
formation of the vATPase complex, in a mammalian target of rapamycin (mTORC1) 
dependant manner, with lysosomes from amino acid starved cells more able to 
translocate protons into the lysosome (Hughes and Gottschling, 2012; Henderson et 
al., 2013).  
 
Such studies are providing links between lysosomal alkalisation in ageing and 
dysfunctional autophagy. This process has been shown to regulate lifespan in simple 
organisms like C.elegans (Hars et al., 2007), and, is recognised as a pathway which 
is decreased in ageing (Cuervo, 2008). It will be interesting to see if in future the 
pathway we have identified in PS1-/- cells, increased TRPML1 activity due to 
lysosomal alkalisation, will play any role in the modulation of autophagic process as 
Ca2+ signalling from the TRPML1 channel has been proposed to stimulate autophagy 
(Medina et al., 2015). However, as discussed in chapter 3, without the correct 
maintenance of lysosomal pH lysosomes fusion of autophagic vacuoles and 
substrate degradation can not proceed which may cause a pathological accumulation 
of autophagic vacuoles (Lee et al., 2010; Lee et al., 2015).  
 
The INPP5D gene, recently implicated in Alzheimer’s (Rosenthal and Kamboh, 
2014), and the FIG4 gene (Zou et al., 2015) may be interesting to study in this 
regard. Both can modulate phosphoinositol biosynthesis and as such affect the levels 
of the endogenous ligand of TRPML1, PI(3,5)P2. This would modulate the activity of 
TRPML1 in cells in which FIG4 or SHIP-1 (the protein coded for by INPP5D) are 
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deficient. This has the potential to be used as a model of perturbed TRPML1 
signalling in the absence of lysosomal alkalisation. This could also be achieved using 
pharmacological inhibition (Jefferies et al., 2008;Viernes et al., 2014).  
 
6.3. – Ca2+ signalling and neurodegenerative disease. 
 
Studies such as those mentioned above may be able to provide further links between 
the lysosome and dysfunctional Ca2+ signalling in neurodegenerative disease. In 
chapter 6 it was detailed how the SNpc DA neurons lost in Parkinson’s are 
susceptible to increased levels of Ca2+ within neurons and in the surrounding brain 
(Surmeier et al., 2011) and how mutations in ATP13A2 or loss of GCase activity 
could potentially contribute to this. The process of Ca2+ dyshomeostasis induced by 
glutamate excitotoxicity, resulting in the loss of the medium spiny neurons of the 
striatum in Huntington’s disease, has also been demonstrated in chapter 4. We are 
also beginning to understand the dysregulation of lysosomal Ca2+ homeostasis in 
familial models of Alzheimer’s, chapter 3. In addition to these Ca2+ dysregulation has 
been observed in amyotrophic lateral sclerosis (ALS), various spinocerebellar 
ataxias, multiple LSDs and in more moderate forms as part of the normal ageing 
process (Bezprozvanny, 2009).   
 
The majority of work on this subject has focussed on extracellular Ca2+ channels and 
the ER and mitochondria with respect to intracellular stores. The impact of these 
channels and stores on processes such as synaptic plasticity, synaptic vesicle 
fusion, phosphorylation, and changes to gene expression means that even subtle 
changes to Ca2+ signalling within the brain can have devastating consequences in 
the long term (Bezprozvanny, 2009). 
 
The role of the lysosome as a Ca2+ store and component of Ca2+ signalling pathways 
is beginning to emerge. There has long been evidence from neuronal models of 
LSDs showing that Ca2+ signalling is dysregulated in these diseases (Platt et al., 
2012); particularly primary sphingolipidoses. Recently there has been a renaissance 
of such studies particularly in relation to Gaucher disease due to the appreciation of 
GBA1 as a risk factor for Parkinson’s (Sidransky et al., 2009, Schondorf et al., 2014).  
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LSDs will play an important role in respect to the future study of the impact the 
lysosome can have on Ca2+ signalling pathways as we can utilise cellular and animal 
models of diseases such as NPC to model the effects of reductions in endolysosomal 
Ca2+ on Ca2+ signalling pathways in the brain. Conversely, we can utilise models of 
disease such as CLN3 to inform us of the impact of increased lysosomal Ca2+ on 
Ca2+ signalling in the brain (Chandrachud et al., 2015). This may be particularly 
informative with respect to the increasing evidence of exaggerated Ca2+ release from 
TPC2 in response to NAADP acting as a trigger for pathogenic Ca2+ elevation in 
Parkinson’s (Hockey et al., 2015). To this end, we have recently been able to reduce 
spontaneous Ca2+ signalling in the forebrains of embryonic zebrafish using Ned-19 – 
interestingly we also observed lysosomal storage phenotypes identical to NPC is 
doing so. Finally, diseases such as Gaucher can be used to model the impact that 
accumulating lipids can have upon Ca2+ signalling – a process which is also of 
potential importance to Parkinson’s. 
 
6.4. – How has the study of lysosomal storage disorders helped facilitate 
research into neurodegenerative disease? 
 
The lysosomal proteins which are at the centre of each chapter of this thesis were 
discovered as a result of research into LSDs. This identification of proteins as a 
result of disease models is particularly evident with respect to lysosomal 
transmembrane proteins, as many more are thought to be present in the limiting 
membrane of the lysosome but remain to be identified (Saftig and Klumpermann, 
2009; Schwake et al., 2013).   
 
If more overlapping pathology with LSDs is discovered in neurodegenerative 
diseases associated with ageing then we may be able to identify therapies from 
LSDs which can be applied to neurodegenerative diseases.  
 
The discovery and application of therapies in the field of LSD research is highly 
dynamic, and, is potentially accelerated by the severity of disease. As previously 
described, primary enzymatic defects of the endolysosomal system can be treated by 
enzyme replacement therapy (ERT) (Brady, 2006). Although this has proven an 
excellent treatment for peripheral pathology in many LSDs it can not be used to treat 
neurodegenerative disease, as enzymes are not BBB permeable so are unable to 
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treat pathology in the CNS (Platt et al., 2012). Accordingly, if an insufficiency of 
enzyme activity was shown to be the cause of pathology in neurodegenerative 
diseases new approaches would be needed to circumvent this problem.  
 
Although bone marrow (BM) transplantation has shown promise in some LSDs, such 
as NPC disease caused by NPC2, this approach is not suitable for age-related 
neurodegenerative diseases as it as require microglia of BM origin to enter the CNS 
and provide local sites of protein production. Accordingly therapy must be conducted 
early in life. The risks involved in this procedure and difficulty in locating tissue 
matched donors also present difficulties with this approach (Platt et al., 2012).  
 
Gene therapy clearly has the potential to address the problem of enzyme delivery to 
the brain in neurodegenerative disease and is the subject of intense research for the 
treatment of LSDs (Sands and Davidson, 2006). Recent results have been 
promising, with clear benefits observed in patients with metachromatic 
leukodystrophy (Biffi et al., 2014). The treatment of neurodegenerative LSDs is likely 
to yield many important lessons for the potential treatment of neurodegenerative 
diseases by such approaches.  
 
The major other therapeutic avenue for the treatment of LSDs is substrate reduction 
therapy (SRT). This treatment has the benefit of utilising small molecules which can 
be made orally available for ease of administration, and, can be BBB permeable 
(Platt et al., 2012). Evidently, these are much more suited to the treatment of age-
related neurodegenerative disease than ERT; importantly they can also be used to 
treat LSDs caused by transmembrane proteins (Patterson et al., 2015). These are 
not corrected by ERT and it is unlikely that gene therapy will be able to correct these 
diseases, due to a lack of scope for cross-correction of cells. This means that 
extremely high levels of gene transduction would be needed in order for disease 
processes to be reduced.  
 
The most well characterised SRT is miglustat, used in the treatment of Gaucher and 
NPC as previously discussed. Another example of SRT is the use of the soy 
isoflavanone Genistein (Piotrowska et al., 2011) to treat mucopolysaccharidoses. 
This is currently being investigated for the treatment of Mucopolysaccharidosis type 
III (Arfi et al., 2010). As with all small molecule drugs, their chemistry can induce side 
effects and these must be managed in patients. For example gastrointestinal 
disturbances in patients treated with miglustat, due to disaccharidase inhibition 
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(Belmatoug et al., 2011). Nevertheless, SRT still remains an attractive therapeutic 
option for LSDs and potentially neurodegenerative diseases as the potential for BBB 
permeable, orally available drugs is very desirable. A particular clinical challenge in 
relation to SRT is early enough treatment of patients, as it stands to reason that this 
would improve benefit. Accordingly it would be best to treat patients in early 
symprtomatic stages – the advent of new screening technologies, biomarkers and 
diagnostic procedures is helping to rectify this. As discussed in chapter 4, some of 
these considerations may mean that SRT has the potential to be utilised in 
neurodegenerative diseases which share lysosomal storage profiles with LSDs.  
 
Recently, other therapeutic directions have been applied to LSDs reflecting their 
complex pathology. These may often target different organelles in an attempt to 
upregulate functions which may be able to reduce lysosomal pathology. An example 
of such a therapy is the neutraceutical curcumin, as a Ca2+ homoestasis modulator 
for the treatment of NPC discussed in section 1.5.2. The efficacy of treatments such 
as curcumin is difficult to evaluate due to a lack of a defined pharmaceutical 
formulation and the availability of a wide variety of supplements with different 
formulations, preventing defined clinical study. Further therapies (such as HPβCD for 
NPC, section 1.5.2.) have no defined mechanism of action and while they may be 
beneficial it is important that the mechanism behind their action is studied so they 
can be either improved by rational alterations or used at the optimal therapeutic 
intervention point. Clearly, more development of such therapies would be needed 
before they could be utilised for the treatment of more common neurodegenerative 
diseases.  
 
The complex pathological cascades present in LSDs may be a limiting factor of 
efficacy with many of these therapeutic options in isolation. This may be 
compounded in neurogenerative diseases of complex, multifactorial aetiology such 
as Parkinson’s and Alzheimer’s.  
 
Considering pathogeneic cascades, it is desirable to try and address an aspect of 
which that is the most fundamental – the primary defect. This explains why ERT is so 
successful; when a limiting factor such as BBB permeability or the primary defect 
occurring in a transmembrane protein are not present. However, most LSDs have 
these limiting factors and the primary defect in these diseases may not be a viable 
therapeutic target or early pathological steps may not be clearly defined. Clearly this 
is also the case in the majority of neurodegenerative diseases of ageing. In such 
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cases combination therapy may be the best therapeutic option. This has recently 
been demonstrated in animal models of NPC in which increased therapeutic benefit 
when mice were treated with miglustat (SRT), curcumin (Ca2+ homeostasis 
modulator) and ibuprofen (non-steroidal anti-inflammatory) to address multiple 
stages of the pathogenic cascade (Williams et al., 2014).  
 
Considering the issues above the lessons learned from LSDs, and, future advances 
in therapy which may be achieved in this area of clinical research have great 
potential to inform the development of novel therapies for other neurodegenerative 
diseases.   
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